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Abstract
Non-invasive imaging software to assess the functional
significance of coronary stenoses: a systematic review and
economic evaluation
Ana Duarte ,1 Alexis Llewellyn ,2 Ruth Walker ,2 Laetitia Schmitt ,1
Kath Wright ,2 Simon Walker ,1 Claire Rothery 1 and
Mark Simmonds 2*
1Centre for Health Economics, University of York, York, UK
2Centre for Reviews and Dissemination, University of York, York, UK
*Corresponding author mark.simmonds@york.ac.uk
Background: QAngio® XA 3D/QFR® (three-dimensional/quantitative flow ratio) imaging software
(Medis Medical Imaging Systems BV, Leiden, the Netherlands) and CAAS® vFFR® (vessel fractional
flow reserve) imaging software (Pie Medical Imaging BV, Maastricht, the Netherlands) are non-invasive
technologies to assess the functional significance of coronary stenoses, which can be alternatives to
invasive fractional flow reserve assessment.
Objectives: The objectives were to determine the clinical effectiveness and cost-effectiveness of
QAngio XA 3D/QFR and CAAS vFFR.
Methods: We performed a systematic review of all evidence on QAngio XA 3D/QFR and CAAS vFFR,
including diagnostic accuracy, clinical effectiveness, implementation and economic analyses. We searched
MEDLINE and other databases to January 2020 for studies where either technology was used and
compared with fractional flow reserve in patients with intermediate stenosis. The risk of bias was
assessed with quality assessment of diagnostic accuracy studies. Meta-analyses of diagnostic accuracy
were performed. Clinical and implementation outcomes were synthesised narratively. A simulation study
investigated the clinical impact of using QAngio XA 3D/QFR.We developed a de novo decision-analytic
model to estimate the cost-effectiveness of QAngio XA 3D/QFR and CAAS vFFR relative to invasive
fractional flow reserve or invasive coronary angiography alone. Scenario analyses were undertaken to
explore the robustness of the results to variation in the sources of data used to populate the model and
alternative assumptions.
Results: Thirty-nine studies (5440 patients) of QAngio XA 3D/QFR and three studies (500 patients) of
CAAS vFFR were included. QAngio XA 3D/QFR had good diagnostic accuracy to predict functionally
significant fractional flow reserve (≤ 0.80 cut-off point); contrast-flow quantitative flow ratio had a
sensitivity of 85% (95% confidence interval 78% to 90%) and a specificity of 91% (95% confidence
interval 85% to 95%). A total of 95% of quantitative flow ratio measurements were within 0.14 of
the fractional flow reserve. Data on the diagnostic accuracy of CAAS vFFR were limited and a full
meta-analysis was not feasible. There were very few data on clinical and implementation outcomes.
The simulation found that quantitative flow ratio slightly increased the revascularisation rate when
compared with fractional flow reserve, from 40.2% to 42.0%. Quantitative flow ratio and fractional flow
reserve resulted in similar numbers of subsequent coronary events. The base-case cost-effectiveness
results showed that the test strategy with the highest net benefit was invasive coronary angiography
with confirmatory fractional flow reserve. The next best strategies were QAngio XA 3D/QFR and
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CAAS vFFR (without fractional flow reserve). However, the difference in net benefit between this
best strategy and the next best was small, ranging from 0.007 to 0.012 quality-adjusted life-years
(or equivalently £140–240) per patient diagnosed at a cost-effectiveness threshold of £20,000 per
quality-adjusted life-year.
Limitations: Diagnostic accuracy evidence on CAAS vFFR, and evidence on the clinical impact of
QAngio XA 3D/QFR, were limited.
Conclusions: Quantitative flow ratio as measured by QAngio XA 3D/QFR has good agreement and
diagnostic accuracy compared with fractional flow reserve and is preferable to standard invasive
coronary angiography alone. It appears to have very similar cost-effectiveness to fractional flow
reserve and, therefore, pending further evidence on general clinical benefits and specific subgroups,
could be a reasonable alternative. The clinical effectiveness and cost-effectiveness of CAAS vFFR are
uncertain. Randomised controlled trial evidence evaluating the effect of quantitative flow ratio on
clinical and patient-centred outcomes is needed.
Future work: Studies are required to assess the diagnostic accuracy and clinical feasibility of CAAS
vFFR. Large ongoing randomised trials will hopefully inform the clinical value of QAngio XA 3D/QFR.
Study registration: This study is registered as PROSPERO CRD42019154575.
Funding: This project was funded by the National Institute for Health Research (NIHR) Evidence
Synthesis programme and will be published in full in Health Technology Assessment; Vol. 25, No. 56.
See the NIHR Journals Library website for further project information.
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Glossary
CAAS® vFFR® Non-invasive imaging technology produced by Pie Medical Imaging BV (Maastricht, the
Netherlands).
Cost-effectiveness analysis An economic analysis that converts effects into health terms and describes
the costs for additional health gain.
Decision modelling A theoretical construct that allows the comparison of the relationship between
costs and outcomes of alternative health-care interventions.
False negative Incorrect negative test result: number of diseased persons with a negative test result.
False positive Incorrect positive test result: number of non-diseased persons with a positive test result.
Incremental cost-effectiveness ratio The difference in the mean costs of two interventions in the
population of interest divided by the difference in the mean outcomes in the population of interest.
Index test The test whose performance is being evaluated.
Markov model An analytic method particularly suited to modelling repeated events or the progression
of a chronic disease over time.
Meta-analysis A statistical technique used to combine the results of two or more studies and obtain a
combined estimate of effect.
Metaregression A statistical technique used to explore the relationship between study characteristics
and study results.
Negative predictive value Proportion of patients who tested negative on the test that do not have the
condition of interest.
Opportunity cost The cost of forgone outcomes that could have been achieved through alternative
investments.
Percutaneous coronary intervention A non-surgical procedure that uses a small structure called a
stent to open up blood vessels in the heart that have been narrowed by plaque build-up.
Positive predictive value Proportion of patients who tested positive on the test that have the
condition of interest.
QAngio® XA 3D/QFR® Non-invasive imaging software produced by Medis Medical Imaging Systems
BV (Leiden, the Netherlands).
Receiver operating characteristic curve A graph that illustrates the trade-offs between sensitivity and
specificity that result from varying the diagnostic threshold.
Reference standard The best currently available diagnostic test against which the index test is compared.
Sensitivity Proportion of people with the target disorder who have a positive test result.
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Specificity Proportion of people without the target disorder who have a negative test result.
True negative Correct negative test result: number of non-diseased persons with a negative test result.
True positive Correct positive test result: number of diseased persons with a positive test result.
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Plain English summary
Stable angina is a type of chest pain; left untreated, it can lead to heart failure, heart attack andsudden death. To avoid these outcomes, patients may require surgical intervention to open
obstructed arteries, known as ‘revascularisation’.
Patients who might need revascularisation undergo tests to identify blocked arteries. The last line of
testing is called invasive fractional flow reserve assessment. This is an invasive measurement of blood
flow that involves inserting a wire into an artery after the patient has taken drugs to dilate the artery.
It carries some risks and may have side effects.
Non-invasive tests have been proposed to precede or replace invasive fractional flow reserve
assessments. These include QAngio® XA 3D/QFR® (three-dimensional/quantitative flow ratio)
(Medis Medical Imaging Systems BV, Leiden, the Netherlands) and CAAS® vFFR® (vessel fractional
flow reserve) (Pie Medical Imaging BV, Maastricht, the Netherlands) imaging software.
This project investigated whether or not these technologies can provide accurate assessments of blood
pressure, and if they are a reasonable use of NHS resources. A thorough review of all the literature on
the technologies was performed. All data were combined and re-analysed to determine whether or not
the tests accurately predict the need for revascularisation and to consider their clinical benefits. An
economic analysis was conducted to investigate whether or not using either of these technologies is
economically viable.
The project found that QAngio XA 3D/QFR can accurately measure blood flow, may be a reasonable
alternative to fractional flow reserve, pending more evidence on benefits to patients’ health, and is
a reasonable use of NHS resources. The current evidence for CAAS vFFR is too limited to draw any
firm conclusions.
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Scientific summary
Background
People with stable angina may require intervention known as ‘revascularisation’ to open obstructed
arteries. QAngio® XA 3D/QFR® (three-dimensional/quantitative flow ratio) (Medis Medical Imaging
Systems BV, Leiden, the Netherlands) and CAAS® vFFR® (vessel fractional flow reserve) (Pie Medical
Imaging BV, Maastricht, the Netherlands) imaging software are two non-invasive technologies used as
adjuncts to invasive coronary angiography. QAngio XA 3D/QFR measures the quantitative flow ratio
and CAAS vFFR measures the vessel fractional flow reserve of coronary lesions to assess the functional
significance of coronary stenoses. There is potential for these technologies to partially or wholly replace
invasive fractional flow reserve assessment as the last-line test to inform revascularisation decisions.
Objectives
This project aimed to evaluate the clinical effectiveness and cost-effectiveness of non-invasive
assessment of the functional significance of coronary stenoses, using QAngio XA 3D/QFR and CAAS
vFFR imaging software.
Methods
Systematic review
A systematic review of the diagnostic accuracy, clinical efficacy and practical implementation of QAngio
XA 3D/QFR and CAAS vFFR imaging software for assessing the functional significance of coronary
obstructions in people with intermediate coronary stenosis (i.e. stenoses where preceding tests have
been insufficient to make a revascularisation decision) was conducted.
Comprehensive bibliographic searches, including of MEDLINE and EMBASE™ (Elsevier, Amsterdam,
the Netherlands) and supplementary sources, were conducted up to 2 January 2020 for published and
unpublished literature.
Diagnostic accuracy and correlation studies in which any version of QAngio XA 3D/QFR or CAAS vFFR
were used, in addition to invasive fractional flow reserve (or instantaneous wave-free ratio) assessment
as a reference standard in the same patients, were included. Empirical studies of quantitative flow
ratio or vessel fractional flow reserve (with or without invasive fractional flow reserve assessment)
that reported relevant clinical outcomes (including morbidity and mortality) or issues relating to
implementation of quantitative flow ratio or vessel fractional flow reserve and their use in clinical
practice were also eligible. Patients with intermediate stenosis referred for invasive coronary
angiography to assess coronary stenosis and the need for revascularisation were eligible for inclusion.
Two researchers independently screened the titles and abstracts of all reports identified by the bibliographic
searches and of all full-text papers subsequently obtained for assessment. Data extraction and quality
assessment were conducted by at least one researcher and checked by a second. The risk of bias of
diagnostic accuracy studies was assessed using quality assessment of diagnostic accuracy studies.
For diagnostic accuracy outcomes, bivariate models were fitted to calculate summary estimates of
sensitivity and specificity with 95% confidence intervals using aggregate data and data extracted from
study plots. Additional diagnostic accuracy results that could not be pooled in a meta-analysis and
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clinical effectiveness and implementation outcomes were synthesised narratively. Data from figures
reported in studies were digitised to simulate the accuracy of a ‘grey-zone’ strategy, whereby confirmatory
fractional flow reserve is performed only in patients with a quantitative flow ratio between 0.78 and 0.84.
Economic analysis
Cost-effectiveness literature on QAngio XA 3D/QFR and CAAS vFFR was reviewed. The titles and
abstracts of all reports identified by the bibliographic searches were screened independently by two
researchers. A subsequent pragmatic review of existing decision models evaluating invasive coronary
angiography and/or fractional flow reserve/invasive fractional flow reserve was also conducted by one
researcher, and key findings were summarised narratively.
A decision-analytic model was developed to estimate the cost-effectiveness of QAngio XA 3D/QFR
and CAAS vFFR used during invasive coronary angiography for assessing the functional significance
of coronary stenosis in patients with stable angina whose angiograms show intermediate stenosis.
Five diagnostic strategies were considered: (1) invasive coronary angiography alone, (2) invasive coronary
angiography followed by confirmatory fractional flow reserve/invasive fractional flow reserve (reference
standard), (3) invasive coronary angiography with quantitative flow ratio, (4) invasive coronary
angiography with quantitative flow ratio, followed by confirmatory fractional flow reserve/invasive
fractional flow reserve when quantitative flow ratio is inconclusive, and (5) invasive coronary angiography
with vessel fractional flow reserve.
The decision model had two components: a diagnostic element and a prognostic element. The diagnostic
component was used to link the diagnostic accuracy of quantitative flow ratio and vessel fractional flow
reserve to short-term costs and consequences [e.g. the impact on the proportion of patients who need
revascularisation (percutaneous or surgical), the proportion of patients who need invasive functional
assessment of stenosis using fractional flow reserve or invasive fractional flow reserve in strategy 4,
and adverse event rates and health-related quality of life associated with the diagnostic interventions],
whereas the prognostic component was used to link the short-term consequences to longer-term costs
and consequences (e.g. the risk of major adverse cardiovascular events including myocardial infarction,
sudden cardiac death and need for urgent/unplanned revascularisations) to ensure that differences in
costs, life-year gains and quality-adjusted life-years were appropriately quantified over a lifetime horizon.
Results
A total of 41 studies were included in the systematic review, of which 39 (5440 patients) evaluated
QAngio XA 3D/QFR and three (500 patients) assessed CAAS vFFR. Only one study directly
compared QAngio XA 3D/QFR with CAAS vFFR. A total of 17 included studies were reported only
as conference abstracts.
Most studies included a mix of patients with stable and unstable coronary syndromes. Stenosis severity
varied widely across studies; mean/median fractional flow reserve ranged from 0.75 to 0.88, and mean
percentage diameter stenosis from 37% to 66%. Only seven studies were conducted prospectively, and
11 studies (all of QAngio XA 3D/QFR) were rated as being at low risk of bias.
Diagnostic accuracy
The average difference between quantitative flow ratio (measured using QAngio XA 3D/QFR) and
fractional flow reserve was 0.01. In 50% of patients, quantitative flow ratio and fractional flow reserve
differed by no more than 0.04; in 95% of patients, values differed by no more than 0.14. The
quantitative flow ratio was highly correlated with the fractional flow reserve (r = 0.8).
The QAngio XA 3D/QFR quantitative flow ratio had good diagnostic accuracy to predict fractional
flow reserve (≤ 0.80 cut-off point); contrast-flow quantitative flow ratio had a sensitivity of
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85% (95% confidence interval 78% to 90%) and a specificity of 91% (95% confidence interval 85% to
95%); fixed-flow quantitative flow ratio mode had a sensitivity of 82% (95% confidence interval 68% to
91%) and a specificity of 89% (95% confidence interval 77% to 95%). Where reported, quantitative
flow ratio had significantly higher diagnostic accuracy than standard invasive coronary angiography.
Data on how diagnostic accuracy may vary by key patient characteristics were too limited to draw
any firm conclusions.
Using data extracted from figures, simulating a grey-zone strategy, where only patients with a QAngio
XA 3D/QFR quantitative flow ratio between 0.78 and 0.84 receive confirmatory fractional flow reserve,
improved diagnostic accuracy compared with quantitative flow ratio alone to a sensitivity of 93.1%
(95% confidence interval 90.1% to 94.9%) and a specificity of 92.1% (95% confidence interval 88.3% to
94.5%). A total of 20.1% patients fell in the grey zone and would receive confirmatory fractional flow
reserve. However, only 30.4% of patients with quantitative flow ratio results in the grey zone had results
that were discordant with their fractional flow reserve.
Only three retrospective studies of CAAS vFFR were available, limiting the scope for reliable meta-analysis.
Only one conference abstract directly compared the diagnostic accuracy of QAngio XA 3D/QFR and CAAS
vFFR with fractional flow reserve. The abstract reported that QAngio XA 3D/QFR quantitative flow ratio
had a higher overall diagnostic accuracy, with areas under the curve of 0.719 (95% confidence interval
0.621 to 0.804) for vessel fractional flow reserve and 0.886 (95% confidence interval 0.807 to 0.940)
for contrast-flow quantitative flow ratio.
Clinical effectiveness
No evidence was found on the effectiveness of QAngio XA 3D/QFR on major cardiovascular events
and death. Three studies that reported clinical outcomes found that QAngio XA 3D/QFR may predict
long-term major cardiovascular adverse events.
A simulation study based on the results of the meta-analysis found that using quantitative flow ratio in
place of fractional flow reserve may slightly increase the number of revascularisations (from 40.2% to
42.0%), with a possible small increase in the number of coronary events (an extra one major adverse
cardiac event per 1000 patients). Using a grey-zone approach of performing a confirmatory fractional
flow reserve where the quantitative flow ratio is close to 0.8 might further increase revascularisations
rates (to 43.2%) but with no impact on incidence of major adverse cardiac events.
Cost-effectiveness
No full cost-effectiveness studies of QAngio XA 3D/QFR or CAAS vFFR were identified by the
systematic review. The pragmatic review identified 21 relevant reports, of which two studies were
selected to inform the conceptualisation of the de novo decision model.
The base-case cost-effectiveness results showed that the test strategy with the highest net benefit
(most cost-effective strategy) was invasive coronary angiography followed by confirmatory fractional
flow reserve/instantaneous wave-free ratio (strategy 2), at a cost-effectiveness threshold of £20,000 per
quality-adjusted life-year gained. However, the difference in net benefit (i.e. the additional health gains
net of health losses in the health-care system due to additional costs, expressed in health or monetary
terms) between this strategy and the next best strategies was relatively small at 0.007 quality-adjusted
life-years (or equivalently £140) per patient diagnosed for invasive coronary angiography with
quantitative flow ratio (strategy 3), 0.012 quality-adjusted life-years (or equivalently £240) per patient
diagnosed for invasive coronary angiography with quantitative flow ratio, followed by confirmatory
fractional flow reserve/instantaneous wave-free ratio when quantitative flow ratio is inconclusive
(strategy 4), and 0.011 quality-adjusted life-years (or equivalently £220) per patient diagnosed for
invasive coronary angiography with vessel fractional flow reserve (strategy 5). The cost-effectiveness
results for strategy 5 must be interpreted with caution because of very limited number of data
available from diagnostic accuracy studies of vessel fractional flow reserve.
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Discussion
This review includes a comprehensive systematic review of all the published literature on quantitative
flow ratio as assessed by QAngio XA 3D/QFR and CAAS vFFR and has been conducted following
recognised guidelines to ensure high quality. The review identified a substantial literature on the
diagnostic accuracy of QAngio XA 3D/QFR, so the findings of the analysis of diagnostic accuracy are
likely to be conclusive.
Although there is substantial evidence demonstrating the good diagnostic accuracy of quantitative flow
ratio assessment using QAngio XA 3D/QFR overall, it remains largely unclear which patient or lesion
characteristics might significantly affect the diagnostic accuracy of QAngio XA 3D/QFR.
The clinical value of QAngio XA 3D/QFR to support decision-making on revascularisation remains
uncertain, particularly regarding what impact it might have on preventing or causing future coronary
events, and whether the 0.8 cut-off point or the proposed grey zone are clinically appropriate.
However, it appears unlikely that its clinical value or use will differ substantially from widespread use
of fractional flow reserve.
The key drivers of cost-effectiveness were (1) the diagnostic sensitivity of test results (rather than
specificity) because ‘true-positive’ test results translated into higher quality-adjusted life-year gains
than mismanagement of ‘false-negative’ test results, (2) the procedural quality-adjusted life-year loss
associated with fractional flow reserve/instantaneous wave-free ratio, (3) the magnitude and duration
of the quality-adjusted life-year gains associated with revascularisation and (4) the additional costs
associated with confirmatory testing with fractional flow reserve/instantaneous wave-free ratio.
Conclusions
Quantitative flow ratio measured using QAngio XA 3D/QFR has good agreement and diagnostic accuracy
compared with fractional flow reserve and is more accurate than standard invasive coronary angiography
for the evaluation of functionally significant stenoses. The good association between quantitative flow
ratio and fractional flow reserve, and the high diagnostic accuracy of quantitative flow ratio, suggest that,
pending further evidence on clinical benefits, quantitative flow ratio assessment could represent a
reasonable alternative to invasive fractional flow reserve, particularly where fractional flow reserve is
not available. The cost-effectiveness of QAngio XA 3D/QFR suggests that it is a reasonable use of NHS
resources, as it is only marginally less cost-effective than invasive fractional flow reserve assessment.
Evidence on the CAAS vFFR technology was limited to three studies. This prevented any full
meta-analyses of diagnostic accuracy for CAAS vFFR, or any assessment of its clinical effectiveness.
The cost-effectiveness results for CAAS vFFR should be interpreted with caution because of the
limited diagnostic information available.
Recommendations for research
The substantial existing evidence for diagnostic accuracy of QAngio XA 3D/QFR suggests that further
studies of diagnostic accuracy are not required. Large, multicentre prospective studies are required to
assess the diagnostic accuracy and clinical feasibility of CAAS vFFR. Ideally these should compare
CAAS vFFR with invasive coronary angiography assessment and, if possible, with quantitative flow ratio.
Large ongoing randomised trials will hopefully inform decision-makers of the clinical value of
quantitative flow ratio compared with angiography and fractional flow reserve-guided revascularisation.
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Study registration
This study is registered as PROSPERO CRD42019154575.
Funding
This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis
programme and will be published in full in Health Technology Assessment; Vol. 25, No. 56. See the NIHR
Journals Library website for further project information.
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Chapter 1 Background
Description of the health problem
Stable angina is a type of chest pain caused by insufficient blood supply to the heart, brought on by
physical activity or emotional stress, which goes away with rest. It is the key symptom of coronary
artery disease (CAD), which remains one of the main causes of morbidity and mortality in high-
income countries. Complications include unstable angina, heart failure, myocardial infarction (MI) and
sudden death.
To alleviate symptoms, patients may receive ‘revascularisation’ to open damaged, obstructed or
blocked arteries. This most commonly consists of inserting a small tube or ‘stent’ into the artery to
keep it open and allow blood flow. Patients who might need revascularisation undergo a number of
tests to identify blocked arteries, including coronary computed tomography angiography (CCTA) and
other non-invasive tests. If these tests are inconclusive, more invasive tests are needed, for example
invasive coronary angiography (ICA), where a contrast medium is injected through a catheter into the
coronary arteries and radiographic images (angiograms) are taken.
Angiograms have limited ability to differentiate between arteries with inadequate blood supply
(which need revascularisation) and those with adequate supply that do not need treatment. To address
this, the procedure may be combined with an invasive measurement of blood flow, such as invasive
fractional flow reserve (FFR) assessment. During this procedure, the blood flow is measured by inserting
a wire into the coronary arteries after the patient has taken drugs to dilate the artery. The procedure is
invasive and, therefore, carries some risks and may have side effects.
The Health Survey for England 2017: Adult Social Care1 reported that the prevalence among adults of
ever having ischaemic heart disease (including MI and angina) was 4%. The prevalence was higher
among men (6%) than women (3%) and increased with age (3% in people aged 45–54 years, 16% in
people aged > 75 years). Prevalence of angina and history of angina among all adults was 3%.
Description of the technologies under assessment
Non-invasive imaging tests have been proposed to precede or replace invasive FFR, by using the
existing angiograms to determine blood flow, without inserting a wire.
QAngio XA 3D/QFR
QAngio® XA 3D/QFR® (three-dimensional/quantitative flow ratio) (Medis Medical Imaging Systems BV,
Leiden, the Netherlands) imaging software is used to perform quantitative flow ratio (QFR) assessment
of coronary artery obstructions. It is designed to be used with all ICA systems: biplane or monoplane.
It uses two standard two-dimensional (2D) angiographic projections, taken at least 25° apart – ideally
between 35° and 50° apart – to create a three-dimensional (3D) reconstruction of a coronary artery;
this shows the QFR values across the artery. QFR is an assessment (by frame count) of the pressure
(blood flow velocity) drop over the artery, with a value of 1 representing a normally functioning artery
with no pressure drop. A drop of ≥ 20 mmHg in blood pressure (QFR value of ≤ 0.8) is considered a
significant obstruction where revascularisation should be considered. QAngio XA 3D/QFR software
is installed on a laptop or workstation that is connected to the ICA system. The Digital Imaging and
Communication in Medicine (DICOM) data from ICA projections are immediately uploaded and viewable
on the connected workstation. The total time for data acquisition and analysis is about 4 to 5 minutes
(as reported by the company).
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AngioPLUS [Pulse Medical Imaging Technology (Shanghai) Co. Ltd, Shanghai, China] is an equivalent
Conformité Européenne-marked version marketed in Asia.
The QAngio XA 3D/QFR software offers two different flow models to calculate QFR:
1. fixed-flow quantitative flow ratio (fQFR), using fixed-flow velocity
2. contrast-flow quantitative flow ratio (cQFR), using contrast frame count in an angiogram
without hyperaemia.
Fixed-flow quantitative flow ratio is faster to compute, but may be less accurate than cQFR.
Furthermore, the QAngio XA 3D/QFR software provides four different QFR indices along the analysed
coronary segment:
1. vessel quantitative flow ratio (vQFR): the QFR value at the distal location of the analysed
vessel segment
2. index quantitative flow ratio (iQFR): a point that can be moved along the QFR pullback curve
3. lesion quantitative flow ratio (lQFR): the contribution to the QFR drop by the selected lesion alone
4. residual vQFR: an indication of the vQFR, if the selected lesion is resolved.
CAAS vFFR
The CAAS® vFFR® (vessel fractional flow reserve) (Pie Medical Imaging BV, Maastricht, the Netherlands)
workflow builds a 3D reconstruction of a coronary artery based on two standard angiograms and assesses
the pressure drop across the stenosis, and quantitative coronary arteriography (QCA) determines a vFFR
value. It gives both anatomical and functional assessment of the stenosis and can be integrated into
catheter laboratories. According to the company, the total time for analysis is approximately 2 minutes
per artery.
All available versions of CAAS (i.e. 8.0, 8.1 and 8.2) use the same algorithm for calculating vFFR. The
CAAS workstation provides various modules (e.g. QCA and left ventricular analysis), and the vFFR
module can be added to the CAAS workstation. In addition to the vFFR, CAAS vFFR provides
measurements at the end of the lesion and at a chosen position in the coronary artery.
Comparators
Invasive coronary angiography may differentiate between arteries with inadequate blood supply
(which need revascularisation) and those with adequate supply that do not need treatment.
During an ICA procedure, a coronary diagnostic catheter is inserted into an artery and moved up
the aorta and into the coronary arteries. A special type of dye called contrast medium is injected
through the catheter into the coronary artery and angiograms are taken. Although providing valuable
information on coronary artery anatomy, visual assessment of angiograms taken during ICA may have
limited ability to differentiate between functionally significant (causing inadequate blood supply) and
non-significant (not significantly affecting blood supply) coronary stenoses.
When ICA is inconclusive, it may be combined with the invasive measurement of FFR. In these
procedures FFR is assessed invasively by advancing a pressure wire towards the stenosis and
measuring the ratio in pressure between the two sides of the stenosis during maximum blood flow
(induced by adenosine infusion). This is associated with risks related to the passage of a guide wire,
side effects of adenosine and additional radiation exposure. The invasive FFR measurement is also
associated with increased procedural time and costs compared with ICA alone. As an alternative to
invasive FFR, the instantaneous wave-free ratio (iFR) may be used. This also uses inserted pressure
wires to assess flow but does not require vasodilator drugs, such as adenosine.
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Current service provision and care pathways
Patients who experience chest pain and may need revascularisation will be assessed for angina and
other cardiovascular conditions. When clinical assessment alone is insufficient for a diagnosis, patients
are referred for a 64-slice (or above) CCTA as the first-line diagnostic test.
Patients may go on to further diagnostic testing. National Institute for Health and Care Excellence (NICE)
guidance2 recommends offering non-invasive functional imaging for myocardial ischaemia if a 64-slice (or
above) CCTA has shown CAD of uncertain functional significance, or is non-diagnostic. This could include:
l myocardial perfusion scintigraphy (MPS) with single-photon emission computed
tomography (SPECT)
l stress echocardiography
l first-pass contrast-enhanced magnetic resonance (MR) perfusion
l MR imaging for stress-induced wall motion abnormalities.
In addition, NICE’s medical technologies guidance3 recommends that HeartFlow FFRCT (HeartFlow, Inc.,
Redwood City, CA, USA) should be considered as an option for patients with stable, recent-onset chest
pain who are offered 64-slice (or above) CCTA. It provides both functional and anatomical assessment
of coronary arteries and has better diagnostic performance than CCTA alone or other non-invasive
or invasive tests. If these tests are also inconclusive, ICA is offered as a third-line diagnostic tool.
A diagnosis of stable angina is made when clinical symptoms are present and:
l Significant CAD is found during ICA or 64-slice (or above) CCTA. This is usually defined as ≥ 70%
diameter stenosis (DS) of at least one major epicardial artery segment, or ≥ 50% DS in the left main
coronary artery.
l Reversible myocardial ischaemia is found during non-invasive functional imaging.
Sometimes ICA is also used to guide treatment strategies for people with a confirmed diagnosis of
stable angina whose symptoms are not satisfactorily controlled with optimal medical treatment (OMT),
and so may require revascularisation. ICA may differentiate between arteries with inadequate blood
supply (which need revascularisation) and those with adequate supply that do not need treatment.
When ICA is used to determine the presence and severity of coronary stenosis and it is inconclusive,
it may be combined with the invasive measurement of FFR using a pressure wire, as recommended by
the European Society of Cardiology4 and American College of Cardiology.5 Lesions with a FFR of ≤ 0.80
are functionally significant and revascularisation may be considered. Should iFR be used, a measure of
≤ 0.89 is considered functionally significant.
Invasive coronary angiography is performed either in diagnostic-only ICA laboratories or in interventional
catheter laboratories as part of the initial stenosis assessment prior to percutaneous coronary intervention
(PCI). In diagnostic-only laboratories, patients in whom ICA alone is inconclusive might be referred to
an interventional laboratory for a FFR or iFR assessment. In interventional laboratories a FFR or iFR
assessment can be performed immediately after ICA, if needed.
The British Cardiovascular Intervention Society (BCIS)’s audit reports that 244,332 ICA procedures
took place in the UK in 2017/18 in NHS and private facilities, with 35,017 procedures performed in
diagnostic-only catheter laboratories.
There is substantial regional variation in the diagnostic pathway for stable angina, due in part to the
availability of imaging modalities at each centre, and experience (or preferences) of the cardiologists
referring for the test. Clinical advisors noted that the pathway recommended by NICE is widely
recognised as current best practice.
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Position of the technology in the diagnostic pathway
Either QFR or vFFR could potentially replace pressure wire FFR, or iFR, by providing a non-invasive
means to assess FFR as part of an ICA assessment in people with stable chest pain of recent onset.
Visual assessment of angiograms taken during ICA may be limited in its ability to differentiate between
functionally significant (causing inadequate blood supply) and non-significant (not significantly affecting
blood supply) coronary stenoses. Alternatively, they may be used as a precursor to invasive FFR, with
the invasive procedure used when QFR or vFFR is inconclusive.
In addition, QFR may be used in other aspects of decision-making, including whether to stent more
than one vessel or to select a stent type or other interventional device for revascularisation.
QAngio XA 3D/QFR and CAAS vFFR could also be used in diagnostic-only laboratories, possibly
reducing the need for referrals to interventional laboratories.
The QAngio XA 3D/QFR instructions recommend the following approach:
l QFR < 0.78 – treat the patient in the catheter laboratory
l QFR > 0.84 – follow the patient medically
l QFR 0.78–0.84 (grey zone) – verify by invasive FFR measurement.
Following request for clarification, Pie Medical Imaging stated that it recommends the same hybrid
approach for CAAS vFFR.
The likely pathway leading to invasive FFR, and including the probable placement of QFR and vFFR,
is summarised in Figure 1.
Diagnosis and
treatment
decision
(including the
need for
revascularisation)
64-slice (or above) CCTA
Non-invasive functional imaginga or FFRCT
Non-invasive functional assessment of stenoses
during invasive coronary angiography (QFR or vFFR)
Invasive functional assessment of stenoses during
invasive coronary angiography/PCI (FFR/iFR)
Invasive coronary angiography
Inconclusive results (QFR or vFFR value close to
the diagnostic cut-off point)
Inconclusive results (intermediate stenosis)
Inconclusive results or persistent symptoms 
despite optimal medical therapy
CCTA has shown CAD of uncertain
functional signif icance or is non-diagnostic
FIGURE 1 Diagnostic pathway for stable angina, including QFR or vFFR (from the NICE Diagnostics Assessment
Programme 48 final scope).6 a, Non-invasive functional imaging includes MPS with SPECT, stress echocardiography,
first-pass contrast-enhanced MR perfusion and MR imaging for stress-induced wall motion abnormalities. © NICE [2019]
QAngio XA 3D/ QFR and CAAS vFFR Imaging Software for Assessing the Functional Significance of Coronary
Obstructions During Invasive Coronary Angiography. Final Scope. Available from www.nice.org.uk/guidance/dg43/
documents/final-scope All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health
Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no
responsibility for the use of its content in this product/publication.
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Chapter 2 Aims and objectives
The aim of the project is to determine the clinical effectiveness and cost-effectiveness of non-invasiveassessment of the functional significance of coronary stenoses, using QAngio XA 3D/QFR and CAAS
vFFR imaging software.
To achieve this, the following objectives were set:
l Clinical effectiveness –
¢ To perform a systematic review and meta-analysis of the diagnostic accuracy and, where
feasible, clinical efficacy of the QAngio XA 3D/QFR imaging software and CAAS vFFR software
used during ICA for assessing the functional significance of coronary obstructions in people with
stable chest pain whose angiograms show intermediate coronary stenosis.
¢ To perform a narrative systematic review of the clinical efficacy and practical implementation
of QAngio XA 3D/QFR and CAAS vFFR imaging software. This includes assessment of the
associated revascularisation rates, mortality and morbidity, patient-centred outcomes, adverse
events and acceptability to clinicians and patients.
l Cost-effectiveness –
¢ To perform a systematic review of published cost-effectiveness studies of the use of the QAngio
XA 3D/QFR and CAAS vFFR imaging software for assessing the functional significance of
coronary stenosis in people with stable chest pain whose angiograms show intermediate stenosis.
¢ To develop a decision model to estimate the cost-effectiveness of the QAngio XA 3D/QFR and
CAAS vFFR imaging software used during ICA to indicate whether or not coronary obstructions
are functionally significant. Consideration will be given to differences in the cost-effectiveness of
the technologies in diagnostic-only or in interventional catheter laboratories.
¢ The decision model will link the diagnostic accuracy of QFR derived from the QAngio XA 3D/QFR
imaging software, and vFFR derived from the CAAS vFFR software, to short-term costs and
consequences (e.g. the impact on the number of revascularisations needed, the proportion of people
who need invasive functional assessment of stenosis, time to test results, and associated risks of the
diagnostic intervention). It will link the short-term consequences to potential longer-term costs and
consequences (e.g. major cardiovascular events such as MI and sudden cardiac death, adverse events
related to revascularisation and diagnosis, and mortality) using the best-available evidence.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
The systematic review was conducted following the general principles recommended in the Centre for
Reviews and Dissemination (CRD) guidance and reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.7
Searches
Comprehensive searches of the literature were conducted to systematically identify all studies relating
to QAngio XA 3D/QFR and CAAS vFFR imaging software.
The searches were carried out during October 2019, with a further updated search undertaken on
2 January 2020. The following databases were searched: MEDLINE, PubMed, EMBASE™ (Elsevier,
Amsterdam, the Netherlands), the Science Citation Index (Clarivate Analytics, Philadelphia, PA, USA),
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials (CENTRAL),
Health Technology Assessment (HTA) database and EconLit (American Economic Association, Nashville,
TN, USA).
Ongoing and unpublished studies were identified by searches of ClinicalTrials.gov; Conference
Proceedings Citation Index: Science (Clarivate Analytics); EU Clinical Trials Register; Open Access
Theses and Dissertations; ProQuest® (ProQuest LLC, Ann Arbor, MI, USA) Dissertations & Theses A&I;
PROSPERO; the World Health Organization’s International Clinical Trials Registry Platform portal; and
manufacturer websites. Abstracts from any recent conferences that are thought to be relevant to the
review were also consulted.
A search strategy for Ovid® (Wolters Kluwer, Alphen aan den Rijn, the Netherlands) MEDLINE is
reported in Appendix 1. The MEDLINE strategy was translated to run appropriately on the other
databases and resources. No language or date restrictions were applied to the searches. No study
design search filters were used.
Reference lists of relevant recent reviews8 were checked to identify additional potentially relevant reports.
Database searches were carried out to identify cost-effectiveness studies where ICA (alone and/or
with FFR) was one of the interventions under comparison. The following databases were searched:
EconLit, EMBASE, HTA database, MEDLINE and NHS Economic Evaluation Database (NHS EED).
The search strategies for EconLit, EMBASE and MEDLINE are reported in Appendix 1.
Pragmatic supplementary PubMed and Google Scholar (Google Inc., Mountain View, CA, USA) searches
were carried out to identify studies of diagnostic data on ICA compared with FFR.
Contact with study authors and manufacturers and request for individual participant data
An individual participant data (IPD) meta-analysis of four studies that has previously been performed
was eligible for this review.8 The review authors contacted the study authors prior to commencing this
assessment, and the study authors agreed, in principle, to share the collected IPD with the review
authors for the purposes of this work. However, because of the slow response from the study authors,
the IPD could not be supplied in time for this report, and the decision was made not to pursue an IPD
analysis. Instead, published data and data presented in figures were used. Where possible, IPD-equivalent
data were extracted from plots using a digitising software. See Data extraction for further detail.
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Selection criteria
Two reviewers independently screened all titles and abstracts. Full papers of any titles and abstracts
that were thought to be relevant were obtained where possible, and the relevance of each study
assessed independently by two reviewers according to the criteria below. Any disagreements were
resolved by consensus or by consulting a third reviewer. Conference abstracts were included where
sufficient data were reported to confirm eligibility. Authors were contacted where insufficient data
were reported to confirm inclusion (for instance, to clarify what index test was used in the study, or to
provide complete 2 × 2 data) and where it was unclear whether or not the same diagnostic accuracy
results were presented in more than one report (e.g. conference abstracts linked to a publication).
Diagnostic accuracy
Included were diagnostic accuracy and correlation studies in which QFR using any version of the
QAngio® system (Medis Medical Imaging Systems BV) or CAAS vFFR were performed in addition to
invasive FFR (or iFR) as a reference standard in the same patients. Only prospective and retrospective
cohorts were included. Case–control studies, letters, editorials and reviews were excluded.
Clinical effectiveness/implementation
Included were observational studies where QFR or vFFR (with or without invasive FFR) have been used
and that report relevant clinical outcomes as detailed. Relevant publications reporting issues related to
implementation of, or practical advice for, QFR or vFFR and their use in clinical practice were also
eligible. Case reports and studies focusing only on technical aspects of QFR or vFFR (such as technical
descriptions of the testing process or specifications of machinery and software) were excluded.
Participants
Patients with intermediate stenosis (however defined) who are referred for ICA to assess coronary
stenosis and the need for revascularisation were included. Although the main focus of this assessment
was on patients with stable chest pain (either suspected stable angina or confirmed angina that is not
adequately controlled by treatment), patients with all types of angina (including unstable, non-specific
and atypical) were eligible for inclusion. Patients with acute MI [ST segment elevation myocardial
infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) < 72 hours] were also
included provided QFR was performed in non-culprit vessels.
Interventions
All versions of QAngio XA 3D/QFR (including AngioPlus) and CAAS vFFR imaging software used in
conjunction with ICA to allow simulation of FFR were included.
All submeasurements of QFR were eligible, including cQFR and fQFR. Eligible health-care settings
were diagnostic-only and interventional catheter laboratories.
Reference standard
The reference standard was FFR assessed using an invasive pressure wire with or without adenosine.
iFR, which was found to be non-inferior to FFR for predicting cardiovascular events and all-cause
mortality,9 was also accepted as a reference standard.
Outcomes
The eligible outcome measures relating to diagnostic accuracy were:
l sensitivity and specificity of QAngio XA 3D/QFR and CAAS vFFR
l positive predictive values (PPVs) and negative predictive values (NPVs)
l estimates of difference in measurements between QFR or vFFR and invasive FFR/iFR (including
Bland–Altman assessments)
l correlation between QFR or vFFR and invasive FFR/iFR measurements.
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Some studies reported differences or concordance between QFR or vFFR and invasive FFR/iFR in
numerous ways, including inter- and intra-rater differences in measurements, mean differences (MDs),
correlation coefficients, sensitivity and specificity, or receiver operating characteristic (ROC) curves.
All relevant outcome definitions and cut-off points were extracted and their applicability to the
decision problem accounted for when presenting the results. Diagnostic accuracy results of ICA
alone were considered if reported alongside QFR or CAAS vFFR.
In addition, the following clinical outcomes were eligible:
l morbidity, mortality and major adverse cardiac events (MACEs) (e.g. MI, heart failure)
l adverse events related to the diagnostic procedure (e.g. pressure wire damage, adenosine side
effects, stroke)
l adverse events related to revascularisation
l distress, anxiety and similar harms caused by QAngio XA 3D/QFR, CAAS vFFR, invasive FFR or iFR
l subsequent use of invasive pressure wire FFR or iFR
l subsequent revascularisation procedures performed (including unscheduled revascularisations)
l number of vessels with stent placements
l health-related quality of life (HRQoL)
l radiation exposure.
Eligible outcomes related to the implementation of the interventions of interest and related practical
issues included:
l acceptability of QFR, vFFR and invasive FFR (to clinicians and patients)
l test failure rates
l inconclusive test rates
l inter-observer variability
l timing of results from data acquisition
l referral times
l patient satisfaction
l training requirements
l uptake and compliance.
Data extraction
A standardised data extraction form was developed, piloted and finalised to data-extract both study
and patient characteristics and eligible outcomes. For studies reporting diagnostic accuracy data, the
number of true-positive (TP), true-negative (TN), false-positive (FP) and false-negative (FN) results
were extracted for each index test evaluated in each study, along with sensitivity and specificity data,
the area under the curve (AUC) and 95% confidence intervals (CIs) and PPVs and NPVs. Whether
diagnostic accuracy was determined per patient, vessel or lesion was recorded.
Where not reported, sensitivity and specificity were calculated if data allowed. Further data were
requested from study authors when required. Correlation and MD between QFR/vFFR and FFR were
recorded along with reasons for any excluded, failed or inconclusive results and any other relevant
clinical outcomes from the studies.
As IPD could not be supplied, digitised data were extracted using WebPlotDigitizer (Ankit Rohatg,
Pacifica, CA, USA) software to approximately reconstruct the individual-level data from included
studies. Data were extracted for all studies that presented a Bland–Altman or correlation plot.
Bland–Altman plots were preferred for extraction, as these were found to be generally clearer and
easier to extract. The extracted averages and differences between QFR and FFR were converted into
QFR and corresponding FFR values for each study. For some studies, the quality of published figures
was not sufficient to extract data.
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Data were extracted by one reviewer using a standardised data extraction form and independently
checked by a second reviewer. Discrepancies were resolved by discussion, with involvement of a third
reviewer when necessary. Data from relevant studies with multiple publications were extracted and
reported as a single study. The most recent or most complete publication was used in situations where
we could not exclude the possibility of overlapping populations across separate study reports.
Critical appraisal
The quality of the diagnostic accuracy studies was assessed using the Quality Assessment of Diagnostic
Accuracy Studies-2 (QUADAS-2) tool. The QUADAS-2 tool evaluates both risk of bias (associated
with the population selection, index test, reference standard and patient flow) and study applicability
(population selection, index test and reference standard) to the review question. The tool was piloted on
a sample of studies. Signalling questions and criteria for decisions were finalised following piloting.
The quality assessments were performed by one reviewer and independently checked by a second reviewer.
Disagreements were resolved through consensus and, when necessary, by consulting a third reviewer.
Methods of data synthesis
The results of data extraction were presented in structured tables and as a narrative summary,
grouped by population and test characteristics. The diagnostic accuracy was calculated for each study
based on extracted data, using the usual index test of QFR ≤ 0.8 and reference standard of FFR ≤ 0.8
as defining patients in need of stenting. Where sufficient clinically and statistically homogenous data
were available, data were pooled using appropriate meta-analytic techniques. Studies that did not
report sufficient information to derive 2 × 2 data (from tables, text or plots) were not included in the
meta-analysis and were synthesised narratively.
Statistical analysis of diagnostic accuracy
Meta-analysis using 2 × 2 diagnostic data
The primary meta-analyses in this report were based on studies that reported 2 × 2 diagnostic data,
or where data could be reconstructed from tables. Both univariate meta-analysis and bivariate meta-
analysis of sensitivity and specificity10 were performed and compared, categorised according to ‘mode’
of QFR used: either fQFR, cQFR or non-specified QFR (referred to as QFR). These analyses included all
patients, vessels and lesions. Results are reported in forest plots and summarised in tables and ROC plots.
Separate (univariate) meta-analyses were performed for each diagnostic outcome [sensitivity,
specificity, PPV and NPV, diagnostic odds ratio (DOR), area under ROC curve, correlation between
QFR and FFR, and MD between QFR and FFR] and presented in forest plots.
A hierarchical bivariate generalised linear mixed model, as described by Simmonds et al.,11 was fitted to
the data to calculate summary estimates of sensitivity and specificity and the associated 95% CIs. The
same model was used to produce summary ROC curves, using the Rutter and Gatsonis formulation for
the hierarchical summary receiver operating characteristic (HSROC) curve.11,12 Results are presented in
ROC plots. Unless otherwise specified, all analyses used a cut-off point for the index test of QFR ≤ 0.8
and reference standard of FFR ≤ 0.8 as defining patients in need of revascularisation.
As some studies reported data on two or more tests (e.g. QFR and ICA or fQFR and cQFR), the
bivariate model was extended to include diagnostic accuracy parameters for multiple tests, which
allowed for formal comparison between models in terms of sensitivity and specificity.11
Investigation of heterogeneity and subgroup analyses
For diagnostic accuracy data, we visually inspected the forest plots and ROC space to check for
heterogeneity between study results. To assess the impact of patient factors, we performed meta-
regressions of sensitivity, specificity and DOR against key patient parameters reported in papers.
All meta-regressions were univariate analyses (i.e. one patient parameter per metaregression).
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Where available, we considered the following factors as potential sources of heterogeneity:
l type and severity of stenosis (e.g. high percentage DS)
l multivessel CAD
l diffuse CAD
l multiple stenoses in one vessel
l microvascular dysfunction (e.g. caused by diabetes)
l chronic total occlusion
l diabetes
l sex
l age
l ethnicity (or study location as a proxy for ethnicity)
l results of previous non-invasive tests
l use of fQFR compared with cQFR (QAngio XA 3D/QFR)
l previous MI.
For these analyses fQFR was not separated from cQFR; instead, one test per study (cQFR for
preference) was analysed to maximise data. This was judged to be reasonable given that diagnostic
accuracy did not appear to vary substantially according to the type of QFR used.
Where studies reported the factors of interest separately by subgroup, these subgroup results were
compared; however, these were too sparsely reported to permit any meta-analysis. For patient factors
where data did not allow for metaregression, a narrative synthesis of the impact of covariates has
been provided.
Sensitivity analyses
We conducted sensitivity analyses to explore the robustness of the results according to study quality
based on QUADAS-2 domain results (e.g. risk of incorporation bias) and study design (e.g. in-procedure
compared with retrospective evaluation of index test results) for diagnostic accuracy studies. ROC plots of
sensitivity and specificity according to risk of bias were produced to visually assess possible bias.Where
feasible, bivariate meta-analyses were repeated, subgrouped according to the assessed risk of bias.
Meta-analysis of data extracted from figures
Using data extracted from figures, estimates of sensitivity and specificity were calculated and presented
on forest plots and in the ROC space to examine the variability in diagnostic test accuracy within
and between studies. These were compared with the diagnostic accuracy results from 2 × 2 table to
investigate whether or not the extracted data could be used for analysis. The bivariate meta-analyses
performed using 2 × 2 data were repeated using the extracted figure data.
Grey-zone analysis
Extracted figure data were used to conduct an analysis where testing includes a grey zone of intermediate
QFR values for which a FFR would be performed as a confirmatory test. The grey-zone diagnostic
procedure considered, following the QAngio XA 3D/QFR instructions, was:
l perform the QFR
l if the QFR is > 0.84, continue without stenting/bypass (test negative)
l if the QFR is ≤ 0.78, proceed to stenting/bypass (test positive)
l if the QFR is between 0.78 and 0.84, perform a FFR test and proceed to stenting/bypass if the FFR
≤ 0.80 (the grey zone).
For the grey-zone analysis, it was assumed that anyone in the grey zone has perfect diagnostic
accuracy (because all received a ‘gold standard’ FFR test); therefore, FPs and FNs are present only in
patients outside the grey zone. The impact of using the grey zone on the diagnostic accuracy of QAngio
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XA 3D/QFR was assessed. The effect of using different FFR thresholds on the diagnostic accuracy of
QAngio XA 3D/QFR was also assessed. Owing to the limited data on CAAS vFFR, no such analyses
were performed for this technology.
Narrative synthesis
Evidence related to clinical effectiveness and implementation of QFR, vFFR and invasive FFR were too
limited to allow meta-analysis. Results were tabulated and presented narratively. Conclusions of these
studies suggested consequences for QFR and ICA and recommendations for practice, and suggested
needs for further research were summarised.
Narrative summaries were used for any diagnostic accuracy outcomes where meta-analyses or other
statistical analyses were not feasible. This included tabulating or plotting results as reported in studies,
and narratively describing and comparing these results.
Statistical analysis of clinical effectiveness
The systematic review identified very few published data on the clinical impact of using QFR and
QAngio screening. In particular, very few data were found on the impact that QFR (with or without a
grey zone) might have on future incidence and prevention of coronary events. Therefore, to investigate
what the clinical impact of using QFR testing might be, a simulation study was performed to identify
the impact that QFR and invasive FFR assessment might have on the number of revascularisations
performed, and on morbidity and mortality and other longer-term outcomes. This simulation used two
key sources of data:
1. The data on FFR and QFR measurements extracted from published Bland–Altman figures were
used as a representative population of patients with intermediate stenosis, with FFR and QFR
measurements for each patient.
2. The IRIS-FFR study13 reported the association between FFR and coronary events in patients who
are revascularised and in patients where revascularisation is deferred. These data were used to
calculate the risk of coronary events, and then to simulate events for each patient in our sample
population (from point 1), given their observed FFR measurement.
Combining these two data sources produced a simulated data set where each patient had the
following data:
l a FFR measurement
l the associated QFR measurement
l the risk of a coronary event if revascularisation were performed
l the risk of a coronary event if revascularisation were deferred
l whether or not the patient had a coronary event (if revascularised)
l whether or not the patient had a coronary event (if deferred).
Three strategies for deciding on whether or not to revascularise were considered:
1. FFR only – perform FFR on all and revascularise if the FFR is ≤ 0.8
2. QFR only – perform QFR on all and revascularise if the QFR is ≤ 0.8, without FFR measurement
3. grey zone – perform a QFR and:
¢ revascularise if the QFR is ≤ 0.78
¢ defer if the QFR is > 0.84
¢ if the QFR is between 0.78 and 0.84, perform FFR and revascularise if the FFR is ≤ 0.8.
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Applying these strategies to the simulated data set, the following data were calculated for each strategy:
l the proportion of patients who would be revascularised
l the total number of coronary events
l the proportion of patients who would undergo unnecessary revascularisation (i.e. revascularised, but
would not have had an event if revascularisation were deferred)
l the proportion of patients in whom revascularisation prevented an event (i.e. are revascularised, and
would have had an event if revascularisation were deferred)
l the proportion of patients in whom revascularisation caused an event (i.e. who would have an event
after being revascularised, but would not have had an event if revascularisation were deferred).
These results were then compared across strategies to investigate how the differing strategies might
alter the incidence of coronary events.
Detailed simulation methods
The sample population for the simulation was taken to be the data extracted from published Bland–Altman
figures. For this analysis, fQFR data were excluded and only cQFR or non-specified QFR data were used,
making a total of 3193 patients, each with a FFR measurement and its associated QFR measurement.
As these data were extracted from figures, they may not be a perfect representation of the actual study
patients (see Data extraction). The simulation did not differentiate between studies, so the patients were
treated as if they came from a single ‘mega-study’.
To predict coronary outcome in this sample population, the results of the recent IRIS-FFR registry
report were used, representing 5846 patients who were either ‘revascularised’ (stent or bypass surgery)
or ‘deferred’ (continued with current management without surgery) based on their measured FFR result.
The IRIS-FFR study13 used major cardiovascular events (MACE, a composite of cardiac death, MI and
repeated/emergency revascularisation) as its primary outcome. The mean incidence rate from MACE
in deferred patients was 1.44 events per 100 lesion-years. For simplicity, it was assumed that each
person has one lesion, equating to a 1.44% risk in 1 year. Based on data reported in the publication, this
equated to a risk of 0.64% at a FFR of exactly 1. According to IRIS-FFR, most of these events are later
revascularisations. The hazard ratio (HR) for MACE was estimated as 1.06 per 0.01 decrease in FFR.
It was assumed that the 1-year relative risk (RR) is the same as this HR. In patients with revascularisations,
the mean risk of MACE was 2.4% in 1 year, with a HR of 1 (so risk is the same regardless of FFR value).
Based on those risks, the predicted risk of MACE for every person in the sample population was
calculated using their reported FFR measurement (this means that risk is not dependent on QFR).
A risk of event if revascularised and a risk if deferred was calculated. A Monte Carlo simulation was
then used to simulate whether or not each person had a MACE if they were ‘deferred’ or if they were
revascularised, based on the calculated risks. Therefore, the incidence of simulated events is solely a
function of FFR values and knowing that the QFR has no impact on risk of MACEs. The simulation
process was repeated 10,000 times to produce a reasonable sample of plausible simulations.
For each simulated sample, who would and would not be revascularised was determined for each of
the three strategies listed above. Given that, and the known MACE status for each patient, the five
statistics in the list above were calculated. The results were pooled across simulations to find median
values across simulations and to plot distributions across all simulations.
All statistical analyses were conducted in R software, version 3.6 or later (The R Foundation for
Statistical Computing, Vienna, Austria).
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Quantity and quality of evidence available
A total of 1248 unique references were screened for eligibility, and 41 unique studies were included
in the systematic review.14–54 A total of 39 studies evaluated QAngio XA 3D/QFR,14–17,20–55 and three
studies evaluated CAAS vFFR.18,19,26 One study directly compared CAAS vFFR with QAngio XA 3D/QFR.26
Full lists of all included references, ongoing studies and studies excluded at full-text screening stage are
presented in Appendix 2, Tables 33–35.
Two studies did not report diagnostic accuracy data, but included other eligible outcomes.25,30
All other studies were included in the diagnostic accuracy review, of which 33 were included in a
meta-analysis.15–21,23,24,26–32,34,35,37,39–46,48–54 Seventeen were conference abstracts.14,16,18,22,25–31,35,36,38,39,44,54
Figure 2 presents an overview of the study selection process.
Characteristics of included studies
Table 1 presents the characteristics of the studies included in the systematic review. Only seven
studies used QFR prospectively as part of the ICA examination preceding FFR.14,44,48–52 Fifteen studies
were conducted in multiple centres.15,22,24,26,34,37,38,41,45–47,50–52
Most studies were conducted in Asia, including Japan (33 studies),20–24,26–53 China (five studies),14,26,45,46,52
the Republic of Korea22,24,34,37 and Singapore.16
Records identif ied through 
database searching
(n = 1193)
Additional records identified
through other sources
(n = 55)
Records after duplicates removed
(n = 1248)
Records screened
(n = 1248)
Records excluded
(n = 1011)
Full-text articles assessed
for eligibility
(n = 237)
Full-text articles excluded,
 with reasons
(n = 136)
• Population, n = 22
• Index test, n = 47
• Reference standard,
    n = 20
• Outcomes, n = 6
• Design, n = 29
• Ongoing, n = 12
    (11 unique studies)
Studies included in
systematic review
n = 41 (of 101 records)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 33)
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FIGURE 2 Study selection process: PRISMA flow diagram.
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TABLE 1 Characteristics of studies included in the systematic review
Main studies
Single/
multicentre Country Population
Number of
patients
(vessels or
lesions)
Age
(years),
mean (SD)
Male,
%
Diabetes,
%
Acute MI,
%
FFR, mean (SD)
or median (IQR)
Mean
DS, %
Stable
angina, %
Stable
CAD, %
Previous
MI, %
Previous
PCI, %
QAngio XA 3D/QFR studies
Cliff (2019),16 conference
abstract
Single Singapore Acute MI and non-acute 33 (41) 59 (20) 69 30 5 NR NR NR NR NR NR
Cortés et al. (2019)17 Single Spain STEMI, > 50% DS in
non-culprit arteries
10 (12) 70 (9) 75 NR 100 0.87 (0.06) NR NR 0 NR NR
Emori et al. (2018)20 Single Japan Intermediate stenosis,
prior/non-prior MI
related
75 (75) 70 (9) 77 47 0 0.79 (0.11)
a
/
0.76 (0.13)
a
53 (14)
a
/
54 (14)
a
NR NR 50 51
Emori et al. (2018)21 Single Japan Intermediate stenosis 100 (100) 70 (10) 71 48 NR 0.75 (0.10) 55 (10) NR NR 22 NR
FAVOR II China: Xu et al.
(2017)52
Multi China CAD (suspected or
known)
308 (332) 61 (10) 74 86 14 0.82 (0.12) 46.5 (11.3) 23 34 48 65
FAVOR II Europe–Japan:
Westra et al. (2018)50
Multi Italy, the Netherlands,
Germany, Poland,
Spain, Japan,
Denmark
Stable angina or
secondary evaluation
post MI
272 (317) 67 (10) 72 29 2 0.83 (0.09) 45 (10) NR NR NR 40
FAVOR pilot: Tu et al.
(2016)46
Multi Belgium, Italy,
the Netherlands,
Germany, China,
Japan, USA
Stable angina, referred
for ICA and FFR
73 (84) 66 (9) 84 27 0 0.84 (0.08) 64.5 (4.5) 100 100 32 38
Goto et al. (2019),22
conference abstract
Multi Spain, Japan, the
Republic of Korea
Intermediate left main
stenosis
62 (NR) NR NR NR NR 0.76 (0.11) 44.1
(13,331.1)
NR NR NR NR
Hamaya et al. (2019)23 Single Japan Stable CAD, three-
vessel disease
NR (154) 68 (10) 76 38 0 NR 36.8 (14.4) NR 100 23 NR
Hwang et al. (2019)24 Multi The Republic of
Korea
Intermediate stenosis,
stable angina or acute
MI (NCLs)
264 (358) 61 (13) 77 33 31 0.80 (0.13) 0.531 NR 69 6 NR
Kajita et al. (2019),27
conference abstract
Single Brazil Stable CAD,
intermediate lesions
24 (34) NR NR NR NR NR NR NR NR NR NR
Kameyama et al.
(2016),28 conference
abstract
Single Japan ACS, emergency ICA,
NCLs
25 (26) NR NR NR 100 NR NR NR NR NR NR
Kanno et al. (2019),29
conference abstract
Single Japan Intermediate stenosis 95 (NR) NR NR NR NR NR NR NR NR NR NR
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TABLE 1 Characteristics of studies included in the systematic review (continued )
Main studies
Single/
multicentre Country Population
Number of
patients
(vessels or
lesions)
Age
(years),
mean (SD)
Male,
%
Diabetes,
%
Acute MI,
%
FFR, mean (SD)
or median (IQR)
Mean
DS, %
Stable
angina, %
Stable
CAD, %
Previous
MI, %
Previous
PCI, %
Kanno et al. (2019),30
conference abstract
Single Japan Intermediate stenosis,
de novo, deferred
revascularisation
212 (NR) NR NR NR NR 0.87 (0.84–0.90) NR NR NR NR NR
Kirigaya et al. (2019),31
conference abstract
Single Japan Stable CAD 95 (NR) NR NR NR NR NR NR NR NR NR NR
Kołtowski et al.
(2018)32
Single Poland Stable CAD 268 (306) 66 (10) 72 28 0 0.80 (0.10) 51.3 (10.2) NR 100 48 59
Kleczyński et al. (2019)33 Single Poland Stable angina,
intermediate stenosis
50 (123) 66 (9) 72 NR 0 0.82 (0.10) 44.2 (11.7) 100 100 NR NR
Liontou et al. (2019)34 Multi Spain, Japan, the
Republic of Korea
Intermediate in-stent
restenosis
73 (78) 68 (11) 81 30 6 0.79 (0.09) 51 (9) 69 69 58 100
Liu et al. 2017,35
conference abstract
Single The Netherlands Stable angina NR (45) NR NR NR NR NR NR NR NR NR NR
Mehta et al. (2019),36
conference abstract
Single Australia NR NR (85) NR NR NR NR 0.86 (0.09) NR NR NR NR NR
Mejia-Renteria et al.
(2019)37
Multi Spain, the Republic of
Korea, the Netherlands
Intermediate stenosis,
stable angina and acute
coronary syndrone
(including MI patients,
non-culprit arteries in
staged procedure)
248 (300) 64 (10) 76 38 17 0.80 (0.11) 52 (12) 70 70 14 NR
Neylon et al. (2016), 38
conference abstract
Multi France NR 36 (38) 64 (18) 66 NR NR 0.88 (0.11) NR NR NR NR NR
Sato et al. (2018),39
conference abstract
Single Japan Intermediate stenosis 68 (70) NR NR NR NR NR NR NR NR NR NR
Smit et al. (2019)40 Single The Netherlands Referred for FFR
following ICA in
diagnostic-only setting
290 (334) 67 (9) 69 24 0 0.85 (0.01) 43.1 (8.5) NR NR 16 33
Spitaleri et al. (2018),41
reproducibility cohort
Multi Italy ACS, multivessel
disease, staged
procedure
31 (34) 64 (12) 81 10 100 NR 59 (13) NR NR 10 19
Spitaleri et al. (2018),41
diagnostic accuracy
cohort
Multi Italy STEMI, multivessel
disease
45 (49) 62 (11) 80 9 100 0.84 (0.11) 66 (10) NR 0 4 4
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Main studies
Single/
multicentre Country Population
Number of
patients
(vessels or
lesions)
Age
(years),
mean (SD)
Male,
%
Diabetes,
%
Acute MI,
%
FFR, mean (SD)
or median (IQR)
Mean
DS, %
Stable
angina, %
Stable
CAD, %
Previous
MI, %
Previous
PCI, %
Spitaleri et al. (2018),41
clinical outcomes cohort
Multi Italy, Spain, the
Netherlands
STEMI, multivessel
disease
110 (NR) 64 (12) 81 22 100 NR 62 (11) NR NR 8 6
Stähli et al. (2019)42 Single Germany Intermediate and
less severe stenosis
(DS 40–70%), stable
and unstable angina
436 (516) 72 68 23 4.1 (NSTEMI) 0.88 (0.82–0.92) 41
(median)
NR 72 33 55
SYNTAX II: Asano et al.
(2019)15
Multi Belgium, the
Netherlands, Spain,
UK
Three-vessel disease 386 (836) 67 (10) 93 32 NR 0.78 (0.73–0.84) NR NR NR 13 NR
Ties et al. (2018)43 Single The Netherlands Stable and unstable
CAD
96 (101) 64 (10) 60 25 16.7 (NSTEMI) 0.87 (0.08) 43.4 (8.4) NR 51 NR 24
Toi et al. (2018),44
conference abstract
Single Japan Stable angina,
intermediate stenosis
50 (NR) 69 (11) 78 43 NR 0.81 (0.09) NR NR NR NR NR
Tu et al. (2014)45 Multi Belgium, Hungary,
China
Stable and unstable
CAD, intermediate
stenosis, de novo
lesions
68 (77) 62 (9) 69 29 0 0.82 (0.11) 46.6 (7.3) 77 87 NR 32
Van Diemen et al.
(2019),47 conference
abstract
Multi The Netherlands,
Canada, UK
NR NR (286) NR NR NR NR NR NR NR NR NR NR
van Rosendael et al.
(2017)48
Single The Netherlands Non-acute, eligible
for FFR
NR (15) 64 (11) 71 6 0 NR 38.7 (8.6) NR 100 6 24
Watari et al. (2019)49 Single Japan Stable CAD,
intermediate stenosis
121 (150) 71 (11) 68 36 3 (NSTEMI/
unstable
angina)
0.81 (0.12) 49 (9) 35 97 21 36
WIFI II: Westra et al.
(2018)51
Multi Denmark CAD, Referred from
CCTA
172 (240) 61 (8) 67 10 NR 0.82 (0.11) 50 (12) 31 NR NR NR
WIFI prototype study:
Andersen et al. (2017),14
conference abstract
NR Denmark (plus
China and the
Netherlands)
Stable angina and
secondary evaluation
after acute MI
93 (NR) NR NR NR NR 0.81 (0.09) 47 (9) NR NR NR NR
Yazaki et al. (2017)53 Single Japan Stable angina and
asymptomatic CAD
142 (151) 73 (10) 70 29 0.7 (NSTEMI/
unstable
angina)
0.84 (0.08) 48.8 (8.2) 51 99 21 41
Ziubryte et al. (2019),54
conference abstract
Single Lithuania Intermediate stenosis 62 (69) NR NR NR NR NR NR NR NR NR NR
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TABLE 1 Characteristics of studies included in the systematic review (continued )
Main studies
Single/
multicentre Country Population
Number of
patients
(vessels or
lesions)
Age
(years),
mean (SD)
Male,
%
Diabetes,
%
Acute MI,
%
FFR, mean (SD)
or median (IQR)
Mean
DS, %
Stable
angina, %
Stable
CAD, %
Previous
MI, %
Previous
PCI, %
CAAS vFFR studies
FAST-EXTEND: Daemen
et al. (2019)18
Single The Netherlands Stable or unstable
angina or NSTEMI
303 (NR) 65 (11) 67 NR NR 0.84 (0.07) NR NR NR NR NR
ILUMIEN I: Ely Pizzato
et al. (2019)19
Single USA Stable CAD, unstable
angina and non-STEMI
undergoing PCI. FFR
measured pre and
post PCI
115 (115) 65 (10) 76 37 11 0.76 (0.12) 53.3 (18.2) 63 67 24 NR
Jin et al. (2019),26
conference abstract
Multiple China, UK Intermediate stenosis 82 (101) NR NR NR NR NR NR NR NR NR NR
ACS, adult cardiac surgery; FAVOR, Functional Assessment by Virtual Online Reconstruction; IQR, interquartile range; NCL, non-culprit lesion; NR, not reported; SD, standard deviation; WIFI, wire-free invasive
functional imaging.
a Prior MI subgroup; no prior MI subgroup.
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Twenty-one studies were conducted in Europe, including Belgium,15,45,46 Denmark,14,50,51 France,38
Germany,42,46,50 Hungary,45 Italy,41,46,50 Lithuania,54 the Netherlands,15,18,35,37,40,41,43,46–48,50 Poland,32,33,50
Spain15,22,34,37,41,50 and the UK.15,26,47 Two studies were conducted in the USA,19,46 one in Brazil,27 one in
Australia36 and one in Canada.47 Eleven studies included an international cohort.14,15,22,26,34,37,41,45–47,50
The QAngio XA 3D/QFR studies analysed a total of 5440 patients (over 6524 vessels or lesions), and
CAAS vFFR studies analysed a total of 500 patients (over 519 vessels or lesions). Most studies included
a mixed population of stable and unstable CAD, although 11 studies focused only on patients with
stable CAD.23,27,31–33,35,44,46,48,49,53 Three studies evaluated non-culprit vessels in patients with MI,17,28,41
two focused exclusively on patients with three-vessel disease,15,23 one study included only patients with
intermediate left main stenosis (mostly left main bifurcation)22 and one focused specifically on in-stent
restenosis.34 Where reported, mean age ranged from 59.0 to 72.5 years, and most participants were
male (60–93%). Patient history and stenosis severity varied widely across studies. The prevalence of
diabetes ranged from 6% to 48%, rates of previous MI from 4% to 58%, and previous PCI 4% to 65%
(not accounting for one study with 100% in-stent restenosis).34 The mean/median FFR ranged from
0.75 to 0.88, and mean DS from 37% to 66%.
Quality of diagnostic accuracy studies
Table 2 summarises the results of the risk-of-bias and applicability assessment for QAngio XA 3D/QFR
for the 24 diagnostic accuracy studies reported in a full-text manuscript, with further details reported in
Appendix 3, Tables 36 and 37. The risk of bias from the 15 studies included in the diagnostic accuracy
review that were reported only as conference abstracts was not formally assessed because of insufficient
reporting.14,16,18,22,25–31,35,36,38,39,44,54 Just as with FAST-EXTEND,18 the extension of the FAST study was
reported as conference abstract only; only the quality of the earlier FAST study was assessed.56
A total of 11 out of the 22 QAngio XA 3D/QFR studies were rated as being at low risk of bias across
all domains.20,21,37,41,42,45,46,49–52 The main source of bias was related to study participant selection;
four studies were considered at high risk of patient selection bias because of high rates of patient
exclusions or significant exclusion of potentially harder to diagnose patients,17,23,24,32 and three studies
did not provide sufficient information on patient selection to assess risk of selection bias (unclear
risk).34,43,48 Exclusion rates and reasons are reported in Appendix 3, Table 37. Risk of bias was rated as
being generally low for other domains, although three studies were rated as being at high risk of bias
because of the conduct of the index test or reference standard (e.g. no reporting of blinding between
QFR and FFR results),33,48,53 and one study was rated as being at high risk of bias because of patient
flow concerns, as FFR was performed only in iFR grey-zone patients.15
The ILUMIEN I19 trial was the only CAAS vFFR complete study with a full-text manuscript. The study was
rated as being at high risk of bias because of the large percentage of lesions excluded from the study
(65%). In an earlier published report of the FAST-EXTEND study, Masdjedi et al.56 also reported a high
rate of exclusions (54%). Although most of these failed tests appear to have been due to angiographic
image processing issues rather than limitations inherent in CAAS vFFR (see Test failures: rates and
reasons), the large exclusion rates reported mean that the risk of selection bias cannot be excluded.
Only three studies raised no concerns about their applicability to the review question.48–50 The main
concern about applicability related to QFR being used retrospectively (offline) rather than as part of
the ICA examination and before FFR; only five studies (all of QAngio XA 3D/QFR) were conducted
prospectively and raised no significant concerns regarding the applicability of the index test.48–52 There
were no significant concerns regarding the applicability of the reference standard in any of the studies.
A total of 12 out of the 22 QAngio XA 3D/QFR studies did not raise significant concerns about the
applicability of their population to the review question;23,32,33,37,40,42,45,46,48–50,53 concerns about study
population applicability were primarily related to the under-representation of patients with stable CAD.
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We note that, because only patients with a FFR measurement could be included in the diagnostic
accuracy review, a subset of patients with intermediate stenosis (including those examined in
a diagnostic-only setting, or with a counter-indication to adenosine) are not represented in the
included evidence.
Seven studies of QAngio XA 3D/QFR14,15,41,45,48,51,52 and one of CAAS vFFR18 reported a conflict of
interest with their respective manufacturers.
TABLE 2 Risk of bias and applicability for diagnostic accuracy studies (QUADAS-2)
Study
Risk of bias Applicability
Patient
selection
Index
test
Reference
standard Flow
Patient
selection
Index
test
Reference
standard
Cortés et al. (2019)17 – + + ? – – +
Emori et al. (2018)20 + + + + ? – +
Emori et al. (2018)21 + + + + ? – +
FAVOR II China: Xu et al. (2017)52 + + + + – + +
FAVOR II Europe–Japan:
Westra et al. (2018)50
+ + + + + + +
FAVOR pilot: Tu et al. (2016)46 + + + + + – +
Hamaya et al. (2019)23 – + + + + – +
Hwang et al. (2019)24 – + + + – – +
Kleczyński et al. (2019)33 + – + + + – +
Kołtowski et al. (2018)32 – + + + + – +
Liontou et al. (2019)34 ? + + + – – +
Mejia-Renteria et al. (2019)37 + + + + + – +
Smit et al. (2019)40 + – – + + – +
Spitaleri et al. (2018)41
(cohort B, diagnostic accuracy)
+ + + + – – +
Stähli et al. (2019)42 + + + + + – +
SYNTAX II: Asano et al. (2019)15 + + + – – – +
Ties et al. (2018)43 ? + + + – – +
Tu et al. (2014)45 + + + + + – +
van Rosendael et al. (2017)48 ? – – ? + + +
Watari et al. (2019)49 + + + + + + +
WIFI II: Westra et al. (2018)51 + + + + – + +
Yazaki et al. (2017)53 + + – + + – +
CAAS vFFR
ILUMEN I: Ely Pizzato et al.
(2019)19
– + + + + – +
FAST: Masdjedi et al. (2020)56 – + + + + – +
+, rated as being at low risk of bias or no significant concerns about applicability to the review question; –, rated as
being at high risk of bias or significant concerns about applicability; ?, rated as being at unclear risk of bias or unclear
about applicability; FAVOR, Functional Assessment by Virtual Online Reconstruction; WIFI, wire-free invasive
functional imaging.
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Overview of the meta-analyses (QAngio XA 3D/QFR)
Meta-analysis of the included studies is focused on the diagnostic accuracy of QFR (measured using
QAngio XA 3D/QFR) to detect lesions or vessels requiring intervention (defined as having a FFR ≤ 0.8).
There were insufficient data to perform meta-analyses of any clinical outcomes; these are discussed in
Clinical outcomes.
Diagnostic accuracy of QFR was analysed in two ways. The first, and primary, analysis consists of a
meta-analysis of reported diagnostic accuracy data (TPs, TNs, FPs and FNs) in studies where these data
were reported or could be derived from reported estimates of sensitivity and specificity. The second
approach was to extract data on FFR and QFR values in each study from published Bland–Altman
plots, or plots of FFR compared with QFR, and to use these to calculate diagnostic accuracy. This
approach may be less accurate, because extracting data from figures is imperfect, but it allowed for a
wider range of analyses, such as considering different QFR and FFR cut-off points, and the impact of
using a grey zone where patients with intermediate QFR values go on to receive confirmatory FFR.
This second approach is considered in Meta-analyses of data extracted from figures (QAngio XA 3D/QFR).
Of all the included studies of QAngio XA 3D/QFR, 26 reported sufficient diagnostic accuracy data to be
included in the primary meta-analysis of diagnostic accuracy (four studies23,34,44,48 were included only in
analyses of data extracted from plots). These are divided into three ‘modes’ of QFR: fQFR, cQFR and studies
where the type of QFR was not specified (listed as QFR or non-specified QFR). Most studies included in the
primary analysis used FFR as the reference standard for determining whether or not intervention was
required, all of these used a cut-off FFR point of 0.8. One study49 used iFR as the reference standard.
Figure 3 shows the general sensitivity and specificity estimates for each study, assuming an index test
cut-off point of QFR ≤ 0.8 and a reference standard cut-off point of FFR ≤ 0.8. The results are plotted
separately for each mode of QFR testing. This suggests that specificity is uniformly high and generally
> 75% (except for two fQFR studies). Sensitivity is more heterogeneous, but is also > 75% in most
studies (except for fQFR). There are no immediately apparent differences in accuracy between the
three modes.
Univariate meta-analyses (QAngio XA 3D/QFR)
Figure 4 shows the forest plot for the univariate meta-analysis of sensitivity, and Figure 5 the same for
specificity. For the random-effect analyses, these show high sensitivity (82–85%) and high specificity
(89–91%) for all three models of QFR. cQFR had a sensitivity of 85% (95% CI 78% to 90%) and
specificity of 91% (95% CI 85% to 95%); fQFR had a sensitivity of 82% (95% CI 68% to 91%) and
specificity of 89% (95% CI 77% to 95%). Studies that did not specify the mode of QFR had a sensitivity
of 84% (95% CI 78% to 89%) and specificity of 89% (95% CI 87% to 91%). Across-study heterogeneity
was moderate to high (e.g. for cQFR sensitivity, I2 = 81%), but there does not appear to be any clear
evidence that the mode of QFR (fQFR vs. cQFR) makes a difference to diagnostic accuracy.
Summary PPVs (see Appendix 4, Figure 18) were 77% (95% CI 69% to 83%) for fQFR, 85% (95% CI 80%
to 89%) for cQFR and 80% (95% CI 76% to 84%) for non-specified QFR. Summary NPVs (see Appendix 4,
Figure 19) were 92% (95% CI 89% to 94%) for fQFR, 91% (95% CI 85% to 94%) for cQFR and 91%
(95% CI 87% to 93%) for non-specified QFR. It should be noted that PPV and NPV depend on the
distribution of FFR in each study, so summary results may not represent PPV or NPV in an ‘average’ study.
Meta-analyses of AUCs and DORs were also performed (see Appendix 4, Figures 20 and 21). Summary
AUCs were 87% (95% CI 83% to 92%) for cQFR, 89% (95% CI 86% to 92%) for fQFR and 92% (95% CI
90% to 94%) for non-specified QFR. Summary DORs were 3.51 (95% CI 2.71 to 4.30) for fQFR, 3.76
(95% CI 3.01 to 4.52) for cQFR and 3.71 (95% CI 3.27 to 4.15) for non-specified QFR.
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FIGURE 3 Sensitivity and specificity estimates for each study, by mode of QFR: (a) cQFR; (b) fQFR; and (c) QFR.
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As both FFR and QFR are continuous measurements, it is also important to consider the agreement
between FFR and QFR, in terms of the MD and variation between them, and their correlation. We
meta-analysed reported MDs between FFR and QFR measurements and reported correlations. Where
studies did not report the standard deviation (SD) of the MD, it was imputed by taking the average
value from studies that did report SDs.
The MD between QFR and FFR was almost exactly zero for all three modes of QFR testing (see
Appendix 4, Figure 22) [MD 0 (95% CI –0.05 to 0.06) for fQFR, –0.01 (95% CI –0.06 to 0.04) for cQFR;
and MD 0.01 (95% CI –0.03 to 0.05) for non-specified QFR]. FFR and QFR were highly correlated in all
Study TP (n) N Sensitivity
(95% CI)
0.88   (0.62 to 0.98)
0.95   (0.89 to 0.98)
0.87   (0.78 to 0.92)
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0.75   (0.65 to 0.84)
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FIGURE 4 Univariate meta-analysis of sensitivity. FAVOR, Functional Assessment by Virtual Online Reconstruction;
WIFI, wire-free invasive functional imaging.
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studies (see Appendix 4, Figure 23): correlation coefficient 0.78 (95% CI 0.72 to 0.82) for fQFR,
0.78 (95% CI 0.70 to 0.85) for cQFR and 0.79 (95% CI 0.73 to 0.83) for non-specified QFR. We note
that correlation coefficients are not a good measure of agreement between diagnostic tests; this
meta-analysis is included here for information only.
Bivariate meta-analysis (QAngio XA 3D/QFR)
The results of the full bivariate meta-analysis are summarised in Table 3 and Appendix 4, Figure 24.
The results are almost identical to the univariate analyses, with no evidence of differences between
fQFR and cQFR.
Study TN (n) N
0.5 0.6 0.7 0.8 0.9 1.0
Mode = QFR
Mode = cQFR
Mode = fQFR
1041
10 10
61 72
27 31
52 57
22 23
193 266
20
143 164
27 29
407 416
190
77 80
257
1481
50 50
26
48 72
49 57
193 215
25 25
112
402
74 80
416
176
1176
93
132
81
50
211
28
40 44
31
229
54
98
152
105
9 11
213
216
2319
198
185
 Sensitivity (95% CI)
0.83   (0.61 to 0.95)
0.92   (0.87 to 0.95)
0.87   (0.82 to 0.91)
0.82   (0.48 to 0.98)
0.91   (0.78 to 0.97)
0.90   (0.74 to 0.98)
0.92   (0.88 to 0.95)
0.93   (0.82 to 0.98)
0.83   (0.74 to 0.90)
0.87   (0.80 to 0.92)
0.89   (0.81 to 0.94)
0.89   (0.87 to 0.91)
0.89   (0.87 to 0.91)
1.00   (0.69 to 1.00)
0.85   (0.74 to 0.92)
0.87   (0.70 to 0.96)
0.91   (0.81 to 0.97)
0.96   (0.78 to 1.00)
0.73   (0.67 to 0.78)
0.77   (0.56 to 0.91)
0.87   (0.81 to 0.92)
0.93   (0.77 to 0.99)
0.98   (0.96 to 0.99)
0.74   (0.68 to 0.79)
0.96   (0.89 to 0.99)
0.86   (0.85 to 0.88)
0.91   (0.85 to 0.95)
0.67   (0.55 to 0.77)
0.86   (0.74 to 0.94)
0.90   (0.85 to 0.93)
1.00   (0.86 to 1.00)
0.64   (0.56 to 0.71)
0.97   (0.94 to 0.98)
0.92   (0.84 to 0.97)
0.87   (0.85 to 0.89)
0.89   (0.77 to 0.95)
1.00   (0.93 to 1.00)
Heterogeneity: I2 = 19%, τ2 = 0.0239; p = 0.31
Heterogeneity: I2 = 91%, τ2 = 0.9938; p < 0.01
Heterogeneity: I2 = 94%, τ2 = 1.1992; p < 0.01
Heterogeneity: I2 = 88%, τ2 = 0.6370; p < 0.01
Cliff and Ong (2019)16
FAVOR II China: Xu et al. (2017)52
FAVOR II Europe–Japan: Westra et al. (2018)50
Kameyama et al. (2016)28
Kirigaya et al. (2019)31
Sato et al. (2018)39
Smit et al. (2019)40
Tu et al. (2014)45
Watari et al. (2019)49
WIFI II: Westra et al. (2018)51
Yazaki et al. (2017)53
Fixed-effects model
Random-effects model
Cortés et al. (2019)17
Emori et al. (2018)20
Emori et al. (2018)21
FAVOR pilot: Tu et al. (2016)46
Kajita et al. (2019)27
Kanno et al. (2019)29
Liu et al. (2017)35
Mejia-Renteria et al. (2019)37
Spitaleri et al. (2018)41
Stähli et al. (2019)42
SYNTAX II: Asano (2019)15
Ties et al. (2018)43
Ziubryte et al. (2019)54
Fixed-effects model
Random-effects model
Emori et al. (2018)20
FAVOR pilot: Tu et al. (2016)46
Fixed-effects model
Random-effects model
Hwang et al. (2019)24
Kajita et al. (2019)27
Stähli et al. (2019)42
Ties et al. (2018)43
Kołtowski et al. (2018)32
FIGURE 5 Univariate meta-analysis of specificity. FAVOR, Functional Assessment by Virtual Online Reconstruction;
WIFI, wire-free invasive functional imaging.
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To include all studies in a single meta-analysis, and given the similarity of results across modes of QFR,
we performed a further bivariate meta-analysis that combined all studies using only a single ‘mode’ of
QFR from each. In practice, this meant combining studies with cQFR results with studies not specifying
how QFR was performed (and, as a result, excluding fQFR assessments). This might be expected to give
the most ‘optimistic’ estimate of diagnostic accuracy because fQFR is excluded. The results for this
combined analysis are also shown in Table 3. The results are, inevitably, very similar to those for cQFR
or non-specified QFR, but with narrower CIs. We note that this arguably represents the best summary
of the diagnostic accuracy of QFR, as it based on the maximum number of studies, but it is a post hoc
analysis not specified in the protocol.
The summary results and HSROC curves in Appendix 4, Figure 24, demonstrate the high diagnostic
accuracy of QFR and the similarity between the three analysed modes. The HSROC curve for fQFR
lies consistently below that for cQFR, suggesting a possibility that fQFR may have slightly inferior
diagnostic accuracy, but this difference is well within the bounds of uncertainty. This is in line with
the expected use of QFR, where cQFR is calculated when the fQFR is in the range of 0.70–0.85.
Meta-analysis of invasive coronary angiography studies
Five studies included in the meta-analysis also reported 2 × 2 table data on the diagnostic accuracy of
using ICA alone, using 50% DS as the cut-off point with FFR < 0.8 as the reference standard. These
five studies are summarised in Table 4. We note that reporting of diagnostic data on ICA may be
subject to selection bias, as only a small subset of studies reported it, and they are likely to do so to
demonstrate the superiority of using QFR over relying on ICA alone.
Given the limited number of studies, and because 2D and 3D ICAs may have very different
performance levels, no bivariate meta-analysis of these data are presented here. Based on the results
of individual studies, the diagnostic accuracy of ICA appears to be poorer than that of QFR.
Twelve included studies reported AUC estimates for diagnostic accuracy of using ICA alone. A meta-
analysis of these studies gave a summary AUC for 3D ICA of 0.71 (95% CI 0.66 to 0.76). For 2D ICA,
the summary AUC was 0.63 (95% CI 0.59 to 0.67). Both 2D and 3D ICA have lower AUC values than
QFR, and it appears that 2D ICA may be inferior to 3D ICA.
TABLE 3 Results of bivariate meta-analysis
Mode Sensitivity (%) (95% CI) Specificity (%) (95% CI)
cQFR 84.32 (77.29 to 89.48) 91.40 (84.96 to 95.24)
fQFR 81.61 (66.97 to 90.66) 89.43 (77.58 to 95.38)
Non-specified QFR 84.25 (78.51 to 88.68) 88.95 (87.02 to 90.61)
cQFR or non-specified QFR 84.34 (80.04 to 87.85) 89.80 (86.36 to 92.45)
TABLE 4 Diagnostic accuracy of included ICA studies
Study 2D or 3D n
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
FAVOR II China: Xu et al. (2017)52 2D 332 62.5 (53.5 to 71.5) 58.2 (51.7 to 64.7)
FAVOR II Europe–Japan: Westra et al. (2018)50 2D 317 44.2 (34.7 to 53.8) 76.5 (70.8 to 82.2)
FAVOR pilot: Tu et al. (2016)46 3D 84 44.4 (25.7 to 63.2) 78.9 (68.4 to 89.5)
Mejia-Renteria et al. (2019)37 3D 300 69.9 (62.1 to 77.6) 70.7 (63.8 to 77.7)
Stähli et al. (2019)42 3D 516 34.0 (24.7 to 43.3) 91.6 (88.9 to 94.3)
FAVOR, Functional Assessment by Virtual Online Reconstruction.
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Bivariate meta-analysis to compare tests
Eight studies in the meta-analysis compared two or more testing approaches: five of these compared
using 2D or 3D ICA to QFR, and five compared fQFR to cQFR. A ROC plot of results from studies
reporting two or more tests is shown in Appendix 4, Figure 25. In all five studies, ICA performed more
poorly than QFR, with lower sensitivity and specificity. Differences between fQFR and cQFR were
more mixed, with three studies suggesting that cQFR has slightly higher sensitivity than fQFR, but the
other two were not consistent with this.
An indirect comparative bivariate meta-analysis accounting for these comparisons between studies is
presented in Table 5 and Figure 6. These analyses show the clear inferiority of using ICA alone when
compared with FFR as a reference standard. It is clearly inferior to using QFR in both sensitivity and
specificity, with a sensitivity of only 51.2% and a specificity of 71.0%.
TABLE 5 Results of bivariate meta-analysis with comparison of tests
Mode Sensitivity (%) (95% CI) Specificity (%) (95% CI)
cQFR 83.97 (78.32 to 88.37) 89.59 (85.15 to 92.82)
fQFR 83.32 (76.42 to 88.50) 83.91 (76.91 to 89.08)
QFR 85.20 (79.76 to 89.38) 90.09 (85.80 to 93.19)
ICA 51.16 (41.86 to 60.38) 70.99 (62.39 to 78.30)
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FIGURE 6 A ROC plot of bivariate with comparisons of tests.
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Unlike the earlier bivariate meta-analysis (see Appendix 4, Figure 24), the comparative analysis suggests that
fQFR is slightly inferior to cQFR, mainly due to an inferior specificity (83.9% instead of 89.6%). This suggests
that fQFR produces slightly too many FP results (where QFR ≤ 0.8 but FFR > 0.8). This might suggest that if
an initial fQFR produces a result less than 0.8 it should be followed up by a confirmatory cQFR.
Impact of patient and study characteristics (QAngio XA 3D/QFR)
Impact of study characteristics
Receiver operating characteristic plots differentiating between studies reporting at patient, vessel
or lesion level found no evidence that this affects diagnostic accuracy (see Appendix 4, Figure 26).
There was also no evidence of any impact on diagnostic accuracy in studies where more than one
approach was reported. We note that, where there was more than one lesion assessed, ‘by-patient’ and
‘by-vessel’ analyses selected a single lesion (either at random or based on clinical importance), so a lack
of difference is unsurprising, as it would only arise if the choice of lesion was biased. It should also be
noted that by-lesion analysis could be biased because of correlation between lesions within patients.
Without full patient-level data, the impact this might have cannot be assessed.
There was no evidence of difference in diagnostic accuracy between prospective and retrospective
analyses of QFR (see Appendix 4, Figure 27).
Impact of patient factors
Few studies reported diagnostic accuracy data in any form according to different patient characteristics
(such as distinguishing between people with and without diabetes, or with and without multivessel
disease). The limited evidence reported is discussed in Clinical outcomes.
Given this lack of evidence, to investigate the impact on diagnostic accuracy of key patient factors we
have performed meta-regressions of sensitivity, specificity and DOR against the mean value of these
factors, where reported in papers. These analyses are obviously limited by being meta-regressions
of study-level proportions, rather than true analyses of patient-level data, and because of limited
reporting of these factors across studies. For these analyses we did not separate fQFR from cQFR but
used one test per study (cQFR for preference) to maximise data. This was considered reasonable given
that diagnostic accuracy does not strongly depend on the mode of QFR used.
Appendix 4, Table 38, shows the regression parameter estimates (change in log-DOR, sensitivity or
specificity per unit of the covariate), their 95% CIs and p-values from these metaregression analyses.
For most parameters there is no evidence of any association with diagnostic accuracy. However, this
may be due to a lack of data rather than no association.
Four patient factors (i.e. diabetes, stable CAD, multivessel disease and mean FFR) suggest a possibility of
association, as all have at least one p-value below 0.05. Plots of the proportions of patients with these
factors, against estimated sensitivity, specificity and log-DOR are shown in Appendix 4, Figures 28–31.
The association between diabetes and diagnostic accuracy is partly driven by one study where nearly all
patients had diabetes, but the trend for studies with more diabetic patients to have higher sensitivity
and DOR remains even if that study is removed. There is a trend for specificity and DOR to decline
as higher proportions of patients have stable CAD. Conversely, specificity and DOR increase as more
patients have multivessel disease (although this is based on only five studies32,37,41,42,51).
There is evidence that the lower the average FFR in a study, the higher the sensitivity and the lower
the specificity (but with no impact on the overall accuracy in terms of the DOR). We might therefore
also expect some variation in diagnostic accuracy with any factor that lowers FFR (DS, medical history,
etc.) but the data are too limited to confirm this.
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Subgroup analyses
Eleven studies reported diagnostic accuracy results stratified by patient or vessel characteristics20,21,24,29,32,
38,42,51,52,57,58 and four studies reported results of multivariate regression analyses of predictors of QFR/FFR
discrepancies.15,37,50,51 All studies were of QAngio XA 3D/QFR.
The number of subgroup analyses was too small to allow meta-analysis and results are summarised
narratively, and in figures. None of the analyses reported in the included studies was prespecified in a
prospectively registered protocol. All patient characteristics for which subgroup data were reported
were specified in the review protocol [high/low index of microcirculatory resistance (IMR) small/
non-small vessel diameter, multiple/single lesion, diabetes/no diabetes, MI history], except three
[left anterior descending (LAD)/no LAD vessel, chronic kidney disease (CKD) and acute MI], which
are presented for the sake of completion.
Appendix 4, Figure 32, shows a ROC plot for five studies reporting sensitivity and specificity by subgroups,
and Appendix 4, Figure 33, shows the DORs for the same studies. The results of subgroup analyses reported
in included diagnostic accuracy studies are summarised in Appendix 5, Tables 44 and 45.
Microcirculatory resistance
Two studies explored the effect of microcirculatory resistance on the accuracy of QAngio XA 3D/QFR
and showed inconsistent results.29,57 In both studies, patient populations were stratified according to
microcirculatory status, defined by the IMR, the product of hyperemic Tmn and hyperemic distal
arterial pressure and measured by pressure wire. Microcirculatory dysfunction was defined as ≥ 23 U
(predefined as 75th centile of IMR values) in one study57 and as ≥ 25 U in the other.29 Results differed
significantly between the two studies. Although both found a statistically significant difference in
diagnostic accuracy between high- and low-IMR groups, one study found that the accuracy of QAngio
XA 3D/QFR was reduced in patients with high IMR compared with low IMR [sensitivity 86% vs. 90%,
specificity 69% vs. 94%, AUC 0.88 vs. 0.96, odds ratio (OR) of misclassification 1.05 (95% CI 1.02 to
1.08)],57 whereas the other29 found that QAngio XA 3D/QFR had higher sensitivity but lower specificity
in the high-IMR group (sensitivity 96.7% vs. 81.5%, specificity 64.2% vs. 77.2%).
Vessel characteristics and location
There was limited evidence that vessel characteristics and location were associated with different rates
of QFR/FFR discrepancies, although two studies reported that vessels with bifurcation/trifurcation
lesions were associated with poorer diagnostic accuracy than other vessels. The SYNTAX59 trial found
that bifurcation/trifurcation were independent predictors for the increased incidence of FP QFR
(OR 1.81, 95% CI 1.10 to 2.98), and one small study of 38 vessels reported that bifurcations lesions
accounted for five out of six (83.3%) false measurements.38 One study22 that included only patients
with left main stenosis (85% left main bifurcation) had high sensitivity (84.8%) and moderate specificity
(68.2%) (AUC 0.82, 95% CI 0.71 to 0.93). No other studies reported on the potential impact of left
main stenosis on diagnostic accuracy.
Results from studies evaluating the effect of small vessel disease on diagnostic accuracy were mixed.
One study found higher sensitivity and AUC for cQFR in patients with small-vessel disease (≤ 2.8 mm
reference diameter), than in other patients [sensitivity 80.0% vs. 65.7%, specificity 98.5% vs. 97.2%,
AUC 0.89 (95% CI 0.85 to 0.93) vs. 0.81 (95% CI 0.76 to 0.86)],60 whereas another study found that
small-vessel disease (≤ 2.5 mm reference diameter) was associated with an increased incidence of FN
QFR (OR 1.67, 95% CI 1.14 to 2.44) in a multivariate analysis.15
One study found that found no significant differences in QAngio XA 3D/QFR accuracy between
subgroups with LAD and non-LAD coronary arteries,21 although a multivariate analysis from SYNTAX II15
found a non-statistically significant trend suggesting LAD may be associated with a higher rate of FPs
(OR 0.53, 95% CI 0.27 to 1.04), and that lesions located in side branches were associated with a higher
rate of FP QFR (OR 2.07, 95% CI 1.14 to 3.76) and FNs (OR 0.47, 95% CI 0.28 to 0.81).
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One study found no significant difference in MDs between QFR and FFR per lesion in patients with
single and multiple lesions,51 and multivessel disease was not a significant predictor of QFR/FFR
discrepancy in a multivariate analysis conducted by another study.37 Functional Assessment by Virtual
Online Reconstruction (FAVOR) II-China52 found that the accuracy of QAngio XA 3D/QFR in patients
with DS 40–80% did not differ from the whole study population results.
Comorbidities and other patient characteristics
There was also limited evidence on the impact of patient comorbidities on the accuracy of QAngio XA
3D/QFR.Two studies found no difference in diagnostic accuracy in subgroup analyses comparing patients
with and without diabetes.42,58 Smit et al.58 found similar accuracy in diagnostic accuracy between diabetics
and non-diabetics (sensitivity: 71.0% vs. 69.0%; specificity: 95.0% vs. 91.0%; AUC: 0.91 vs. 0.93; per-vessel
analysis). The results of per-patient analyses were also not statistically significant. Stähli et al.42 also found
no statistically significant difference in AUC between patients with and without diabetes [AUC 0.84
(95% CI 0.76 to 0.90) vs. 0.87 (95% CI 0.83 to 0.90)]. On the other hand, FAVOR II Europe–Japan50 found
in a multivariate regression that diabetes was associated with an increased chance of discrepancy between
QFR and FFR (OR 2.88, 95% CI 1.30 to 6.46).50 One study found a larger mean discrepancy between
QFR and FFR in a small subgroup of 21 patients with diabetes (MD –0.059± 0.07) compared with
173 non-diabetic patients (MD –0.027± 0.074);32 the difference between the subgroups was statistically
significant (p = 0.039), although no further diagnostic accuracy results were reported.
One study that compared results for vessels of stable CAD patients with non-culprit vessels in MI patients
found no significant difference in diagnostic accuracy between the two groups (sensitivity: 90.1% vs. 96.2%;
specificity: 89.5% vs. 90.6%; AUC: 0.946 vs. 0.967).24 However, in a multivariate analysis another study
found that acute coronary syndrome was associated with a significantly higher rate of misclassification
between QFR and FFR (OR 3.97, 95% CI 1.78 to 8.86).37 One study retrospectively compared single
vessels in groups of 75 patients with and without prior MI and found no significant difference for cQFR
and fQFR between the two groups.20 One study found a statistically significant difference in AUC between
patients with and without CKD [AUC: 0.67 (95% CI 0.46 to 0.88) vs. 0.89 (95% CI 0.84 to 0.94); p= 0.05].
No subgroup data were reported for the following review protocol variables: diffuse CAD, multiple
stenosis in one vessel, chronic total occlusion, sex, age, ethnicity and results of previous non-invasive
tests, although sex, age and chronic total inclusion were reported as non-significant variables in
reported regression analyses (see Appendix 5, Table 46).
Overall, results from subgroup and regression analyses were limited by the number of studies and
design issues such as small sample size and risk of confounding and should therefore be interpreted
with caution. There was some evidence suggesting that diagnostic accuracy of QFR is reduced in
bifurcation/trifurcation lesions. However, because of limited and sometimes inconsistent data there
is insufficient evidence to conclude that patient or lesion characteristics significantly affect the
diagnostic accuracy of QAngio XA 3D/QFR.
Sensitivity analyses
We performed a number of sensitivity analyses to examine the impact of QUADAS-2 risk-of-bias
assessment, QUADAS-2 applicability assessment and other potential causes of bias on the diagnostic
accuracy meta-analyses.
As noted in Impact of study characteristics there was no evidence that diagnostic accuracy varied by
whether studies collected data prospectively or retrospectively, or if the analysis was performed at
patient, vessel or lesion level.
Repeating the main bivariate meta-analyses [as in Bivariate meta-analysis (QAngio XA 3D/QFR)] by whether
the QUADAS-2 assessment was high risk of bias, low risk of bias or unclear (note that all conference
abstracts were classified as unclear in this analysis) for each QUADAS-2 category found no evidence of
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bias in diagnostic accuracy (see Appendix 4, Figure 34). There is no obvious pattern in the data for each
study (small dots) and bivariate meta-analyses by risk-of-bias assessment (larger dots with CIs) are
consistent between categories, and with the overall analysis.
Similar repetitions of the bivariate meta-analysis by applicability concerns from the QUADAS-2
assessment (see Appendix 4, Figure 35), and by other factors that might bias results (see Appendix 4,
Figure 36), likewise showed no evidence of actual bias in any analysis. One possible exception is that
studies in which patients did not have stable CAD had higher estimated sensitivity, but this was based
on three small studies. Removal of these studies would not meaningfully alter the main results.
Meta-analyses of data extracted from figures (QAngio XA 3D/QFR)
To further investigate the diagnostic properties of QFR, we digitally extracted data from all papers that
presented either a plot of FFR against QFR, or a Bland–Altman plot of QFR and FFR. We preferred
Bland–Altman plots for extraction, as these were found to be generally clearer and easier to extract.
All extraction was performed by a single reviewer using the WebPlotDigitizer software.
We used digitised data extraction to reconstruct, approximately, the individual-level data for all included
studies that presented a suitable figure. The extracted averages and differences between QFR and FFR
from Bland–Altman plots were converted into their equivalent QFR and FFR values. This extraction
generated, approximately, the FFR and corresponding QFR for each participant in each study.
The extraction could not be perfect; the digitally extracted points were placed with some minor errors
owing to overlap and low image quality. This meant that the number of extracted points was smaller
than the total number of participants. We note also that the set of studies is not the same as in
previous sections because some studies presented diagnostic accuracy results, but no figure, or vice
versa. In all analyses, we focus on cQFR or non-specified QFR; fQFR is excluded.
Figure 7 shows the complete extracted data for QFR compared with FFR, and Figure 8 a Bland–Altman
plot of all data. The different colours for the dots represent the separate studies. The pattern of data is
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FIGURE 7 Fractional flow reserve against QFR for data extracted from figures. Each colour represents a separate study.
The black line indicates where FFR=QFR. The upper-left shaded region shows the FNs where QFR > 0.8 but FFR ≤ 0.8
(6.5% of patients); the lower-right shaded region shows the FPs where QFR ≤ 0.8 but FFR > 0.8 (8.2% of patients).
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similar to that observed in most individual studies, with FFR and QFR being highly correlated (the
correlation coefficient across all data being 0.803). The distribution of data appears homogeneous across
studies; the data are centred around the line where FFR =QFR (black line in figures). The data seem to
broadly fit a highly correlated bivariate normal distribution, truncated at QFR and FFR values of 1.
In Figure 7, the upper-left shaded region shows the FNs where QFR > 0.8 but FFR ≤ 0.8 (6.5% of patients);
the lower-right shaded region shows the FPs where QFR ≤ 0.8 but FFR > 0.8 (8.2% of patients). Therefore,
a minority of patients fall in these regions.
The Bland–Altman plot shows that QFR and FFR values are generally similar: the average difference
between QFR and FFR is 0.001; 95% of QFR values are within 0.14 of the FFR, 90% are within 0.11
and 50% are within 0.04.
Meta-analysis of diagnostic accuracy
We calculated the diagnostic accuracy for each study based on extracted data, using the usual index
test of QFR ≤ 0.8 and reference standard of FFR ≤ 0.8 as defining patients in need of coronary
intervention. To investigate whether or not the extracted data could be used for analysis, we compared
these diagnostic accuracy results to the results from 2 × 2 tables [used in previous meta-analyses in
Bivariate meta-analysis (QAngio XA 3D/QFR)]. The extracted sensitivity and specificity estimates are
summarised in Appendix 4, Table 39. Overall, 30 studies reported either 2 × 2 table data or data that
could be extracted from a figure. Nine studies did not present an extractable figure, and three studies
presented a figure, but no summary data.
In general, the number of data points from the extracted figure data was smaller than that reported in
the studies. This is to be expected, as overlapping points will be missed when extracting from figures.
There is mostly good agreement in diagnostic accuracy between the data sources, except for a few
cases where the figure data have lower sensitivity and mostly lower specificity.24,40,52,61 Only one study28
had better diagnostic accuracy when using data extracted from figures. This consistency suggests that
using the extracted figure data for diagnostic analysis is reasonable, even though it represents a
smaller sample size. The results of performing a bivariate meta-analysis for diagnostic accuracy using
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FIGURE 8 Bland–Altman plot for data extracted from figures. Each colour represents a separate study. Black solid line
indicates the mean difference between FFR and QFR; black dotted lines indicate the 95% range of differences.
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the extracted figure data are shown in Appendix 4, Figure 37. The black points are the results in
each study, and the blue dot is the result of the meta-analysis (with its HSROC curve). The summary
sensitivity is 84.6% (95% CI 80.7% to 87.8%) and specificity is 87.2% (95% CI 83.4% to 90.3%). This
is similar to the results from the main analysis when cQFR and non-specified QFR were combined
(sensitivity 84.3%, specificity 89.8%), albeit with slightly lower specificity, further confirming that
analysing the extracted figure data are reasonable.
We note that this bivariate meta-analysis is presented to confirm that the extracted data reasonably
represent the properties of the included studies; the bivariate meta-analyses in Bivariate meta-analysis
(QAngio XA 3D/QFR) should be taken as the primary analyses.
Grey-zone analysis
The main purpose of extracting data from figures is to permit an analysis where testing includes a grey
zone of intermediate QFR values for which a FFR would be performed as a confirmatory test. The
grey-zone diagnostic procedure is:
l perform QFR
l if the QFR is > 0.84, continue without stenting/bypass and defer FFR (test negative)
l if the QFR is ≤ 0.78, proceed directly to stenting/bypass without FFR (test positive)
l otherwise, perform a FFR and proceed based on that result (i.e. at a 0.8 cut-off point) (the grey zone).
This means that for anyone within the grey zone there is perfect diagnostic accuracy, so FPs and FNs
occur only in patients outside the grey zone.
Appendix 4, Figure 38, shows the FFR and QFR data again, with the proposed grey zone highlighted.
In total, across studies, 20.1% of all patients lie within the grey zone (accordingly, up to 79.9% of
patients would theoretically have a wire-free and adenosine-free procedure in this scenario). Of these
grey-zone patients, 19.1% are TPs with both QFR and FFR below 0.8, and 50.2% are TNs with both
tests above 0.8. Only 18.3% are FNs and 12.4% FPs. Hence, only 30.4% of patients in the grey zone
have discordant FFR and QFR results (relative to the 0.8 threshold).
Within the grey zone, differences between FFR and QFR are small. This is shown in Appendix 4, Figure 39,
categorised by TPs, FPs, etc. Very few patients in the grey zone differ in test values by > 0.1, and most
differ by ≤ 0.05.
The diagnostic accuracy when using the grey zone improves, as would be expected, to a sensitivity of
93.1% (95% CI 90.1% to 94.9%) and a specificity of 92.1% (95% CI 88.3% to 94.5%). Appendix 4, Figure 40,
shows the result of this meta-analysis (with its HSROC curve) compared with the meta-analysis without
the grey zone presented in Bivariate meta-analysis (QAngio XA 3D/QFR). Clearly using the grey zone improves
diagnostic accuracy compared with QFR alone because of the 3.7% of patients reclassified from test
negative to positive and 2.5% who are reclassified in the opposite direction. However, this improvement
depends on assuming that the 0.8 threshold of FFR genuinely separates those who need intervention from
those who do not.
As an alternative to using the manufacturer-specified grey zone, we also examined what grey-zone
thresholds would be required to achieve a sensitivity and specificity of 90% and 95% respectively.
This is summarised in Appendix 4, Table 40. This suggests that the manufacturer-recommended grey
zone favours high sensitivity over high specificity.
Alternative fractional flow reserve thresholds
The IRIS-FFR study13 found that only for a FFR ≤ 0.75 did the risk of MACEs become significantly lower
in patients with revascularised lesions than in those in whom revascularisation was deferred. This
suggests that the current threshold of 0.8 for planning revascularisation may not be clinically appropriate.
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Using the extracted figure data, we can investigate the diagnostic accuracy of QFR compared with FFR at
other thresholds. For example, if the threshold for both QFR and FFR is 0.75 then the diagnostic accuracy
becomes a sensitivity of 75.4% (95% CI 69.0% to 80.8%) and a specificity of 90.6% (95% CI 87.9% to
92.7%). This is compared with the previous meta-analysis at the threshold of 0.8 in Appendix 4, Figure 41.
Using a 0.75 threshold leads to slightly lower sensitivity, but higher specificity. The two ROC curves,
however, are almost identical, suggesting no overall change in diagnostic accuracy.
Meta-analysis of extracted figure data for two-dimensional invasive coronary angiography
To inform the economic analyses an additional pragmatic search for studies that compared 2D ICA
with FFR assessment was performed to identify studies that presented sufficient granular data (such as
scatterplots or Bland–Altman plots) from which ICA and FFR data could be extracted. This search
identified four such studies (see Appendix 4, Table 41).62–65
Figure 9 shows the plot of all extracted data from these four studies. The colours of the dots indicate
the studies. It can be seen that, when compared with the equivalent figure for QFR (see Figure 7),
2D ICA is much more weakly correlated with FFR (correlation coefficient –0.432). There are many FNs
(bottom-left shaded region, 13.0% of patients) and FPs (top-right shaded region, 25.5% of patients)
when using 50% DS and the index test and FFR ≤ 0.8 as the reference standard.
We performed a bivariate meta-analysis of these extracted data, using the same approach as for
QAngio XA 3D/QFR. The summary sensitivity was 62.6% (95% CI 51.5% to 72.5%) and specificity
was 61.6% (95% CI 53.1% to 69.4%). This is a substantially lower diagnostic accuracy than for
QAngio XA 3D/QFR.
QAngio XA 3D/QFR: studies not included in meta-analysis
Appendix 5, Table 42, presents results from the six studies of QAngio XA 3D/QFR that reported diagnostic
accuracy results but were not included in the meta-analysis because of insufficient data.14,22,33,36,38,47
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FIGURE 9 Extracted data on 2D ICA compared with FFR. Each colour represents a separate study. Black line indicates
where FFR = ICA. The lower-left shaded region shows the FNs where ICA < 50% but FFR ≤ 0.8; the upper-right shaded
region shows the FPs where ICA > 50% but FFR > 0.8.
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All studies were reported as conference abstracts only (although one was subsequently published after
the cut-off date for conducting meta-analyses).33 One QAngio XA 3D/QFR prototype study recorded
QAngio XA 3D/QFR analyses prospectively (on-site analysis), and re-ran analyses retrospectively after
‘essential modifications’ (no further details reported). All other studies were retrospective and did not
report which version of QAngio XA 3D/QFR was used.22,33,36,38,47
The results broadly reflected the findings of the meta-analysis. All studies reported moderate to high
diagnostic accuracy for QAngio XA 3D/QFR compared with FFR. There was significant heterogeneity
in reported diagnostic accuracy estimates. Sensitivity ranged from 64.0% to 91.8%, and specificity from
68.2% to 97.3%. Where reported, PPV estimates ranged from 74.0% to 84.8% and NPV from 68.2%
to 93.0%. AUC ranged from 0.77 (95% CI 0.67 to 0.87) to 0.99 (95% CI 0.97 to 1.00). Correlation
coefficients (r) also varied significantly, ranging from 0.578 to 0.801.
The wire-free invasive functional imaging (WIFI) prototype study14 reported moderate sensitivity (0.64,
95% CI 0.48 to 0.77) and specificity (0.8, 95% CI 0.66 to 0.89) in its initial analyses. Following ‘essential
modifications’ (no further details reported) a blinded in-centre core laboratory reanalysis was performed,
and this improved both sensitivity (0.66, 95% CI 0.51 to 0.79) and specificity (0.86, 95% CI 0.73 to 0.93).
QAngio XA 3D/QFR: other modes
Three studies reported results for QAngio XA 3D/QFR modes other than cQFR and fQFR.32,46,48 Their
results are presented in Appendix 5, Table 43. Two small studies (n = 15 and 84 vessels) reported results
for adenosine–flow quantitative flow ratio (aQFR),46,48 and one larger study (n = 306 lesions) tested
iQFR, lQFR and vQFR.32 Sensitivity of aQFR per vessel ranged from 78% to 100%, and specificity from
91% to 93%; one study reported a high AUC (0.90, 95% CI 0.81 to 0.96) for aQFR, and similar results
in per-patient analyses. One study found that iQFR had higher diagnostic accuracy overall (sensitivity:
83.3%; specificity: 86.6%; AUC: 0.936) than vQFR (sensitivity: 90.5%; specificity: 69.7%; AUC: 0.900)
and lQFR (sensitivity: 91.1%; specificity: 71.7%; AUC: 0.822).
CAAS vFFR
The review identified four publications reporting the diagnostic accuracy of CAAS vFFR.18,19,26,56
One is the original FAST study of vFFR,56 and one is a conference abstract reporting an update to
FAST (FAST-EXTEND).18 There were two other independent studies, one of which has only been
published as a conference abstract.26 All studies performed CAAS vFFR analyses retrospectively
(offline), and two were conducted in a single centre.18,19 One study was funded by the CAAS vFFR
manufacturer.18 All studies compared CAAS vFFR with FFR as reference standard.18,19 One study was
funded by the CAAS vFFR manufacturer.18 Two studies included a mixed population of stable angina,
unstable angina or NSTEMI.18,19
We included only studies that explicitly reported that the CAAS system was used, or where this was
confirmed by the authors. Other studies of vFFR were identified but were not included if other
technologies were used or the precise technology used could not be determined. Further details on
excluded studies are reported in Appendix 2, Table 35. Only one of the studies19 reported a 2 × 2 table
of diagnostic accuracy, and only one56 presented a Bland–Altman plot, which we digitally extracted to
calculate diagnostic accuracy. The two conference abstracts reported only sensitivity and specificity without
CIs. To construct approximate CIs, we assumed that the proportion of patients with FFR ≤ 0.8 was 29%
(the rate observed in the FAST study56), and constructed 2 × 2 diagnostic data under that assumption.
Table 6 summarises the properties of the CAAS vFFR studies. The sensitivity and specificity from all
publications is summarised in Figure 10. There is notable heterogeneity across even this small number
of studies. In particular, the ILUMIEN I study19 found considerably lower sensitivity and specificity that
the FAST studies,18,56 and the Jin et al. study26 had lower sensitivity, but slightly higher specificity.
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TABLE 6 Properties of the CAAS vFFR studies
Study n Test
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
% AUC (95% CI) Correlation, r
Jin et al. (2019),26
conference
abstract
101 vessels
(82 patients)
CAAS vFFR 68.2 87.3 NR NR 0.719
(0.621 to 0.804)
NR
QAngio
XA 3D/QFR
(cQFR)a
83.5 31.9 NR NR 0.886
(0.807 to 0.940)
NR
QAngio XA
3D/QFR
(fQFR)a
72.7 89.9 NR NR 0.882
(0.803 to 0.938)
NR
ILUMIEN I:
Ely Pizzato
et al. (2019)19
115 lesions
(115 patients)
CAAS
vFFR 8.1
75.0* 46.5 70.1a 52.6a NR 0.449 (95% CI
0.290 to 0.584;
p < 0.0001)
FAST: Masdjedi
et al. (2020)56
100 patients CAAS vFFR NR NR NR NR 0.93
(0.88 to 0.97)
0.89
3D ICA NR NR NR NR 0.66
(0.55 to 0.77)
FAST-EXTEND:
Daemen et al.
(2019),18
conference
abstract
303 patients CAAS vFFR
8.0
97 74 85 89 0.95
(0.93 to 0.98)
0.89
3D ICA NR NR NR NR 0.63
(0.55 to 0.67)
NR
NR, not reported.
a ICA at lower radiation saved mode of 7.5 frames/second.
FAST-EXTEND (2019)18
ILUMIEN I (2019)19
Jin et al. (2019)26
Masdjedi et al. (2019)56
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FIGURE 10 Sensitivity and specificity of CAAS vFFR studies.
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Bivariate meta-analysis (CAAS vFFR)
The results of bivariate meta-analysis of these studies are presented in Table 7. It should be noted that,
because there are only three independent studies, and as data had to be imputed, meta-analyses of
these studies may not be robust, and are included only to permit some comparison with QAngio XA
3D/QFR analyses.
As the FAST56 and FAST-EXTEND18 studies overlap, we report meta-analysis using each of these
(and excluding the other). Although diagnostic accuracy is reasonable in both analyses, CIs are wide,
reflecting the limited data and high heterogeneity. In both cases, specificity is lower than estimated for
QFR (around 89%). When using FAST-EXTEND, sensitivity is similar to QFR (around 84%), but when
using the earlier FAST study, sensitivity for CAAS vFFR is lower than for QFR. These meta-analyses
should be interpreted with caution because they required imputation of data for two studies on the
prevalence of FFR results below and above the cut-off point of ≤ 0.80, and because of the high
heterogeneity across studies.
Only one study26 has directly compared CAAS vFFR with QFR, and this is currently reported only
as a conference abstract. That study concluded that diagnostic performance of vFFR was poorer than
for QFR, with AUCs of 0.719 (95% CI 0.621 to 0.804) for vFFR and 0.886 (95% CI 0.807 to 0.940)
for cQFR.
Subgroup and sensitivity analyses (CAAS vFFR)
There were insufficient data to conduct any subgroup analyses or meta-regressions to investigate
whether the diagnostic accuracy of CAAS vFFR varied by patient or study characteristics. Sensitivity
analyses according to study quality were not feasible.
As only one study presented a figure with extractable data, analyses of these data were not performed.
No further data suitable for narrative review or synthesis were identified.
Clinical outcomes
Morbidity, mortality and major adverse cardiac events
Three cohort studies reported mortality or major clinical outcomes in eligible patients with QFR
(QAngio XA 3D/QFR) measurements.30,41 All found that a clinically significant QFR was associated
with a higher incidence of long-term MACEs. No data were reported for CAAS vFFR. Results are
summarised in Appendix 5, Table 48, and below.
Spitaleri et al.41 included patients with multivessel disease who underwent revascularisation as part of a
large randomised trial of PCI in 1498 STEMI patients in whom at least one non-culprit lesion (NCL) was
left untreated.66 QFR was calculated in NCLs in a subgroup of 110 patients following revascularisation.
Patients with QFR values > 0.80 in all NCLs were classified as having functional complete revascularisation
(n = 54), and those with at least one NCL with QFR value ≤ 0.80 were classified as having functional
incomplete revascularisation (n = 56). Patient-oriented cardiac events (POCEs, defined as cumulative
occurrence of all-cause death, any MI and any coronary revascularisation) were measured at the
TABLE 7 Bivariate meta-analysis of CAAS vFFR studies
Analysis Sensitivity (%) (95% CI) Specificity (%) (95% CI)
Using FAST: Masdjedi et al. (2020)56 75.98 (66.86 to 83.22) 74.38 (51.32 to 88.89)
Using FAST-EXTEND: Daemen et al. (2019)18 84.86 (61.76 to 95.11) 72.20 (50.30 to 86.95)
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5-year follow-up. A total of 39 (35%) patients experienced an adverse event. The cumulative incidence
of POCEs was higher in the group with QFR ≤ 0.80 (46%) than in the group with QFR > 0.80 (24%)
(HR 2.3, 95% CI 1.2 to 4.5; p = 0.01). Further individual POCE outcomes are reported in Appendix 5,
Table 48.
Kanno et al.30 (conference abstract only) evaluated 212 de novo intermediate coronary lesions in
212 patients with deferred revascularisation based on FFR values above 0.80. Baseline and physiological
indices including cQFR were compared between patients with and without MACEs (cardiovascular death,
non-fatal MI, target vascular revascularisation and non-target vascular revascularisation) during the
4-year follow-up. MACE incidence at the 4-year follow-up was 5.7%. In patients with MACEs, cQFR
was lower than that in patients without MACEs (mean or median 0.80 vs. 0.88; p = 0.030). On logistic
regression analysis, cQFR≤ 0.8 was a significant predictor of MACEs (OR 5.60, 95% CI 1.69 to 18.6;
p = 0.005).
Hamaya et al.23 included a population of 549 patients with stable three-vessel disease who underwent
cQFR. At the median 2.2 years’ follow-up, patients with MACEs had lower cQFR in all three vessels
than those without MACEs [2.76 (95% CI 2.64 to 2.88) vs. 2.64 (95% CI 2.49 to 2.73); p < 0.001], and
three-vessel cQFR was a statistically significant predictor of MACEs in multivariate analyses (HR 0.97,
95% CI 0.96 to 0.99). cQFR was also a better predictor of remote revascularisation (≥ 3 months) than
DS [AUC 0.73 (95% CI 0.65 to 0.79) vs. AUC 0.66 (95% CI 0.56 to 0.74); p = 0.043].
Subsequent use of invasive pressure wire fractional flow reserve
No studies of QFR prospectively evaluated the impact of QFR use and subsequent reductions in the
use of adenosine and pressure wire procedures. However, five studies included in the diagnostic
accuracy review retrospectively derived a grey-zone strategy based on their diagnostic accuracy results
to model a potential reduction in adenosine and FFR use.29,37,40,50,51
Results are summarised in Appendix 5, Table 49. None of these studies used the grey-zone boundaries
recommended by the manufacturer (0.78–0.84), and only two studies used the same grey zone.40,50 All
studies derived their grey-zone boundaries from their own cohort, except one40 that used boundaries
defined by another study.50 Diagnostic accuracy criteria of QFR against FFR used to derive grey-zone
boundaries varied across the studies (e.g. minimum sensitivity and specificity of the grey zone was
> 95% in one study50 and > 90% in another51). Each study retrospectively modelled a QFR–FFR hybrid
strategy using QFR as the main diagnostic method and only performing FFR measurements in their
defined grey zone. Despite the variety of choice of grey zones and how they were defined, all are
broadly similar to each other and to the manufacturer-specified definition used in the meta-analysis in
Bivariate meta-analysis (QAngio XA 3D/QFR).
All simulated grey-zone strategies were associated with a large percentage of adenosine/FFR procedures
(hypothetically) avoided, ranging from 42% to 68%. The widest grey-zone area (0.71–0.90)51 was associated
with the lowest proportion of adenosine/FFR-free procedures (42%), and the narrowest boundaries
(0.77–0.86, 0.78–0.87) associated with the highest proportion of procedures avoided (61–68%).40,50,51
None of the simulations modelled the clinical impact of delayed FFR in patients with a FFR below 0.8.
Interobserver variability
Eight studies reported outcomes data on the reproducibility of QFR readings between two different
analysts (see Appendix 5, Table 50). One study directly compared QAngio XA 3D/QFR and CAAS
vFFR,26 six studies evaluated QAngio XA 3D/QFR only17,24,25,27,33,45 and one CAAS vFFR only.56 Three
studies were reported only as conference abstracts.25–27 The number of single measurements analysed
ranged from 10 to 101 vessels. All QFR measurements were performed and compared retrospectively
(offline) where reported. Only two studies explicitly reported blinding analysts to each other’s readings.45,56
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It was found that QFR had a moderate to high level of inter-rater reliability. Two studies of QAngio
XA 3D/QFR reported MDs ≤ 0.01 in repeated QFR measurements between analysts.24,45 One study
reported a moderate correlation between three separate raters [mean intraclass correlation (ICC)
0.614, 95% CI 0.464 to 0.728]. Two studies reported high ICC results, one in stable angina patients
(r = 0.990)33 and the other in NCLs of STEMI patients (r = 0.991).17 Another study found that inter-
rater reliability was higher for cQFR (R2 = 0.82) than for fQFR (R2 = 0.70) and ICA DS (R2 = 0.67).27
One study found high inter-rater repeatability for QAngio XA 3D/QFR [fQFR 0.001 (SD 0.036) and
cQFR 0.001 (SD 0.049)] as well as CAAS vFFR [0.005 (SD 0.037)] and no statistically significant
differences between raters’ measurements. Inter-rater reliability was also high in the FAST study
across 100 repeated CAAS vFFR measurements (r = 0.95).56
Intraobserver variability
Eight studies reported outcomes data on intraobserver reproducibility of QFR readings (see Appendix 5,
Table 51). Seven studies evaluated QAngio XA 3D/QFR only,16,17,25,27,33,45,54 and one study directly compared
QAngio XA 3D/QFR and CAAS vFFR.26 Five studies were reported only as conference abstracts.16,25–27,54
Where reported, all measurements were performed retrospectively (offline). The time gap between initial
and repeated measurements was reported in four studies and ranged from 3 days to 2 weeks.16,27,45,54
All studies except one25 reported a high level of intrarater reliability for QFR. One study that assessed
QFR readings independently by three analysts twice among 100 vessels reported a moderate ICC
coefficient (r = 0.428). Where reported, r coefficients for QAngio XA 3D/QFR in other studies ranged
from 0.958 to 0.997, and MDs between repeat measurements from 0.00 (SD 0.03) to 0.016 (SD 0.06).
One study found that R2 was higher for fQFR (0.91) and cQFR (0.94) than DS measured by ICA
(0.76).27 One study that evaluated both QAngio XA 3D/QFR and CAAS vFFR found high levels of
repeatability and no statistically significant changes between repeated tests (cQFR: MD 0.009 ± 0.053,
p = 0.230; fQFR: MD 0.016 ± 0.060, p = 0.066; vFFR: MD 0.008 ± 0.040, p = 0.175).
Test failures: rates and reasons
Appendix 5, Table 52, reports rates of exclusions from diagnostic accuracy studies and reasons for exclusion.
Sixteen studies did not report rates of patient exclusions or reasons for exclusion.14,16,18,22,23,25,29,31,33,35,36,38,39,44,48,54
Exclusion rates varied widely, from 6% to 92%, although this is partly due to differences in patient
selection criteria, reporting and methods of calculating exclusions rates (e.g. out of total population
considered for eligibility vs. out of total number of patients with FFR). This limits the comparability of
exclusion rates across the studies.
Issues with the acquisition and quality of angiographic images (e.g. lack of at least two projections with
a 25% degree angle in between, or poor image quality) were the most reported cause of exclusion,
with 15 studies reporting it as their main reason for excluding patients from QFR analyses.15,17,19–21,24,28,32,
37,42,43,46,49,50,56 Anatomical features of arteries (e.g. excessive overlapping or foreshortening, ostial lesions,
severe tortuosity) were the second most commonly listed reason for exclusion. Rates of exclusions
were higher overall in retrospective studies (median 28%, range 6–92%) compared with prospective
studies (median 17%, range 7–52%). This may be partly explained by the fact that ICA images in
retrospective studies were less likely to have been collected following manufacturer instructions to
acquire images suitable for QFR.
Both CAAS vFFR that reported reasons for exclusion reported high exclusion rates (63% and 65%),
although both studies were retrospective.19,56 In both studies, the majority of exclusions were explained
by angiographic image processing issues (rather than CAAS vFFR directly). For instance, 83% of exclusions
in ILUMIEN I19 were due to the lack of at least two angiographic projections, table movement during ICA
or pixel resolution incompatibility. ILUMIEN I19 concluded that careful adaptions in acquisitions of ICA
images could reduce test failure.
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Other outcomes
No evidence was reported in QAngio XA 3D/QFR and CAAS vFFR studies for any of the following
protocol-specified outcomes: impact of QFR on the rate revascularisation procedures, adverse events
related to the diagnostic procedure, adverse events related to revascularisation, distress, anxiety and
similar harms caused by QFR, vFFR, invasive FFR or iFR, number of vessels with stent placements,
HRQoL and radiation exposure.
Simulation study of clinical effectiveness
Given the very limited data on clinical effectiveness of QAngio XA 3D/QFR reported in publications,
we performed a simulation study to investigate the possible impact of using QAngio XA 3D/QFR,
compared with FFR, on actual coronary outcomes. This simulation study treats the complete data
extracted from figures (3192 observations) as a representative sample from the true population of FFR
and QFR measurements. To predict coronary outcomes we used the results of the recent IRIS-FFR
registry report, representing 5846 patients who were either revascularised (stent or bypass surgery)
or deferred (continued with current management without surgery) based on their measured FFR result.
The full methods are set out in Statistical analysis of clinical effectiveness.
The IRIS-FFR study used major cardiovascular events (MACE, a composite of cardiac death, MI and
repeated/emergency revascularisation) as its primary outcome. The reported hazard of MACEs by FFR
value was used to estimate the risk for each person in the extracted data. Based on those risks we
simulated whether or not each person had a MACE if they were ‘deferred’ or if they were revascularised.
Note that this assumes that risk is solely a function of FFR values, and that knowing the QFR has no
impact on risk of MACEs.
We investigated three strategies for deciding on whether or not to revascularise:
l FFR only – perform FFR on all and revascularise if the FFR is ≤ 0.8
l QFR only – perform QFR on all and revascularise if the QFR is ≤ 0.8, without FFR measurement
l grey zone – perform a QFR and:
¢ revascularise if the QFR is ≤ 0.78
¢ defer if the QFR is > 0.84
¢ if the QFR is between 0.78 and 0.84, perform FFR and revascularise if the FFR is ≤ 0.8.
Results of the simulation study
Appendix 6, Figure 42, presents an example simulation, showing the distribution of simulated MACEs
according to FFR and QFR. For ease of interpretation, the majority of patients with no MACE are
excluded and only patients with MACE are shown. Preventable MACEs (i.e. patients who would have
MACE if not revascularised) are evenly distributed across both FFR and QFR ranges. MACEs caused
by revascularisation (i.e. where MACE occurs if revascularised, but would be avoided if deferred) are
concentrated above values of 0.75 for both FFR and QFR, in line with the suggestion in IRIS-FFR that
deferral is preferable for a FFR > 0.75.
In Appendix 6, Figure 42, most events occur in the white regions, where the same revascularisation
decision would be made using either FFR or QFR. There are few patients, and hence few MACEs, in
the FP region (upper-left shaded area), where patients would be revascularised based on FFR but not
if using QFR. Hence, using QFR would miss out on preventing some events in this region (green dots)
but equally would avoid causing MACEs due to revascularisation (blue dots).
In Appendix 6, Figure 42, in the FP region (lower-right shaded area), where patients would be revascularised
based on QFR but not if using FFR, there are also few events. QFR prevents some events in this region
(green dots) that would be missed by FFR, but equally would cause MACEs due to revascularisation (blue
dots). The ‘preventable’ and ‘caused’ events in these two regions approximately balance each other out.
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Based on the data extracted from figures, if using the ‘FFR only’ strategy 40.2% of patients would be
revascularised; using the ‘QFR-only’ strategy 42.0% would be revascularised; and using the grey-zone
strategy 43.2% would be revascularised. So, using QFR moderately increases the revascularisation rate,
and using it in combination with a grey zone increases it further.
Table 8 summarises the key results of the simulation. FFR is slightly more effective at preventing
MACEs, but QFR leads to only about one extra unprevented MACE per 1000 patients. If the grey zone
is used the total number of MACEs is closer to that of using FFR for everyone. Using QFR results in
around 1.3 to 1.6 more revascularisations to prevent one MACE.
Using QFR with or without with a grey zone leads to more revascularisations, and so more MACEs
caused by revascularisation (6 or 9 per 10,000 more, respectively), which leads to a larger number of
revascularisations per MACE prevented.
Table 8 presents only the median values across all simulations. Figure 11 shows the distribution of
revascularisations per MACE prevented. Appendix 6, Figures 43–45, show the prevented and unprevented
events, and events caused by revascularisation across all simulations. These show the substantial overlap
between the distributions, so, although the results in Table 8 suggest some difference between strategies,
it is not clear if these are genuine differences that would be observed in actual clinical practice.
Overall, these simulations suggest that there is little conclusive clinical difference between using QFR and
FFR to make revascularisation decisions. Using FFR may prevent slightly more MACEs, at around 1 event
per 1000 patients, but the overlap in simulated distributions means it is highly uncertain whether or not
the difference is genuine. By contrast, the simulation suggests that QAngio XA 3D/QFR increases the
number of revascularisations performed, without substantially improving the number of MACEs prevented.
The simulation has numerous limitations as a result of its assumptions. Most important is that the risk
of MACE depends only on a patient’s FFR. The simulation could not account for any other key patient
factors, and there is the possibility that knowing the QFR as well as the FFR might alter the predicted
risk. The IRIS-FFR risks may not match the risks in the UK population eligible for FFR or QFR
assessment. The simulation is also based only on the data extracted from figures, which is a small
sample and may not represent the patients seen in practice. The simulation considers only a single
lesion per patient, when QFR may be used to assess multiple stenoses in a patient.
Implementation evidence
Timing of results from data acquisition
Six studies of QAngio XA 3D/QFR reported measuring the time required to complete QFR
analysis.14,32,45,50,52,53 The results are summarised in Appendix 5, Table 53. Two studies were prospective,14,52
and one was reported only as a conference abstract.14 Sample size ranged from 68 to 268 patients.
TABLE 8 Key results of the simulation study
Strategy
Percentage
with MACE
Percentage
with prevented
MACE
Percentage with
MACE caused by
revascularisation
Percentage with
unprevented
MACE
Number of
revascularisations
per MACE prevented
FFR 1.75 1.60 0.91 0.78 25.18
QFR 1.85 1.57 0.97 0.81 26.80
Grey zone 1.82 1.63 1.00 0.75 26.50
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The reporting of methods for calculating time to QFR acquisition differed among the studies. For instance,
only two studies specified that calculations included time required to select appropriate angiographic
images for generating 3D images.50,53
Time to QFR data acquisition ranged from an average of 2 minutes 7 seconds to 10 minutes (SD 3 minutes).
One study of 268 patients reported that time to image acquisition significantly decreased with the number
of ICAs analysed, from 5 minutes 59 seconds to 2 minutes 7 seconds, between the first and last 50 cases.
One conference abstract of an earlier prototype version of QAngio XA 3D/QFR reported a mean total
time to QFR of 10 minutes (SD 3 minutes). The study reported that the application required essential
modifications during the study and retrospective reanalysis of ICA and QFR was performed with
the final version of QFR, although it was not clear which analysis was used to derive mean time to
data acquisition.
Other outcomes
No evidence was found for any of the following review protocol-specified implementation outcomes:
acceptability of QFR, vFFR and invasive FFR (to clinicians and patients), referral times, patient satisfaction,
training requirements, test uptake and compliance.
Conclusions and recommendations for research from included studies
Most studies concluded that QAngio XA 3D/QFR had good diagnostic accuracy for detecting significant
coronary stenosis and good correlation and agreement with both wire-based FFR14,15,20,21,23,24,26–30,32,34–46,
48,50–54,56,67 and iFR,16,21,24,36,49 and is able to improve angiographic assessment for evaluation of intermediary
coronary artery stenosis.14,50,52
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FIGURE 11 Estimated revascularisations per MACE prevented across all simulations.
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Studies of CAAS also concluded that QFR had good correlation and agreement with wire-based
FFR,18,19,24,56 although one concluded that only one-third of routinely acquired coronary angiographic
images were appropriate for retrospective vFFR analysis.19
Studies conducted in patients with acute coronary syndrome concluded that QFR was safe and
accurate in assessment of non-culprit vessels.17,28,31,41 Some studies suggested that diagnostic accuracy
of QFR may be affected by specific clinical characteristics, namely small vessels,15,32 presence of
bifurcated lesions and trifurcated lesions,15,38 left main stenosis,22 prior MI-related coronary arteries20
and microvascular function.29,41
Several studies concluded that QFR may be a good alternative tool for identifying significant coronary
stenosis in various clinical settings or may complement invasive wire-based options;23,31,37,49 it is applicable
to patients allergic to adenosine and adenosine triphosphate (ATP) vasodilators and may avoid procedural
risks or patient discomfort associated with invasive wire-based options.23,52 Some studies noted that QFR
may reduce procedure time, be associated with reduced cost and allow for wider adoption of functional
assessment of coronary stenosis.23,33,46
Some studies recommended using a hybrid approach to reduce the need for invasive FFR, although
there was no consensus on an optimal grey zone.16,33,43 In some cases, patients may be unsuitable for
evaluation of stenosis severity using angiography, including diffuse tandem disease, tandem lesions,
lesions with angiographic haziness caused by calcification or thrombus and lesions with ulceration
cause by plaque rupture.20 Diagnostic accuracy could be affected in patients with bifurcation lesions,32,50
patients with prior MI-related coronary arteries20 and patients with left main location of stenoses.22
Some studies suggested that confirmation with FFR may be required close to values of 0.8.33,53
One CAAS study noted that careful adaptations in image acquisition will be required to reduce the
risk of test failures if used in daily clinical practice.
Further prospective online investigation into the clinical benefit of QFR-based revascularisation was
recommended by multiple studies,17,37,42,43,45,46,48,50 including using appropriately powered randomised
controlled trials (RCTs) with relevant clinical end points before implementing the device as a definite
alternative to invasive FFR,24,32,37,40,50 such as the ongoing FAVOR III China trial (NCT03656848).
Some recommended further testing of modelled hybrid QFR/FFR approaches.51
A number of studies recommended that that testing of the diagnostic accuracy and feasibility of QFR
in clinical practice in different settings is needed.17,32,36–38,40,43,45,48,49
Further investigation of diagnostic precision and the application of the current QFR methodology in
patients with different lesion subtypes,38 including bifurcation lesion,32,50 patients with prior MI-related
coronary arteries20 and patients with left main location of stenoses22 was recommended.
Clinical effectiveness summary and conclusions
The diagnostic accuracy of QAngio XA 3D/QFR has been widely studied in 39 studies to date with a
total of 5949 patients (7034 vessels or lesions).
At a cut-off point of 0.8, QFR has good diagnostic accuracy to predict FFR (also at a cut-off point
of 0.8) with sensitivity around 84% and specificity around 89%. Although this means there is some
discordance between QFR and FFR, most FPs or FNs arise near the boundary (e.g. where one is 0.81
and the other 0.79), and the discordance may not be clinically meaningful. Data on how this accuracy
may vary by key patient characteristics was very limited, and no conclusive variation could be found.
QFR, as measured using QAngio XA 3D/QFR, is generally similar to FFR measured with an invasive
pressure wire. The average difference between the two values was 0.001, and values rarely differed by
more than 0.14, and, in 50% of patients, by less than 0.04.
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The use of a grey zone, where patients with intermediate QFR values go on to have confirmatory FFR,
was found to increase diagnostic accuracy. Around 20% of patients fall in the grey zone and would
receive confirmatory FFR. Of these, only around 30% have discordant FFR and QFR results, so the
confirmatory FFR is unnecessary for the majority of patients in the grey zone.
Diagnostic accuracy data for CAAS vFFR were limited to only three studies. The results from the
studies were heterogeneous, limiting meta-analysis and a full evaluation of CAAS vFFR. Hence its
diagnostic value is currently uncertain, but it may be a potential alternative to QAngio XA 3D/QFR.
This report did not perform a full systematic review of 2D or 3D ICA, but in those studies that we did
identify, the diagnostic accuracy of ICA was substantially inferior to QAngio XA 3D/QFR, with DS from
ICA being poorly correlated with FFR.
There were very few reported data on clinical effectiveness and implementation outcomes when using
QAngio XA 3D/QFR, as nearly all studies published to date have focused on diagnostic accuracy.
What data there is suggests that the QFR results of 0.80 or below for QAngio XA 3D/QFR may be
significant predictors of subsequent MACE, and that a grey-zone strategy is likely to lead to substantial
reductions in adenosine and FFR procedures. Timing of results, inter-rater and intrarater reliability
were generally acceptable for QAngio XA 3D/QFR, indicating that the technology is feasible in a
clinical context. However, data were limited and quality of blinding uncertain, so levels of inter-rater
reliability in general use remain unclear. The feasibility of CAAS vFFR is uncertain notably because of
lack of evidence on repeatability within and between raters and the high rate of patient exclusions
from retrospective evidence.
The simulation study to investigate the clinical impact of using QAngio XA 3D/QFR found that QAngio
XA 3D/QFR may lead to a slight increase in revascularisations compared with using FFR, but both
methods prevent broadly the same number of MACEs. Up to 1 person in 1000 may have a MACE if
using QAngio XA 3D/QFR that could have been prevented with FFR, but this is highly uncertain. Using
a grey zone seems to lead to an increase in the number of revascularisations, but with no improvement
in MACE prevention compared with using FFR alone or QFR alone.
Overall, this review suggests that making decisions on revascularisation in patients with intermediate
stenosis using QFR as measured by QAngio XA 3D/QFR is a reasonable diagnostic strategy, and so
QFR assessment may be a reasonable alternative to invasive FFR. The trade-off appears to be a
balance between avoiding the side effects of FFR (particularly adenosine use) at a cost of possibly
slightly more revascularisation procedures. The use of QFR appears to be conclusively preferable to
using DS measured by standard ICA alone.
The review did not find a strong case for consistently using FFR in patients in whom QFR is borderline
(i.e. around 0.8, the grey-zone approach). This seems to place too strong an emphasis on patients close
to the 0.8 threshold. Most patients in this region have similar FFR and QFR results (within 0.05), and
so any discordance between QFR and FFR may not be clinically meaningful. A large proportion of
people who go on to receive FFR have the same conclusion as their original QFR, exposing them to
a potentially harmful, unnecessary test. This conclusion, however, does not prevent the use of FFR
when clinicians might think it necessary for reasons other than the QFR being close to 0.8.
Data on CAAS vFFR are currently too limited and heterogeneous to draw any useful conclusions on its
clinical value.
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Chapter 4 Assessment of existing
cost-effectiveness evidence
This chapter provides an overview of existing cost-effectiveness evidence on the use of the QAngioXA 3D/QFR and CAAS vFFR imaging software for assessing the functional significance of coronary
obstructions in patients with suspected stable chest pain whose angiograms show intermediate stenosis
and who may require revascularisation. The literature was systematically searched to identify and describe
relevant evidence on the cost-effectiveness of the two new technologies within the indication for which
these are being evaluated. This systematic review also aimed to identify the central issues associated with
adapting existing decision models to address the current decision problem and to assist in the development
of a new decision model drawing on the issues identified in the clinical effectiveness and cost-effectiveness
review. Given that the two technologies under assessment have only recently been commercialised, it
was anticipated that there would be a dearth of relevant economic evidence. Therefore, to assist the
development of a new decision-analytic model, a pragmatic review of published cost-effectiveness studies
evaluating ICA (alone and/or with FFR) in the management of CAD was also conducted.
Methodology of the cost-effectiveness review of QAngio XA 3D/QFR and
CAAS vFFR
Searches
The bibliographic search detailed in Chapter 3, Searches, was used to identify studies reporting on the
cost-effectiveness of QAngio XA 3D/QFR and CAAS vFFR.
Selection process
The review considered a broad range of economic studies including economic evaluations conducted
alongside trials, modelling studies and analyses of administrative databases. The inclusion criteria
considered were full economic evaluations comparing two or more alternatives and considering both
costs and consequences (i.e. cost-minimisation, cost-effectiveness, cost–utility and cost–benefit analyses).
The protocol for the selection of relevant studies defined two selection stages: (1) assessment and
screening for possible inclusion of titles and abstracts identified by the search strategy, and (2) acquisition
and screening for inclusion of the full texts of potentially relevant studies. Two researchers independently
screened the titles and abstracts of all reports identified by the bibliographic searches. Full-text papers
were to be subsequently obtained for assessment and screened by at least two researchers, with any
disagreement resolved by consensus.
Results of the cost-effectiveness review of QAngio XA 3D/QFR and CAAS vFFR
The initial search identified a total of 1243 records (after deduplication). No studies were identified as
potentially relevant from their titles and/or abstracts, as none evaluated the cost-effectiveness of either
QAngio XA 3D/QFR or CAAS vFFR.
Methodology of the review of decision models evaluating invasive
coronary angiography
Given the lack of cost-effectiveness studies evaluating QAngio XA 3D/QFR and CAAS vFFR used
during ICA, a pragmatic review of published cost-effectiveness studies evaluating ICA (alone and/or
with FFR) in the management of CAD was conducted. The search targeted cost-effectiveness studies
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where ICA was one of the interventions under comparison. The aim of the review was to help inform the
conceptualisation of the decision problem and identify any relevant sources of evidence. Importantly, the
review aimed to assess how the link between short-term diagnostic outcomes and longer-term impact
and subsequent prognosis associated with the diagnostic pathways in the management of CAD and
associated costs and outcomes had been established in the literature. Given that the purpose of the
review was broader than to inform specific inputs of the cost-effectiveness model, it was not considered
appropriate to conduct a full systematic review.
Searches
Targeted searches were conducted in October 2019 in the following databases: MEDLINE databases
(i.e. MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily,
and Ovid MEDLINE), EconLit, EMBASE, NHS EED and the HTA database. Search strategies are
detailed in Appendix 1.
Study selection
Cost-effectiveness studies published after the year 2000 where ICA (alone and/or with FFR) was one of
the interventions under comparison were considered for inclusion. Only cost-effectiveness, cost–utility
and cost–benefit analyses were considered eligible. Studies that presented results as a cost per
diagnosis were not considered for inclusion, as the key aim of the review was to assess how the link
between short-term diagnostic outcomes and longer-term impact and subsequent prognosis associated
with the diagnostic pathways in the management of CAD and associated costs and outcomes had been
established in the literature. The patient population of this review was defined as patients with stable
chest pain and suspected or known CAD. Studies in patients with acute coronary syndromes and
NSTEMI as the primary diagnosis were excluded. The inclusion criteria further specified that only titles
in English would be considered eligible. Titles that were books, editorials, letters to the editor and
reviews that did not include a de novo model were excluded from the review.
One researcher (AD) conducted the two-step selection process consisting of screening for inclusion
(1) the titles and abstracts of studies identified by the bibliographic searches, and (2) the full-text
articles identified at the previous step as potentially relevant.
Results of the review of decision models evaluating invasive
coronary angiography
A total of 1740 records were identified during the initial search of economic databases, of which
1264 remained after deduplication. The first step of screening identified 25 titles as potentially
relevant based on their titles and/or abstracts. After the full-text articles of these records were
obtained and assessed for eligibility, 21 studies68–88 were considered to meet the selection criteria
and included in the review. The studies are summarised in detail in Appendix 7, Table 56. Results of
the searches and the list of excluded studies are presented in Appendix 7, Tables 54 and 55.
Given the aim of the review, a formal assessment using checklists to assess the quality of the included
cost-effectiveness studies was not conducted. Instead, a narrative review of key model features,
including testing and management strategies, and assumptions to support the conceptualisation and
development of a de novo analytical model is presented below.
The majority of studies68–72,75,77,79,81,83,85,86,88 used a decision tree to model the diagnostic pathway and
short-term outcomes, and a long-term Markov model (or multiple Markov models) to characterise
disease progression. Two studies used microsimulation models74,82 that also combined a decision tree
structure to model diagnostic outcomes followed by a lifetime disease progression state-transition
model. Of the five studies that modelled the full-time horizon with a decision tree model, three
models71,73,80 captured only short-term outcomes (1-year time horizon), whereas two others comprised
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longer time horizons (10 years84 and lifetime87). One study78 used a Bayesian mathematical model
based on two equations to estimate costs and quality-adjusted life-years (QALYs) for each strategy
under comparison over a 10-year time horizon. The equations appear to be equivalent to the
calculations in a decision tree’s rollback algorithm.
Among the 21 studies, two models77 were considered to be good examples of alternative ways to
evaluate diagnostic strategies in patients with suspected stable angina. These studies were selected on
the basis that they encompassed many of the features identified in the other studies. The two models
differed in terms of how they modelled the diagnostic pathway and subsequent long-term risks of
major cardiovascular-related events and associated costs and outcomes. The first study77 was a cohort
model that estimated outcomes for an average patient in clinical practice, and the second study74
was a microsimulation model that estimated outcomes for hypothetical patients at different levels of
disease severity (defined in terms of number of coronary vessels affected and whether or not patients
have ischaemia). A key difference of the two models was the approach taken to assess the long-term
impact of the diagnostic strategies on the risk of major cardiovascular events. In one study,77 the model
transition probabilities were based on risk prediction equations and patient covariates from a previously
published model on angina, which allowed estimation of the occurrence of a primary cardiovascular
event (with risk conditioned on factors such as age and sex) and of subsequent events conditional on
having and surviving a first cardiovascular event. By contrast, the second study74 estimated the risk of
primary and subsequent cardiovascular events dependent on disease severity, based on the rates of
MACEs from the literature. A summary of both models is presented below.
Walker et al.77
Walker et al.77 developed a decision tree and Markov model structure to evaluate the cost-effectiveness
of eight alternative testing sequences, including different combinations of exercise treadmill testing,
SPECT, cardiovascular MR and coronary angiography, to identify patients with angina who require
revascularisation (i.e. those with significant stenosis) derived from the CE-MARC (Clinical Evaluation of
Magnetic Resonance Imaging in Coronary Heart Disease) trial.89 The study population included patients
with angina (with and without significant stenosis) and those without angina, based on characteristics
of patients in the CE-MARC trial.89 The base-case analysis considered the case of a 60-year-old man,
classified as grade 2 on the Canadian Cardiovascular Society (CCS) scale, with a prior likelihood of
significant stenosis requiring revascularisation of 39.5%. Patients with angina were assumed to have
had no previous MI. The Markov model had a 50-year time horizon with a 3-month cycle length.
The perspective of the study was NHS and Personal Social Services (PSS), and health outcomes
were measured in terms of QALYs. Costs were expressed in term Great British pounds (GBP)
(2010/11 price year), and costs and health outcomes were discounted at a rate of 3.5% per annum.
The aim of the diagnostic testing was to identify patients with significant coronary artery stenosis
who require revascularisation [either PCI or coronary artery bypass graft (CABG)]. It was assumed
that all patients suspected of having significant coronary stenosis would undergo coronary angiography
as a definitive test before revascularisation. ICA was considered the reference standard test with
perfect sensitivity and specificity. As ICA was performed on all patients indicated for revascularisation,
the model did not consider any FP test results. The diagnostic component of the model divided the
patient cohort according to their underlying disease status based on characteristics of patients in the
CE-MARC trial,89 survival to interventional and diagnostic procedures, test results and subsequent
clinical management conditional on test results. All patients with positive and inconclusive test results
progressed to a further test in the sequence, although the type of the next test depended on whether
the result was positive or inconclusive for some strategies (e.g. in strategy 8 a positive exercise
treadmill test result would be followed by ICA, whereas inconclusive test results would be followed by
a SPECT test). Patients whose overall testing sequence resulted in a positive result were managed with
either PCI or CABG. The relative proportion of patients who underwent each type of revascularisation
was sourced from UK clinical registries. Patients who tested negative at any point in the test sequence
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were managed with optimal medication if they had angina, or with no further medical therapy for
those without angina. The decision tree captures mortality associated with both invasive tests and
revascularisation, and separately applies procedure-specific mortality rates for ICA, PCI and CABG.
At the end of the decision tree, patients with significant stenosis could be classified as TP, FN or
dead. Patients without significant stenosis could be classified as TN with angina, TN without angina
or dead. All testing strategies are assumed to take the same time and do not account for delays to
revascularisation resulting from strategies that involve more tests.
The diagnostic accuracy estimates for the different tests considered in the alternative strategies
were conditional on positive/inconclusive results in previous tests in the strategy, thus accounting
for correlations between tests within diagnostic strategies. This is possible only with access to IPD
from studies that include all the tests used across the full set of diagnostic strategies, as was the case
for the CE-MARC study,89 which informed diagnostic accuracy in this model. However, the people
interpreting each test were blinded to the results of previous tests in each diagnostic sequence,
so the data would not have captured the influence of knowledge on previous tests on the diagnostic
accuracy estimates of subsequent tests.
The long-term model is composed of three submodels. Patients with significant stenosis enter one
submodel at either the TP or FN state. The key difference between TP and FN patients is that TP patients
have undergone revascularisation. In the base-case analysis, the treatment effect of revascularisation
is limited to a reduction from angina symptoms, with improved HRQoL for TP patients compared
with FN patients, whereas the same baseline risk of cardiovascular events is applied for TP and FN
patients. A proportion of FN patients are assumed be correctly diagnosed over time (conditional on
their CCS grade), and transition to the TP health state. Patients can remain event free, have a primary
non-fatal cardiovascular event, or die from a cardiovascular event or other causes. Patients who survive
a primary non-fatal cardiovascular event transition to the non-fatal cardiovascular event state and have
an increased risk of further cardiovascular events for 12 months, after which they transition to the
non-fatal event post 12 months state. The risk of cardiovascular events in this state is lower than in
the non-fatal event post 12 months state, but higher than the baseline risk (TP and FN states). Patients
in all health states are subject to a mortality risk from non-cardiovascular death, which is sourced from
UK life tables (with cardiovascular deaths removed to avoid double counting). A similar submodel to the
one described above, this is used to estimate the cost and health outcomes of TN patients with angina.
TN patients without angina go into a two health states (alive and dead) submodel that derived transition
probabilities from sex- and age-adjusted UK life tables for all-cause mortality.
The probabilities of fatal and non-fatal cardiovascular events in the submodels for patients with angina
were estimated based on risk equations from the EUROPA (EUropean trial on Reduction Of cardiac
events with Perindopril in stable coronary Artery) trial.90 This study estimated risk equations to predict
(1) the risk of a first primary event, cardiovascular death, MI or cardiac arrest (see equation 1), (2) the
odds of that event being fatal (see equation 2) and (3) the risk of a further primary event in the first
year after a first non-fatal event (see equation 3). The equations allow for the adjustment of the rate
of events dependent on the patient characteristics (age, sex, medication, comorbidities, etc.) and,
importantly, accounting for the occurrence of previous MI. Walker et al.77 applied a fourth equation to
model the risk of secondary cardiovascular events, which captures the excess cardiovascular risk for
patients who had had a previous MI.
The model also considers cancer-related mortality due to radiation exposure during some testing
procedures (ICA and SPECT) and PCI (assumed to be performed at the same time as ICA). The model
quantified the average radiation exposure in each test sequence; these radiation dosages were then
combined with cancer incidence and mortality estimates from the literature to calculate lifetime
incidence and mortality conditional on the patient’s age when they were tested. The costs and
morbidity associated with cancer were not modelled.
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The HRQoL in the model was dependent on age, sex, CCS grade and whether or not the patient
had undergone revascularisation. EuroQol-5 Dimensions (EQ-5D) utility weights by CCS grade from a
study on angina were combined with UK-population norm EQ-5D estimates by age and sex to obtain
age- and CCS-specific HRQoL estimates. The underlying assumption was that the relative impact of
CCS grade on HRQoL compared with the population is the same across all age groups.
One important base-case assumption of the Walker et al.77 model is that revascularisation has no
impact on the risk of cardiovascular events, and provides relief only from angina symptoms (captured
by change in CCS score). HRQoL scores for patients with angina (with and without significant stenosis)
are based on age- and sex-adjusted UK population scores with a relative adjustment made based on
CCS grade. Data from a RCT comparing coronary angioplasty with medical management was used to
link CCS scores at baseline and 6 months after intervention with the two treatments. Patients with
angina and significant stenosis who receive revascularisation (TP) are attributed the HRQoL based on
the average CCS grade of those following treatment with angioplasty conditional on initial CCS grade.
Patients with angina and significant stenosis who are misclassified (FN) are attributed the HRQoL
based on the average CCS grade of those following treatment with medical management conditional
on initial CCS grade. It was assumed that angina patients without significant stenosis received the
same HRQoL as FN patients, whereas the HRQoL of the other TN patients without angina was based
on age- and sex-adjusted UK population scores.
Costs included in the model were those of tests and interventional procedures, treatment costs in
the long-term model and health-state costs (namely fatal and non-fatal cardiovascular events, and
other-cause mortality). Treatment and health-state costs were also sourced from the EUROPA trial90
(with a price year inflation adjustment). Background treatment costs were the same for all patients
with angina and an additional background cost was applied for patients after a cardiovascular event.
Patients without angina were assumed to have no costs in the long-term model.
The authors considered uncertainty by performing probability sensitivity analysis and scenario analysis
where they varied assumptions on baseline characteristics (CCS grade, sex and age), prior likelihood of
coronary heart disease requiring revascularisation, rediagnosis rate of FN patients, clinical management of
TP patients, the impact of radiation exposure on cancer (risk assumed to be zero), risk of cardiovascular
events following revascularisation (treatment effect from the EUROPA trial90), HRQoL decrements and
the cost of diagnostic tests. The model was sensitive to prior likelihood of disease, reducing the starting
age and increasing baseline CCS grade in the model, use of absolute HRQoL decrements by CCS grade,
allowing for a proportion of TP patients to not receive revascularisation, reidentification rate of FN
patients, and costs of tests. The prior likelihood of coronary heart disease requiring revascularisation
was considered a key driver of cost-effectiveness.
Genders et al.74
The model developed by Genders et al.74 was a microsimulation model comprising a decision tree and
a lifetime state-transition model to assess the cost-effectiveness of invasive and non-invasive testing
strategies for patients with stable chest pain. The base-case population consisted of 60-year-old
patients with a 30% pretest probability of obstructive CAD (defined as ≥ 50% stenosis on at least
one vessel) who had never undergone revascularisation procedures and had no prior history of CAD.
The study presents cost-effectiveness results for the separate jurisdictions. We refer here to inputs
and results specific to the analyses under the UK NHS perspective, as they are more relevant to our
study. Costs were calculated in GBP (2011 price year), and health outcomes were calculated as QALYs.
Both costs and QALYs were discounted at an annual rate of 3.5%.
The diagnostic strategies in the model are evaluated under two different diagnostic workups. In the
invasive workup, patients with obstructive CAD on CCTA and patients with inducible ischaemia on
cardiac stress imaging were referred for ICA prior to a decision regarding medical management. In the
conservative workup, only patients identified as having higher CAD severity by CCTA or cardiac stress
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imaging would be referred to ICA and patients with milder forms of the disease managed with OMT.
Patients with normal arteries or mild CAD (< 50% stenosis) received no further testing under either
diagnostic workup.
The decision tree starts by classifying patients according to eight categories of disease severity based
on percentage stenosis, number of vessels affected, location of lesion (left main trunk or not) and
severity of inducible stenosis (where present). Patient distribution across disease severity categories
was sourced from hospital records for patients who had undergone CCTA and ICA. Diagnostic
accuracy estimates derived from published meta-analyses were then applied to split patients according
to the test results for each diagnostic strategy. For the purpose of applying these estimates, patients
who were considered correctly classified with a negative result had normal coronary arteries or mild
CAD (< 50% stenosis). Patients correctly identified with a positive result had moderate CAD, severe
CAD or three-vessel disease/left main coronary stenosis. The model did not consider inconclusive test
results. The authors assumed independence of diagnostic accuracy estimates for CCTA and cardiac
stress imaging, and further assumed that FP results were possible only for mild CAD and mild inducible
ischaemia (under the conservative diagnostic workup). Patients with FP results are assumed to receive
unnecessary optimal medication for the full time horizon, incurring a treatment cost and utility decrement
in the long-term model. As in Walker et al.,77 adverse events from testing and revascularisation procedures
were considered. However, in this model adverse events are not limited to procedural mortality, but also
include non-fatal MI with ICA. This adverse event had a cost attributed to it, but did not translate into an
increased risk of further events in the long-term model.
The decision tree splits the patient population according to disease severity, test results and survival to
testing (ICA and FFR) and revascularisation procedures. It also allows quantifying the average exposure
to radiation with the different tests and PCI.
In the ICA strategy, all patients were tested with ICA. Those who tested negative received risk factor
management and those who tested positive would be tested with FFR to decide treatment. ICA is assumed
to be a perfect test, and FFR appears to allow prefect distinction between disease severity categories,
although this is not explicitly stated in the paper. OMTwas then given to patients with mild ischaemia and
moderate to severe CAD, PCI was given to patients with severe CAD and severe ischaemia, and CABG
was given to patients with three-vessel disease or left main coronary stenosis. Revascularised patients
would also receive OMT, and all individuals in the model received risk factor management.
Subsequent to the decision tree, patients entered a state-transition model comprising three health
states: alive, post MI and dead. Patients enter the model through the alive state, where they could
remain until death or suffering a non-fatal MI. Patients who suffered a non-fatal MI would transition to
the post-MI state, where they could remain or transition to the dead state. The transition probabilities
were derived from published trial data that reported risk of MACE (cardiovascular death, non-fatal MI
and repeated revascularisation) in patients treated with CABG, PCI and OMT. The rates of MACE
were dependent on disease severity and whether patients were treated with optimal medication or
revascularisation. All FN patients were assumed to be correctly identified and treated by the end of
the first year, with the exception of those with moderate CAD without ischaemia, of whom only 25%
were rediagnosed. Patients who experienced a primary cardiovascular event would have a higher risk
of subsequent cardiovascular events, which was modelled by applying a HR of 1.44 to their baseline
risk. The model also considered mortality from non-cardiovascular causes. This was estimated based on
age- and sex-specific general mortality data from which deaths attributed to cardiovascular causes had
been removed to avoid double counting. The mortality, morbidity and costs due to cancer incidence
were not modelled, although the model calculated cumulative radiation exposure over the time horizon.
The risk of MACE was estimated from the trial data separately for the first year and all subsequent
years to allow for a higher event rate in the first year after starting treatment. The rates were
estimated based on the CABG arm of the SYNTAX trial59 for patients with three-vessel disease or left
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main coronary stenosis, and the optimal medication and PCI arms of the COURAGE trial91 for the
patients with suspected or mild inducible ischaemia and moderate to severe CAD (treated with optimal
medication) and patients with severe CAD and severe inducible ischaemia (treated with PCI). The
reciprocal of the treatment HR was applied to this risk to estimate the baseline probability of
cardiovascular events for untreated patients (FN), who have a higher rate of events until they are
correctly diagnosed. A single treatment effect hazard for optimal medication, PCI and CABG (HR 0.70)
was sourced from three meta-analyses of OMT comparing treatment with no treatment, but it is
unclear how this estimate was calculated. The rates of MACE applied in the model are summarised in
Appendix 7, Table 57.
We note that the MACE rates without treatment seem counterintuitive (e.g. higher MACE rates for
untreated moderate CAD with mild ischaemia compared with untreated severe CAD with severe
ischaemia). The authors did not comment on the MACE rates.
If the treatment effect applied in the model is indeed the same for optimal medication and revascularisation,
this is similar to the absence of a treatment effect of revascularisation in addition to optimal medication
in Walker et al.77 This is an important interpretation of the clinical evidence on the treatment effect of
revascularisation, and one that is discussed further in Chapter 5, Treatment effect of revascularisation.
In previous studies where a treatment effect on the rate of cardiovascular events for revascularisation
compared with optimal medication was considered explicitly for comparable patients (e.g. same disease
severity), seven models included the existence of a treatment effect68,69,76,83,85,86,88 and six studies did
not,70–72,79,84,87 in line with Walker et al.77 and Genders et al.74
The HRQoL in the model was assigned to individuals according to disease severity and treatment
received. Patients without CAD or inducible ischaemia were assumed to have the HRQoL of the general
population based on age- and sex-specific EQ-5D estimates for the US population. For patients with
CAD and inducible ischaemia who underwent active treatment (optimal medication or revascularisation),
mapped EQ-5D utility decrements were applied to the general population HRQoL estimates. In the first
year of treatment, the utility decrements of treatment relative to the general population were derived
from the average utility decrement as observed in the same trial data that informed the rates of MACE
for treated patients, whereas for the subsequent year the last observed value in the trials was carried
forward. The authors state that a disutility was considered for patients with FP results. It was not
clear how the utility decrements for FN patients were estimated. Appendix 7, Table 58, summarises the
utility values for the start age in the model conditional on treatment and disease severity. The HRQoL
estimates for the first year and subsequent years of treatment are presented for the same age solely for
ease of comparison.
The model considers costs of tests, test adverse events, medication, MI in the long-term model, and
incidental findings from CCTA. Unit costs were mostly sourced from UK published data. Based on the
description of the unit cost selected for PCI, this procedure was assumed to take place in an outpatient
setting. It is not, however, clear what assumptions were made regarding the setting for ICA, CABG and
treatment of non-fatal MIs. The unit cost for FFR was sourced from a previous cost-effectiveness study
in a US setting.87 An annual cost of medication was included in the model according to disease severity
and treatment received (OMT, PCI or CABG). The resource use assumed for patients who received
optimal medication alone and in addition to PCI was sourced from the COURAGE trial,91 whereas for
those who received CABG and optimal medication it was taken from the SYNTAX trial.59 The distribution
of medication use applied in the model is shown in Appendix 7, Table 59.
Model parameters were entered as distributions, and probabilistic sensitivity analysis was performed
to incorporate joint parameter uncertainty. Scenario analysis was performed to test assumptions
on diagnostic accuracy of stress echocardiography, cost of tests, alternative diagnostic pathways,
probability of CAD, time to rediagnose FN patients, and treatment effect of optimal medication for
FP patients. A subgroup analysis by sex was also performed. The authors do not identify any drivers
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of cost-effectiveness, but note that the assumption that FP patients will remain misclassified over the
time horizon and that FN patients will be rediagnosed after 1 year is likely to have biased results
against strategies with low specificity.
Conclusions of the assessment of existing cost-effectiveness evidence
The review did not identify any studies that evaluated the cost-effectiveness of QAngio XA 3D/QFR
or CAAS vFFR. A supplementary review of published cost-effectiveness studies evaluating ICA (alone
and/or with FFR) in the management of CAD identified 21 relevant studies. Two studies were considered
to be particularly good examples of alternative modelling approaches to establish the link between
short-term diagnostic outcomes and the longer-term impact and subsequent prognosis associated with
the diagnostic pathways in the management of CAD and associated costs and outcomes. The modelling
approaches identified in Results of the review of decision models evaluating invasive coronary angiography
were used to inform the conceptualisation of the de novo model described in Chapter 5, Model structure,
and allowed identifying relevant evidence sources to inform model inputs and assumptions.
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Chapter 5 Independent economic assessment:
York model
Overview
The review of cost-effectiveness studies in Chapter 4 identified no studies evaluating the cost-effectiveness
of QAngio XA 3D/QFR and CAAS vFFR for assessing the functional significance of coronary stenosis.
Therefore, a de novo decision-analytic model was developed to formally estimate the cost-effectiveness of
QAngio XA 3D/QFR and CAAS vFFR for assessing the functional significance of coronary obstructions
during ICA in patients with stable angina and intermediate stenosis, relative to the comparators of invasive
FFR or iFR measurement or clinical decision-making based on visual interpretation of ICA alone, alongside
clinical judgement, in the UK NHS.
In developing and populating the decision model, three issues are considered central to the approaches
and methods employed:
1. the need to link the diagnostic accuracy of QFR and vFFR to short-term costs and consequences
[e.g. the impact on the proportion of patients who need revascularisation (percutaneous or surgical),
the proportion of patients who need invasive functional assessment of stenosis using FFR or iFR,
and adverse event rates and HRQoL associated with the diagnostic interventions]
2. the need to link the short-term consequences to potential longer-term costs and consequences
(e.g. the risk of major adverse cardiovascular events such as MI, sudden cardiac death and need for
urgent/unplanned revascularisations) using the best-available evidence to ensure that differences in
costs, life-years gains, and QALYs are appropriately quantified over a lifetime horizon
3. the need to ensure that the data inputs and assumptions are relevant to inform current NHS
practice, with particular consideration given to any differences in the cost-effectiveness of the
technologies in diagnostic-only laboratories or interventional catheter laboratories.
The decision-analytic model provides a framework for combining the diagnostic outcomes and the
subsequent prognosis associated with the diagnostic outcomes over the long term, and other inputs
reflecting current NHS practice. The model evaluates costs from the perspective of the NHS and PSS,
expressed in GBP (2018/19 price year). Outcomes in the model are expressed in terms of QALYs.
Both costs and outcomes are discounted using a 3.5% annual discount rate, in line with current
NICE guidelines.92 The model was developed using Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA).
The model is probabilistic in that uncertainty in input parameters are reflected through the use of
appropriate probability distributions, rather than using fixed mean estimates for input parameters.93
A Monte Carlo simulation is used to propagate uncertainty in input parameters through the model
to capture the uncertainty in overall results. Scenario analyses are undertaken to explore the
robustness of the cost-effectiveness results to changes in the parameter inputs and assumptions
of the model.
The following sections outline the decision problem and the structure of the model, and provide an
overview of the key assumptions and data used to populate the model.
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Decision problem and population
The decision problem addressed by the model relates to the cost-effectiveness of QAngio XA 3D/QFR
and CAAS vFFR imaging software used during ICA for assessing the functional significance of coronary
stenosis in patients with stable angina whose angiograms show intermediate stenosis.
The model considers this in the context of the NICE Clinical Guideline Pathway,94 where ICA is used
to guide the treatment strategy for patients with a confirmed diagnosis of stable CAD of uncertain
functional significance and whose symptoms are not satisfactorily controlled with OMT and so may
require revascularisation.
QAngio XA 3D/QFR and CAAS vFFR can be used in the same clinical settings where ICA is performed.
These settings include diagnostic-only laboratories and interventional catheter laboratories. One
key difference between the two settings is that assessments with FFR/iFR are performed only
in interventional catheter laboratories. When patients assessed in a diagnosis-only laboratory
require a FFR/iFR measurement because of inconclusive ICA results, they have to be referred to an
interventional catheter laboratory. Therefore, inconclusive results obtained with QAngio XA 3D/QFR
and CAAS vFFR that require confirmation with FFR/iFR would also need to be referred to an
interventional catheter laboratory. In contrast, a FFR/iFR assessment can be performed immediately
after ICA, QAngio XA 3D/QFR or CAAS vFFR in an interventional catheter laboratory if needed.
The target population of the model consists of patients with stable CAD whose angiograms taken
during ICA show intermediate stenosis. Although various definitions of intermediate stenosis exist,
the modelled population considers intermediate stenosis to be any stenosis where there is clinical
uncertainty about its functional significance and the potential appropriateness of revascularisation.
No subgroup data are available to permit a separate consideration of subpopulations.
Diagnostic strategies
The aim of diagnostic testing is to identify patients with functionally significant coronary stenosis who
would benefit from revascularisation (PCI or CABG), in addition to OMT. As ICA is required to show
intermediate stenosis, the starting diagnostic test is visual assessment with ICA. In the absence of
other tests, clinical decision-making would be based on visual interpretation of the images taken during
ICA, alongside clinical judgement. However, ICA alone is not sufficient to indicate whether anatomical
obstructions are functionally significant or functionally non-significant; therefore, confirmatory FFR/iFR
is considered the reference standard test for functional assessment of coronary obstructions. Because
FFR/iFR is regarded as the ‘gold standard’ diagnostic test for assessing functional significance of
stenosis, it is assumed to have perfect sensitivity and specificity of 100%. This means that all patients
would receive an appropriate treatment based on the results of FFR/iFR (either revascularisation for
TP test results or OMT for TN test results). The comparator diagnostic tests for QAngio XA 3D/QFR
and CAAS vFFR are ICA alone (without the functional assessment of coronary obstructions) or ICA,
followed by invasive FFR/iFR measurement using pressure wire.
The interventions are clinical decision-making based on QAngio XA 3D/QFR and CAAS vFFR (used
during ICA), alongside clinical judgement. These technologies are alternatives to pressure wire
FFR/iFR and provide a non-invasive means to simulate FFR measurement during ICA assessment.
The technologies may also be used as a precursor to invasive FFR/iFR, with the invasive pressure
wire FFR/iFR only used as a confirmatory procedure when QFR or vFFR test results are inconclusive.
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The decision model evaluates the following five diagnostic strategies:
1. ICA alone (i.e. visual interpretation of angiographic images taken during ICA without additional
testing to assess the functional significance of intermediate stenosis)
2. ICA, followed by confirmatory FFR/iFR (reference standard)
3. ICA with QFR using QAngio XA 3D/QFR
4. ICA with QFR using QAngio XA 3D/QFR, followed by confirmatory FFR/iFR if the QFR is inconclusive
5. ICA with vFFR using CAAS vFFR.
The strategy of ICA alone, referred herein as strategy 1, is based on the use of a diagnostic threshold
of 50% DS to define the need for revascularisation (i.e. ≥ 50% DS in the left main coronary artery,
alongside clinical judgement, is sufficient to indicate the need for revascularisation). Strategy 1 means
that treatment decisions based on DS and clinical judgement alone are used to stratify treatment
decisions. However, it is widely accepted that DS has only modest correlation with physiological
indexes of myocardial ischaemia such as FFR/iFR. Therefore, the more appropriate comparator strategy
for the new technologies is ICA followed by confirmatory FFR/iFR, referred herein as strategy 2. The
diagnostic threshold for strategy 2 is a FFR value of 0.8, where revascularisation can be safely deferred
for stenoses with a FFR > 0.8, whereas stenoses with a FFR ≤ 0.8 are functionally significant and
should be considered for revascularisation.
The strategy of ICA with QFR, referred herein as strategy 3, is based on the use of a single diagnostic
threshold of 0.8 to define functionally significant and non-significant stenoses. A QFR value of ≤ 0.8 is
considered a significant obstruction and revascularisation should be considered, whereas stenoses with
a QFR value > 0.8 are considered to be functionally non-significant and revascularisation can be
deferred (i.e. patients receive OMT alone).
The strategy of ICA with QFR, followed by confirmatory FFR/iFR when QFR is inconclusive, referred
herein as strategy 4, is considered an alternative strategy to strategy 3. In strategy 4 a dual threshold
is used to represent a ‘hybrid’ approach of QFR, followed by FFR when the test results of QFR are
inconclusive (grey zone). A QFR value below 0.78 is considered to have sufficiently high accuracy to
indicate functionally significant stenosis and that revascularisation should be considered, whereas a
QFR value above 0.84 is considered to have sufficiently high accuracy to indicate functionally non-
significant stenosis and that revascularisation may be deferred (i.e. patients receive OMT alone). QFR
values that are inconclusive and lie in the grey-zone region (0.78–0.84) should be verified by invasive
FFR/iFR measurement before a decision is taken on the need for revascularisation. This strategy uses
the same grey-zone region as described in the QAngio XA 3D/QFR instructions and corresponds to
Medis Medis Medical Imaging Systems BV’s recommended use of the technology.
The strategy of ICA with vFFR, referred herein as strategy 5, is the same as strategy 3 but with
the alternative technology CAAS vFFR rather than QAngio XA 3D/QFR. A vFFR value of ≤ 0.8 is
considered a significant obstruction and indicates revascularisation should be considered, whereas
stenoses with a vFFR value of > 0.8 are considered to be functionally non-significant and indicate
revascularisation can be deferred.
Note that it is not possible to consider a sixth strategy using CAAS vFFR, followed by confirmatory
FFR/iFR, when vFFR is inconclusive because there is no diagnostic accuracy data available to inform
this strategy (and it is not possible to infer diagnostic information from the very limited diagnostic data
available for vFFR) (see Chapter 3, CAAS vFFR).
For all strategies, patients who receive revascularisation (TP and FP patients) are assumed to be
treated with PCI or CABG. The proportion of patients receiving either procedure is independent of the
diagnostic strategy with fixed proportions assumed of PCI (87%) and CABG (13%) for all strategies
(see Complications due to revascularisation).
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Model structure
The model is made up of two components: a diagnostic element that characterises the diagnostic
outcomes and costs and consequences associated with diagnostic testing and revascularisation, and a
longer-term prognostic element that considers the subsequent prognosis associated with the diagnostic
outcomes and associated costs and consequences of treatment over the remaining lifetime of a patient.
The period represented by the diagnostic element (referred herein as diagnostic model) takes account
of the diagnostic accuracy of the non-invasive functional tests (QAngio XA 3D/QFR and CAAS vFFR
used during ICA) relative to the reference standard measurement using the invasive test of FFR/iFR
(assumed to have a sensitivity and specificity of 100%). Patients correctly identified as having functionally
significant stenosis (TP result) will progress to revascularisation, in addition to OMT, whereas patients
correctly identified as having functionally non-significant stenosis (TN result) will receive OMTwithout
the need for revascularisation. Patients incorrectly identified as having functionally significant stenosis
(FP result) will undergo unnecessary revascularisation, whereas patients incorrectly identified as not
having functionally significant stenosis (FN result) will not receive an appropriate revascularisation
procedure. The non-invasive tests may also lead to inconclusive results about the functional significance
of stenosis, which leads to further invasive testing with pressure wire FFR/iFR to confirm whether or
not there is a need for revascularisation.
The longer-term prognostic element of the model (referred herein as prognostic model) takes account
of the impact and subsequent prognosis associated with the diagnostic outcomes and models the
risk of MACEs such as MI, sudden cardiac death and need for urgent/unplanned revascularisation,
as well as adverse events related to revascularisation and MI. The costs and HRQoL implications of
treatment are modelled over a lifetime horizon.
Diagnostic model
Diagnostic outcomes are modelled with a decision tree, which takes account of the diagnostic accuracy
of the tests and subsequent treatment pathway. The decision tree is constructed to compare the TP,
FP, TN and FN rates of the alternative diagnostic strategies.
The decision tree starts with the alternative diagnostic strategies that are used to diagnose the
functional significance of stenosis. The outcomes of each strategy are governed by the sensitivity and
specificity of the particular test strategy. The accuracy of the tests is defined independently of disease
prevalence (i.e. underlying prevalence of functionally significant stenosis in the population); however,
the expected proportion of tests with positive and negative results in the population is dependent on
the underlying prevalence. Therefore, for all strategies, patients are separated into their ‘true’ status of
either functionally significant stenosis or functionally non-significant stenosis based on the distribution
of the population with a FFR value ≤ 0.8. Patients with functionally significant stenosis requiring
revascularisation are allocated to one of three outcome states as a result of the diagnostic strategy:
(1) TP, who are correctly identified and treated with revascularisation, (2) FN, who are misidentified
and do not receive revascularisation, and (3) death as a result of the mortality risks associated with
the diagnostic and revascularisation procedures. Patients without functionally significant stenosis who
do not require revascularisation are also allocated to one of three outcome states as a result of the
diagnostic strategy: (1) TN, who are correctly identified and treated with OMT, (2) FP, who are misidentified
and receive an inappropriate revascularisation, and (3) death as a result of the mortality risks associated
with the diagnostic and revascularisation procedures. For revascularisation, a proportion of patients are
assumed to be treated with either PCI or CABG, in addition to OMT.
A schematic of the diagnostic model for each of the five strategies is shown in Figures 12–16 (with
outcome of death not shown in the figures for simplicity). Strategies 1 (ICA alone), 3 (ICA plus QFR)
and 5 (ICA plus vFFR) have four possible diagnostic test results of TP, FN, FP and TN based on the
diagnostic accuracy of the tests relative to the reference standard test of FFR ≤ 0.8. Strategy 2 is the
INDEPENDENT ECONOMIC ASSESSMENT: YORK MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
reference standard test (ICA plus FFR), and TP and TN are the only diagnostic outcomes under this
strategy because FFR/iFR is assumed to be a perfect test (100% sensitivity and specificity). Strategy 4
is the hybrid approach of QFR where the possible diagnostic outcomes are TP, FN, FP and TN for those
considered to have conclusive QFR (values outside the grey zone), whereas TP and TN are the only
possible outcomes for those with inconclusive QFR (grey zone) because these patients undergo
confirmatory FFR/iFR. Death can occur as a result of the diagnostic and revascularisation procedures.
The model assumes that all diagnostic tests in each strategy are performed in the same medical
appointment, and that revascularisation procedures are performed either immediately after testing or
Diagnostic test True disease status Test results, ICA Treatment
ICA alone
Functionally signif icant
stenosis (+)
TP
TN
FN
FP
Functionally
non-signif icant stenosis (–)
Intermediate stenosis
Optimal medical
therapy
Optimal medical
therapy
Revascularisation
Revascularisation
CABG
PCI
CABG
PCI
FIGURE 12 Strategy 1 of ICA alone, without additional testing to assess the functional significance of stenosis.
Diagnostic test True disease status Test results, FFR/iFR Treatment
ICA, followed by
conf irmatory FFR/iFR
Functionally signif icant
stenosis (+)
TP
TN
Functionally
non-significant stenosis (–) 
Intermediate stenosis
Optimal medical
therapy
Revascularisation
CABG
PCI
FIGURE 13 Strategy 2 of ICA, followed by confirmatory FFR/iFR.
Diagnostic test True disease status Test result, QFR Treatment
ICA with QFR
Intermediate stenosis
Functionally signif icant
stenosis (+)
Functionally
non-signif icant stenosis (–)
TP
TN
FN
FP
Revascularisation
Revascularisation
Optimal medical
therapy
Optimal medical
therapy
PCI
CABG
PCI
CABG
FIGURE 14 Strategy 3 of ICA with QFR.
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without a delay that might lead to a deterioration of the patient’s condition. Therefore, the base-case
analysis is more representative of an interventional setting. The assumption that all diagnostic tests in
each strategy are performed in the same medical appointment is relaxed in a scenario analysis so as to
explore the cost-effectiveness of the strategies in a diagnostic-only setting.
For the diagnostic model, costs are incurred according to the type of diagnostic test, adverse events
associated with FFR, and treatment received. Procedural HRQoL loss is included for FFR and
revascularisation. Costs, HRQoL and mortality effects associated with ICA are excluded from the
model because these are incurred equally across all strategies.
The diagnostic model represents the start of the long-term prognostic model. The proportion of
patients starting in the health states in the prognostic model is based on the expected proportion
of tests with positive and negative results in the population (TP, TN, FP, FN).
Prognostic model
The prognostic implications of receiving treatment (either revascularisation in addition to OMT or
OMT alone) based on being in one of the four diagnostic outcome states (TP, FN, FP or TN) is
quantified using a Markov model that captures the progression of disease through the risk of MACEs
and associated costs and consequences, and the risk of death from non-cardiac causes, over a lifetime
horizon. A cycle length of 1 year is used in the model. A schematic of the model structure is shown
in Figure 17.
Diagnostic test
Intermediate stenosis
ICA with QFR,
followed by
conf irmatory FFR/iFR
when QFR is
inconclusive
Functionally signif icant
stenosis (+)
Functionally
non-signif icant stenosis (–)
Inconclusive QFR
Inconclusive QFR
TP
TN
PCI
CABG
PCI
CABG
Optimal medical
therapy
Optimal medical
therapy
Revascularisation
Revascularisation
Conclusive QFR,
TP
Conclusive QFR,
FN
Conclusive QFR,
TN
Conclusive QFR,
FP
Test result, QFRTrue disease status Test result, FFR/iFR Treatment
FIGURE 15 Strategy 4 of ICA with QFR, followed by confirmatory FFR/iFR when QFR is inconclusive.
Diagnostic test True disease status Test result, vFFR Treatment
ICA with vFFR
Intermediate stenosis
Functionally significant 
stenosis (+)
Functionally
non-significant stenosis (–) 
TP
FN
FP
TN
PCI
CABG
PCI
CABG
Revascularisation
Revascularisation
Optimal medical
therapy
Optimal medical
therapy
FIGURE 16 Strategy 5 of ICA with vFFR.
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Patients with stable CAD and intermediate stenosis enter the model in one of four diagnostic outcome
health states: TN (functionally non-significant stenosis with FFR > 0.8 and received OMT), FN
(functionally significant stenosis with FFR ≤ 0.8 and received OMT), TP (functionally significant stenosis
with FFR ≤ 0.8 and have undergone revascularisation), FP (functionally non-significant stenosis with
FFR > 0.8 and have undergone revascularisation) or death.
All patients alive may remain in their initial health state over time with no MACEs, or have a primary
MACE. The primary MACE is defined as cardiovascular death, non-fatal MI and unplanned (urgent)
revascularisation, where the risk differs between the first year and subsequent years from model entry.
Each MACE is assumed to be mutually exclusive. If the primary MACE is fatal, the patient enters an
absorbing state of cardiovascular death. If the event is a non-fatal MI, they enter the post-MI health
state where the risk of a subsequent cardiovascular event (cardiovascular death or MI) is increased
as a result of having had a previous MI. Patients in the post-MI state are assumed to not be at further
risk of unplanned revascularisation. If the primary MACE is an unplanned revascularisation, it is
assumed that patients will receive an appropriate revascularisation procedure, with the same associated
costs and risks as those patients who entered the model in the TP state (i.e. it is assumed that patients
who require a subsequent targeted revascularisation have the same risk of MACE as patients who enter
the model in the TP state, under the assumption that the need for urgent revascularisation is indicative
of functionally significant stenosis with FFR ≤ 0.8). Patients enter the unplanned revascularisation event
state for one cycle only and, for the following 12 months, are at an increased risk of cardiovascular
death or MI compared with subsequent years. Those who have a cardiovascular death or non-fatal MI
during this period enter the cardiovascular death state or post-MI state, respectively. If no event occurs
in 12 months following an unplanned revascularisation, the patient moves into the post-revascularisation
health state, where the risk of cardiovascular death or MI relates to the risk post 12 months from the
TP state. From any of the states in the model where patients are alive, there is a competing risk of a
non-cardiovascular death.
CV death
Post
revascularisation
(subsequent
years)
Unplanned
revascularisation
(First year)
Primary MACE
Entry
TP
Entry
FN
Entry
TN
Entry
FP
Entry from all
health states
Non-CV
death
Non-fatal MI
event
Post MI
FIGURE 17 Schematic of prognostic model. CV, cardiovascular.
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Model input parameters
Patient population
The population consists of patients with stable CAD whose angiograms taken during ICA show
intermediate stenosis. The age and sex distribution varies across the studies informing the diagnostic
accuracy of the technologies (mean age ranging from 61 to 72 years and proportion of males from
67% to 81%). The IRIS-FFR registry is the largest registry to investigate the prognosis of coronary
stenosis assessed by FFR. The mean age and proportion of males in the IRIS-FFR registry was
64 years and 72%, respectively. These values are within the range reported in the diagnostic accuracy
studies and the patient populations of the largest RCTs undertaken to evaluate clinical outcomes of
revascularisation for patients with stable CAD [e.g. the International Study of Comparative Health
Effectiveness With Medical and Invasive Approaches (ISCHEMIA),95 mean age 64 years and 77% male;
the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial,96 mean age 62 years
and 70% male; and the COURAGE trial,91 mean age 62 years and 85% male]. These studies, however,
were mainly or wholly undertaken outside the UK. The smaller ORBITA (Objective Randomised Blinded
Investigation with optimal medical Therapy of Angioplasty in stable angina) trial,97 which enrolled
patients with stable angina and angiographically severe single-vessel CAD at five UK sites, had a mean
age of 66 years and was 73% male. The IRIS-FFR registry includes mostly patients with stable angina
(76%), although 18% had unstable angina and nearly 6% had NSTEMI/STEMI.
Given that the IRIS-FFR registry is the largest registry to investigate the prognosis of coronary
stenosis assessed by FFR and that the mean age and proportion of males is very similar to the ORBITA
trial,97 this is used to inform the base-case population in the model (mean age 64 years and 72% male).
Prevalence of functionally significant stenosis
The prior likelihood of functionally significant stenosis in the population is based on the distribution of
FFR values ≤ 0.8 in the recreated individual-level patient data used to inform the diagnostic accuracy of
QFR compared with FFR [see Chapter 3, Meta-analyses of data extracted from figures (QAngio XA 3D/QFR)].
In the absence of alternative individual-level data to provide the underlying distribution of FFR/iFR
values in the population, the analysis assumes that the population in the QAngio XA 3D/QFR studies is
reflective of the UK population in terms of underlying prevalence of functionally significant stenosis for
which the technologies (QAngio XA 3D/QFR and CAAS vFFR) would be used.
In the base-case analysis, the FFR distribution is based on the subset of studies that jointly reported
values of FFR and cQFR or non-specified QFR to be consistent with the set of studies informing the
diagnostic accuracy for strategy 4, which considers QFR followed by FFR when the test results of QFR
are inconclusive (see QAngio XA 3D/QFR and CAAS vFFR). This distribution of FFR values suggests a
prior likelihood of functionally significant stenosis of 40.2% based on the proportion of participants
who had a FFR ≤ 0.8.
Patient throughput
The cost of the diagnostic tests (QAngio XA 3D/QFR and CAAS vFFR) per patient depends on the
average annual throughput per centre. To estimate this throughput, assumptions about patient eligibility
for testing with FFR/iFR are combined with data from the BCIS audit return (data from the 2017/18
BCIS audit return98 are used, as the information in the 2018/19 audit99 is only partially reported).
Patients with stable CAD are expected to constitute approximately one-third of patients who undergo
ICA in the UK (Dr Gerald Clesham, Essex Cardiothoracic Centre, Mid and South Essex NHS Foundation
Trust, 2020, personal communication). In 2017/18, and in an interventional setting, the average
annual number of patients undergoing ICA in the NHS was 205,085, and the average number of ICA
procedures per centre was 2093 (see Appendix 8, Table 60).98
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Under a very broad definition of intermediate stenosis, where all stable CAD patients would undergo
confirmatory testing with FFR/iFR, the average annual throughput for an NHS interventional centre
could be as much as one-third of the average number of ICA procedures per centre, which would yield
an expected upper bound of 698 patients per centre for annual throughput in an NHS interventional
setting (which is the setting considered in the base-case analysis; see Diagnostic model and Setting).
A more realistic assumption would be to consider that only patients with stable CAD who currently
undergo FFR/iFR have intermediate stenosis. According to the BCIS audit returns,98 21,098 pressure
wire procedures were performed annually in the UK in 2017/18 (11,726 for diagnostic-only purposes
and the rest followed by PCI). This gives an average of 215 pressure wire procedures per intervention
centre per year. In the base-case analysis, it is assumed that the majority of these procedures are
performed in stable CAD in patients with intermediate stenosis. An average annual throughput
of 200 patients per centre is assumed in the base case. Alternative throughput assumptions are
considered in a scenario analysis.
Setting
In UK clinical practice, ICA can be used in two settings: diagnostic-only and interventional catheter
laboratories. QAngio XA 3D/QFR and CAAS vFFR can be used in the same settings as ICA, whereas
FFR/iFR is currently performed only in an interventional setting.
The base-case analysis assumes that the tests in each of the five diagnostic strategies are performed
at the same medical appointment and, thus, implicitly assumes an interventional setting. Although
the large majority of ICA procedures in the NHS are conducted in an interventional setting (see
Appendix 8, Table 60),98 it is important to consider the differences between settings that may affect
the cost-effectiveness of the strategies under comparison.
The key difference between diagnostic-only and interventional catheter laboratories is that FFR/iFR can
be performed only in the latter. In a diagnostic-only setting, strategies that include FFR/iFR in the testing
sequence (strategies 2 and 4) require that at least some patients undergo two separate diagnostic
catheterisation procedures. The initial catheterisation corresponds to the ICA that is common to all
strategies in the model and is performed in the diagnostic-only catheter laboratory. Patients who have
an inconclusive QFR measurement with QAngio XA 3D/QFR (patients in the grey zone for strategy 4)
and all patients in strategy 2 are referred to an interventional catheter laboratory where they undergo a
second catheterisation to obtain a FFR/iFR measurement. This is in contrast with how patients would be
tested in an interventional setting, as all tests could be performed with a single catheterisation, and at
the same point in time. One of the implications of conducting two separate catheterisations is that
strategies that involve FFR/iFR will be more costly in a diagnostic-only setting than in an interventional
setting. Another potential consequence of this is that the condition of patients initially tested in a
diagnostic-only setting deteriorates while waiting for the referral to the interventional catheter
laboratory and subsequent clinical management with revascularisation where appropriate. However, the
delays to patient management are unlikely to result in significant condition deterioration with impact on
patients’ health outcomes (Dr Gerald Clesham, personal communication). This is supported by evidence
of the ORBITA trial97 (see Treatment effect of revascularisation), which showed that PCI compared with
a placebo (mock PCI) did not demonstrate a statistically significant increase in the exercise time or
change in HRQoL of patients with medically treated angina and severe coronary stenosis at 6 weeks
post procedure.97
Another difference between settings is the expected annual patient throughput in diagnostic-only
compared with interventional catheter laboratories. Appendix 8, Table 60, shows that, on average,
584 patients undergo ICA in a diagnostic-only setting compared with 2093 in an interventional setting.
However, the proportion of patients with stable CAD who undergo ICA in a diagnostic-only setting is
likely to be higher than in an interventional catheter laboratory. The expected patient throughput in a
diagnostic-only setting is unknown but needs to be considered when evaluating the cost-effectiveness
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of the alternative diagnostic strategies, as it determines the cost of the QAngio XA 3D/QFR and CAAS
vFFR tests. This is discussed further in Test costs.
It is possible that the diagnostic accuracy of QAngio XA 3D/QFR and CAAS vFFR is also linked to the
diagnostic setting. The diagnostic accuracy studies identified in Chapter 3 do not provide evidence to
ascertain whether or not there are any differences in the diagnostic accuracy of these technologies
across settings, as the patient population in the review may not represent patients examined in a
diagnostic-only setting. This is because only patients with a FFR measurement could be included in the
diagnostic accuracy review (see Chapter 3, Selection criteria).
Finally, it is possible that there are additional training requirements for QAngio XA 3D/QFR and CAAS
vFFR in diagnostic-only catheter laboratories, as staff in these centres may need more training and
support to correctly calculate and interpret the QFR and vFFR measurements. It is, however, uncertain
what resource use is associated with these additional training requirements, so this could not be
reflected in the cost-effective analysis.
The base-case scenario assumes that all diagnostic procedures take place in an interventional setting.
The diagnostic-only setting is considered in scenario analyses where the impact on cost-effectiveness
estimates of the following is explored: (1) additional costs due to the need to refer patients who
require FFR/iFR measurements to an interventional catheter laboratory and (2) alternative throughput
assumptions (see Results of the alternative scenario analyses).
Diagnostic accuracy
The model considers the diagnostic accuracy of ICA, QFR and vFFR, and FFR/iFR is the reference
standard test with 100% sensitivity and specificity. The diagnostic accuracy of iFR is assumed to be
equivalent to that of FFR. The definition of functionally significant stenosis is based on a FFR value
≤ 0.8. The following sections present the diagnostic accuracy estimates used in the model.
QAngio XA 3D/QFR and CAAS vFFR
For strategies 3 (QFR) and 5 (vFFR) that consider a single diagnostic threshold of 0.8, the test results
are dichotomous (either positive or negative for functionally significant stenosis) based on the
estimates of sensitivity and specificity of the tests relative to the reference standard of FFR ≤ 0.8.
For strategy 4, where a hybrid QFR and FFR approach is considered, the QFR test results are no longer
classified as dichotomous. Under this strategy, test results are classified as positive (QFR < 0.78),
negative (QFR > 0.84) or inconclusive (QFR 0.78–0.84) based on the dual thresholds of 0.78 and 0.84.
Diagnostic accuracy of QFR in strategy 4 is informed by the joint probabilities of having a FFR
measurement below or above the 0.8 threshold and a QFR measurement within the intervals defined
by the dual thresholds of 0.78 and 0.84.
Single diagnostic threshold: sensitivity and specificity estimates
The diagnostic accuracy of QFR for strategy 3 is informed by the results of the bivariate meta-analysis
reported in Chapter 3, Bivariate meta-analysis (QAngio XA 3D/QFR), which combined results of studies
that reported cQFR or non-specified QFR. Alternative estimates for sensitivity and specificity based
on studies reporting fQFR only and cQFR only are considered in separate scenario analyses. Table 9
presents the diagnostic accuracy estimates for QFR in strategy 3 used in the base-case analysis and
alternative scenarios.
The diagnostic accuracy of vFFR for strategy 5 is informed by the sensitivity and specificity estimates
of the FAST-EXTEND study,18 an update on the FAST study.56 This study is chosen to represent the
base-case analysis as it is the largest (n = 303) of the four included CAAS vFFR diagnostic accuracy
studies (see Chapter 3, CAAS vFFR).18,19,26,56 A pooled meta-analysis is not considered appropriate because
of the limited reported data, wide CIs, and high heterogeneity across the limited number of vFFR
studies. The limited number of vFFR studies means that the diagnostic accuracy estimates for
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strategy 5 are highly uncertain and the outcomes of this strategy must be interpreted with caution.
The robustness of the cost-effectiveness results to alternative estimates about the diagnostic accuracy
of vFFR is considered in scenario analyses, whereby the estimates are informed by the remaining vFFR
studies. Table 9 presents the diagnostic accuracy estimates for vFFR in strategy 5 used in the base-case
analysis and alternative scenarios.
The sensitivity and specificity estimates in the model are randomly drawn from probability distributions
to reflect uncertainty in these parameters. Where diagnostic accuracy was sourced from meta-analyses,
the log-odds sensitivity and specificity (with CIs) and the correlation between these two test accuracy
dimensions were used to inform multivariate log-normal distributions from which the probabilistic
estimates are drawn. For individual studies, beta-distributions were fitted to the sensitivity and
specificity estimates. To preserve the correlation between sensitivity and specificity, the diagnostic
accuracy 2 × 2 tables for each study were recreated (assuming a common prevalence for functionally
significant stenosis of 0.402 (see Prevalence of functionally significant stenosis) and used to inform the
alpha and beta parameters of the beta distributions.
Probability of quantitative flow ratio in the hybrid approach with confirmatory fractional flow reserve
The diagnostic accuracy of QFR in strategy 4 was based on the joint distribution of QFR and FFR
measurements in the extracted individual-level patient data (n = 3194) (see Chapter 3, Grey-zone
analysis) for the combined cQFR and non-specified QFR data. The probabilities of QFR test results
being positive (QFR < 0.78), negative (QFR > 0.84) or inconclusive (QFR 0.78–0.84) were conditional
on FFR values above and below 0.8. Table 10 presents the diagnostic accuracy estimates for strategy 4.
In the probabilistic analysis, the joint QFR and FFR probabilities in Table 10 were sampled from a set
of 5000 simulated values. These values were derived from 5000 simulations of the joint distribution
of FFR and QFR, generated by bootstrapping the extracted individual-level data from which the
probabilities in Table 10 were derived.
TABLE 9 Diagnostic accuracy estimates for QAngio XA 3D/QFR and CAAS vFFR
Test Analysis Sensitivity (%) Specificity (%) Source
QAngio XA 3D/QFR Base case 84.34 89.80 Bivariate meta-analysis (see Table 3) for
combined cQFR and non-specified QFR
Scenario 1 81.61 84.93 Bivariate meta-analysis (see Table 3) for fQFR
Scenario 2 84.32 91.40 Bivariate meta-analysis (see Table 3) for cQFR
CAAS vFFR Base case 97.00 74.00 FAST-EXTEND (2019)18
Scenario 4 75.00 46.50 ILUMIEN I (2019)19
Scenario 5 68.20 87.30 Jin et al. (2019)26
TABLE 10 The QAngio XA 3D/QFR diagnostic accuracy estimates for strategy 4
QAngio XA 3D/QFR test result QFR
Positive Negative
FFR ≤ 0.80 FFR > 0.8
Positive < 0.78 0.744 0.095
Inconclusive (grey area) 0.78–0.84 0.188 0.212
Negative > 0.84 0.069 0.693
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The diagnostic accuracy of an equivalent hybrid diagnostic approach for vFFR was not possible
because of data limitations. The diagnostic accuracy data for vFFR are very scarce (see Chapter 3, CAAS
vFFR), and only 81 data points for the joint FFR and vFFR distribution were available from one single
study.56 Furthermore, the underlying distribution of FFR values in this single study was considerably
different from that of the data extracted for QFR (probability of FFR ≤ 0.80 was 0.296 in the single
vFFR study, compared with 0.402 across 3194 data points in the QFR studies).
Invasive coronary angiography
The base-case diagnostic accuracy of ICA was informed by the bivariate meta-analysis of extracted
data presented in Meta-analysis of extracted figure data for two-dimensional invasive coronary angiography.
The model considered ICA to have a sensitivity and a specificity of 62.61% and 62.59%, respectively,
when using a diagnostic threshold of 50% DS. Alternative sensitivity and specificity estimates based
on a meta-analysis by Danad et al.100 (per-vessel analysis) for diagnostic performance of ICA compared
with FFR are used in a scenario analysis. In this study, ICA was found to have a sensitivity of 71% and
a specificity of 66% based on a diagnostic threshold of 50% DS.
Procedural adverse events
Procedures involving catheterisation for diagnostic testing (ICA and FFR/iFR) or revascularisation
(PCI and CABG) have associated complications that may result in health-care resource and HRQoL
loss. The diagnostic model considers the impact of serious procedural complications from FFR/iFR
and revascularisation. The procedural complications of ICA are excluded from the model because all
patients undergo this procedure in all strategies and, therefore, procedural complications associated
with ICA do not result in differences in costs and HRQoL across strategies.
The diagnostic pathway explicitly distinguishes between complications associated with invasive testing
with FFR/iFR and revascularisation so that the potential benefits of less invasive testing can be
captured (i.e. non-invasive testing with QFR and vFFR in strategies 3 and 5, respectively). However,
revascularisation is often performed immediately after FFR/iFR and, therefore, the rates are often not
reported separately in the literature by type of procedure.
Complications due to fractional flow reserve/instantaneous wave-free ratio
Three studies were identified that reported procedural complication rates in a format suitable to
inform those associated with FFR/iFR alone (i.e. unrelated to the revascularisation procedure). The
RIPCORD trial101 compared the clinical management (OMT alone or in addition to PCI or CABG)
of patients with stable chest pain with ICA compared with pressure wire FFR assessment.101 The
placebo arm of the ORBITA trial97 is also potentially relevant to inform the rates of FFR-/iFR-related
complications. In this study, patients were randomised to either PCI or a placebo procedure for angina
relief, with all patients undergoing FFR/iFR prior to randomisation. Thus, patients who had serious
periprocedural complications in the placebo arm had undergone FFR/iFR but not PCI. The IRIS-FFR
registry data also reports serious complications associated with FFR measurement.13 The rates of
serious events reported in the three studies are summarised in Appendix 8, Table 61.
Data from the IRIS-FFR registry are used to inform the base-case analysis because this registry is
considerably larger than the other studies and is used as a source of baseline clinical effectiveness
in the prognostic model (see Baseline risk of major adverse cardiac events). A scenario analysis uses the
alternative source of data from the RIPCORD trial101 because this is a UK study and the patient population
appears comparable to that of the base-case population (mean age 64 years and 75% male).
The majority of complications reported in the ORBITA trial97 appear to be related to ICA (major
bleeding and pulmonary oedema) and not to FFR/iFR based on the description of the complications
reported in the manuscript’s supplementary materials. The conversion to PCI as a result of procedural
complications in ORBITA97 appears to be because of coronary dissection caused by the pressure wire,
and suggests a much higher rate for this complication than that reported in the IRIS-FFR registry.
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The patient population in ORBITA97 may represent a more severe population (mean baseline FFR
0.69 ± 0.16) than the population in the IRIS-FFR registry (mean baseline FFR 0.83 ± 0.11). Therefore,
the rate of procedural adverse events in ORBITA97 is expected to be an overestimate of the
complication rates in the base-case population.
None of the studies above reported procedural mortality as a result of FFR/iFR. In the IRIS-FFR
registry, deaths due to FFR may have been captured within the rates of MACEs, but this is unclear.
A procedural death rate associated with FFR/iFR of 0.015% is included in the diagnostic model based
on an estimate sourced from Fearon et al.,87 which was the only study identified in the review of
decision models evaluating ICA (see Results of the review of decision models evaluating invasive coronary
angiography) to include FFR-specific procedural death. The rates of FFR/iFR procedural complications
applied in the base-case analysis are summarised in Appendix 8, Table 73.
Note that, although patients underwent iFR and FFR in ORBITA,97 all patients underwent FFR only in
the IRIS-FFR registry and RIPCORD.101 The base-case analysis assumes that there are no differences in
the rates of procedural complications because of FFR and iFR, that is the complication rates associated
with pressure wire FFR in IRIS-FFR are also reflective of the average rates of iFR as an alternative to
FFR in UK clinical practice.
Probabilistic estimates of the FFR procedural complication rates were obtained by randomly sampling
from independent beta distributions for each event rate.
Complications due to revascularisation
Death was the most common revascularisation complication reported in the cost-effectiveness models
reviewed in Results of the review of decision models evaluating invasive coronary angiography. Two studies
also considered non-fatal MI, but one reports complication rates jointly for ICA and revascularisation74
and the other88 sources complication rates from a very early 1996 study.
The IRIS-FFR registry does not report procedural complications associated with revascularisation
separate from the risk of MACEs. The rate of procedural deaths associated with revascularisation
is sourced from UK audit data. A 0.99% death risk for non-emergency CABG102 and 0.17% for
in-hospital mortality for PCI103 are applied in the diagnostic model. The mortality rate associated
with revascularisation is estimated as a weighted average of the mortality rates for PCI and CABG,
where the weights correspond to the relative proportion of PCI and CABG procedures. In the base-
case analysis, 87% of revascularisation procedures are assumed to be PCI, whereas the remaining
13% are CABG based on BCIS audit returns.98 The External Assessment Group (EAG) did not find data
suggesting these proportions differ depending on the diagnostic pathway (e.g. patients for whom the
revascularisation decision is made based on ICA results only vs. on ICA plus FFR/iFR results). It is also
unknown whether or not these proportions may differ for patients tested with QAngio XA 3D/QFR
or CAAS vFFR. This area of uncertainty was not explored in the analysis, as it would require strong
assumptions on clinician behaviour without data to inform a plausible range of alternative assumptions.
The EAG notes, however, that the impact of varying the relative proportion of PCI and CABG is likely
to be limited given the high rate of PCI in clinical practice.
Other procedural adverse events: radiation exposure
Patients who undergo cardiac catheterisation are exposed to ionising radiation, which may increase
the lifetime risk of malignancy and associated mortality. Some of the previous cost-effectiveness
models of ICA68,71,72,74,77,79 reviewed in Results of the review of decision models evaluating invasive coronary
angiography considered radiation exposure due to ICA testing and revascularisation.
QAngio XA 3D/QFR or CAAS vFFR may reduce the magnitude of radiation exposure by reducing
the procedural time to less than that of FFR/iFR. However, radiation exposure even with FFR/iFR is
expected to be very low, and the reduction in exposure through the use of QFR or vFFR is expected
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to be very marginal (Dr Gerald Clesham, personal communication). Therefore, the impact of radiation
exposure on cost-effectiveness is expected to be very minimal and is not quantified in the model. This
is supported by the previous cost-effectiveness models; for example, Walker et al.77 explicitly modelled
an increased risk of cancer death conditional on the amount of radiation exposure for several different
diagnostic strategies that included ICA, and found that the cost-effectiveness results were robust to
the exclusion of radiation effects.
Risk of major adverse cardiac events and treatment effects of revascularisation
Baseline risk of major adverse cardiac events
The benefits of treatment by correctly identifying patients suitable for revascularisation, or to have
their ischaemia treated by OMT, are modelled through the impact on risk of MACEs and HRQoL. The
baseline risk of MACEs in the absence of revascularisation depends on disease severity as measured by
FFR/iFR, where lower FFR values are indicative of a higher cardiovascular event rate, and higher FFR
values of a lower cardiovascular event rate.104 Thus, there is an inverse relationship between FFR value
and subsequent outcomes.
The IRIS-FFR registry is the largest registry to prospectively evaluate the natural history of lesions
after measurement of FFR in routine clinical practice.13 Revascularisation was deferred in 6468 lesions
(75%) and performed in 2165 lesions (25%) after FFR assessment. Treatment with revascularisation
was generally recommended in participating centres when the FFR was ≤ 0.75, and deferred when
the FFR was > 0.8. For FFR values between 0.75 and 0.8 the decision regarding revascularisation
was left to the operator’s discretion. Of the deferred lesions, 85.1% had a FFR value > 0.8, 9.2% had a
FFR value of between 0.76 and 0.8, and 5.7% had a value of ≤ 0.75. The reasons for deferred lesions
despite low FFR, that is, ≤ 0.75, included minimal coronary artery stenosis on ICA, diffuse disease
without focal stenosis, no symptoms, small myocardial territory or unsuitability for PCI.13
The primary end point in the IRIS-FFR registry was MACE arising from FFR-measured lesions, which
was a composite of cardiac death, MI and repeat revascularisation. Cardiac death was defined as any
death caused by a proximate cardiac cause, including cardiac arrest, MI and fatal arrhythmia. MI was
defined as a non-fatal MI event within the first 48 hours of the procedure or ≥ 48 hours after the
procedure accompanied by ischaemic symptoms. Repeat revascularisation was defined as any PCI or
CABG of a lesion with an index FFR measurement.13 The registry data provide a source of baseline risk
of MACE according to FFR value in deferred lesions in the absence of revascularisation.
The overall incidence rate of MACE in the IRIS-FFR registry across the range of FFR values was
1.44% (95% CI 1.15% to 1.73%) during the median follow-up of 1.9 years in deferred lesions. The
corresponding incidence rates of clinical events were 0.09% for cardiac death, 0.14% for MI, and 1.34%
for repeat revascularisation. When the 5.7% of deferred lesions with a FFR value of ≤ 0.75 were
excluded, the overall incidence rate of MACE was 1.24% (95% CI 0.96% to 1.52%).
The risk of MACE in deferred lesions increased significantly, whereas FFR decreased. The adjusted
HR for the risk of MACE when the FFR was included as an independent predictor in deferred lesions
was 1.06 (95% CI 1.05 to 1.08) per 0.01 decrease in the FFR (using FFR values ≥ 0.91 as a reference).
The corresponding adjusted HRs for the risk of clinical events were 1.06 (95% CI 0.99 to 1.13) for
cardiac death, 1.09 (95% CI 1.05 to 1.14) for MI and 1.07 (95% CI 1.06 to 1.09) for revascularisation.
The reported 1-year and long-term (up to 3 years) cumulative incidence of MACE in the IRIS-FFR
registry for deferred lesions is used in the model to provide an estimate of the baseline risk of MACE
(i.e. MACE risk in the absence of revascularisation procedure) for the first year and subsequent years.
The risk of MACE and the associated consequences in terms of health-care resource use and HRQoL
is modelled by stratifying patients into subgroups of FFR values, to take account of the relationship
linking FFR value to subsequent prognosis. To adjust for competing risks across cardiac events, the rate
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of each MACE component was divided by the sum of the rates of the components. The resulting
proportions (6% for cardiac death, 9% for MI and 85% for repeat revascularisation) were multiplied
by the baseline rate of the composite MACE outcome for the reference group with FFR values ≥ 0.91,
which resulted in rates adjusted for competing hazards from the MACE components.
The baseline risk of MACE used in the model for individuals in the group with highest FFR values
(FFR values ≥ 0.91) is 0.64% per annum in the first year and 0.32% per annum in subsequent years.
This risk was used as a reference to compute the baseline risk of MACE components in categories
with lower FFR values (i.e. < 0.91), using the adjusted HRs of 1.06, 1.09 and 1.07 per 0.01 decrease in
FFR for cardiac death, MI and revascularisation, respectively. The corresponding annual baseline risk of
MACE in deferred lesions by FFR value and by component of the composite outcome are shown in
Appendix 8, Figure 46, for the first year. The values for subsequent years are approximately half of the
values for the first year.
This approach implies that the baseline risk of MACE used in the model is conditional on FFR value
and that the distribution of FFR values differs by diagnostic strategy. Therefore, the baseline risk of
MACE from the TN and FN entry states in the model (in the absence of revascularisation) for each
diagnostic strategy is based on the joint conditional distribution of FFR values for the diagnostic
strategy across the FFR categories shown in Appendix 8, Figure 46; that is, the expected proportions
of TN outcomes with a FFR 0.81–0.85, FFR 0.86–0.90 and FFR ≥ 0.91; and FN outcomes with a FFR
0.76–0.80, FFR 0.71–0.75 and FFR ≤ 0.70 for each diagnostic strategy are dependent on the underlying
distribution of FFR values across these categories in the population. The same approach is used to
establish the risk of MACE following revascularisation for the TP and FP entry states in the model
(see Treatment effect of revascularisation). An alternative assumption is considered in a scenario analysis
in which the risk of MACE is assumed to be completely independent of FFR and diagnostic test results.
The main limitation of using the IRIS-FFR registry data as a source of baseline risk of MACE for the
model is that unobserved selection factors may have influenced the decision to perform or not to
perform revascularisation, which, in turn, may have exerted a modifying effect on outcomes. In addition,
the registry is based outside the UK in participating centres in the Republic of Korea. In the absence of
an alternative source of data that evaluates the natural history of lesions after measurement of FFR
in routine UK clinical practice, the model assumes that any potential selection factors in the IRIS-FFR
registry have no causal relation to outcomes and that any underlying reasons would not be expected
to differ from UK practice.
Treatment effect of revascularisation
The treatment effect of revascularisation on MACE in patients with stable CAD is highly uncertain
and has been an area of considerable debate over the past decades. Early RCTs examining the benefit
of PCI and CABG surgery compared with OMT suggested a survival benefit for revascularisation.
However, more recently, the benefits of revascularisation have been questioned as a result of similar
rates of death and MI observed in patients who have been optimally pharmacologically managed
without PCI.
Appendix 8, Table 62, summarises the main findings of recent RCTs (post year 2000) in stable CAD that
have compared revascularisation (in addition to OMT) with OMT alone. The focus on studies after the
year 2000 is because of the changes in interventions over the past decades. For example, PCI using
bare metal stents or early-generation drug-eluting stents have now been shown to be less safe and
effective than currently available second-generation stents,105 whereas pharmacological interventions
have changed over time.
The definition of MACE differs across the studies, but it is generally defined as a composite of
cardiovascular death (or all-cause mortality), MI and hospital admission, with or without the need
for revascularisation. The RCTs that showed a statistically significant difference in MACE between
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revascularisation and medical therapy were the Trial of Invasive versus Medical therapy in the Elderly
(TIME),106 Medicine, Angioplasty, or Surgery Study II (MASS II)107 and BARI 2D96 for CABG surgery;
COURAGE91 and the Fractional flow reserve versus Angiography for Multivessel Evaluation (FAME) II
trial108 for repeat revascularisation; and the DEFER (DEFERral vs. performance of percutaneous
coronary intervention of functionally non-significant coronary stenosis) trial109 in low FFR (i.e. < 0.75).
In TIME,106 305 patients aged 75 years and older with stable CAD of at least Canadian Cardiac Society
Class II, despite at least two antianginal drugs, were randomly assigned to PCI, CABG or OMT. A
significant difference in MACE rate between the revascularisation (19%) and medical therapy (49%)
groups was observed over a mean follow-up of 184.4 days. This difference was mainly due to higher
rates of hospital admission for acute coronary syndrome that required revascularisation.
In MASS II,107 611 patients with proximal multivessel stenosis and documented ischaemia were
randomly assigned to PCI, CABG or OMT. At the 5-year follow-up, a significant difference in MACE
was observed for CABG (21.2%) compared with PCI (32.7%) and OMT (36%). This difference suggests
a protective effect of CABG, but no significant difference in MACE was observed between PCI and
OMT. The difference in MACE for CABG was because of a significant difference in the need for repeat
revascularisation and MI; however, there was no significant difference in overall mortality. In the BARI
2D trial,96 2368 patients with stable CAD and type 2 diabetes were randomly assigned to PCI, CABG
or OMT.110 At the 5-year follow-up, patients in the CABG stratum, who had more advanced CAD than
those in the PCI stratum, had a significantly lower rate of MACE (22.4%) than the medical therapy
group (30.5%), which was largely driven by fewer MIs.
In the COURAGE trial,91 2287 patients with stable CAD were randomly assigned to PCI or OMT.
A statistically significant difference in the cumulative rate of additional revascularisation at 4.6 years
was observed between PCI (21.1%) and OMT (32.6%). The corresponding HR was 0.60 (95% CI 0.51 to
0.71). In the FAME II trial,108 888 patients with stable CAD were randomly assigned to FFR-guided PCI
for patients in whom at least one stenosis was functionally significant (i.e. FFR ≤ 0.80) or OMT. At the
2-year follow-up, a significantly lower rate of MACE was observed in the PCI group (8.1%) than in the
OMT group (19.5%), which was largely driven by a lower rate of urgent revascularisation in the PCI
group. The corresponding HR was 0.39 (95% CI 0.26 to 0.57). In the DEFER trial,109 325 patients with
stable CAD and intermediate stenosis were randomly assigned to PCI for a FFR ≥ 0.75, PCI for a FFR
< 0.75 or OMT.109 At the 2-year follow-up, a significantly lower rate of MACE was observed in the PCI
group with FFR < 0.75 (78%) than in the OMT group (89%) and the PCI group with a FFR ≥ 0.75
(83%), suggesting that FFR identifies those who will benefit the most from revascularisation in terms of
MACE outcomes.
The RCTs that showed a non-statistically significant difference in MACE between revascularisation and
medical therapy were MASS II107 and BARI 2D96 for PCI, COURAGE91 for the outcomes of mortality
and MI, and Japanese Stable Angina Pectoris (JSAP)111 and ISCHEMIA.95
In the MASS II trial107 at the 5-year follow-up, there was no statistically significant difference in MACE
between PCI (32.7%) and OMT (36%), whereas in the BARI 2D trial96 there was no statistically significant
difference in MACE between the revascularisation group (77.2%) and the OMT group (75.9%). In the
COURAGE trial,91 there was no statistically significant difference in 4.6-year cumulative event rates for
the composite end point of all-cause mortality and MI (HR 1.05 for PCI, 95% CI 0.87 to 1.27).
In the JSAP trial111, 384 patients with stable CAD and ≥ 75% coronary stenosis were randomly assigned
to PCI or OMT.111 At the 3.3-year follow-up, there was no statistically significant difference in MACE
between the PCI group (2.9%) and OMT group (3.9%). In the largest and most recent ISCHEMIA,95 5179
patients with stable CAD and moderate or severe ischaemia were randomly assigned to a revascularisation
group (74% PCI and 26% CABG) and OMT group.95 Over a median follow-up of 3.2 years, 318 primary
outcome events (composite of death from cardiovascular causes and MI, or hospitalisation for unstable
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angina, heart failure or resuscitated cardiac arrest) occurred in the revascularisation group and 352
occurred in the OMT group. At 6 months, the cumulative event rate was 5.3% in the revascularisation
group and 3.4% in the OMT group, whereas at 5 years the cumulative event rate was 16.4% in the
revascularisation group and 18.2% in the OMT group. The trial findings were sensitive to the definition
of MI and the timing of results; procedural MI was increased with revascularisation, and spontaneous
MI was reduced with revascularisation; thus, the net effect of MI was dependent on the time point at
which it was measured. The evidence from the trial suggests that there is no statistically significant
difference in MACE between revascularisation and OMT.
There have been several meta-analyses that have synthesised the results of trials examining the
treatment effect of revascularisation on MACE in patients with stable CAD.112–119 Of the most recent
meta-analyses that include new-generation stents, the following findings were identified:
l Pursnani et al.119 included RCTs comparing revascularisation with PCI with OMT in patients
with stable CAD, dating from 1980 until 2012. This study found that PCI was associated with
a non-statistically significant improvement in mortality (RR 0.85, 95% CI 0.71 to 1.01), cardiac
death (RR 0.71, 95% CI 0.47 to 1.06), non-fatal MI (RR 0.93, 95% CI 0.70 to 1.24) or repeat
revascularisation (RR 0.93, 95% CI 0.76 to 1.14), when compared with OMT. These results were
consistent across different follow-up time points.
l Thomas et al.115 included RCTs comparing revascularisation with PCI with OMT in patients with
stable CAD, dating from 1980 until 2011. When compared with OMT, PCI was associated with no
statistically significant improvement in all-cause mortality (RR 0.97, 95% CI 0.84 to 1.12), cardiac
death (RR 0.91, 95% CI 0.70 to 1.17) and non-fatal MI (RR 1.09, 95% CI 0.92 to 1.29).
l Stergiopoulos et al.118 included RCTs comparing revascularisation with PCI with OMT in patients with
stable CAD, dating from 1970 until 2012. When compared with OMT, PCI was associated with no
statistically significant improvement in all-cause mortality (OR 0.90, 95% CI 0.71 to 1.16), non-fatal
MI (OR 1.24, 95% CI 0.99 to 1.56) and unplanned revascularisation (OR 0.64, 95% CI 0.35 to 1.17).
l Windecker et al.117 undertook a Bayesian network meta-analysis comparing revascularisation
(PCI or CABG) with OMT among patients with stable CAD, dating from 1980 until 2013. CABG was
associated with a survival benefit (RR 0.80, 95% CI 0.70 to 0.91) compared with OMT. New generation
drug-eluting stents [everolimus-eluting Xience/Promus™ stent (Boston Scientific, Marlborough, MA,
USA): RR 0.75, 95% CI 0.59 to 0.96; zotarolimus-eluting Resolute™ stent (Medtronic plc, Dublin,
Ireland): RR 0.65, 95% CI 0.42 to 1.00], but not balloon angioplasty (RR 0.85, 95% CI 0.68 to 1.04),
bare-metal stents (RR 0.92, 95% CI 0.79 to 1.05) or early-generation drug-eluting stents [paclitaxel-
eluting Taxus® stent (Boston Scientific): RR 0.92, 95% CI 0.75 to 1.12; sirolimus-eluting Cypher™ stent
(Cordis Corporation, Hialeah, FL, USA): RR 0.91, 95% CI 0.75 to 1.10; zotarolimus-eluting Endeavor®
stent (Medtronic plc): RR 0.88, 95% CI 0.69 to 1.10], were associated with improved survival compared
with OMT. CABG reduced the risk of MI compared with OMT (RR 0.79, 95% CI 0.63 to 0.99), and
everolimus-eluting stents showed a trend towards a reduced risk of MI (RR 0.75, 95% CI 0.55 to 1.01).
The risk of subsequent revascularisation was noticeably reduced by CABG (RR 0.16, 95% CI 0.13 to
0.20) followed by new-generation drug-eluting stents (zotarolimus-eluting Resolute stent: RR 0.26,
95% CI 0.17 to 0.40; everolimus-eluting Xience/Promus stent: RR 0.27, 95% CI 0.21 to 0.35), early-
generation drug-eluting stents (zotarolimus-eluting Endeavor stent: RR 0.37, 95% CI 0.28 to 0.50;
sirolimus-eluting Cypher stent: RR 0.29, 95% CI 0.24 to 0.36; paclitaxel-eluting Taxus stent: RR 0.44,
95% CI 0.35 to 0.54) and bare-metal stents (RR 0.69, 95% CI 0.59 to 0.81) compared with OMT.
l Chacko et al.116 included RCTs comparing PCI with OMT in patients with stable and unstable CAD, dating
from 1992 until 2019, which included ISCHEMIA,95 to examine the effects on death and MI. For stable
CAD, PCI did not show a statistically significant reduction in mortality (RR 0.98, 95% CI 0.87 to 1.11),
cardiac death (RR 0.89, 95% CI 0.71 to 1.12) or MI (RR 0.96, 95% CI 0.86 to 1.08).
The IRIS-FFR registry13 prospectively evaluated the natural history of lesions after measurement of
FFR in routine clinical practice in those revascularised [95.7% PCI, with the majority new-generation
drug-eluting stents (85.1%) and 4.3% CABG] compared with deferred lesions. The overall incidence
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
69
rate of MACE in revascularised lesions was 2.4%, compared with 1.44% in deferred lesions during the
median follow-up of 1.9 years. The corresponding incidence rates of clinical events were 0.71% for
cardiac death or MI and 1.83% for repeat revascularisation compared with 0.21% and 1.34% in deferred
lesions, respectively. However, unlike the deferred lesions, the risk of MACE was not associated with
FFR measurement. After adjustment for independent predictors of MACE, the risk of MACE was not
statistically significantly different between revascularised and deferred lesions for FFR values ≥ 0.76
(HR 0.83, 95% CI 0.46 to 1.50 for a FFR 0.76–0.80 and HR 1.21, 95% CI 0.44 to 3.36 for a FFR
0.81–0.85). Revascularisation was associated with improved MACE rates, compared with deferred
lesions, for lesions with FFR ≤ 0.75 (HR 0.47, 95% CI 0.24 to 0.89 for a FFR 0.71–0.75 and HR 0.47,
95% CI 0.26 to 0.84 for a FFR ≤ 0.70). The findings from the IRIS-FFR registry are consistent with the
study by Johnson et al.,104 which examined the prognostic value of FFR on clinical outcomes. Johnson
et al.104 undertook a meta-analysis of study-level (9173 lesions) and patient-level (6961 lesions) data
investigating prognoses of MACE outcomes after FFR measurement by revascularisation compared
with OMT. The study-level metaregression indicated that revascularisation was associated with a
lower normalised 1-year MACE rate (composite of death, MI and repeat revascularisation), than OMT,
when the FFR was ≤ 0.75. The corresponding patient-level metaregression after adjustment for DS
indicated that revascularisation was associated with a lower 1-year MACE rate, than OMT, when the
FFR was ≤ 0.76.
In summary, the treatment effect of revascularisation on MACE in patients with stable CAD is highly
uncertain. The primary aim of the largest and most recent ISCHEMIA trial,95 which included UK centres,
was to address the limitations of previous trials by determining whether or not revascularisation plus
OMT, compared with a conservative strategy of OMT alone, would reduce the primary composite
outcome of death from cardiovascular causes or MI, and hospitalisation for unstable angina, heart
failure or resuscitated cardiac arrest in patients with stable ischaemic heart disease with moderate or
severe ischaemia. As indicated above, the trial did not find evidence that revascularisation reduced the
risk of MACE. Therefore, it seems appropriate for the base-case analysis to consider that the benefits of
the diagnostic tests in identifying the appropriateness for revascularisation confers no benefit on MACE
outcomes. This means that in the base-case analysis the risk of MACE following revascularisation for the
TP and FP entry states in the model is the same as the baseline risk of MACE conditioned on FFR value.
That is, the expected proportion of TP outcomes with a FFR of 0.76–0.80, 0.71–0.75 and ≤ 0.70, and FP
outcomes with a FFR of 0.81–0.85, 0.86–0.90 and ≥ 0.91 for each diagnostic strategy, is dependent on
the underlying distribution of the FFR values across these categories in the population.
Alternative scenarios are considered in the model where revascularisation does confer a benefit on
MACE outcomes compared with OMT. Three alternative scenarios are considered:
1. A significant reduction in MACE only for a FFR ≤ 0.76, in line with the findings of the IRIS-FFR
registry. In this scenario, the HR for revascularisation is set equal to 0.47 (95% CI 0.24 to 0.89 for
a FFR 0.71–0.75 and 95% CI 0.26 to 0.84 for a FFR ≤ 0.70) for all components of MACE for a FFR
≤ 0.75, whereas the HR is set equal to 1 for a FFR > 0.75.
2. A significant reduction in the component of MACE of unplanned revascularisation only and no
reduction for cardiac death or MI. This is in line with the findings of the trials that found there was
a positive effect of revascularisation on MACE outcomes but that this positive effect was largely
determined by a reduction in the number of repeat/emergency or unplanned revascularisations
rather than cardiac death or MI. In this scenario, the HR is set equal to 0.26 (95% credible interval
0.17 to 0.40) for repeat revascularisation from the meta-analysis by Windecker et al.117 for
new-generation drug-eluting stents, whereas the HR is set equal to 1 for cardiac death or MI.
3. A non-statistically significant reduction in MACE for all components. This is in line with the findings
of the trials that found a modest improvement in MACE outcomes for revascularisation compared
with OMT, but this improvement was not statistically significant. In this scenario, the HR is set equal
to 0.71 (95% CI 0.47 to 1.06) for cardiac death, 0.93 (95% CI 0.70 to 1.24) for non-fatal MI and 0.93
(95% CI 0.76 to 1.14) for repeat revascularisation based on the meta-analysis by Pursnani et al.119
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Additional sensitivity analyses using the results from the individual RCTs and meta-analyses reported
above are considered to assess the impact of alternative assumptions about the treatment effect of
revascularisation for MACE outcomes on the cost-effectiveness results.
Other-cause mortality
Mortality due to non-cardiovascular causes was estimated based on age- and sex-specific UK life
tables120 and by deducting the mortality due to ischaemic heart disease (International Classification of
Diseases, codes 20–25).121 The age-specific probability of death was estimated as a weighted average of
male and female mortality.
Health-related quality of life
To estimate QALYs, it is necessary to quality-adjust the period of time for which the average patient
is alive within the model using an appropriate utility or preference score. QALYs are calculated by
summing the time spent in a health state weighted by the utility value associated with the health state.
Additional adjustments are made to QALYs to reflect a decrement in utility associated with an acute
or adverse event. The NICE methods guide advocates a preference for EQ-5D data with utility values
using UK population weights when available.92
In the diagnostic model a one-off utility decrement is applied to patients undergoing invasive FFR/iFR
and those who undergo revascularisation (known as procedural disutility). At the end of the diagnostic
model, patients who survive enter the long-term prognostic model in one of the four health states of TP,
FN, FP or TN. The implications on HRQoL of receiving treatment (either revascularisation in addition to
OMT or OMT alone) based on being in one of the four diagnostic health states is quantified by attaching
a utility value to each of the health states. A one-off utility decrement is also applied in the prognostic
model to those who experience a non-fatal MI or require an unplanned revascularisation. To reflect a
decrease in HRQoL for those with a history of MI, a separate utility decrement is applied to the post-MI
health state. For those patients who experience an unplanned revascularisation, the utility value
associated with the TP health state is applied based on the assumption that patients who undergo a
targeted revascularisation achieve the same benefits of revascularisation, in terms of symptom relief,
as patients who had a successful initial revascularisation procedure.
The utility values are used to calculate the expected number of QALYs for each diagnostic strategy
over the duration of the model.
Procedural disutility
The model considers the procedural disutility associated with FFR/iFR, PCI and CABG. The disutility
associated with ICA is not included because all patients undergo the procedure. Targeted literature
searches were used to identify sources to inform procedural disutility parameters.
No studies reporting HRQoL loss associated with FFR/iFR were identified. However, FFR/iFR, particularly
FFR, which requires the administration of a hyperaemic agent, can cause discomfort to patients.
The administration of the most commonly used hyperaemic agent, adenosine, can result in chest pain,
dyspnoea, bronchospasm, conduction disturbances, facial flushes, headaches and hypotension.122–125
Patient discomfort can therefore arise from adverse events associated with the hyperaemic agent, but
also relate to vasodilation that is a consequence of inducing a hyperaemic state to perform FFR. In the
absence of suitable estimates to inform the disutility associated with FFR/iFR, a disutility equivalent to
that of a PCI procedure is assumed. Furthermore, this is assumed to apply to all patients undergoing
FFR/iFR and not just to those who incurred procedural complications (see Complications due to FFR/iFR).
An additional disutility resulting from procedural complications was not included in the model to
avoid double counting. It is expected that iFR is more tolerable to patients as it does not require the
administration of a hyperaemic agent; however, a specific disutility estimate for iFR was not identified.
Furthermore, the proportion of patients with intermediate stenosis who undergo iFR in UK clinical
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
71
practice is also unknown. Therefore, the base-case analysis makes a simplifying assumption that the
QALY loss estimate applied for FFR/iFR is representative of both types of pressure wire procedures.
One UK study126 was identified as relevant to inform the procedural disutility of revascularisation
(PCI and CABG). Bagust et al.126 conducted a cost-effectiveness study comparing drug-eluting stents
with conventional stents for the treatment of symptomatic CAD. The model considered the QALY loss
per percutaneous transluminal coronary angioplasty (PTCA) and per CABG by combining EQ-5D data
from two clinical trials in multivessel CAD that compared alternative revascularisation procedures
(PTCA with bare and drug-eluting stents, and CABG) with assumptions on the duration of the disutility.
The disutility for each procedure was estimated as the difference in utility scores before and after
the revascularisation procedure. The disutility was assumed to be incurred for 1 month for PTCA
and 6 months for CABG, resulting in a QALY loss of 0.0056 and 0.033 QALYs per PTCA and CABG
procedure, respectively. The authors noted, however, that the QALY losses may be an overestimate as all
patients had multivessel disease. These QALY loss estimates are used to inform the base-case scenario.
Appendix 8, Table 63, summarises the QALY loss estimates associated with each procedure in the
diagnostic model. The QALY loss associated with PCI and CABG is applied in the model as a weighted
average, assuming that 87% of revascularisation procedures are PCI and 13% CABG (see Complications
due to revascularisation). The QALY loss associated with revascularisation is also applied in the prognostic
model to capture the HRQoL impact of unplanned revascularisation. Gamma distributions were fitted to
the procedural HRQoL loss to generate probabilistic estimates.
Health state utilities
The benefits of the diagnostic tests in identifying the appropriateness for revascularisation can confer
health benefits through greater symptom relief and, therefore, higher HRQoL. Given that the base-case
analysis assumes that there is no treatment effect of revascularisation on MACE, the improvement in
symptom relief is the only benefit of revascularisation. Of the recent RCTs (post year 2000) in stable
CAD that have compared revascularisation with OMT (see Treatment effect of revascularisation), there
was a general trend towards significantly greater improvement in HRQoL after revascularisation.
In TIME,106 after 6 months, angina severity decreased and measures of HRQoL using the Short Form
questionnaire-36 items (SF-36), Duke Activity Score Index (DASI) and Rose Angina Questionnaire
showed a significantly greater improvement after revascularisation compared with OMT.106 In the
MASS II trial,107 HRQoL using the SF-36 instrument was better in both the CABG and PCI groups
compared with OMT at the 1-year follow-up, with the CABG group presenting the greater and
progressive improvement in HRQoL.127 In the COURAGE trial,91 HRQoL using the Seattle Angina
Questionnaire (SAQ) showed a very modest improvement in SAQ score for the PCI group, compared
with OMT, at the 1-year follow-up.128 In the BARI 2D trial,96 HRQoL was reported using the DASI,
RAND 36-Item Health Survey and patients’ self-rated health, and demonstrated that, compared
with OMT, revascularisation was associated with significantly greater improvements in DASI, energy
and self-rated health components but not health distress.129 The HRQoL effects of revascularisation
in BARI 2D96 were largely maintained over a 4-year follow-up. In the FAME II trial,108 HRQoL was
measured using EQ-5D at the 1-month and 1-year follow-ups and reported based on patients’ index
FFR measurement.130 The results of the trial showed that HRQoL improved significantly from baseline
after PCI, with the largest marked improvement in those with a lower FFR value, whereas it did not
change significantly in the OMT group. In ISCHEMIA,95 HRQoL using the SAQ at 3, 12 and 36 months
showed a significant, durable improvement in angina control and HRQoL with revascularisation
compared with OMT.131 The smaller ORBITA trial,97 which reported HRQoL using SAQ and the
EuroQol-5 Dimensions, five-level version (EQ-5D-5L) visual analogue scale, was the only study that
demonstrated a non-statistically significant difference in HRQoL for PCI compared with OMT.97
In summary, the evidence from the most recent RCTs suggests that revascularisation has a significantly
greater improvement in HRQoL than OMT alone. This is supported by a recent systematic review and
meta-analysis summarising the evidence to determine the impact of coronary revascularisation on HRQoL,
which showed that both PCI and CABG had significantly greater effects on HRQoL than medication,
but the effects of the revascularisation procedures did not differ significantly from each other.132
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Of the most recent RCTs, only one trial, FAME II,108 measured improvement in HRQoL using EQ-5D.
This trial was a subsequent RCT to the FAME I trial133 that compared two different revascularisation
strategies in patients with stable CAD and multivessel disease using standard ICA-guided revascularisation
of lesions with a > 50-mm DS and a FFR-guided revascularisation approach for lesions with a FFR
≤ 0.80. The FAME II trial108 was designed to clarify whether PCI of functionally significant stenoses
(i.e. lesions with FFR ≤ 0.80) combined with OMTwould be superior to OMT alone in patients with
stable CAD. In a study by Nishi et al.,130 patient-level pooled analysis from the FAME I and II trials was
used to assess whether or not the benefit to HRQoL after PCI depends on the severity of the stenosis
as determined by FFR measurement. The study is based on patients with stable CAD who underwent
PCI with a FFR ≤ 0.80 from the FFR-guided arm of the FAME I trial and the PCI arm of the FAME II
trial.108 The study reports the change from baseline in EQ-5D utility values by FFR 0.70–0.80, FFR
0.51–0.69 and FFR ≤ 0.50. The study also reports the change from baseline in EQ-5D utility values for
lesions with a FFR ≤ 0.80 that were treated medically from the OMT arm of the FAME II trial.108 The
results of this study are directly relevant for informing the HRQoL improvement from revascularisation
compared with OMT in the model.
Table 11 presents the change in EQ-5D utility values from baseline to 1 month and 1 year in the PCI
(in addition to OMT) group and the OMT-alone group by FFR value based on Nishi et al.130 The EQ-5D
improved significantly from baseline after PCI in all FFR subgroups at both the 1-month and the 1-year
follow-ups, with a progressive improvement with lower FFR values. The EQ-5D improved slightly from
baseline in the OMT group to both 1 month and 1 year, but this improvement was not statistically
significant (note that the results in Table 11 exclude crossovers to PCI in the OMT group).
The utility values in Table 11 are used to represent the change in baseline utility for the TP and FN health
states. For the TP health state, the utility value for revascularisation is used to provide a weighted change
in utility value based on the expected proportion of TP outcomes with a FFR 0.70–0.80, 0.51–0.69 and
≤ 0.50, which differs by diagnostic strategy and is dependent on the underlying distribution of FFR values
across these categories in the population. For the FN health state, the utility value for OMTwith a FFR
≤ 0.80 is used to provide the change in baseline utility. For the FP and TN health states with a FFR > 0.80
(functionally non-significant stenosis), it is assumed that there is no change in baseline utility for patients
with intermediate stenosis.
The underlying baseline utility for a 64-year-old UK patient with stable CAD is also taken from Nishi et al.,130
where the average age of patients in the FAME trials108 was the same as the modelled population.
To reflect the decreasing utility of patients as they age through the model, age- and sex-adjusted
EQ-5D norms for the UK based on Ara et al.134 were adjusted to reflect the existence of stable CAD.
The adjustment factor was estimated by comparing the baseline utility of Nishi et al.130 to the average
utility of a 64-year-old UK patient, derived from a nationally representative UK sample using EQ-5D.
Patients who experience a non-fatal MI receive a one-off utility decrement, whereas those in the
post-MI health state are subject to a decrease in HRQoL for the duration of time spent in this state.
Both these utility decrements were sourced from Sullivan et al.135, a study that estimated a catalogue
of marginal disutilities for a wide range of health conditions based on UK-specific health preferences.
TABLE 11 Change in EQ-5D utility values from baseline for PCI and OMT by FFR value (Nishi et al.130)
Time point
EQ-5D value (95% CI)
Revascularisation OMT
FFR 0.70–0.80 FFR 0.51–0.69 FFR ≤ 0.50 FFR ≤ 0.80
At 1 month 0.039 (0.019 to 0.059) 0.056 (0.036 to 0.075) 0.080 (0.058 to 0.101) 0.003 (–0.012 to 0.017)
At 1 year 0.038 (0.013 to 0.063) 0.057 (0.037 to 0.078) 0.065 (0.040 to 0.089) 0.015 (–0.004 to 0.033)
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In this study, marginal disutilities were estimated as EQ-5D index score decrements adjusted for patient
characteristics (age, comorbidity, sex, ethnicity, income and education). The marginal disutility for ‘acute
MI’ (International Classification of Diseases, Ninth Edition, code 410) informed the utility decrement for
non-fatal MI events [–0.0626, standard error (SE) 0.0132], and the estimate for previous MI informed
the post-MI health state (–0.0368, SE 0.0252). Gamma distributions were fitted to the utility decrements
for the uncertainty analysis.
Resource use and costs
This section details the resource use and costs applied in the model. The diagnostic model considers the
costs of diagnostic testing, revascularisation and treatment of procedural complications. The prognostic
model considers the costs of OMT, health state and clinical events. Costs in the model are fixed estimates.
Details by category of resource use and costs are presented in the sections below.
Test costs
QAngio XA 3D/QFR costs
The costs of QAngio XA 3D/QFR include the cost of the software licence, and training and certification
fees. These costs are summarised in Appendix 8, Table 64 (adapted from the company’s response to
NICE’s information request and additional EAG questions). Costs were originally reported in euros,
and have been converted to GBP at an exchange rate of 0.86295, based on the average exchange rate
between 25 August 2019 and 19 February 2020.136
Software licence costs The costs of the QAngio XA 3D/QFR software licence are dependent on the
number of patients tested (‘per-patient-study basis’). The cost per patient of the software licence is the
same for the 10-patient and 50-patient vouchers, whereas the 100-patient voucher offers a discount of
£8.63 per patient compared with the other two options (assuming the same 100 patients are tested).
To simplify cost calculations, it is assumed that annual throughput is a multiple of 10. It is further
assumed that an NHS trust would purchase the least costly combination of vouchers that would cover
the expected annual throughput. For example, if annual expected throughput was 180 patients, the
trust would purchase one 100-patient voucher and eight 10-patient vouchers. For the base-case annual
throughput of 200 patients, the trust would purchase two 100-patient vouchers, at a total cost of
£84,569.10 (approximately £423 per patient).
Training costs The cost of the 100-patient voucher also covers the training and certification of up to
four QAngio XA 3D/QFR users. The cost of the 10-patient and 50-patient vouchers does not include any
training and certification. When training and certification are required and this cost is not covered by
the voucher, a fee of £3020 for up to four software users applies for both on-site and online training.
It was assumed that for every 100 patients, four members of staff would require training, and so the
training fee would, therefore, be covered by the voucher for an average annual throughput ≥ 100. It is
only when annual throughput is lower than 100 patients and, therefore, the trust does not purchase at
least one 100-patient voucher, that this cost will be incurred. In addition to the training and certification
fees charged by the company, the staff time costs required for training activities should also be considered.
According to Medis Medical Imaging Systems BV, on-site training is currently available only for groups of
a minimum of 10 participants, but an e-learning platform is being developed to deliver training. E-learning
is expected to be available before the fourth quarter of 2020. Another alternative for large research
groups is to have training delivered over 1.5 days at Leiden but without travel and accommodation costs
included. Medis Medical Imaging Systems BV states that using the e-learning platform training should
require 5 hours of staff time, whereas certification would be done on a cloud-based solution, taking
1–2 hours. This training would typically be required by an observer or technician in the catheterisation
laboratory, who uses the QFR software solution and carries out the analyses. The company also has a
shortened e-learning module for the interventional cardiologist that should take 30 minutes to complete.
As more details have been provided for online training, and on-site training appears to require a large
number of participants, we have estimated costs of training assuming that this is delivered online.
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It was assumed that for each four-member group of staff requiring training, one would be an
interventional cardiologist and the other three cardiac physiologists. The cardiac physiologists are
assumed to be the software operators, and thus undergo both the training and the certification
module. The first module takes 5 hours to complete, whereas the second requires 1.5 hours (mid-point
of the range of time provided by the company). Unit costs for staff time were taken from the Personal
Social Services Research Unit (PSSRU) costs.137 The cost per working hour of a surgical consultant
was assumed to cost the same as a cardiologist’s time, and that of an allied professional (band 5) for a
cardiac physiologist’s time. Staff time and costs associated with NHS staff training and certification per
100 patients are shown in Appendix 8, Table 65.
It is assumed that the additional staff time and cost of that time will increase at the same rate as
throughput, which corresponds to a staff cost per patient of £7.76. We assume the same staff cost per
patient for an annual throughput lower than 100 patients. This simplifying assumption effectively
implies that staff time is independent of throughput.
Total cost per patient tested The costs of QAngio XA 3D/QFR disaggregated by cost element are
presented in Appendix 8, Table 66, for the base-case throughput assumption of 200 patients per year.
The cost per patient tested with QAngio XA 3D/QFR is £430.61.
CAAS vFFR costs
The costs of CAAS vFFR include the cost of (1) the software licence, (2) training and (3) annual
maintenance. Pie Medical Imaging BV has two different pricing models for CAAS vFFR, which are
summarised in Appendix 8, Table 67 (adapted from the company’s response to NICE’s information
request). Costs were originally reported in euros, and have been converted to GBP at the same
exchange rate used to estimate the costs of QAngio XA 3D/QFR.136
Software licence costs The cost of the software licence for CAAS vFFR per patient tested varies
according to the pricing model selected. Under pricing model 1, the software licence costs £31,929
and is described as perpetual. The total number of tests covered by the licence depends on the lifespan
of the technology, which is unknown. For the purpose of determining a cost per patient tested, it is
conservatively considered that the perpetual licence covers the annual patient throughput independently
of its size (i.e. the lifespan of the technology is 1 year). Under pricing model 2, the cost per patient tested
is fixed at £172.59. Assuming that annual throughput is a multiple of 10 (as assumed for QAngio XA
3D/QFR cost calculations), the software licence cost per patient is lower for pricing model 2 than for
pricing model 1 only when the annual throughput is ≤ 10 patients. For the base-case assumption of
200 patients per year, the software licence cost per patient tested with pricing model 1 is £159.65.
Training costs CAAS vFFR training can be delivered through three alternative platforms: e-learning,
WebexTM (Cisco Systems, Milpatas, CA, USA) or on-site training. The training fee depends on the
delivery platform, with e-learning offered at no cost and Webex and on-site training offered at a cost
of £215.74 and £2157.38, respectively. Pie Medical Imaging BV does not specify if there is a maximum
number of NHS staff covered by the training fee. It is assumed that only one training session by either
Webex or on-site delivery would be required independent of annual throughput, and that any
additional training would be delivered online at no additional cost. We calculated the cost of the
training fee as the average between on-site and Webex training costs (£1186.56).
Pie Medical Imaging BV states that the same training should be delivered to staff using the CAAS vFFR
software and the interventional cardiologist who interprets the result. Training delivered through
e-learning and Webex requires 2 hours per member of staff, whereas on-site training requires 4 hours.
We made the same assumptions regarding numbers of staff members who would require training as
for QAngio XA 3D/FR, that is one cardiologist and three cardiac physiologists would require training
for every 100 patients tested. We also assumed that the additional staff training time and cost of that
time would increase at the same rate as the throughput. Thus, the staff training cost per patient is
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independent of throughput, but depends on the training platform. The same unit costs were applied for
the calculation of staff training costs as for QAngio XA 3D/QFR. Appendix 8, Table 68, shows the staff
training cost per 100 patients tested with CAAS vFRR.
The staff training cost per patient is £4.40 when delivered online (Webex or e-learning) and £8.80
when delivered on site. In the base case we assumed that the staff training cost per patient tested
would correspond to £6.60, the average cost of online and on-site staff training.
Maintenance costs Pie Medical Imaging BV charges a fee for annual maintenance of CAAS vFFR. The
cost of maintenance varies by pricing model. For pricing model 1 there is no maintenance cost in the
first year, and an annual cost of £4746.23 applies for subsequent years. For pricing model 2 there is
an annual cost of £3023.44 incurred every year. As we have made a simplifying assumption that the
lifespan of the technology is 1 year when considering the licence fee costs, we did not include an
annual maintenance cost for pricing model 1.
Total cost per patient tested We assumed that the NHS trust would select the pricing model that
would result in fewer costs according to the expected annual throughput. Pricing model 1 results in
a lower cost per patient tested when annual throughput is greater than 10. The costs of CAAS vFFR
broken down by cost element are presented in Appendix 8, Table 69, for the base-case assumption of
200 patients per year. The cost per patient tested with CAAS vFFR is £172.18.
Comparison of QAngio XA 3D/QFR and CAAS vFFR testing costs
The cost per patient tested with QAngio XA 3D/QFR and with CAAS vFFR varies with annual throughput,
as shown in Appendix 8, Figure 47. The cost per patient tested with CAAS vFFR under pricing model 1 is
more sensitive to alternative throughput estimates than QAngio XA 3D/QFR, especially for throughputs
lower than 100 patients. The cost of QAngio XA 3D/QFR is robust to alternative throughput estimates
for throughputs greater than 100 patients. This cost is also consistently higher than that of CAAS
vFFR for throughputs greater than 70 patients. Appendix 8, Figure 47, shows two curves for the cost per
patient tested with CAAS vFFR to illustrate the difference between assuming that training is delivered
over Webex and assuming it is delivered on site. The cost per patient tested with CAAS vFFR seems
consistently similar for the two modes of training delivered; therefore, an average between the two modes
was used to estimate the cost per patient tested with CAAS vFFR.
Invasive coronary angiography and fractional flow reserve
The unit costs used to estimate the costs of catheterisation tests currently used in NHS clinical
practice were sourced from NHS reference costs 2017/18138 and uprated to 2018/19 prices.137
The cost of ICA was calculated as the activity-weighted average of the Healthcare Resource Group
(HRG) codes for simple catheterisation. However, the model did not consider a cost for ICA because
all patients who enter the diagnostic model undergo this test. In line with the NICE scope, the unit
cost for FFR/iFR, that is, £436.80, was estimated as the difference between the activity-weighted
average of the HRG codes for complex (£2202.26; currency codes: EY42A–D) and standard cardiac
catheterisation (£1765.46; currency codes: EY43A–F). This difference represents the incremental cost
of FFR/iFR compared with ICA alone. The cost of iFR was not estimated separately, as it was assumed
that this cost was already captured in the complex cardiac catheterisation HRG codes.
Revascularisation costs
Patients who test positive at the last step of each testing strategy undergo revascularisation with either
PCI or CABG. The unit cost for these procedures was sourced from NHS reference costs 2017/18138
and uprated to 2018/19 prices.137 We estimated the activity-weighted average cost of (1) complex and
standard percutaneous transluminal coronary angioplasty and (2) complex major and standard CABG
across all HRGs to inform the unit cost of PCI and CABG, respectively. Costs applied in the model and
the NHS currency codes used to inform these are presented in Appendix 8, Table 70.
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As the costs of PCI and CABG were estimated across all HRGs, their unit cost reflects the cost of
the procedures across all settings under which the procedures are performed in the NHS (adjusted by
activity). We considered this to be the most appropriate assumption in the absence of clear evidence
on the proportion of procedures per setting for patients in our study population. However, patients
who are treated electively for stable angina do not usually require an overnight stay. Despite the NHS
target to have at least 75% of elective PCIs performed as a day case, recent audit data show that there
is extremely wide variation in day-case rates139 and that only 30.4% of PCI is performed as day cases.98
Some centres will perform PCI almost exclusively as a day case, whereas others will require patients
to stay overnight in hospital following the procedure. Given the considerable variation in the NHS in
terms of the need for overnight stays following PCI, we considered only the cost of PCI to correspond
to that of a day-case admission in a scenario analysis.
In the base-case scenario, patients revascularised after their index testing were assumed to incur a
cost of £3005 and £10,899 if they underwent PCI and CABG, respectively. This resulted in a cost per
revascularisation of £4031.22, assuming that 87% of revascularisation procedures are PCI and 13% are
CABG (see Complications due to revascularisation).
Procedural complications costs
The cost of procedural complications for FFR/iFR was calculated based on the rates of complications
in Appendix 8, Table 71. Unit costs were sourced from NHS reference costs 2017/18138 and uprated to
2018/19 prices.137 These costs are summarised in Appendix 8, Table 71, and range between £834.57
for bronchospasm and £3005.07 for coronary dissection. Patients who die are assumed to incur no
additional costs.
Optimal medical treatment costs
It was assumed that all patients in the prognostic model are treated with OMT for stable angina. The
NICE existing guidance was reviewed to define OMT. The NICE Clinical Guideline on the management
of stable angina (i.e. CG126)140 recommends that patients with stable angina receive a beta-blocker or
a calcium channel blocker in either monotherapy or combination therapy as the first line of treatment.
The alternative to the first-line treatment for patients who cannot tolerate it is monotherapy with
a long-acting nitrate or one of the novel anti-ischaemic drugs (ivabradine, nicorandil or ranolazine).
The use of three anti-angina drugs is not recommended unless patients are not satisfactorily controlled
with two anti-angina drugs or are waiting for revascularisation or cannot undergo revascularisation.
Drugs for secondary prevention of cardiovascular disease should also be considered for patients
with stable angina. These drugs include aspirin, angiotensin-converting enzyme (ACE) inhibitors, other
antihypertension drugs and statins. The guideline does not make specific recommendations regarding
medication for patients who have undergone PCI or CABG, but revascularised patients will still need to
receive anti-angina and secondary prevention drugs after the procedures. We have, thus, considered that
OMT comprises both anti-angina secondary prevention drugs. Given that revascularisation will resolve or
reduce some of the angina symptomology, it is likely that the composition of OMT varies depending on
whether or not patients have received revascularisation and on the type of procedure received.
One of the models74 described in Results of the review of decision models evaluating invasive coronary
angiography assumed that the relative proportion of each drug class comprised by OMT would vary
depending on the patient’s index treatment. We assumed the same, but sourced data on anti-angina
medication use where available from Nishi et al.,130 the same study from which we sourced estimates
of HRQoL (see Results of the review of decision models evaluating invasive coronary angiography). Nishi
et al.130 reported anti-angina medication use at 1 year post diagnosis for patients treated with OMT in
isolation (TN) or in addition to PCI (TP). This study also reported the use of these drugs for patients
treated with OMT in isolation despite requiring revascularisation (FN). As the study did not include
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patients who had undergone CABG, data on the medication use for these groups (also TPs) were taken
from the same source used in Genders et al.,74 namely the SYNTAX trial.59 As Nishi et al.130 did not
report the use of secondary prevention drugs, data on medication use for these drugs were taken from
the SYNTAX trial59 and the COURAGE trial91 (also used in Genders et al.74).
The cost of medication was estimated by combining the proportion of medication use for each type of
treatment [OMT alone for patients who did not required revascularisation (TNs) and those who did
(FNs), OMT for patients who underwent PCI (TPs) and CABG (TPs)], with unit costs from the British
National Formulary (BNF).141 Patients who underwent revascularisation without needing it (FPs) were
assumed to have the same medication use as the corresponding TP patients. The active substances
and dosages selected, as well as proportion of medication use, were validated by the clinical adviser
to the EAG. Medication use and estimated costs per annum of OMT conditional on patient clinical
management after diagnosis are summarised in Table 12. These costs are applied in the prognostic
model at each annual cycle, and it was assumed that if the patient underwent revascularisation in the
model, the cost of OMT would then correspond to OMT in addition to revascularisation regardless of
the patient classification at the start of the prognostic model (TN, FN, TP or FP).
Health state and clinical event costs
The costs associated with health state membership and clinical events in the prognostic model are
summarised in Appendix 8, Table 72.
It was assumed in the base-case analysis that only MI and unplanned revascularisation events would
incur costs. This equates to assuming that all health-care resource use other than anti-angina and
secondary prevention medication use (see Optimal medical treatment costs) is the same across health
states. The unit costs of MI and unplanned revascularisation events were sourced from the NHS reference
costs 2017/18138 and uprated to the 2018/19 price year.137 The cost of a MI was estimated as the activity-
weighted average across all HRG codes for actual or suspected MI (EB10A–E). The cost of an unplanned
revascularisation (£4812.23) comprises the cost of PCI (activity-weighted average of EY40A–D and
EY41A–D codes: £3923) and CABG (activity-weighted average of ED26A–C, ED27A–C and ED28A–C
codes: £10,762) for non-elective long stays, and assumes that 87% of revascularisation performed is PCI
(see Complications due to revascularisation).
Analytic methods
Overview
The cost-effectiveness of the QAngio XA 3D/QFR and CAAS vFFR imaging software used during ICA
for assessing the functional significance of coronary obstructions in patients with intermediate stenosis
is evaluated by comparing the total expected costs and QALYs with those obtained using pressure wire
FFR/iFR measurement or visual interpretation of angiographic images alone.
Summarising cost-effectiveness using conventional incremental cost-effectiveness ratios (ICERs) requires
consideration of which pairwise comparisons are appropriate when calculating incremental costs and
effects. With multiple strategies there are several different comparisons that could be made, each
resulting in different incremental QALYs, costs and ICERs. In this case, a fully incremental ICER
comparison is required to rule out any strategies based on the principles of dominance or extended
dominance. However, even with a fully incremental ICER comparison, strategies that are dominated
and would not be considered cost-effective may be ‘better’ than other non-dominated (but not cost-
effective) strategies. The ICER comparison is also particularly sensitive to small differences between
the strategies (e.g. small changes to the denominator in terms of QALY differences may result in highly
variable ICERs). For these reasons, the cost-effectiveness of the interventions is summarised in terms
of net benefit, which applies a single unambiguous decision rule when there are multiple strategies; the
cost-effective strategy is the one with the highest net benefit for a given cost-effectiveness threshold.
INDEPENDENT ECONOMIC ASSESSMENT: YORK MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
TABLE 12 Optimal medical treatment use and costs in the model
Treatment type Drug and dosage
Unit
cost (£)a Source
Medication use
OMT (%) Source
PCI and
OMT (%) Source OMT (FN) (%) Source
CABG and
OMT (%) Source
Anti-angina
Beta-blocker Bisoprolol, 5 mg/day 0.17 aBNF141 75.0 Nishi et al.
(2018)130
77.0 Nishi et al.
(2018)130
81.0 Nishi et al.
(2018)130
77.2 SYNTAX
(2011)59
Calcium channel blocker Amlodipine, 5 mg/day 0.17 40.0 27.0 32.0 22.7
Long-acting nitrate Isosorbide mononitrate,
60 mg/day
0.18 36.0 23.0 47.0 8.0
Secondary prevention
Aspirin Aspirin, 75 mg/day 0.02 aBNF141 95.0 COURAGE
(2007)91
95.0 COURAGE
(2007)91
95.0 Assumed the
same as for
OMT (TN)
83.3 SYNTAX
(2011)59
Statin Atorvastatin, 80 mg/day 0.02 95.0 93.0 95.0 85.5
ACE inhibitor Ramipril, 10 mg/day 0.24 62.0 64.0 62.0 52.5
Cost (£) per year 163.63 150.10 169.68 126.27
BNF, British National Formulary.
a Drug tariff value.
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In this analysis, the net benefit is expressed in terms of net health benefit (NHB), estimated by
rearranging the ICER equation into the following equation:
NHB =QALYs−
Costs
Cost−effectiveness threshold
. (1)
Strategies are ranked in terms of NHB from highest to lowest, which is used to identify the cost-effective
strategy (highest NHB), but NHB is also used to interpret the next best choice (second highest NHB) and
so on. A cost-effectiveness threshold of £20,000 per additional QALY is used in the analysis.
Uncertainty in the estimates of cost-effectiveness of the alternative strategies is reflected in
probabilistic analysis, and the probability that each strategy is more cost-effective than the others
at the cost-effectiveness threshold of £20,000 per QALY is presented for the base-case scenario.
Base-case analysis
The base-case parameters and associated assumptions are listed alongside their sources in Appendix 8,
Table 73.
Scenario analyses
Alternative assumptions to those of the base-case analysis are made in a number of scenarios analyses.
The aim of these analyses is to assess the robustness of the base-case results to alternative assumptions
and sources of data used to parametrise the model.
Table 13 summarises the alternative scenarios analyses undertaken. The position in the base-case
analysis and the alternative assumption applied is described for each element.
Model validation
The model was developed in Microsoft Excel by two analysts (AD and LS) and the programming
checked by a third analyst (CR). As part of an overall quality assurance process, the internal validity of
the model was assessed by extensively exploring logical consistency in the model results. A separate
version of the prognostic model was also independently programmed by the third analyst (CR) to
successfully replicate the base-case results.
Results of the independent economic assessment
Results of the base-case scenario
Deterministic and probabilistic cost-effectiveness results expressed in terms of NHB at a cost-
effectiveness threshold of £20,000 per additional QALY for the base-case scenario are presented in
Tables 14 and 15, respectively. Strategy ranking from highest to lowest NHB is presented in both
tables. The incremental net health benefit (INHB) is calculated for each strategy relative to ICA alone.
The probability that each strategy is cost-effective at a threshold of £20,000 per additional QALY is
presented in Table 15 for the probabilistic analysis. The results are consistent for both the deterministic
and probabilistic analyses.
The strategy with the highest NHB is strategy 2 (ICA plus FFR) but the difference between all the
strategies is small. Strategy 2 is also the strategy with the highest probability of being cost-effective
(27.8%). The least costly strategy is strategy 1 (ICA alone), which also has the lowest QALY gain,
whereas the most costly strategy is strategy 5 (ICA plus vFFR) but this has the highest QALY gain.
The INHB per patient diagnosed for each of the strategies relative to ICA alone is 0.027 QALYs
(or equivalently £544) for ICA plus FFR; 0.020 QALYs (or equivalently £400) for ICA plus QFR;
0.015 QALYs (or equivalently £298) for ICA plus QFR, followed by confirmatory FFR when QFR is
inconclusive; and 0.016 QALYs (or equivalently £316) for ICA plus vFFR.
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TABLE 13 Details of the key elements of the base-case analysis and the variation used in the scenario analysis
Scenario Element Position in base-case analysis Variation in scenario analysis
Diagnostic accuracy
1 Diagnostic accuracy
of QAngio XA
3D/QFR
Sensitivity and specificity estimates
based on the bivariate meta-analysis
for all studies using cQFR or non-
specified QFR
Sensitivity and specificity estimates
based on studies reporting fQFR only
2 Sensitivity and specificity estimates
based on studies reporting cQFR only
3 Perfect sensitivity and specificity for
QFR (i.e. the same as FFR)
4 Diagnostic accuracy
of CAAS vFFR
Sensitivity and specificity estimates
based on the largest study of vFFR,
FAST-EXTEND18
Sensitivity and specificity estimates
based on ILUMIEN I19
5 Sensitivity and specificity estimates
based on Jin et al.26
6 Same sensitivity and specificity for
vFFR and QFR
7 Diagnostic accuracy
of ICA
Sensitivity and specificity estimates
based on the bivariate meta-analysis
of studies comparing 2D ICA with
FFR
Sensitivity and specificity estimates
based on meta-analysis by Danad
et al.100 for diagnostic performance of
ICA compared with FFR
8 Diagnostic threshold
of QFR and FFR
Diagnostic threshold of 0.8 used to
define functionally significant stenosis
for QFR and FFR
An alternative diagnostic threshold of
0.75 used for FFR and QFR based on
the findings of the IRIS-FFR registry
data (note it is not possible to explore
an alternative diagnostic threshold for
vFFR because of an absence of data)
9 Grey-zone boundary
for hybrid QFR and
confirmatory FFR
strategy
Grey-zone boundary of 0.78–0.84
for QFR as recommended by the
manufacturer of QAngio XA 3D/QFR
A wider grey-zone boundary of
0.70–0.90 for strategy 4 of QFR plus
confirmatory FFR when QFR is
inconclusive
Risk of MACEs
10 Baseline risk of
MACE
The baseline risk of MACE in the
absence of revascularisation depends
on disease severity as measured by
FFR, whereas the distribution of FFR
values differs by diagnostic strategy
The baseline risk of MACE is
independent of FFR and diagnostic
test results
11 Treatment effect of
revascularisation on
MACE
No treatment effect of
revascularisation on risk of
MACE based on the findings
from ISCHEMIA95
A significant reduction in the risk of
MACE for revascularisation in FFR
values < 0.76 based on the findings
of the IRIS-FFR registry data
12 A significant reduction in the risk of
unplanned revascularisation and no
reduction for cardiac death or MI based
on the findings of trials that showed
a positive effect of revascularisation
on MACE for repeat/emergency or
unplanned revascularisation rather
than cardiac death or MI
13 A reduction in the risk of MACE for all
components based on the findings of
trials that reported a modest (but non-
statistically significant) improvement in
MACE for revascularisation
continued
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TABLE 13 Details of the key elements of the base-case analysis and the variation used in the scenario analysis (continued )
Scenario Element Position in base-case analysis Variation in scenario analysis
Costs of diagnostic tests
14 Patient throughput Costs of QFR and vFFR based on
an average annual throughput of
200 patients
Alternative average annual
throughput of 100 patients for
QFR and vFFR
Costs of revascularisation
15 Cost of PCI Cost of PCI across all HRGs Cost of PCI based on day cases only
16 Revascularisation
procedure
Proportion of revascularisations
assumed to be PCI in 87% of cases
and CABG in 13% based on BCIS
audit data
Alternative assumption of 75% PCI
and 25% CABG
HRQoL
17 Duration of HRQoL
benefits
HRQoL benefits of revascularisation
and OMT observed at 1 year based
on the findings of Nishi et al.130 for the
TP and FN health states applied for a
lifetime duration
Alternative assumptions about the
duration of HRQoL benefits of
revascularisation and OMT
18 Magnitude of
HRQoL benefits
No HRQoL benefits associated with
treatment based on the findings from
ORBITA97
19 Procedural disutility Procedural disutility associated with
FFR, equivalent to that of PCI
Higher procedural disutility
associated with FFR, equivalent to
that of CABG
Procedural complications associated with FFR
20 FFR procedural
death rate
Procedural death risk sourced from
Fearon et al.87
No procedural death risk from FFR
21 FFR adverse event
rates
Adverse event rates sourced from
IRIS-FFR registry13
Adverse event rates sourced from
RIPCORD101
22 Adverse event rates sourced from
ORBITA97
Setting
23 Cost of FFR/iFR Unit cost of FFR/iFR corresponds to
the incremental cost of FFR/iFR
compared with ICA alone (i.e.
difference between a complex and a
standard catheterisation)
Unit cost of FFR/iFR corresponds to
the cost of a complex catheterisation
24 Patient throughput Costs of QFR and vFFR based on
an average annual throughput of
200 patients
Costs of QFR and vFFR based on
an average annual throughput of
500 patients
TABLE 14 Deterministic cost-effectiveness results for base-case scenario
Strategy Identification
Total
QALYs
Total
costs (£) NHBa INHBa,b
NHB
rank
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus confirmatory
FFR (grey zone)
11.093 5019 10.843 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
a At a cost-effectiveness threshold of £20,000 per QALY.
b INHB is relative to ICA alone.
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To understand the difference in NHB between the alternative strategies, the disaggregated results for
total expected costs and QALYs are informative. Table 16 shows the expected costs and QALYs for
each strategy from the diagnostic and prognostic components of the model separately. The diagnostic
model includes the costs of the diagnostic tests, revascularisation, and costs associated with treating
adverse events related to FFR, and the prognostic model includes costs related to unplanned/repeat
revascularisation, MI events and long-term OMT use. The diagnostic model includes a procedural
disutility associated with invasive FFR/iFR and revascularisation, and the prognostic model includes
the long-term symptom-free benefits of revascularisation, a disutility associated with unplanned/
repeat revascularisation, MI events and history of MI, applied to a baseline utility for patients with
intermediate stenosis. Note that costs, adverse events and disutility associated with invasive ICA are
excluded from the model because all strategies undergo ICA. The disaggregated costs and QALYs from
the diagnostic component of the model are shown in Table 17, and the proportion of patients who
enter the long-term prognostic model in each of the TN, FN, TP and FP entry states for each of the
alternative strategies (based on the diagnostic accuracy results) is shown in Table 18.
Certain strategies have among the highest diagnostic model costs, as they result in a greater
proportion of revascularisations. The percentage of revascularisation is dependent on the rate of TP
and FP results. The PPV is highest for strategies involving QFR [strategies 3 (84.8%) and 4 (86.8%)],
compared with vFFR (71.5%) or ICA alone (52.3%), whereas FFR is assumed to have perfect PPV. This
means that there are more unnecessary revascularisations for vFFR and ICA alone, than for QFR or
FFR, which increases the costs of revascularisation for these tests. Some of the total diagnostic model
cost is offset by differences in costs of testing. The costs of the diagnostic tests are dependent on the
level of patient throughput, and for the base-case scenario (throughput assumed to be 200) vFFR has
TABLE 15 Probabilistic cost-effectiveness results for base-case scenario
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Probability
cost-effective at
£20,000/QALY
1 ICA alone 11.039 4696 10.804 – 5 0.100
2 ICA plus FFR 11.073 4825 10.831 0.027 1 0.278
3 ICA plus QFR 11.065 4813 10.824 0.020 2 0.218
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.070 5020 10.819 0.015 4 0.199
5 ICA plus vFFR 11.076 5119 10.820 0.016 3 0.204
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
TABLE 16 Total expected costs and QALYs from the diagnostic and prognostic model by strategy
Strategy Identification
Model
Total model resultsDiagnostic Prognostic
Costs (£) QALYs Costs (£) QALYs Costs (£) QALYs
1 ICA alone 1940 –0.0044 2757 11.043 4696 11.039
2 ICA plus FFR 2059 –0.0093 2766 11.082 4825 11.073
3 ICA plus QFR 2044 –0.0037 2769 11.069 4813 11.065
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
2259 –0.0051 2761 11.075 5020 11.070
5 ICA plus vFFR 2373 –0.0050 2747 11.081 5119 11.076
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lower costs (£172 per patient tested) than QFR (£431) and FFR (£437). The cost of adverse events
associated with FFR increases the total cost of FFR but this is very marginal because of a low likelihood
of adverse events occurring. The difference in total diagnostic model costs between strategies 2 (ICA
plus FFR) and 3 (ICA plus QFR) is £15 per patient diagnosed, whereas the total diagnostic model cost for
strategy 4, with the addition of FFR when QFR is inconclusive, increases the cost of a QFR strategy by
£215 per patient because of a higher rate of TP results. The difference in total diagnostic model costs of
strategy 5 relative to strategies 2 and 3 is £314 and £329 per patient, respectively, and this is because
of a higher percentage of revascularisation as a result of more FP test results. The procedural QALY loss
associated with invasive FFR and revascularisation ranges from 0.0037 for ICA plus QFR (no additional
adverse events for QFR relative to ICA) to 0.0093 QALYs for ICA plus FFR.
The difference in total costs between the strategies from the prognostic model is much smaller than
the diagnostic model because the base-case scenario assumes that there is no treatment effect associated
with revascularisation on the rates of MACE. The only difference between the strategies in terms of costs
associated with MACE is because of the inverse relationship between underlying FFR and subsequent risk
of MACE, that is those with lower FFR have a higher risk of a cardiovascular event, whereas those with
higher FFR have a lower risk of a cardiovascular event. The prognostic model also includes a difference in
annual costs for OMT between those who receive OMT in addition to revascularisation (£150 for PCI and
£126 for CABG) and those who receive OMT alone (£163 for TN and £169 for FN). Strategies 5 (ICA plus
vFFR) and 1 (ICA alone) have the lowest prognostic costs, which is mainly due to the lower total costs of
OMT associated with a greater number of revascularisations in these strategies. The difference in total
prognostic costs between strategy 3 (ICA plus QFR), with the highest cost, and strategy 5 (ICA plus vFFR),
with the lowest cost, is £22 per patient.
TABLE 17 Disaggregated costs and QALYs from the diagnostic model by strategy
Strategy Identification
Costs (£) QALY loss
Testing Revascularisation
Adverse events
(FFR)
Testing
(FFR) Revascularisation
1 ICA alone – 1940 – – –0.00440
2 ICA plus FFR 437 1620 1.49 –0.00559 –0.00367
3 ICA plus QFR 431 1613 – – –0.00365
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
519 1739 0.21 –0.00113 –0.00394
5 ICA plus vFFR 172 2199 – – –0.00498
TABLE 18 Diagnostic accuracy results by strategy
Strategy Identification
Diagnostic accuracy
Percentage of
revascularisationTN (n) FN (n) TP (n) FP (n) PPV (%) NPV (%)
1 ICA alone 0.368 0.150 0.251 0.229 52.3 71.0 48.0
2 ICA plus FFR 0.598 0.000 0.401 0.000 100 100 40.1
3 ICA plus QFR 0.537 0.063 0.338 0.061 84.8 89.5 39.9
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
0.541 0.028 0.373 0.057 86.8 95.2 43.0
5 ICA plus vFFR 0.443 0.012 0.389 0.155 71.5 97.3 54.4
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The difference in total QALYs between the strategies from the prognostic model is largely due to the
HRQoL gain associated with TP test results. The base-case scenario assumes that there is no change
in baseline HRQoL associated with TN and FP test results, whereas there is a small non-statistically
significant change associated with FN test results. This means that the total expected QALYs is greater
for strategies with more TP test results (better sensitivity), whereas there are no HRQoL benefits
associated with more TN test results (better specificity). As a result, strategies 2 (ICA plus FFR) and
5 (ICA plus vFFR) have the highest prognostic model QALY gains, and strategy 1 (ICA alone) has the
lowest. These QALY gains, however, are offset by the disutility associated with diagnostic testing that
is highest for strategies 2 and 5 and lowest for strategy 1.
The benefits of revascularisation, in terms of improved HRQoL, mean that the sensitivity of test results is
a more important driver of cost-effectiveness than specificity because TP test results translate into higher
QALY gains than mismanagement of FN results. The base-case cost-effectiveness results are largely driven
by the balance between the costs of the diagnostic tests and the costs and benefits of revascularisation.
Results of the alternative scenario analyses
Diagnostic accuracy
Scenarios 1–3: using alternative sensitivity and specificity estimates for quantitative flow ratio
The sensitivity (84.3%) and specificity (89.8%) estimates for QFR, which are used to inform strategy 3
in the base-case scenario, are based on the primary bivariate meta-analysis described in Chapter 3,
Bivariate meta-analysis (QAngio XA 3D/QFR), from all studies that reported diagnostic accuracy data for
cQFR mode or non-specified QFR. Two separate scenarios consider the impact on cost-effectiveness
of small differences in diagnostic accuracy by mode of QFR: scenario 1 uses sensitivity (81.6%) and
specificity (89.4%) estimates for QFR based on studies that report only fQFR mode, whereas scenario 2
uses sensitivity (84.3%) and specificity estimates (91.4%) for QFR based on studies that report only
cQFR mode. Table 19 presents the cost-effectiveness results for scenarios 1 and 2.
TABLE 19 Deterministic cost-effectiveness results for scenarios 1 and 2
Strategy Identification
Total
QALYs
Total
costs (£) NHBa INHBa
NHB
rank
Scenario 1: sensitivity and specificity estimates based on fQFR mode only for strategy 3
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.084 4778 10.845 0.019 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
Scenario 2: sensitivity and specificity estimates based on cQFR mode only for strategy 3
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.088 4775 10.849 0.023 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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In scenario 1, there is a reduction in both the PPV (from 84.8% to 83.8%) and NPV (from 89.5% to
87.9%) for strategy 3, ICA plus QFR, compared with the base-case scenario. This results in a marginally
smaller reduction in total QALYs (0.003 QALYs per patient) and a decrease in total costs (£34 per
patient) for strategy 3 compared with the base case, with no change in the overall ranking of NHB across
strategies. In scenario 2, there is an increase in both the PPV (from 84.8% to 86.8%) and NPV (from
89.5% to 89.7%) for strategy 3 compared with the base case, due to more TN test results as a result
of better specificity. This results in a marginally small increase in total QALYs (0.001 QALYs per patient)
and a decrease in total costs (£37 per patient) for strategy 3 compared with the base-case scenario. This
means that the sensitivity and specificity estimates used in scenario 2 are slightly more favourable for
the cost-effectiveness of QFR compared with scenario 1 or the base-case scenario; however, the more
favourable estimates do not result in a change in NHB ranking across the strategies.
To understand the trade-off in diagnostic test costs and adverse events associated with FFR/iFR
(strategy 2) compared with QFR (strategy 3), scenario 3 considers the impact on cost-effectiveness
when QFR and FFR are assumed to be a perfect test (i.e. 100% sensitivity and specificity and the same
underlying distribution of FFR values are used as in the base case for strategy 2). The total number
of QALYs and costs for strategy 3 increase by 0.017 QALYs and £6 per patient from the base-case
scenario, which is largely due to a small increase in the number of revascularisations (from 39.9%
to 40.2%). With QFR assumed to be a perfect test, strategy 3 has a higher NHB than strategy 2
(an increase of 0.008 QALYs per patient) and is ranked the most cost-effective strategy. The increase
in NHB is largely due to greater total QALYs gained for strategy 3 compared with strategy 2, whereas
the difference in total costs between the strategies is small (£7 per patient). The difference in total
costs is small because QFR and FFR have similar costs of diagnostic testing (£431 for QFR vs. £437
for FFR/iFR), the number of revascularisations is the same under this scenario and the costs associated
with treating adverse events of FFR/iFR are small (average of £1.49 per patient tested). The difference
in total QALYs is due to the disutility associated with FFR/iFR and an increased risk of procedural
mortality for FFR/iFR.
Scenarios 4–6: using alternative sensitivity and specificity estimates for vFFR
The sensitivity (97.0%) and specificity (74.0%) estimates for vFFR, which are used to inform strategy 5
in the base-case scenario, are based on the largest (303 patients) study of vFFR. As noted in Chapter 3,
CAAS vFFR, there are only three independent studies of CAAS vFFR, one of which was published only
as a conference abstract.26 As reported in Chapter 3, Bivariate meta-analysis (CAAS vs. vFFR), the
bivariate meta-analysis of CAAS vFFR studies should be interpreted with caution owing to limited
data and high heterogeneity across studies. Therefore, this meta-analysis was not used to inform
the economic model. Two scenarios consider the impact on cost-effectiveness of different diagnostic
accuracy estimates for vFFR based on the two studies not included in the base-case scenario: scenario
4 uses sensitivity (75%) and specificity (46.5%) estimates for vFFR based on the ILUMIEN I study,19 and
scenario 5 uses sensitivity (68.2%) and specificity (87.3%) estimates for vFFR based on the Jin et al.26
conference abstract. Table 20 presents the cost-effectiveness results for scenarios 4 and 5.
In scenario 4, there is decrease in both the PPV (from 71.5% to 48.5%) and NPV (from 97.3% to
73.5%) for strategy 5 compared with the base-case scenario. This results in a substantial decrease in
total QALYs (0.033 QALYs per patient) and an increase in total costs (£294 per patient) for strategy 5
compared with the base case. Strategy 5 is now ranked the least cost-effective strategy (lowest in
terms of NHB), with lower NHB than in strategy 1 of ICA alone (a reduction of 0.031 QALYs per
patient, equivalent to £620 per patient diagnosed at a cost-effectiveness threshold of £20,000 per
QALY). In scenario 5, there is an increase in the PPV (from 71.5% to 78.3%) but a decrease in the
NPV (from 97.3% to 80.3%) for strategy 5 owing to lower sensitivity and better specificity than the
base-case scenario. This results in a substantial decrease in both total QALYs (0.030 QALYs per patient)
and total costs (£758 per patient) for strategy 5 compared with the base-case scenario. Strategy 5,
ICA plus vFFR, now appears a more cost-effective strategy than strategies 3 and 4 based on QFR
and is ranked second in terms of NHB, with FFR remaining the strategy with the highest NHB.
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To understand the impact of differences in diagnostic test costs between vFFR and QFR, scenario 6
considers the impact on cost-effectiveness by assuming that both tests have the same diagnostic
accuracy as in strategies 3 and 5 (i.e. the sensitivity and specificity for vFFR is set equal to the
base-case scenario for QFR). Table 21 presents the cost-effectiveness results for scenario 6.
In scenario 6, the total QALYs and costs are reduced for strategy 5, largely owing to a decrease in the
number of revascularisations (from 54.5% to 40.0%). The only difference between strategies 5 and 3 is
the difference in the costs of diagnostic testing of £258 less per patient for vFFR compared with QFR
for the base-case throughput assumption of 200 patients per year. This difference in the cost of testing
between vFFR and QFR, under the scenario of equivalent diagnostic accuracy, is sufficient to change
the ranking of NHB across the strategies, with strategy 5 now ranked with the highest NHB.
TABLE 20 Deterministic cost-effectiveness results for scenarios 4 and 5
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 4: sensitivity and specificity estimates based on the ILUMIEN I study19 for vFFR in strategy 5
1 ICA alone 11.061 4697 10.826 – 4
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.065 4813 10.824 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.016 3
5 ICA plus vFFR 11.065 5412 10.795 –0.031 5
Scenario 5: sensitivity and specificity estimates based on the Jin et al.26 for vFFR in strategy 5
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.065 4813 10.824 0.020 3
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.016 4
5 ICA plus vFFR 11.068 4360 10.850 0.024 2
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
TABLE 21 Deterministic cost-effectiveness results for scenario 6: same sensitivity and specificity estimates for vFFR and
QFR in strategies 3 and 5
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 2
3 ICA plus QFR 11.087 4812 10.847 0.020 3
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.016 4
5 ICA plus vFFR 11.087 4554 10.860 0.034 1
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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Scenario 7: using alternative sensitivity and specificity estimate for invasive
coronary angiography
The sensitivity (62.6%) and specificity (61.6%) estimates for ICA, which are used to inform strategy 1 in the
base-case scenario, are based on the bivariate meta-analysis in Chapter 3, Meta-analysis of extracted figure
data for two-dimensional invasive coronary angiography, from studies that reported diagnostic accuracy data
for 2D ICA compared with FFR. Scenario 7 is used to assess the impact on cost-effectiveness of an
alternative (higher) estimate of diagnostic accuracy for ICA based on a meta-analysis by Danad et al.100 for
diagnostic performance of ICA compared with FFR (sensitivity 71% and specificity 66% from per-vessel
analysis). Table 22 presents the cost-effectiveness results for scenario 7.
In scenario 7, there is an increase in both the PPV (from 52.3% to 58.4%) and NPV (from 71.0% to
77.2%) for strategy 1 compared with the base-case scenario. This results in an increase in total QALYs
(0.012 QALYs per patient) and a marginal increase in total costs (£29 per patient) for strategy 1 but
with no change in the NHB ranking, with ICA alone ranked the least cost-effective strategy.
Scenario 8: using an alternative diagnostic threshold for fractional flow reserve and
quantitative flow ratio
The base-case scenario uses a diagnostic threshold of FFR ≤ 0.8 to define functionally significant
stenosis. In scenario 8, an alternative diagnostic threshold of FFR ≤ 0.75 is used to assess the impact
on cost-effectiveness results for strategies 1, 2 and 3 compared with the base-case scenario (note that
there were insufficient diagnostic accuracy data for vFFR to inform an alternative diagnostic threshold
for strategy 5, whereas strategy 4 uses a hybrid approach rather than a single diagnostic threshold).
In scenario 8, the diagnostic accuracy of QFR is based on the estimates reported in Chapter 3, Alternative
FFR thresholds, for this alternative threshold (sensitivity 75.4% and specificity 90.6%), whereas the
diagnostic accuracy of ICA was estimated at FFR ≤ 0.75 and ≥ 50% DS using the approach described
in Chapter 3, Meta-analysis of extracted figure data for two-dimensional invasive coronary angiography
(sensitivity 74.0% and specificity 56.4%). The use of an alternative threshold also changes the prior
probability of functionally significant stenosis from 40% in the base-case scenario to 25% in scenario 8.
This means that the underlying distribution of FFR values for the different diagnostic outcomes
(TN, FN, TP and FP) shifts for these strategies, as the category of FFR 0.76–0.80 is ‘moved’ from the
distribution of FFR in patients with functionally significant stenosis (TP and FN) to those without
(TN and FP). This shift in the FFR distribution also changes the utility increment for TP, slightly increasing
it for all strategies (the size of the increment varies by strategy as it is dependent on the underlying FFR
distribution). The utility increment for FN was assumed to remain the same, even though this increment
was estimated in patients with FFR ≤ 0.80 who did not receive revascularisation.
TABLE 22 Deterministic cost-effectiveness results for scenario 7: sensitivity and specificity estimates for ICA based on
the meta-analysis by Danad et al.100 in strategy 1
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.073 4726 10.837 – 5
2 ICA plus FFR 11.096 4825 10.855 0.018 1
3 ICA plus QFR 11.087 4812 10.847 0.010 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.006 3
5 ICA plus vFFR 11.098 5118 10.842 0.005 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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Table 23 presents the cost-effectiveness results for scenario 8. The NHB decreases for all three strategies
but the ranking of strategies follows the same order as the base-case scenario, with strategy 2 ranked as
the most cost-effective option. The total QALYs for all three strategies are reduced owing to the reduction
in prior probability of functionally significant stenosis, which means that fewer patients are able to benefit
from revascularisation. The proportion of patients who undergo revascularisation is reduced for both
strategies 2 and 3 compared with the base-case scenario. The changes in diagnostic accuracy of strategy 3
(lower sensitivity and increased specificity) combined with lower prior probability of significant stenosis
compared with the base-case results in a lower PPV (72.8% vs. 84.8%) and higher NPV (91.7% vs. 89.5%).
In this scenario, the greater increase in FP compared with FN for strategy 3 results in a greater number
of revascularisations for this strategy compared with strategy 2 (25.9% vs. 25%). The diagnostic accuracy
of strategy 1 changes in the opposite way to strategy 3 (i.e. the sensitivity increases and the specificity
decreases). Despite the lower prior probability of functionally significant stenosis, this results in more
revascularisation procedures overall (51.2% vs. 48.1%), with associated higher costs and greater QALY
loss compared with the base-case scenario. In the prognostic model, all three strategies accrue more costs
and fewer QALYs than the base-case scenario. The lower QALY gains and higher costs result from fewer
patients with TP results entering the prognostic model in all three strategies, so fewer patients benefit
from the utility increment and lower medication costs associated with a TP test result.
Scenario 9: using an alternative definition of the grey zone for strategy 4
In the base-case scenario, a hybrid approach is used for strategy 4, with QFR followed by confirmatory
FFR when the results of QFR are inconclusive (grey zone). The definition of the grey zone is based on
the manufacturer’s recommendation of QFR 0.78–0.84. In scenario 9, an alternative wider definition
is used for the grey zone of between 0.70 and 0.90 to assess the impact on the cost-effectiveness of
strategy 4.
Table 24 presents the cost-effectiveness results for scenario 9.
TABLE 23 Deterministic cost-effectiveness results for scenario 8: alternative diagnostic threshold (≤ 0.75) for QFR
and FFR
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.018 4793 10.779 – 3
2 ICA plus FFR 11.039 4248 10.826 0.048 1
3 ICA plus QFR 11.029 4276 10.815 0.036 2
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
TABLE 24 Deterministic cost-effectiveness results for scenario 9: alternative definition of the grey zone (QFR 0.70–0.90)
for strategy 4
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.061 4697 10.826 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.097 5097 10.842 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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The wider definition of the grey zone in scenario 9 increases the proportion of patients in the grey zone
compared with the base-case scenario from 20.2% to 61.6%, which changes the diagnostic accuracy of
strategy 4 with more confirmatory FFR tests. The PPV and NPV of strategy 4 increases by 10.9% and
3.7%, respectively, compared with the base-case scenario. By widening the grey-zone definition, more
patients undergo FFR, which increases the costs of testing for strategy 4 by £181 compared with the
base-case scenario. However, an increase in FFR also results in fewer revascularisations than in the
base-case scenario (reduced from 43.1% in the base-case scenario to 40.4% in scenario 9 for strategy 4),
with a corresponding reduction in revascularisation costs of £108. The reduction in revascularisations
also reduces the QALY loss owing to this procedure compared with the base-case scenario, but this is
offset by the increase in QALY loss owing to FFR. In the diagnostic model, strategy 4 is more costly
(£73 per patient) and incurs more QALY loss (0.0021 QALYs per patients) compared with the base-case
scenario. The reduced misclassification and consequent improved clinical management of patients
results in higher QALY gains (0.005 QALYs per patient) for strategy 4 in the prognostic model, than in
the base-case scenario.
Overall, both the total QALYs (0.04 QALYs per patient) and total costs (£78 per patient) are higher
for strategy 4 compared with the base-case scenario, which results in a small reduction in NHB (0.001
QALYs), compared with the base-case scenario, which leads to the same NHB for strategies 4 and 5.
Risk of major adverse cardiovascular events
Scenario 10: baseline risk of major adverse cardiac events independent of fractional flow reserve
and diagnostic test results
The baseline risk of MACE in the base-case scenario depends on disease severity as measured by FFR
value, where lower FFR values are indicative of a higher cardiovascular event rate and higher FFR
values of a lower rate, where the distribution of FFR values differs by diagnostic strategy. In scenario
10, the dependency on FFR is removed and the impact on cost-effectiveness is assessed by considering
the baseline risk of MACE to be completely independent of FFR and diagnostic test results.
Table 25 presents the cost-effectiveness results for scenario 10.
In scenario 10, the overall risk of MACE is 1.44% in the first year and 0.72% in subsequent years based
on the IRIS-FFR registry data across all FFR values, whereas in the base-case scenario it ranges from
4.33% for FFR values < 0.70 to 0.64% for FFR values > 0.90. In scenario 10, this results in an increase
in total QALYs (0.048 for strategy 1, 0.080 for strategy 2, 0.067 for strategy 3, 0.075 for strategy 4
and 0.074 for strategy 5) and a decrease in total costs per patient for each strategy (£124 for strategy 1,
£127 for strategy 2, £124 for strategy 3, £126 for strategy 4 and £139 for strategy 5) compared with
TABLE 25 Deterministic cost-effectiveness results for scenario 10: the baseline risk of MACE is independent of FFR and
diagnostic test results
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.109 4573 10.881 – 5
2 ICA plus FFR 11.176 4698 10.942 0.061 1
3 ICA plus QFR 11.154 4688 10.920 0.039 4
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.168 4893 10.923 0.042 2
5 ICA plus vFFR 11.172 4979 10.923 0.042 3
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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the base-case scenario. The corresponding NHB ranking changes because strategies 3–5 are very similar
in terms of NHB (10.920 QALYs for strategy 3 and 10.923 QALYs for strategies 4 and 5), and strategy 2
remains the most cost-effective option and strategy 1 the least. The removal of dependency on FFR
values appears to have the greatest impact on strategy 5, ICA plus vFFR. This is largely because this
strategy has more TP test results (better sensitivity) than strategies 3 and 4 using QFR. In scenario 10, the
baseline risk of MACE is lower for FFR values ≤ 0.80 and greater for FFR values > 0.80, compared with
the baseline risk of MACE used in the base-case scenario. This means that strategies with more TN test
results (better specificity) are penalised with a higher risk of MACE, and strategies with more TP test
results (better sensitivity) benefit from a lower risk of MACE. As a result, the NHB for strategy 5
improves more than for strategies 3 and 4. This is in line with the base-case conclusion that sensitivity
of test results is a more important driver of cost-effectiveness than specificity because TP test results
translate into higher QALY gains than mismanagement of FN results.
Scenarios 11–13: treatment effect of revascularisation on major adverse cardiac event
The base-case scenario assumes that there is no treatment effect associated with revascularisation
on the risk of MACE based on the findings of ISCHEMIA95 (i.e. revascularisation does not confer
additional benefits over and above OMT on the risk of MACE). Three separate scenarios are used to
consider the impact on cost-effectiveness of alternative assumptions about the benefits of revascularisation
on MACE outcomes compared with OMT: scenario 11 considers a significant reduction in the risk of MACE
for revascularisation in patients with a FFR value < 0.76, based on the findings of the IRIS-FFR registry
data, which show that there was a statistically significant reduction in the risk of clinical outcomes only for
lesions with a FFR < 0.76; scenario 12 considers a statistically significant reduction in the risk of unplanned
revascularisation, and there is no reduction for cardiac death or MI, based on the findings of trials
that showed a positive effect of revascularisation on MACE for repeat/emergency or unplanned
revascularisation rather than cardiac death or MI; and scenario 13 considers a reduction in the risk of
MACE for all components (unplanned revascularisation, cardiac death or MI) based on the findings of
trials that reported a modest (but non-statistically significant) improvement in MACE for revascularisation
compared with OMT. Table 26 presents the cost-effectiveness results for scenarios 11–13.
In scenario 11, the HR for revascularisation compared with OMT is set equal to 0.47 for the risk of
MACE (across all components) for FFR values ≤ 0.75, whereas the HR is set equal to 1 for FFR values
> 0.75. Thus, strategies with more TP test results and a higher proportion of lower FFR values are
expected to have better outcomes than the base-case scenario. Scenario 11 results in an increase in
total QALYs (0.019 for strategy 1, 0.022 for strategy 2, 0.021 for strategy 3, 0.021 for strategy 4 and
0.024 for strategy 5) and a decrease in total costs per patient for each strategy (£91 for strategy 1,
£116 for strategy 2, £108 for strategy 3, £111 for strategy 4 and £125 for strategy 5) compared with
the base-case scenario. The corresponding NHB ranking switches for strategies 4 and 5, with strategy
5 appearing marginally more cost-effective than strategy 4. This is largely because strategy 5 has
marginally more TP test results, which benefit from a lower risk of MACE, compared with strategy 4.
In scenario 12, the HR for revascularisation compared with OMT for lesions with a FFR ≤ 0.8 is set
equal to 0.26 for the risk of unplanned revascularisation, whereas the HR is set equal to 1 for cardiac
death or MI. In this scenario, there is very little impact on total QALYs across strategies, whereas the
total costs per patient decrease for each strategy (£155 for strategy 1, £235 for strategy 2, £203 for
strategy 3, £220 for strategy 4 and £233 for strategy 5) compared with the base-case scenario. The
corresponding NHB ranking switches for strategies 4 and 5, with strategy 5 appearing marginally more
cost-effective than strategy 4. Again, this is largely because strategy 5 has marginally more TP test
results, which benefit from a lower risk of revascularisation, compared with strategy 4.
In scenario 13, the HR for revascularisation compared with OMT for lesions with a FFR ≤ 0.8 is set equal
to 0.71 for the risk of cardiac death, 0.93 for non-fatal MI and 0.93 for unplanned revascularisation.
Scenario 11 results in an increase in total QALYs (0.012 for strategy 1, 0.016 for strategy 2, 0.014 for
strategy 3, 0.015 for strategy 4 and 0.016 for strategy 5) and a decrease in total costs per patient for
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each strategy (£11 for strategy 1, £18 for strategy 2, £15 for strategy 3, £16 for strategy 4 and £17
for strategy 5), compared with the base-case scenario. The corresponding NHB ranking switches for
strategies 4 and 5, with strategy 5 appearing marginally more cost-effective than strategy 4 (see Table 26).
Again, strategies with more TP test results benefit most from improved clinical outcomes than strategies
with more TN test results.
Scenario 14: costs of diagnostic tests
The cost per test of QFR and vFFR in the base-case scenario is based on an average annual throughput of
200 patients per centre, which corresponds to an average cost of £431 per patient for QFR and £172 per
patient for vFFR. Based on the base-case assumptions, the average cost per test of QFR is constant for an
annual throughput > 100 patients, and it is expected to range from £473 (throughput of 90 patients) to
£741 (throughput of 10 patients) per patient for a throughput < 100 patients. For vFFR, the average cost
per test varies for throughput < 200 patients, with an average cost per test of £338 for throughput of
100 patients and increasing to £2153 for a throughput of 10 patients per centre. Scenario 14 considers
the impact on cost-effectiveness of an alternative average annual throughput of 100 patients for QFR
and vFFR. Table 27 presents the cost-effectiveness results for scenario 14.
Scenario 14 results in an increase in the total costs of strategy 5, which is £166 per patient. The
corresponding NHB ranking of strategies is unchanged. As an additional exploratory analysis, the
average annual throughput for vFFR was varied to establish the point of indifference in NHB between
TABLE 26 Deterministic cost-effectiveness results for scenarios 11–13
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 11: a significant reduction in the risk of MACE for FFR values < 0.76 for revascularised lesions
1 ICA alone 11.080 4606 10.850 – 5
2 ICA plus FFR 11.118 4709 10.882 0.032 1
3 ICA plus QFR 11.108 4704 10.873 0.023 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.114 4908 10.869 0.019 4
5 ICA plus vFFR 11.122 4993 10.872 0.022 3
Scenario 12: a significant reduction in the risk of unplanned revascularisation following an index revascularisation procedure
1 ICA alone 11.062 4542 10.835 – 5
2 ICA plus FFR 11.097 4590 10.868 0.033 1
3 ICA plus QFR 11.088 4609 10.858 0.023 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.094 4799 10.854 0.019 4
5 ICA plus vFFR 11.099 4885 10.855 0.020 3
Scenario 13: a modest reduction in the risk of MACE following an index revascularisation procedure
1 ICA alone 11.073 4686 10.838 – 5
2 ICA plus FFR 11.112 4807 10.871 0.033 1
3 ICA plus QFR 11.101 4797 10.861 0.023 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.108 5003 10.858 0.020 4
5 ICA plus vFFR 11.114 5101 10.859 0.021 3
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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strategies 3 and 5, with everything else held equal to the base-case scenario. The NHB for strategies 3
and 5 are equal (and ranked as the second highest NHB across strategies after ICA plus FFR) at an
average annual throughput of 500 patients per centre, where the average cost per test of QFR is
expected to be £431, while it is only £73 for vFFR.
Scenarios 15 and 16: costs of revascularisation
In the base-case scenario, the costs of revascularisation for PCI and CABG are based on a weighted
average of NHS reference costs across all HRGs, whereas the proportion of patients who undergo PCI
and CABG as the index procedure is based on BCIS audit data. Two alternative scenarios are used to
consider the impact on cost-effectiveness of a variation in the costs of revascularisation: scenario 15
considers a lower cost of PCI (reduced from £3005 to £2179 per patient) based on day cases only
from NHS reference costs, and scenario 16 considers an alternative assumption of PCI in 75% of cases
(reduced from 87% in the base case) and CABG in 25% of cases (increased from 13% in the base case),
which increases the average cost of revascularisation from £4031 to £4978 per patient. Table 28
presents the cost-effectiveness results for scenarios 15 and 16.
TABLE 28 Deterministic cost-effectiveness results for scenarios 15 and 16
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 15: cost of PCI based on day cases only
1 ICA alone 11.061 4351 10.844 – 5
2 ICA plus FFR 11.096 4536 10.869 0.025 1
3 ICA plus QFR 11.087 4525 10.861 0.017 3
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 4709 10.858 0.014 4
5 ICA plus vFFR 11.098 4726 10.862 0.018 2
Scenario 16: proportion of revascularisations assumed to be PCI in 75% of cases and CABG in 25%
1 ICA alone 11.054 5218 10.793 – 5
2 ICA plus FFR 11.090 5274 10.826 0.033 1
3 ICA plus QFR 11.081 5259 10.818 0.025 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.087 5495 10.812 0.019 3
5 ICA plus vFFR 11.090 5699 10.805 0.012 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
TABLE 27 Deterministic cost-effectiveness results for scenario 14: throughput of 100 patients per year for QFR and vFFR
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4825 10.855 0.029 1
3 ICA plus QFR 11.087 4812 10.847 0.021 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5019 10.843 0.017 3
5 ICA plus vFFR 11.098 5283 10.834 0.008 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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In scenario 15, the total QALYs are unchanged, whereas the total costs per patient for each strategy
are reduced compared with the base-case scenario (£346 for strategy 1, £289 for strategy 2, £287 for
strategy 3, £310 for strategy 4 and £392 for strategy 5). The corresponding NHB ranking for strategies 3,
4 and 5 are changed, with strategy 5 appearing marginally more cost-effective than strategies 3 and 4.
This is largely because strategy 5 has more TP and FP test results that benefit from a lower cost of
revascularisation compared with strategies 3 and 4, which have more TN test results (better specificity).
In scenario 16, the total QALYs for each strategy are marginally reduced (ranging from 0.006 to 0.008
QALYs per patient) owing to a higher procedural disutility associated with revascularisation as a result
of an increase in CABG surgery, whereas the total costs for each strategy are increased as a result of
higher costs associated with CABG compared with PCI (£521 for strategy 1, £449 for strategy 2, £447
for strategy 3, £476 for strategy 4 and £581 for strategy 5). The corresponding NHB ranking of
strategies is unchanged.
Scenarios 17–19: health-related quality of life
In the base-case scenario, improvement in symptom relief is the only benefit of revascularisation compared
with OMT, which is assumed to be maintained over a lifetime duration. The HRQoL benefits in the FAME I
and II trials108,133 observed at 1 year for the TP (revascularised with a FFR ≤ 0.8) and FN (OMTwith a FFR
≤ 0.8) health states are applied in the model over a lifetime duration. Two separate scenarios are used
to consider the impact on cost-effectiveness of both the duration and magnitude of HRQoL benefits of
revascularisation: scenario 17 considers the impact on cost-effectiveness of the duration of HRQoL
benefits by assuming that benefits are maintained for a limited duration of 5 years only and then return
to baseline, whereas scenario 18 considers the impact of assuming no HRQoL benefits associated with
revascularisation, over and above OMT, based on the findings of the ORBITA trial.97 Table 29 presents
the cost-effectiveness results for scenarios 17 and 18.
TABLE 29 Deterministic cost-effectiveness results for scenarios 17 and 18
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 17: HRQoL benefits associated with revascularisation and OMT maintained for 5 years only
1 ICA alone 10.903 4697 10.668 – 3
2 ICA plus FFR 10.913 4825 10.672 0.004 2
3 ICA plus QFR 10.915 4812 10.674 0.006 1
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
10.915 5019 10.664 –0.004 4
5 ICA plus vFFR 10.913 5118 10.657 –0.011 5
Scenario 18: no HRQoL benefits associated with revascularisation
1 ICA alone 10.843 4697 10.608 – 1
2 ICA plus FFR 10.840 4825 10.598 –0.010 3
3 ICA plus QFR 10.847 4812 10.606 –0.002 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
10.844 5019 10.593 –0.015 4
5 ICA plus vFFR 10.839 5118 10.583 –0.025 5
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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Scenario 17 results in a significant reduction in total QALYs for each strategy compared with the base-
case scenario (0.158 QALYs for strategy 1, 0.183 QALYs for strategy 2, 0.172 QALYs for strategy 3,
0.178 QALYs for strategy 4 and 0.185 QALYs for strategy 5), while the total costs remain unchanged.
The corresponding impact on NHB is a change in ranking, with strategy 3 now ranked marginally
more cost-effective than strategy 2, and strategy 5 is ranked the least cost-effective strategy. In fact,
the shorter the duration of HRQoL benefits, the more cost-effective strategy 3 appears relative to
strategy 2.This is because the benefits of revascularisation need to be maintained for longer to offset the
procedural disutility associated with FFR.The point of indifference in duration of HRQoL benefits between
strategies 2 and 3, with everything else held the same as the base-case scenario, is 7 years (i.e. strategy 2
appears the most cost-effective strategy only if the HRQoL benefits associated with revascularisation are
maintained for at least 7 years to offset the procedural disutility associated with FFR).
Scenario 18 results in a significant reduction in total QALYs across all strategies compared with the base-
case scenario (0.218 QALYs for strategy 1, 0.256 QALYs for strategy 2, 0.240 QALYs for strategy 3, 0.249
QALYs for strategy 4 and 0.259 QALYs for strategy 5), and the total costs remain unchanged. The smallest
reduction in QALYs is for strategies 1 and 3 because these strategies have the lowest proportion of TP test
results compared with the other strategies. The corresponding impact on NHB is a change in ranking, with
strategy 1 now ranked the most cost-effective strategy, followed by strategy 3, and strategy 5 is ranked
the least cost-effective strategy. ICA alone appears the most cost-effective option because there are no
benefits associated with revascularisation compared with OMT and, therefore, limited benefits associated
with diagnostic testing to correctly identify patients suitable for revascularisation.
An additional scenario 19 is used to assess the impact on cost-effectiveness of assuming a higher
procedural disutility associated with FFR compared with the base-case scenario. In the absence of
identifying an estimate of EQ-5D disutility associated with FFR, the base-case scenario assumes that
the procedural disutility for FFR is equivalent to the disutility associated with PCI (a decrement of
0.0056 QALYs). In scenario 19, the impact on cost-effectiveness is assessed by considering a higher
procedural disutility associated with FFR, which is equivalent to that of CABG surgery (a decrement of
0.0330 QALYs). Table 30 present the cost-effectiveness results for scenario 19.
Scenario 19 results in a change in the NHB of strategies 2 and 4 with FFR. The total QALYs for both
strategies are reduced, with the largest reduction, as expected, in strategy 2 (0.027 QALYs per patient for
strategy 2 and 0.005 QALYs per patient for strategy 4). This changes the NHB ranking such that strategy 2
is now only marginally more cost-effective than strategy 1 of ICA alone, and strategy 3 is ranked the most
cost-effective option. As an additional exploratory analysis, the procedural disutility associated with FFR
was varied to establish the point of indifference in NHB between strategies 2 and 3, with everything else
held equal to the base-case scenario. The NHB for strategies 2 and 3 are equal (and ranked the highest
across all strategies) at a procedural disutility of 0.014 QALYs for FFR, which is 2.5 times greater than the
disutility associated with PCI but less than half the disutility associated with CABG.
TABLE 30 Deterministic cost-effectiveness results for scenario 19: higher procedural disutility associated with FFR
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.069 4825 10.828 0.002 4
3 ICA plus QFR 11.087 4812 10.847 0.021 1
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.088 5019 10.837 0.011 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 2
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
95
Scenarios 20–22: using alternative sources to inform fractional flow reserve/instantaneous
wave-free ratio procedural complication rates
The base-case scenario assumes that procedural death associated with FFR/iFR is 0.015% based on
Fearon et al.,87 and the rates of other adverse events associated with FFR/iFR are taken from the
IRIS-FFR study.13 Three separate scenarios are used to explore the impact on cost-effectiveness of
alternative assumptions and data sources used to inform procedural complication rates of FFR/iFR:
scenario 20 sets the procedural death rate equal to zero, whereas scenarios 21 and 22 use the rates
informed by the RIPCORD101 and ORBITA97 trials, respectively (both these studies were identified in
Complications due to FFR/iFR (subsection of procedural adverse events) as potentially relevant data
sources). In scenario 21, a procedural complication rate of 0.5% is assumed for the following adverse
events: ventricular arrhythmia, vessel occlusion, coronary dissection and deep-vein thrombosis. The unit
cost applied for vessel occlusion is the same as for CABG (£10,896) because this was the procedure
used to treat this adverse event in the RIPCORD trial.101 For deep-vein thrombosis, a unit cost of
£997.40 was estimated based on the activity weighted average of currency codes for deep-vein
thrombosis (YQ51A–E) across all HRG codes from NHS reference costs 2017/18138 and uprated to
2018/19 prices.137 All other adverse events use the same unit costs as the base-case scenario. Scenario 22
considers only a 4.21% rate of coronary dissection, as observed in the ORBITA trial.97 Table 31 presents
the cost-effectiveness results for scenarios 20–22.
Scenario 20 results in only a very small impact on the cost-effectiveness results. The NHB of strategies 2
and 4 increase by 0.002 and 0.0004 QALYs, respectively, compared with the base-case scenario because
TABLE 31 Deterministic cost-effectiveness results for scenarios 20–22
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 20: no procedural death with FFR/iFR
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.098 4825 10.857 0.030 1
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.094 5019 10.843 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
Scenario 21: FFR/iFR complication rates from RIPCORD101
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4875 10.853 0.026 1
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5026 10.842 0.016 4
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
Scenario 22: FFR/iFR complication rates from ORBITA97
1 ICA alone 11.061 4697 10.826 – 5
2 ICA plus FFR 11.096 4899 10.851 0.025 1
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5029 10.842 0.016 3
5 ICA plus vFFR 11.098 5118 10.842 0.016 4
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
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more patients survive FFR procedure to receive revascularisation. The small increase in revascularisations
leads to more QALYs and costs accrued for both strategies, compared with base-case scenario. These
differences have no impact on the ranking of NHB across strategies.
Scenarios 21 and 22 lead to an increase in the costs of adverse events for strategy 2 compared with
the base-case scenario (£50 and £74 per patient, respectively), and the cost increase for strategy 4
compared with the base case is £6 and £9, respectively. Overall, this translates into a small decrease in
the NHB of strategies 2 and 4, with no change in the ranking of NHB across strategies.
Scenarios 23 and 24: diagnostic-only setting
Setting details key differences between diagnostic-only and interventional settings. Scenarios 23 and
24 reflect the diagnostic-only setting by considering (1) the additional costs due to the need to refer
patients who require FFR/iFR measurements to an interventional catheter laboratory and (2) alternative
throughput assumptions.
In scenario 23, the unit cost of FFR/iFR corresponds to the cost of a complex catheterisation (£2202)
so as to account for the additional catheterisation that would be required under this scenario (see
Invasive coronary angiography and fractional flow reserve). In the base-case scenario the cost of FFR/iFR
only includes the incremental cost of FFR/iFR compared with ICA (£437), as a single catheterisation
allows both procedures to be performed. Scenario 24 builds on the assumptions of scenario 23 on the
cost of FFR/iFR and further assumes an average annual throughput of 500 patients per diagnostic-only
centre. This is the average annual throughput value at which (with everything else held equal to the
base-case scenario) strategies 3 and 5 became equivalent in terms of NHB, as identified by a previous
exploratory analysis. This throughput estimate is close to the average annual number of ICA procedures
per diagnostic-only centre (584; see Model input parameters, Patient population, Patient throughput).
Cost-effectiveness results for scenarios 23 and 24 are presented in Table 32.
TABLE 32 Cost-effectiveness results for scenarios 23 and 24
Strategy Identification Total QALYs Total costs (£) NHBa INHBa NHB rank
Scenario 23: cost of FFR/iFR accounts for additional catheterisation in a diagnostic-only setting
1 ICA alone 11.061 4697 10.826 – 3
2 ICA plus FFR 11.096 6590 10.767 –0.060 5
3 ICA plus QFR 11.087 4812 10.847 0.020 1
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5376 10.825 –0.002 4
5 ICA plus vFFR 11.098 5118 10.842 0.016 2
Scenario 24: throughput of 500 patients per year for QFR and vFFR, and cost of FFR/iFR accounts for additional
catheterisation in a diagnostic-only setting
1 ICA alone 11.061 4697 10.826 – 3
2 ICA plus FFR 11.096 6590 10.767 –0.060 5
3 ICA plus QFR 11.087 4812 10.847 0.020 2
4 ICA plus QFR plus
confirmatory FFR
(grey zone)
11.093 5376 10.825 –0.002 4
5 ICA plus vFFR 11.098 5018 10.847 0.021 1
a At a cost-effectiveness threshold of £20,000 per QALY. INHB is relative to ICA alone.
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
97
In scenario 23, the cost of testing increases considerably for strategies 2 (£1765) and 4 (£357)
compared with the base-case scenario. The sharp increase in cost for these strategies reduces their
NHB, with strategy 1 now having the lowest NHB followed by strategy 4. In this scenario, strategy 3
has the highest NHB across all strategies.
In scenario 24, in addition to the changes to the testing costs of strategy 2 and 4 found for scenario 23,
the increase of annual patient throughput reduces the testing costs of strategy 5 (£99 less than in the
base-case scenario), and the testing costs of strategy 3 remain £431. The difference in total costs between
strategy 5 and strategy 3 is reduced to £206, which is offset by the QALY gains of strategy 5 compared
with strategy 3 (0.011). In this scenario, strategy 5 has the highest NHB across all strategies, but this
result needs to be interpreted cautiously given the uncertainties in the diagnostic accuracy of CAAS vFFR.
The deterministic cost-effectiveness results of the base-case and scenario analyses are summarised in
Appendix 9, Table 74.
Discussion of the independent economic assessment
The decision problem addressed by the model relates to the cost-effectiveness of QAngio XA 3D/QFR
and CAAS vFFR imaging software used during ICA for assessing the functional significance of coronary
stenosis in patients with stable angina whose angiograms show intermediate stenosis. Five diagnostic
strategies were addressed: strategy 1 of ICA alone (visual interpretation of angiographic images without
additional testing to assess the functional significance of intermediate stenosis), strategy 2 of ICA
followed by confirmatory FFR/iFR (reference standard), strategy 3 of ICA with QFR, strategy 4 of ICA
with QFR, followed by confirmatory FFR/iFR when QFR is inconclusive, and strategy 5 of ICA with vFFR.
The decision model considered the diagnostic accuracy of the non-invasive functional tests (QAngio XA
3D/QFR and CAAS vFFR) and ICA relative to the reference standard of pressure wire FFR/iFR to
determine whether or not patients were correctly identified as having functionally significant stenosis
and should progress to revascularisation (in addition to OMT) or functionally non-significant stenosis
and should receive OMTwithout the need for revascularisation. The short-term costs and consequences
associated with diagnostic testing and revascularisation were considered. These short-term consequences
were then linked to longer-term costs and consequences associated with the diagnostic outcomes and
treatment by modelling the risk of major adverse cardiovascular events (MI, sudden cardiac death and
need for urgent/unplanned revascularisation) over a lifetime horizon.
The cost-effectiveness of the diagnostic strategies was assessed by ranking the strategies in terms of
NHB from highest to lowest. The strategy with the highest NHB represents the cost-effective strategy,
and the ranking is used to interpret the next best choice (second highest NHB) and so on. A cost-
effectiveness threshold of £20,000 per additional QALY was used to determine cost-effectiveness. The
strategy with the highest NHB was strategy 2, FFR, and the strategy ranked with the lowest NHB was
strategy 1, ICA alone. The strategy with the second highest NHB was strategy 3, QFR, and the next
best strategies were either strategy 4, QFR and confirmatory FFR, or strategy 5, vFFR. Strategy 2 was
also the strategy with the highest probability of being cost-effective (27.8%) and strategy 1 had the
lowest probability (10.0%), whereas strategies 3–5 had similar probabilities of cost-effectiveness
(21.8% for strategy 3, 19.9% for strategy 4 and 20.4% for strategy 5).
The difference in NHB between strategies 2 (cost-effective) and 3 (next best strategy) was 0.007 QALYs,
which is equivalent to £140 per patient diagnosed at a cost-effectiveness threshold of £20,000 per QALY
gained. The diagnostic test costs for QFR and FFR were similar (£437 per test for FFR vs. £431 per
test for QFR). The difference between the two strategies was largely driven by the trade-off in HRQoL
between the procedural disutility associated with FFR/iFR and the HRQoL benefits associated with
revascularisation. The procedural QALY loss associated with FFR/iFR was not sufficient to offset
the higher QALY gains associated with revascularisation for FFR owing to more TP test results for
strategy 2 than for strategy 3.
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The difference in NHB between strategies 3 and 4 was 0.005 QALYs, which is equivalent to £100 per
patient diagnosed at a cost-effectiveness threshold of £20,000 per QALY gained. This difference was
largely driven by the additional costs of testing for strategy 4 (£519 per patient tested, with QFR
followed by confirmatory FFR when QFR is conclusive), compared with strategy 3 (£431 per test for
QFR without additional testing). The higher QALY gains associated with more TP test results for
strategy 4 (due to the addition of confirmatory FFR in the inconclusive QFR test results) was not
sufficient to offset the additional costs of testing with both QFR and FFR in strategy 4.
The difference in NHB between strategies 4 and 5 was minimal, at 0.001 QALYs (or equivalently
£20 per patient diagnosed at a cost-effectiveness threshold of £20,000 per QALY gained), and the
difference in NHB between strategies 3 and 5 was 0.004 QALYs (or equivalently £80 per patient
diagnosed). The diagnostic test costs for vFFR were smaller than QFR (£172 per test for vFFR vs.
£431 per test for QFR), and the PPV was lower and the NPV higher in strategy 5 than in strategy 3.
The higher QALY gains associated with more TP test results, and the lower diagnostic testing costs, for
strategy 5, compared with strategy 3, was not sufficient to offset the additional costs associated with
unnecessary revascularisations due to a greater number of FP test results in strategy 5. Therefore, the
benefits of improved test sensitivity of vFFR in strategy 5 are not sufficient to offset the better test
specificity with QFR.
The cost-effectiveness results for strategy 5 should be interpreted with caution because of the limited
availability of diagnostic accuracy studies for vFFR. The estimates of sensitivity and specificity for vFFR
in strategy 5 were based on one study with 303 patients, whereas the diagnostic accuracy estimates
for QFR were based on 26 studies and > 3000 lesions, which was used to inform strategies 3 and 4.
A number of alternative scenarios were considered in which the assumptions used as part of the base-
case results were varied. These analyses were undertaken to assess the robustness of the base-case
results to variation in the sources of data used to populate the model and alternative assumptions.
These alternative scenarios showed that the cost-effectiveness results for strategy 3 were robust to
the mode of flow used for QFR measurement, contrast-flow QFR or fixed-flow QFR. The results were
also robust to the use of an alternative diagnostic threshold of 0.75 for FFR and QFR in strategies 2
and 3, and to a wider definition of the grey-zone region for confirmatory FFR in strategy 4. The use of
different diagnostic accuracy estimates for vFFR based on two alternative studies highlighted the
substantial uncertainty surrounding the cost-effectiveness of vFFR in strategy 5. In particular, the
diagnostic accuracy results reported for vFFR in a conference abstract were much more favourable
than in the largest single study used in the base-case analysis, which resulted in strategy 5 being
ranked the second best cost-effective strategy after strategy 2.
To understand the trade-off in costs and benefits associated with strategies 2 (cost-effective) and 3
(next best strategy), a scenario was undertaken that considered both tests, FFR and QFR, to have the
same diagnostic accuracy (i.e. both tests perfect, with the same underlying distribution of FFR values).
In this case, the total QALYs and costs for strategy 3 increased by 0.017 QALYs and £6 per patient
from the base-case scenario. Strategy 3 became cost-effective with the highest NHB (an increase of
0.008 QALYs per patient for strategy 3 compared with strategy 2). The increase in NHB was largely
due to greater total QALYs gained for strategy 3 compared with strategy 2, with the difference mainly
due to the procedural disutility associated with FFR/iFR and, to a lesser extent, the increased risk of
procedural mortality for FFR/iFR.
In an additional exploratory scenario, the procedural disutility associated with FFR/iFR was also varied
to establish the point of indifference in cost-effectiveness between strategies 2 and 3, with the diagnostic
accuracy for QFR the same as used in the base case (and all other parameters the same as base case).
The NHB for strategies 2 and 3 were equal (and ranked the highest across all strategies) at a procedural
disutility of 0.014 QALYs for FFR/iFR, which is 2.5 times greater than the procedural disutility associated
with PCI but less than half the disutility associated with CABG surgery.
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A scenario was also undertaken to assess the impact on cost-effectiveness of the duration of HRQoL
benefits associated with revascularisation. This scenario highlighted that the benefits need to last for at
least 7 years to offset the disutility associated with FFR/iFR in the base case for strategy 2 to remain
cost-effective above strategy 3.
The benefits of revascularisation, in terms of improved HRQoL, suggest that the sensitivity of test
results is a more important driver of cost-effectiveness than specificity because TP test results
translate into higher QALY gains than mismanagement of FN test results. This was further supported
by scenario analyses that included a benefit of revascularisation on the risk of MACE. Furthermore,
strategy 1 appeared cost-effective relative to the alternative strategies only when it was assumed that
there were no benefits of revascularisation (i.e. no impact on risk of MACE or HRQoL gain).
When considering a diagnostic-only setting, the large additional costs of repeating diagnostic
catheterisation in a subsequent health-care contact in an interventional laboratory for strategies
involving a FFR/iFR measurement (strategies 2 and 4) favoured the cost-effectiveness of strategies
without this testing component. Strategy 3 (QFR alone) became the strategy with the highest net
benefit, followed by strategy 5 (vFFR) alone.
Conclusions from cost-effectiveness results
The base-case cost-effectiveness results showed that the test strategy with the highest net benefit
(most cost-effective strategy) was ICA followed by confirmatory FFR/iFR, for a cost-effectiveness
threshold of £20,000 per QALY gained. However, the difference in net benefit between this strategy
and the next best strategies for the assessment of functional significance of coronary obstructions was
relatively small at 0.007 QALYs (£140) for ICA with QFR, 0.012 QALYs (£240) for ICA with QFR,
followed by confirmatory FFR/iFR when QFR is inconclusive, and 0.011 QALYs (£220) for ICA with
vFFR. The cost-effectiveness results for the strategy of ICA with vFFR must be interpreted with
caution owing to very limited data available from diagnostic accuracy studies of vFFR. In addition,
there was no diagnostic information available to inform a strategy of ICA with vFFR followed by
confirmatory FFR/iFR when vFFR is inconclusive.
The key drivers of cost-effectiveness were (1) the sensitivity (rather than specificity) of the tests
because TP test results translated into higher QALY gains than mismanagement of FN test results,
(2) the procedural QALY loss associated with FFR/iFR, (3) the magnitude and duration of the QALY
gains associated with revascularisation and (4) the additional costs associated with confirmatory
testing with FFR/iFR.
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Chapter 6 Discussion
Statement of principal findings
Diagnostic accuracy
The diagnostic accuracy of QFR has been widely studied, with 39 studies in this review, including
5940 patients (over 7043 vessels or lesions). QFR, as measured using QAngio, is highly correlated
with FFR measured with an invasive pressure wire. The average difference between FFR and
QFR measurements is almost zero, and they rarely differ by more than 0.1, with about 50% of
measurements differing by less than 0.04.
QAngio XA 3D/QFR at a cut-off point of 0.8 has good diagnostic accuracy to predict FFR (also at a
cut-off point of 0.8), cQFR mode had a sensitivity of 85% (95% CI 78% to 90%) and a specificity of
91% (95% CI 85% to 95%) and fQFR mode had a sensitivity of 82% (95% CI 68% to 91%) and a
specificity of 89% (95% CI 77% to 95%). Although there is some discordance between QFR and
FFR, most FPs or FNs arise near the boundary (e.g. where one is 0.81 and the other 0.79), and the
discordance may not be clinically meaningful. Data on how this accuracy may vary by key patient
characteristics was very limited, and no conclusive variation could be found.
The use of a ‘grey-zone’ strategy, where patients with a QFR between 0.78 and 0.84 receive confirmatory
FFR, improves diagnostic accuracy, compared with using QFR alone, to a sensitivity of 93.1% and a
specificity of 92.1%. However, this improvement is dependent on assuming that the exact FFR cut-off
point of 0.8 is clinically meaningful. Most FFR and QFR values differ by 0.05 or less; therefore, the
grey-zone approach is mainly identifying discordant FFR and QFR results very close to the 0.8 boundary;
30.4% of patients with QFR results in the grey zone have results that are discordant with their FFR.
Data on the diagnostic accuracy of CAAS vFFR were limited to only three studies. Owing to variable
reporting of results and apparent substantial heterogeneity in results across studies, a full meta-
analysis was not feasible.
Although assessing the diagnostic accuracy of using standard ICA alone was not the focus of this
report, studies that reported data on ICA, and targeted searches for additional data, found that ICA
alone had poor diagnostic accuracy when compared with FFR. All studies that compared QFR with ICA
found QFR to be superior in diagnostic accuracy.
Clinical value and implementation
This review found limited evidence on the clinical impact of using QFR. The use of a grey zone could
significantly reduce the proportion of adenosine and pressure-wire-free procedures compared with
universal use of FFR, without significantly affecting diagnostic accuracy. Evidence on the applicability of
QAngio XA 3D/QFR suggests that the technology is applicable in a clinical context.
Given the limitations in the evidence, a simulation study was performed to investigate the impact of
using QFR, with or without a grey zone, on future coronary events. The simulation found that using
QFR slightly increased the revascularisation rate compared with using FFR for all, from 40.2% to 42%.
Using a grey-zone strategy increased it further to 43.2%. However, all three strategies had similar
numbers of resulting coronary events, suggesting that all have a broadly similar benefit when making
decisions as to who should receive revascularisation.
Although CAAS vFFR appears promising, its clinical value is currently uncertain because of limited
evidence and a lack of on-site prospective studies.
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
101
Cost-effectiveness
The base-case cost-effectiveness results showed that the test strategy with the highest net benefit
(most cost-effective strategy) was ICA followed by confirmatory FFR/iFR (strategy 2) at a cost-
effectiveness threshold of £20,000 per QALY gained. However, the difference in net benefit between
this strategy and the next best strategies was relatively small at 0.007 QALYs (or equivalently £140)
per patient diagnosed for ICA with QFR (strategy 3), 0.012 QALYs (or equivalently £240) per patient
diagnosed for ICA with QFR followed by confirmatory FFR/iFR when QFR is inconclusive (strategy 4)
and 0.011 QALYs (or equivalently £220) per patient diagnosed for ICA with vFFR (strategy 5).
A number of alternative scenarios were considered in which the assumptions used as part of the
base-case results were varied. These alternative scenarios showed that the cost-effectiveness results
were robust to the mode of QFR measurement (contrast-flow QFR or fixed-flow QFR), the use of an
alternative diagnostic threshold of 0.75 for FFR and QFR, the use of a wider definition of the grey-
zone region for confirmatory FFR/iFR when QFR is inconclusive, throughput assumptions for QFR and
vFFR, alternative estimates of procedural complication rates for FFR/iFR, and dependency of MACE
risk on FFR. The scenarios were also used to identify the main drivers of cost-effectiveness. The key
drivers identified were (1) the sensitivity (rather than specificity) of test results because TP test results
translated into higher QALY gains than mismanagement of FN test results, (2) the procedural QALY
loss associated with FFR/iFR, (3) the magnitude and duration of the QALY gains associated with
revascularisation and (4) the additional costs associated with confirmatory testing with FFR/iFR in
strategy 4. Strategy 1 of ICA alone, without additional testing, appeared cost-effective relative to
the other strategies only when it was assumed that there were no benefits of revascularisation.
Overall, the differences in net benefit at a cost-effectiveness threshold of £20,000 per QALY between
ICA followed by confirmatory FFR/iFR (strategy 2), and ICA with QFR (strategy 3) are small in an
interventional setting. When considering a diagnostic-only setting, ICA with QFR may result in higher
net benefit at a cost-effectiveness threshold of £20,000 per QALY than strategy 1, assuming QAngio
XA 3D/QFR has similar diagnostic accuracy across settings.
Strengths and limitations of the assessment
Strengths
This review includes a comprehensive systematic review of all the published literature on QFR as
assessed by QAngio XA 3D/QFR and CAASS vFFR technologies, and has been conducted following
recognised guidelines to ensure high quality.
The review identified a substantial literature on the diagnostic accuracy of QAngio XA 3D/QFR
(37 studies and > 5000 patients) and, despite evidence of heterogeneity and variable quality in the
evidence, future research is unlikely to significantly change the overall diagnostic accuracy review
findings. Study authors were contacted to provide additional data, and the review includes additional
data from published studies and data from as yet unpublished studies.
This review has made best use of all available data, including extracting data from published figures,
to maximise the range of analyses, including analysing the diagnostic impact of using a grey zone with
QFR, and performing a simulation study to assess the clinical impact of QFR on future coronary events.
To our knowledge, this goes beyond any previous review or meta-analysis in the field.
This is the first study, to our knowledge, to assess the cost-effectiveness of QAngio XA 3D/QFR and
CAAS vFFR. The decision model comprehensively assessed both the short-term costs and consequences
associated with diagnostic testing and the longer-term impact of treatment on both costs and consequences
to ensure that lifetime differences (e.g. the risk of major adverse cardiovascular events and HRQoL
benefits associated with revascularisations) were appropriately quantified.
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Limitations
Evidence on the CAAS vFFR technology was limited to four studies, which varied in their reporting,
and appeared to have heterogeneous results. This prevented any full meta-analyses of diagnostic
accuracy for CAAS vFFR or any assessment of its clinical effectiveness.
There were insufficient data allowing exploration of the impact of key patient characteristics (such as
multivessel disease or diabetes) on diagnostic accuracy or clinical effectiveness, so these could not be
fully investigated.
As is common in reviews of diagnostic tests, data beyond basic diagnostic accuracy, such data on the
clinical impact of QAngio XA 3D/QFR, or its practical implementation, were extremely limited and
could not be fully reviewed. Although a simulation study was performed to address this, it was innately
limited by having to make strong assumptions about the relevant population, and the risk of events,
in that population.
The cost-effectiveness results for strategy 5 with vFFR must be interpreted with caution because of
very limited data available from diagnostic accuracy studies of vFFR. The use of alternative diagnostic
accuracy estimates for vFFR highlighted the substantial uncertainty surrounding the cost-effectiveness
of vFFR. The cost-effectiveness results were very sensitive to the procedural disutility assumed in the
model for FFR/iFR and the duration of HRQoL benefits associated with revascularisation.
Uncertainties
Although there is substantial evidence of the diagnostic accuracy of QFR assessment using QAngio, it
remains largely unclear which patient or lesion characteristics might significantly affect the diagnostic
accuracy of QAngio XA 3D/QFR.
The clinical value of QAngio XA 3D/QFR to support decision-making on revascularisation remains
uncertain, particularly what impact it might have on preventing or causing future coronary events,
and whether the 0.8 cut-off point, or the proposed grey zone, is clinically appropriate. However, it
appears unlikely that its clinical value or use will differ substantially from widespread use of FFR.
Prospective evidence for the clinical benefit of QFR-guided PCI is lacking. Results from the large RCTs
FAVOR III Europe–Japan142 (non-inferiority trial comparing QFR with standard FFR-guided PCI) and
FAVOR III China143 (superiority trial comparing QFR with angiography-alone-guided PCI), with a
target recruitment of 2000 and 3860 and due to be completed in March 2022 and February 2023,
respectively, will be informative.
Current evidence on CAAS vFFR is very limited, so its diagnostic accuracy, clinical value and
cost-effectiveness are highly uncertain.
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Chapter 7 Conclusions
Implications for health care
Clinical implications
The results of this review suggest that making revascularisation decisions using QFR as measured with
QAngio XA 3D/QFR is preferable to making decisions based on DS assessment using standard ICA alone.
The high level of correlation between QFR and FFR, and the high level of diagnostic accuracy of QFR,
suggest that QFR assessment could potentially replace FFR entirely, and hence remove the need for
invasive pressure wire and adenosine use. Simulations suggest that replacing FFR with QFR entirely
might slightly increase the number of patients who are revascularised, but would have minimal or no
impact on the incidence of coronary events.
The use of a grey zone, where patients with borderline QFR values proceed to a FFR assessment, would
require around 20% of patients to have a FFR. However, for around 70% of these patients the FFR
assessment would agree with the existing QFR assessment. The use of a grey zone might increase the
number of patients being revascularised but would appear to have almost the same future incidence of
coronary events as if FFR had been used in all patients.
The current evidence on CAAS vFFR appears to be too limited for it to be used in clinical practice at
this time.
Economic implications
The economic evidence suggests small differences in net benefit at a cost-effectiveness threshold of
£20,000 per QALY between ICA followed by confirmatory FFR/iFR (strategy 2), and ICA with QFR
(strategy 3) in an interventional setting. In a diagnostic-only setting, ICA with QFR may yield a higher
net benefit at a cost-effectiveness threshold of £20,000 per QALY than ICA followed by confirmatory
FFR/iFR, provided that the diagnostic accuracy of QAngio XA 3D/QFR is comparable across settings.
Therefore, the use of QAngio XA 3D/QFR in line with strategy 3 is potentially a good use of NHS
resources, particularly in a diagnostic-only setting.
Suggested research priorities
The substantial existing evidence for diagnostic accuracy of QAngio XA 3D/QFR suggests that further
studies of diagnostic accuracy are not required. However, further prospective investigation of the
diagnostic accuracy of QAngio XA 3D/QFR in patients with different lesion subtypes, including
bifurcation lesion and left main location stenoses, or with three-vessel disease, may be needed to
confirm trends reflected in existing evidence.
Large, prospective studies are required to assess the diagnostic accuracy and clinical feasibility of
CAAS vFFR. Ideally, these should compare CAAS vFFR with ICA assessment and, if possible, with QFR.
Randomised controlled trials are required to investigate whether or not the use of QFR-guided PCI (with
or without a grey zone) results in improved clinical outcomes. Such studies should follow up patients for
all key coronary events, including events caused by unnecessary revascularisation and report rates of and
reasons for test failure in a clinical setting and in a wide range of patients with intermediate stenosis.
Results from the FAVOR III Europe–Japan142 and FAVOR III China143 will be informative.
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Appendix 1 Clinical review literature
search strategies
MEDLINE (via OVID)
Date searched: 1 October 2019.
Date range searched: 1946 to 25 September 2019.
Search strategy
1. QANGIO$.ti,ab,kw. (8)
2. quantitative flow ratio$.ti,ab,kw. (36)
3. QFR.ti,ab,kw. (82)
4. “3D/QFR”.ti,ab,kw. (1)
5. aQFR.ti,ab,kw. (2)
6. adenosine-flow QFR.ti,ab,kw. (2)
7. cQFR.ti,ab,kw. (6)
8. contrast-flow QFR.ti,ab,kw. (7)
9. fQFR.ti,ab,kw. (5)
10. fixed-flow QFR.ti,ab,kw. (5)
11. iQFR.ti,ab,kw. (1)
12. index QFR.ti,ab,kw. (1)
13. LQFR.ti,ab,kw. (4)
14. lesion QFR.ti,ab,kw. (1)
15. vQFR.ti,ab,kw. (1)
16. vessel QFR.ti,ab,kw. (1)
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (99)
18. vessel FFR.ti,ab,kw. (11)
19. vFFR.ti,ab,kw. (8)
20. CAAS vFFR.ti,ab,kw. (0)
21. 18 or 19 or 20 (19)
22. 17 or 21 (118)
23. animals/not (humans/and animals/) (4,586,208)
24. 22 not 23 (107)
25. “quinol:fumarate reductase”.ti,ab. (29)
26. 24 not 25 (88).
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Appendix 2 Included, excluded and
ongoing studies
TABLE 33 All studies included in the systematic review of clinical effectiveness
Main studies Linked studies
Cliff and Ong (2019),16 conference abstract Cliff et al.144
Cortés et al. (2019)17 Cortes Villar et al.145 and Cortes et al.146
Emori et al. (2018)20 Emori et al.20
Emori et al. (2018)21 Emori et al.147,148 and Tanigaki et al.149
FAST-EXTEND: Daemen et al. (2019),18
conference abstract
Masdjedi et al.56 and Daemen150
FAVOR II China: Xu et al. (2017)52 Ding et al.,62 Chang et al.,151 Fuwai Hospital152 and Zhang et al.153
FAVOR II Europe–Japan: Westra et al. (2018)50 Holm154
FAVOR pilot: Tu et al. (2016)46 Tu et al.155
Goto et al. (2019),22 conference abstract
Hamaya et al. (2019)23 Hamaya et al.156
Hwang et al. (2019)24 Choi157
ILUMIEN I: Ely Pizzato et al. (2019)19 Palma Dallan et al.158
Ishihara et al. (2019),25 conference abstract
Jin et al. (2019),26 conference abstract
Kajita et al. (2019),27 conference abstract Hideo-Kajita et al.159
Kameyama et al. (2016),28 conference abstract
Kanno et al. (2019),29 conference abstract Sugiyama et al.160 and Kanno et al.161,162
Kanno et al. (2019),30 conference abstract
Kirigaya et al. (2019),31 conference abstract
Kołtowski et al. (2018)32 Kołtowski et al.61 and Zaleska et al.163,164
Kleczyński et al. (2019)33 Legutko et al.55
Liontou et al. (2019)34
Liu et al. (2017),35 conference abstract
Mehta et al. (2019),36 conference abstract Mehta et al.165
Mejia-Renteria et al. (2019)37 Xu et al.,57 Mejia-Renteria et al.,64,167–169 Liontou et al.,166
Macaya et al.170 and Lauri et al.171
Neylon et al. (2016),38 conference abstract
Sato et al. (2018),39 conference abstract
Smit et al. (2019)40 Smit et al.40,58,172–174
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TABLE 33 All studies included in the systematic review of clinical effectiveness (continued )
Main studies Linked studies
Spitaleri et al. (2018)41
Stähli et al. (2019)42 Erbay et al.60,175,176 and Leistner et al.177
SYNTAX II: Asano et al. (2019)15 Kobayashi and Fearon,178 Asano et al.179 and Kogame et al.180,181
Ties et al. (2018)43
Toi et al. (2018),44 conference abstract
Tu et al. (2014)45
Van Diemen et al. (2019)47 van Diemen et al.67
van Rosendael et al. (2017)48 van Rosendael et al.48
Watari et al. (2019)49
WIFI II: Westra et al. (2018)51 Westra et al.182,183
WIFI Prototype study: Andersen et al. (2017),14
conference abstract
Andreasen et al.184 and Holm185
Yazaki et al. (2017)53 Otsuka et al.186
Ziubryte et al. (2019),54 conference abstract
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TABLE 34 Ongoing studies
Setting Recruitment years Interventions Main indications Responsible party
Registration
number N
RCTs
l FAVOR III
Europe–Japan50
l Multicentre
l NR
l Estimated start date
November 2018
l Last updated May
2019 (recruiting)
l Estimated completion
March 2022
l QFR-guided
revascularisation vs. ICA
and FFR-guided
revascularisation
l CAD EH Christiansen, Aarhus
University Hospital,
Skejby
NCT03729739 Target: 2000
l FAVOR III
China52
l Multicentre
l NR
l Actual start date
December 2018
l Last updated February 2020
(active, not recruiting)
l Estimated completion
February 2023
l Estimated completion
March 2022
l QFR vs. ICA alone l CAD
l Myocardial ischaemia
l Coronary circulation
l Coronary stenosis
l PCI
Bo Xu, China National
Centre for Cardiovascular
Diseases
NCT03656848 Actual: 3860
l China l NR
l Registration date May 2017
l QFR plus virtual stenting
vs. FFR plus real stent
l Major epicardial coronary
artery stenosis, multivessel
and long lesions
X Qu, Shanghai Chest
Hospital
ChiCTR-INR-
17011360
Target: 100
l FAVOR IV China
l Multicentre
l NR
l Actual start date August 2019
l Last updated August
2019 recruiting
l QFR-guided vs.
CAG-guided strategy
l Primary valvular heart
disease with comorbid
CAD, planned elective
on-pump valve surgery
due to primary mitral
and/or aortic valvular
heart disease
Qiang Zhao, Ruijin
Hospital
NCT03977129;
2018CR001
Target: 792
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TABLE 34 Ongoing studies (continued )
Setting Recruitment years Interventions Main indications Responsible party
Registration
number N
Single-arm diagnostic accuracy studies
l China l NR
l Registration date January 2018
l Index test: cQFR
l Reference standard: FFR
l Coronary artery stenosis Z Zhang, Department of
cardiovascular medicine,
Hospital of Third Military
Medical University
ChiCTR1800014516 Target: 200
l FORTRESS
l China
l NR
l Estimated start date
February 2018
l Estimated completion date
February 2019
l Last updated January 2018
(not yet recruiting)
l Index test: QFR
l Reference standard: FFR
l Stable and unstable
angina or secondary
evaluation of stenosis
after acute MI
Pulse Medical Imaging
Technology (Shanghai)
Co. Ltd (Shanghai, China)
NCT03405506;
CARDIAC201701
Target: 69
l DETECT-
ISCHAEMIA
Germany
l NR
l Estimated start date July 2017
l Last updated February
2018 (recruiting)
l Index test: QFR
l Reference standard: FFR
and iFR
l CAD and intermediate
stenosis
C Jensen, Contilia Clinical
Research Institute
NCT03420131;
U1111–1199–4364;
DRKS00012757
Target:
250–80
l The Republic
of Korea
l Multicentre
l January 2012 to
September 2019
l Completed
l Index test: QFR
l Reference standard: FFR
l Ischaemic heart disease C Kiyuk, Seoul St Mary’s
Hospital
NCT04102917;
XC18REDI0035
Actual: 915
l Dan-NICAD 2 l NR
l Actual start date January 2018
l Last updated December
2019 (recruiting)
l Index test: QFR
l Reference standard: FFR
l Angina pectoris
atherosclerosis
l CAD
l Myocardial ischaemia
University of Aarhus NCT03481712 Target: 2000
l Multicentre
l The Republic
of Korea
l NR
l Actual start date April 2016
l Last updated January 2020
(active not recruiting)
l Index test QFR
l Reference standard: FFR
l Ischaemic heart disease Joo Myung Lee, Samsung
Medical Centre
NCT03791788 Target: 524
l QIMERA-I
l Multicentre
l Spain
l NR
l Estimated start date
January 2020
l Last updated December 2019
(not yet recruiting)
l Index: QFR
l Reference: standard dPR,
RFR and FFR
l Coronary occlusion Carlos Baladron, Hospital
Clínico Universitario de
Valladolid
NCT04200469;
CASVE-PI-19–1515
Target: 100
dPR, diastolic pressure ratio; NR, not reported; RFR, resting full–cycle ratio.
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage
Reason for exclusion Study
Population not eligible Adjedj J, Hyafil F, Aminfar F, Farnoud A, Rubimbura V, Fournier S, et al. Hemodynamic and
clinical impact in adult patients with anomalous aortic origin of the coronary artery evaluated
with quantitative flow reserve. Eur Heart J 2019;40(Suppl. 1):1687
Adjedj J, Hyafil F, Muller O, Aubry P. Hemodynamic and Clinical Impact in Adult Patients with
Anomalous Aortic Origin of the Right Coronary Artery Evaluated with Quantitative Flow Ratio.
Paper presented at EuroPCR, 21–24 May 2019, Paris, France
Biscaglia S. Prognostic Value of QFR Measured Immediately After Successful Stent Implantation:
The International Multicenter Prospective HAWKEYE Study. Paper presented at EuroPCR,
21–24 May 2019, Paris, France
Biscaglia S, Tebaldi M, Brugaletta S, Cerrato E, Erriquez A, Passarini G, et al. Prognostic value
of QFR measured immediately after successful stent implantation: the international
multicenter prospective HAWKEYE study. JACC Cardiovasc Interv 2019;12:2079–88
Zhu Y. Effect of QFR-guided Revascularisation on 30-day mortality in Patients Undergoing Valve
Surgery With Concomitant Coronary Artery Disease. 2018. URL: www.chictr.org.cn/com/25/
showprojen.aspx?proj=30416
Ishibashi Y, Grundeken MJ, Nakatani S, Iqbal J, More MA, Genereux P, et al. In vitro validation
and comparison of different software packages or algorithms for coronary bifurcation analysis
using calibrated phantoms: implications for clinical practice and research of bifurcation
stenting. Catheter Cardiovasc Interv 2015;85:554–63
Masdjedi K, Ligthart J, Witberg K, Tomaniak M, Zandvoort L, Diletti R, et al. The prognostic
value of angiography-based vessel-FFR after successful percutaneous coronary intervention:
the FAST outcome study. J Am Coll Cardiol 2019;74(Suppl.):B110
Campo G. Angio-based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation.
2016. URL: https://clinicaltrials.gov/show/NCT02811796.
Renji Hospital. Early Prediction of QFR in STEMI-I. 2018. URL: https://clinicaltrials.gov/show/
NCT03780335
Renji Hospital. Early Assessment of QFR in STEMI-II. 2019. URL: https://clinicaltrials.gov/show/
NCT03910400
Ozaki Y, Gonzalo N, Salazar CH, Kuku KO, Mejia-Renteria H, Hideo-Kajita A, et al. Comparison
of quantitative flow ratio value of left anterior descending and circumflex coronary artery in
patients with Takotsubo syndrome. Int J Cardiovasc Imaging 2019;36:3–8
Rubimbura V, Guillon B, Fournier S, Amabile N, Chi Pan C, Combaret N, et al. Validation of
Quantitative Flow Reserve and Residual Quantitative Flow Reserve to Predict FFR Post-Stenting from
the Does Optical Coherence Tomography Optimise Results of Stenting Study (DOCTORS) Population.
Paper presented at EuroPCR, 21–24 May 2019, Paris, France
Solanki R, Gosling R, Rammohan V, Hose R, Lawford P, Gunn J, et al. Assessing the accuracy of
a novel in silico imaging tool for the 3D reconstruction of coronary vasculature in the context
of virtual fractional flow reserve. Heart 2019;105:A14
Suzuki N, Nishide S, Kimura T, Aoyagi T, Kanamori K, Shiratori Y, et al. Relationship of
quantitative flow ratio after second-generation drug-eluting stent implantation to clinical
outcomes. Heart Vessels 2020;35:743–9
Tar B, Bakk S, Beres Z, Molnar F, Santa J, Svab M, et al. Calculation of the residual pressure
gradient after stent implantation of the coronary lesions on the basis of 3D coronary
angiography and fluid dynamic equations. Eur Heart J 2014;1:810–11
Tu S, Koszegi Z, Tar B, Reiber J. Calculation of hyperemic stenosis resistance and myocardial
resistance using computational fluid dynamics combined with three-dimensional angiographic
reconstruction and intracoronary pressure measurement. EuroIntervention 2013;9:93
Vedia OVC, Macaya FMT, Lauri LF, Mejia-Renteria MH, Gonzalo GN, Trigo TM, et al. Diagnostic
performance of quantitative flow ratio in predicting fractional flow reserve in patients with
takotsubo syndrome. Eur Heart J 2018;39(Suppl. 1):1151
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Waksman R, Ozaki Y, Gonzalo N, Trivino CS, Kuku K, Renteria HM, et al. Assessment of
microvascular dysfunction using quantitative flow ratio in patients with Takotsubo syndrome.
J Am Coll Cardiol 2019;73(Suppl. 1):1630
Zhuk S, Smith O, Thondapu V, Halupka K, Moore S. Using contrast motion to generate patient
specific blood flow simulations during invasive coronary angiography. J Biomech Eng
2019;142:021001
No eligible index test Boogers MJ, Schuijf JD, Broerse A, Kitslaar PH, Van Velzen JE, Dijkstra J, et al. Automated
quantification of area stenosis using a novel dedicated registration algorithm: a feasibility
study with multi-detector row computed tomography and intravascular ultrasound. Eur Heart J
2012;33:1007–16
Boogers MM, Schuijf JD, Van Werkhoven JM, Kitslaar PH, Frenay M, Dijkstra J, et al. Novel
dedicated approach for automatic quantification of the degree of coronary artery stenosis
on 64-slice multi-slice computed tomography: a comparison with quantitative coronary
angiography. Eur Heart J 2009;1:484
Chung WY, Choi BJ, Lim SH, Matsuo Y, Lennon RJ, Gulati R, et al. Three dimensional
quantitative coronary angiography can detect reliably ischaemic coronary lesions based on
fractional flow reserve. J Korean Med Sci 2015;30:716–24
Chung WY, Lim SH, Matsuo Y, Gulati R, Sandhu G, Lerman A. Three dimensional quantitative
coronary angiography can detect reliably ischaemic coronary lesions based on fractional flow
reserve. J Am Coll Cardiol 2012;59:E172
Cook C, Kousera C, Ahmad Y, Nijjer S, Petraco R, Al-Lammee R, et al. Can computational
fluid dynamics (CFD) predictions of FFR agree with invasive FFR in intermediate stenoses?
Lessons from a study using OCT and invasive measures of coronary flow. EuroIntervention
2016;France.:230
Dębski M, Kruk M, Bujak S, Dzielinska Z, Demkow M, Kepka C. Coronary computed
tomography angiography equals invasive angiography for the prediction of coronary
revascularisation. Postepy Kardiol Interwencyjnej 2019;15:308–13
Ejlersen JA, Poulsen SH, Mortensen J, May O. Accuracy of adenosine 2D strain stress
echocardiography in the detection of coronary artery disease in patients with chest pain.
Eur Heart J 2015;1:601
Ferencik M, Mayrhofer T, Puchner SB, Lu MT, Maurovich-Horvat P, Liu T, et al. Computed
tomography-based high-risk coronary plaque score to predict acute coronary syndrome among
patients with acute chest pain – results from the ROMICAT II trial. J Cardiovasc Comput Tomogr
2015;9:538–45
Gosling R, Morris P, Lawford P, Hose R, Gunn J. Virtual (computed) FFR and virtual coronary
intervention (VCI) vs angiography for guiding PCI: a virtual study. Heart 2019;105:A45
Gosling RC, Morris PD, Silva Soto DA, Lawford PV, Hose DR, Gunn JP. Virtual coronary
intervention: a treatment planning tool based upon the angiogram. JACC Cardiovasc Imaging
2019;12:865–72
Hebsgaard L, Nielsen TM, Tu S, Krusell LR, Maeng M, Veien KT, et al. Advanced Angiography
Compared with OCT for Sizing of Coronary Stents. A Does Optical Coherence Tomography Optimise
Revascularisation (DOCTOR) Fusion Substudy. Paper presented at EuroPCR, 20–23 May 2014,
Paris, France
Ishibashi Y, Onuma Y, Nakatani S, Morel MA, Girasis C, Wentzel JJ, et al. In Vitro Validation
of Two Bifurcation Algorithms of Quantitative Coronary Angiography in Calibrated Phantoms:
Comparison with a CAAS System and with a QAngio XA. Paper presented at EuroPCR,
20–23 May 2014, Paris, France
Johnson NP, Matsumura M, Achenbach S, Engstrom T, Assali A, Jeremias A, et al. Angiography-
derived fractional flow reserve versus invasive nonhyperemic pressure ratios. J Am Coll Cardiol
2019;73:3232–3
Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to
evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA).
Int J Cardiovasc Imaging 2017;33:779–87
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Kornowski R, Vaknin-Assa H, Assali A, Greenberg G, Valtzer O, Lavi I. Online angiography
image-based FFR assessment during coronary catheterization: a single-center study. J Invasive
Cardiol 2018;30:224–9
Lal K, Gunn J, Morris P, Gosling R, Lawford P, Hose R, et al. Computational modelling of
fractional flow reserve from coronary angiography: expert training required. Heart
2019;105:A15–16
Lee JH, Yoon MH, Tahk SJ, Shin JH, Hwang GS, Choi SY, et al. Comparision of 3-dimensional
quantitative coronary angiography and intravascular ultrasound for detecting functionally
significant coronary lesions. Eur Heart J 2018;39(Suppl. 1):525
Lee JM, Koo BK, Shin ES, Nam CW, Doh JH, Hu X, et al. Clinical outcomes of deferred lesions
with angiographically insignificant stenosis but low fractional flow reserve. J Am Heart Assoc
2017;6:e006071
Lee JM, Koo BK, Shin ES, Nam CW, Doh JH, Hwang D, et al. Clinical implications of 3-vessel
fractional flow reserve measurement in patients with coronary artery disease. J Am Coll Cardiol
2017;70(Suppl. 1):B137–8
Lee JM, Koo BK, Shin ES, Nam CW, Doh JH, Hwang D, et al. Clinical implications of
three-vessel fractional flow reserve measurement in patients with coronary artery disease.
Eur Heart J 2018;39:945–51
Leone AM, De Caterina AR, De Maria GL, Scalone G, Tagliaferro F, Gardi A, et al. Three-
dimensional quantitative coronary angiography and quantification of jeopardised myocardium
to predict functional significance of intermediate coronary artery stenosis. EuroIntervention
2015;11:308–18
Li J, Gong Y, Yi T, Hong T, Liu Z, Zheng B, et al. TCT-323 angiography-derived contrast
fractional flow reserve from a specially designed computational fluid dynamic method. J Am
Coll Cardiol 2019;74(Suppl.):B321
Li S, Chin C, Thondapu V, Poon EKW, Monty JP, Li Y, et al. Numerical and experimental
investigations of the flow-pressure relation in multiple sequential stenoses coronary artery.
Int J Cardiovasc Imaging 2017;33:1083–8
Mangiacapra F, Conte M, Tu S, Peace AJ, Di Serafino L, Ntarladinias I, et al. Performance of
three-dimensional vs. two-dimensional quantitative coronary angiography in discriminating
functionally significant coronary stenoses according to fractional flow reserve. EuroIntervention
2011;M:M144
Matar F, Falasiri S, Caruncho C, Leung C, Glover C, Sullebarger JT. When should FFR be used
during coronary angiography? The importance of left anterior descending artery and minimal
lumen diameter measurement. Catheter Cardiovasc Interv 2015;2:S67–8
Mohee K, Mynard J, Dhunnoo G, Halcox J, Obaid D. Diagnostic performance of virtual FFR
derived from routine coronary angiography using 1D flow modelling: validation against
fractional flow reserve. J Am Coll Cardiol 2017;70(Suppl. 1):B306–7
Morris PD, Ryan D, Morton AC, Lycett R, Lawford PV, Hose DR, et al. Virtual fractional flow
reserve from coronary angiography: modelling the significance of coronary lesions: results
from the VIRTU-1 (VIRTUal Fractional Flow Reserve From Coronary Angiography) study.
JACC Cardiovasc Interv 2013;6:149–57
Morris PD, Silva Soto DA, Feher JFA, Rafiroiu D, Lungu A, Varma S, et al. Fast virtual fractional
flow reserve based upon steady-state computational fluid dynamics analysis: results from the
VIRTU-Fast study. JACC Basic Transl Sci 2017;2:434–46
Koo BK. Clinical Implication of 3-vessel Fractional Flow Reserve (FFR). URL: https://clinicaltrials.
gov/ct2/show/NCT01621438 (accessed June 2021)
Newcombe R, Gosling R, Gunn J, Narracott A, Hose R, Morris P, et al. An atlas of computed
FFR in common patterns of coronary artery disease. Heart 2019;105:A51–2
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Nishi T, Kitahara H, Fujimoto Y, Nakayama T, Sugimoto K, Takahara M, et al. Comparison of
3-dimensional and 2-dimensional quantitative coronary angiography and intravascular
ultrasound for functional assessment of coronary lesions. J Cardiol 2017;69:280–6
Nishi T, Nakayama T, Fujimoto Y, Kobayashi Y. Comparison of three-dimensional and
two-dimensional quantitative coronary angiography and intravascular ultrasound for the
functional assessment of coronary lesions. Circulation 2014;130:A17712
Papafaklis M, Muramatsu T, Ishibashi Y, Tsirka G, Bourantas C, Fotiadis D, et al. Virtual resting
Pd/Pa from 3-dimensional quantitative coronary angiography and flow modelling: comparison
against fractional flow reserve in real-world patients. J Am Coll Cardiol 2016;67:370
Papafaklis MI, Muramatsu T, Ishibashi Y, Bourantas CV, Fotiadis DI, Brilakis ES, et al. Virtual
resting Pd/Pa from coronary angiography and blood flow modelling: diagnostic performance
against fractional flow reserve. Heart Lung Circ 2018;27:377–80
Papafaklis MI, Muramatsu T, Ishibashi Y, Lakkas LS, Nakatani S, Bourantas CV, et al. Fast
virtual functional assessment of intermediate coronary lesions using routine angiographic data
and blood flow simulation in humans: comparison with pressure wire – fractional flow reserve.
EuroIntervention 2014;10:574–83
Peña J, Shaw L, Lin F, Andreini D, Cademartiri F, Chinnaiyan K, et al. The association of acute
coronary syndrome and coronary plaque features by sex: the iconic study. J Am Coll Cardiol
2018;71(Suppl.):A1632
Piroth Z, Toth GG, Tonino PAL, Barbato E, Aghlmandi S, Curzen N, et al. Prognostic value
of fractional flow reserve measured immediately after drug-eluting stent implantation.
Circ Cardiovasc Interv 2017;10:e005233
Pyxaras SA, Tu S, Barbati G, Barbato E, Di Serafino L, De Vroey F, et al. Quantitative
angiography and OCT for the functional assessment of mild-to-moderate coronary stenoses:
comparison with FFR. EuroIntervention 2013;9:144
Pyxaras SA, Tu S, Barbati G, Barbato E, Di Serafino L, Toth G, et al. Quantitative angiography
and optical coherence tomography for the functional assessment of mild-to-moderate coronary
stenoses: comparison with fractional flow reserve. Eur Heart J 2013;34(Suppl. 1):706
Pyxaras SA, Tu S, Barbato E, Barbati G, Di Serafino L, De Vroey F, et al. Quantitative angiography
and optical coherence tomography for the functional assessment of nonobstructive coronary
stenoses: comparison with fractional flow reserve. Am Heart J 2013;166:1010–18.e1
Saad M, Toelg R, Khattab AA, Kassner G, Abdel-Wahab M, Richardt G. Determination of
haemodynamic significance of intermediate coronary lesions using three-dimensional coronary
reconstruction. EuroIntervention 2009;5:573–9
Tar B, Koszegi Z. Smart calculation of the virtual functional assessment index with separate
determination of the laminar and turbulent flow resistance. EuroIntervention 2016;France:297
Tu S, Echavarria-Pinto M, von Birgelen C, Holm NR, Pyxaras SA, Kumsars I, et al. Fractional
flow reserve and coronary bifurcation anatomy: a novel quantitative model to assess and
report the stenosis severity of bifurcation lesions. JACC Cardiovasc Interv 2015;8:564–74
Yong AS, Ng AC, Brieger D, Lowe HC, Ng MK, Kritharides L. Three-dimensional and two-
dimensional quantitative coronary angiography, and their prediction of reduced fractional flow
reserve. Eur Heart J 2011;32:345–53
Yu W, Huang JY, Jia D, Chen SL, Raffel C, Ding DX, et al. Diagnostic accuracy of intracoronary
optical coherence tomography-based quantitative flow ratio for assessment of coronary
stenosis. J Am Coll Cardiol 2018;72(Suppl.):B18
Zhang J, Wu W, Zou H, Fam J, Luo T, Lomarda A, et al. Diagnostic performance of fractional
flow reserve derived from simplified modelling and computed tomography coronary
angiography on discriminating ischaemic coronary lesions. J Cardiovasc Comp Tomogr
2017;11(Suppl. 1):S36–7
Zhang JM, Zhong L, Luo T, Lomarda AM, Huo Y, Yap J, et al. Simplified models of non-invasive
fractional flow reserve based on CT images. PLOS ONE 2016;11:e0153070
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
No eligible reference
standard
Adjedj J, Hyafil F, Muller O, Aubry P. Hemodynamic and Clinical Impact in Adult Patients with
Anomalous Aortic Origin of the Right Coronary Artery Evaluated with Quantitative Flow Ratio.
Paper presented at EuroPCR, 21–24 May 2019, Paris, France
Erbay A, Penzel L, Heuberger A, Steiner J, Lauten A, Skurk C, et al. The Diagnostic Reliability
of Quantitative Flow Ratio (QFR) for Assessment of Non-Culprit Lesions in ACS Patients. Paper
presented at the Annual Meeting of the German Society of Cardiology, 24–27 April 2019,
Mannheim, Germany
Hamaya R, Horie T, Yonetsu T, Sugano A, Kanaji Y, Usui E, et al. High-sensitivity cardiac
troponin decrease after percutaneous coronary intervention in patients with stable coronary
artery disease. Heart Vessels 2019;34:948–56
Lauri F, Macaya F, Mejia-Renteria H, Goto S, Yeoh J, Nakayama M, et al. Angiography-derived
functional assessment of non-culprit coronary stenoses in primary percutaneous coronary
intervention. EuroIntervention 2020;15:e1594–601
Liu L, Yang W, Nagahara Y, Li Y, Lamooki SR, Muramatsu T, et al. The impact of image
resolution on computation of fractional flow reserve: coronary computed tomography
angiography versus 3-dimensional quantitative coronary angiography. Int J Cardiovasc Imaging
2016;32:513–23
Di Girolamo D. Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure.
2016. URL: https://clinicaltrials.gov/show/NCT02998853 (accessed June 2021)
Okamoto H, Kume T, Yamada R, Imai K, Neishi Y, Uemura S. Comparison of optical coherence
tomography measurements with 3-dimensional quantitative coronary angiography-derived
quantitative flow ratio. Eur Heart J 2018;39(Suppl. 1):1379–80
Okamoto H, Kume T, Yamada R, Neishi Y, Uemura S. Comparison of Optical Coherence
Tomography Measurements with 3-Dimensional Quantitative Coronary Angiography – Derived
Computed Fractional Flow Reserve. Journal of the American College of Cardiology. Conference:
67th Annual Scientific Session of the American College of Cardiology, 10–12 March 2018,
Orlando, FL, USA
Qi Q, Liu G, Yuan Z, Liu L, Tu S, Zhao Q. Quantitative Flow Ratio-guided surgical intervention
in symptomatic myocardial bridging. Cardiol J 2020;27:685–92
Sejr-Hansen M, Westra J, Thim T, Christiansen E, Eftekhari A, Kristensen SD, et al. Comparison
of quantitative flow ratio and instantaneous wave-free ratio for immediate assessment of
non-culprit lesions in patients with ST-segment elevation myocardial infarction an iSTEMI
substudy. J Am Coll Cardiol 2018;72(Suppl.):B248–9
Sejr-Hansen M, Westra J, Winther S, Tu S, Nissen L, Gormsen L, et al. Comparison of QFR and
FFR with myocardial perfusion scintigraphy and cardiovascular magnetic resonance as
reference standard. A Dan-NICAD substudy. Int J Cardiovasc Imaging 2020;36:395–402
Smit JM, Koning G, van Rosendael AR, Dibbets-Schneider P, Mertens BJ, Delgado V, et al. The
relationship between contrast-flow quantitative flow ratio and ischaemia assessed by SPECT
MPI. Eur Heart J 2017;38(Suppl. 1):825
Smit JM, Koning G, van Rosendael AR, Dibbets-Schneider P, Mertens BJ, Jukema JW, et al.
Relationship between coronary contrast-flow quantitative flow ratio and myocardial ischaemia
assessed by SPECT MPI. Eur J Nucl Med Mol Imaging 2017;44:1888–96
Smit JM, van Rosendael AR, Koning G, Reiber JH, Dibbets-Schneider P, Mertens BJ, et al. The
relationship between contrast-flow QFR and ischaemia assessed by SPECT MPI. Eur Heart J
Cardiovasc Imaging 2017;18(Suppl. 1):i45–6
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Suetomi T, Okamura T, Nakao F, Yamada J, Oda T, Mochizuki M, et al. Impact of Jailing
Configuration and Bifurcation Angle on Incomplete Stent Apposition After Single Crossover Stenting
with Final Kissing Balloon Dilatation, Assessed by Three-Dimensional OCT. Paper presented at
EuroPCR, 19–22 May 2015, Paris, France
Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang CC, Modolo R, et al. TCT-326
diagnostic performance of angiography-based quantitative flow ratio with respect to fractional
flow reserve derived from computed tomography angiography: insight from the SYNTAX III
trial. J Am Coll Cardiol 2019;74(Suppl.):B324
Tomaniak M, Masdjedi K, Zandvoort L, Neleman T, Tovar M, Vermaire A, et al. TCT-331
correlation between 3D-QCA-based FFR and quantitative lumen assessment by IVUS for left
main coronary stenoses: the FAST Left Main study. J Am Coll Cardiol 2019;74(Suppl.):B329
Westra J, Winther S, Tu S, Nissen L, Gormsen L, Petersen S, et al. Comparison of quantitative
flow ratio and fractional flow reserve to identify myocardial ischaemia: validation with
myocardial perfusion scintigraphy and cardiovascular magnetic resonance. J Am Coll Cardiol
2017;70(Suppl. 1):B30
No eligible outcome Kanno Y, Hoshino M, Sugano A, Kanaji Y, Yamaguchi M, Sumino Y, et al. Optical coherence
tomography-defined plaque vulnerability in relation to functional stenosis severity stratified
by fractional flow reserve and contrast quantitative flow ratio. J Am Coll Cardiol
2019;73(Suppl. 1):1172
Kanno Y, Hoshino M, Sugiyama T, Kanaji Y, Yamaguchi M, Hada M, et al. Impact of subtended
myocardial mass on the assessment of functional ischaemia as evaluated by FFR and QFR.
Eur Heart J 2019;40(Suppl. 1):1654
Kleczyński P, Dziewierz A, Wiktorowicz A, Bartus S, Rzeszutko L, Bagienski M, et al. Contrast
medium Pd/Pa ratio in comparison to fractional flow reserve, quantitative flow ratio and
instantaneous wave-free ratio – a comprehensive assessment. Postepy w Kardiologii
Interwencyjnej 2017;13:356
Sejr-Hansen M,Westra J, Thim T, Christiansen EH, Eftekhari A, Kristensen SD, et al. Quantitative
flow ratio for immediate assessment of nonculprit lesions in patients with ST-segment elevation
myocardial infarction – an iSTEMI substudy. Catheter Cardiovasc Interv 2019;94:686–92
Yamaguchi M, Hoshino M, Horie T, Yuki H, Kanno Y, Hirano H, et al. Evaluation of non-culprit
lesions in acute coronary syndromes using quantitative flow ratio. J Am Coll Cardiol
2019;73(Suppl. 1):1473
Study design not
eligible
Accuracy of angiography-derived fractional flow reserve: a systematic review and meta-
analysis. PROSPERO 2017 CRD42017084512 Available from: www.crd.york.ac.uk/prospero/
display_record.php?ID=CRD42017084512
Anonymous. Corrigendum to: diagnostic performance of angiography-derived fractional flow
reserve: a systematic review and Bayesian meta-analysis. Eur Heart J 2019;40:356
Asano T, Katagiri Y, Collet C, Tenekecioglu E, Miyazaki Y, Sotomi Y, et al. Functional
comparison between BuMA Supreme biodegradable polymer sirolimus-eluting and durable
polymer zotarolimus-eluting coronary stents using quantitative flow ratio: PIONEER QFR
Substudy. EuroIntervention 2018;14:e570–9
Chahour K, Aboulaich R, Habbal A, Abdelkhirane C, Zemzeme N. Numerical simulation of the
fractional flow reserve (FFR). Math Model Nat Phenom 2018;13
Collet C, Onuma Y, Sonck J, Asano T, Vandeloo B, Kornowski R, et al. Diagnostic performance
of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis.
Eur Heart J 2018;39:3314–21
Dan K, Shinoda A, Tsuzura D, Garcia-Garcia HM. Triple coronary vessel disease including
double vessel chronic total occlusion: quantitative flow ratio minimises injury of the single
vessel that provides collaterals. Cardiol J 2019;26:407–9
Collet C, Onuma Y, Sonck J, Asano T, Vandeloo B et al. Corrigendum to: Diagnostic performance
of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis.
Eur Heart J 2019;40:356–56
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Erbay A, Abdelwahed YS, Stahli BE, Landmesser U, Leistner DM. The danger lurks dastardly in
the coronary vessel wall: spotlight on patients’ vulnerability. Eur Heart J 2018;39:1656
Cesaro A, Gragnano F, Di Girolamo D, Moscarella E, Diana V, Pariggiano I, et al. Functional
assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio
a step to the future? Expert Rev Cardiovasc Ther 2018;16:951–62
Giddens DP. Computing fractional flow reserve during coronary angiography: how good is good
enough? JACC Cardiovasc Interv 2016;9:2036–8
Guillon B, Rubimbura V, Fournier S, Eeckhout E, Schiele F, Muller O, et al. Validation of
Quantitative Flow Reserve and Residual Quantitative Flow Reserve To Predict Fractional Flow
Reserve Post Stenting from the DOCTORS (Does Optical Coherence Tomography Optimise Results of
Stenting) Study Population. Paper presented at the Joint Annual Meeting of the Swiss Society of
Cardiology and the Swiss Society of Cardiac Surgery, 19–21 June 2019, Interlaken, Switzerland
Hirshfeld Jr JW, Nathan AS. QFR and FFRCT: accurate enough? JACC Cardiovasc Interv
2019;12:2060–3
Howard JP, Murthy VL. A song of pressure and flow, or there and back again. JACC Cardiovasc
Interv 2018;11:754–6
Lansky AJ, Pietras C. Fractional flow reserve from 3-dimensional quantitative coronary
angiography: fresh light through an old window. JACC Cardiovasc Interv 2014;7:778–80
Mejia-Renteria H, Tu S, Macaya F, Escaned J. Influence of coronary microcirculatory
dysfunction on FFR calculation based on computational fluid dynamics. Eur Heart J Cardiovasc
Imaging 2017;18:1066
Morris PD, van de Vosse FN, Lawford PV, Hose DR, Gunn JP. ‘Virtual’ (computed) fractional
flow reserve: current challenges and limitations. JACC Cardiovasc Interv 2015;8:1009–17
Nørgaard BL, Ko B. Angiography based quantitative flow ratio in coronary artery disease:
mimic of FFR – ready for clinical use? Int J Cardiol 2019;279:29–30
Rasmussen LD, Winther S, Westra J, Isaksen C, Ejlersen JA, Brix L, et al. Danish study of
Non-Invasive testing in Coronary Artery Disease 2 (Dan-NICAD 2): study design for a
controlled study of diagnostic accuracy. Am Heart J 2019;215:114–28
Rubimbura V, Guillon B, Fournier S, Amabile N, Chi Pan C, Combaret N, et al. Validation of
Quantitative Flow Reserve and Residual Quantitative Flow Reserve to Predict FFR Post-stenting from
the Does Optical Coherence Tomography Optimise Results of Stenting Study (DOCTORS) Population.
Paper presented at EuroPCR, 21–24 May 2019, Paris, France.
Tang CX, Wang YN, Zhou F, Schoepf UJ, Assen MV, Stroud RE, et al. Diagnostic performance of
fractional flow reserve derived from coronary CT angiography for detection of lesion-specific
ischemia: a multi-center study and meta-analysis. Eur J Radiol 2019;116:90–7
Tu S, Bourantas C, Nørgaard B, Kassab G, Koo B-K, Reiber J. Image-based assessment of
fractional flow reserve. EuroIntervention 2015;11(Suppl. V):V50–4
Tu S, Westra J, Yang J, Li Y, Holm N, Reiber J. Functional Coronary Assessment Based on
Three-Dimensional Quantitative Coronary Angiography. In Escaned J, Serruys PW, editors.
Coronary Stenosis Imaging, Structure and Physiology, Part IV. London: PCR Publishing; 2010
Vestergaard MB, Andersen BK, Westra JS, Christiansen EH, Holm NR. Optimal assessment of
lesion severity in the left anterior descending artery by quantitative flow ratio. The wire-free
invasive functional imaging WIFI LAD study. JACCCardiovasc Interv 2017;10(Suppl.):S50–1
Westra J, Tu S, Campo G, Qiao S, Matsuo H, Qu X, et al. Diagnostic performance of quantitative
flow ratio in prospectively enrolled patients: an individual patient-data meta-analysis. Catheter
Cardiovasc Interv 2019;94:693–701
Xing Z, Pei J, Huang J, Hu X, Gao S. Diagnostic performance of QFR for the evaluation of
intermediate coronary artery stenosis confirmed by fractional flow reserve. Braz J Cardiovasc
Surg 2019;34:165–72
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TABLE 35 Excluded studies from systematic review of clinical effectiveness at full-text screening stage (continued )
Reason for exclusion Study
Zaleska M, Koltowski L, Maksym J, Tomaniak M, Opolski M, Kochman J. Alternative methods
for functional assessment of intermediate coronary lesions. Cardiol J 2019;27:825–35
Zhang J, Zhang R, Guo L. Diagnostic potency of contrast induced fractional flow reserve versus
quantitative flow ratio for assessing the functional significance of coronary stenosis: a meta-
analysis. J Interv Cardiol 2020;2020:7352150
Zhenhua X. Diagnostic performance of quantitative flow ratio (QFR) for the evaluation of
intermediate coronary stenosis severity confirmed by fractional flow reserve. 2018
Zuo W, Yang M, Chen Y, Xie A, Chen L, Ma G. Meta-analysis of diagnostic performance of
instantaneous wave-free ratio versus quantitative flow ratio for detecting the functional
significance of coronary stenosis. BioMed Res Int 2019;2019:5828931
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Appendix 3 Risk-of-bias and applicability
assessment: Quality Assessment of
Diagnostic Accuracy Studies-2
Risk-of-bias assessment
Signalling question (SQ)1: was a consecutive or random sample of patients enrolled?
SQ2: did the study avoid inappropriate exclusions? (Note exclusion of tandem lesion and percentage.)
Risk of bias (participant selection): could the selection of patients have introduced bias?
SQ3: was QFR performed during the same exam as angiography (i.e. online)?
SQ4: was the same cut-off point used for the index test and FFR?
SQ5: was interpretation of QFR blinded to FFR? (Note that, if done prospectively, and if FFR was done
by separate staff/in separate room, then fine.)
Risk of bias (index test): could the conduct or interpretation of the index test have introduced bias?
SQ6: is the reference standard likely to measure FFR accurately enough?
SQ7: was interpretation of FFR blinded to QFR?
Risk of bias (reference standard): could the conduct or interpretation of the reference standard test
have introduced bias?
SQ8: did all patients analysed receive both the index test and FFR (or some received iFR only)?
SQ9: were all or nearly all patients included in the analysis?
SQ10: were QFR and FFR measured during the same examination?
Risk of bias (flow and timing): could the patient flow have introduced bias?
TABLE 36 Risk-of-bias assessment with justifications
Study Comments SQ1 SQ2 PS SQ3 SQ4 SQ5 IT SQ6 SQ7 RS SQ8 SQ9 SQ10 FT
Cortés et al.
(2019)17
Very small sample of
12 patients with FFR.
Retrospective, offline
QFR. Exclusions and
reasons for exclusion not
reported. Only 12 patients
included. Exclusion of
patients not reported.
FFR blinded because
performed before QFR
(retrospective)
N UC – N Y Y + Y Y + Y N N ?
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TABLE 36 Risk-of-bias assessment with justifications (continued )
Study Comments SQ1 SQ2 PS SQ3 SQ4 SQ5 IT SQ6 SQ7 RS SQ8 SQ9 SQ10 FT
Emori et al.
(2018)20
If lesions in multiple
arteries, only one (most
severe stenosis) was
selected as the target
vessel. FFR blinded
because performed before
QFR (retrospective). A
total of 15% excluded
(reasons provided)
Y Y + N Y Y + Y Y + Y Y N +
Emori et al.
(2018)21
Retrospective but
consecutive, with few
exclusions (reasons
provided). FFR blinded
because performed before
QFR (retrospective)
Y Y + N Y Y + Y Y + Y Y N +
FAST:
Masdjedi et al.
(2020)56
[CAAS vFFR]
Large number excluded,
notably owing to lack of
two adequate orthogonal
views (58), overlap or
foreshortening (35) and
inadequate pressure
waveform (25). FFR
blinded because
performed before
QFR (retrospective)
Y UC – N Y Y + Y Y + Y N N +
FAVOR II
China: Xu
et al. (2017)52
Consecutive, prospective.
No significant concerns
Y Y + Y Y Y + Y Y + Y Y Y +
FAVOR II
Europe–Japan:
Westra et al.
(2018)50
UC if consecutive UC Y + Y Y Y + Y Y + Y Y Y +
FAVOR pilot:
Tu et al.
(2016)46
Excluded ostial left main
or ostial right (unclear
how many)
N UC + N Y Y + Y Y + Y Y Y +
Hamaya et al.
(2019)23
Retrospective selection of
subgroup of 154 vessels
with FFR (out of 549
patients and 1595
vessels). Large proportion
excluded owing to
anatomy: 140 vessels
excluded owing to small
(< 2 mm) right coronary
artery or left circumflex
coronary artery (52),
arrhythmia during
ICA (32), ineligible
coronary anatomy (98) or
insufficient image quality
(10). FFR blinded because
performed before QFR
(retrospective). Large
proportion excluded
owing to anatomy
N UC – N Y Y + Y Y + Y N N +
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TABLE 36 Risk-of-bias assessment with justifications (continued )
Study Comments SQ1 SQ2 PS SQ3 SQ4 SQ5 IT SQ6 SQ7 RS SQ8 SQ9 SQ10 FT
Hwang et al.
(2019)24
Large number of vessels
excluded (124; 25.7%)
because of calibration
failure (49), ostium lesion
(35) or insufficient
projection (25). FFR
blinded because
performed before QFR
(retrospective). A total of
25.7% excluded (reasons
provided)
Y N – N Y Y + Y Y + Y N N +
ILUMIEN I:
Ely Pizzato
et al. (2019)19
Large percentage (65%)
of lesions excluded.
FFR blinded because
performed before QFR
(retrospective)
UC UC – N Y Y + Y Y + Y N N +
Kleczyński
et al. (2019)33
The analysis was
conducted twice by two
analyzers and the mean
value (from four
calculations) was used for
further analysis. This may
have reduced the risk of
inter-rater and intrarater
variability. Results per
analyser not reported
Y UC + N Y Y – Y Y + Y UC N +
Kołtowski
et al. (2018)32
Retrospective selection;
large number excluded,
including 299 owing to
lack of proper ICA
projections (34.9%),
bifurcation lesions (5%),
tandem lesions (2.5%) or
ostial lesion (3%)
N Y – N Y Y + Y Y + Y N N +
Liontou et al.
(2019)34
Large number of vessels
excluded (124/202 or
61.4%); reasons provided.
Unclear how many ostial
lesions, overlapping and
tortuous vessels were
excluded. FFR blinded
because performed before
QFR (retrospective)
UC N ? N Y Y + Y Y + Y N N +
Mejia-Renteria
et al. (2019)37
Retrospective; large
number of exclusions
(101), including ostial in
left main or right coronary
artery (10), grafted target
vessels (2), inadequate
projections (28),
significant overlapping
(17), inadequate ICA
quality (19), resting
haemodynamic data not
available (6) and contrast
filling not optimal for TIMI
frame count analysis (15)
N Y + Y Y Y + Y Y + Y N N +
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TABLE 36 Risk-of-bias assessment with justifications (continued )
Study Comments SQ1 SQ2 PS SQ3 SQ4 SQ5 IT SQ6 SQ7 RS SQ8 SQ9 SQ10 FT
Smit et al.
(2019)40
Retrospective but
consecutive. A total of
13.5% vessels excluded
but reasons reported and
acceptable. Unlikely to
have been blinded. Mean
time between ICA and
invasive FFR 22.8 ±
25.1 days. The majority of
patients included in our
study (97%) underwent
FFR measurement within
3 months after the initial
ICA. A total of 13% of
patients excluded
Y Y + N Y UC – Y UC – Y N N +
Spitaleri et al.
(2018)41
[cohort B,
diagnostic
accuracy]
Vessels with diffuse
disease excluded, but
relatively low (n= 8/76;
11% of otherwise eligible
patients) and no other
significant concerns.
FFR blinded because
performed before QFR
(retrospective)
Y N + N Y Y + Y Y + Y N N +
Stähli et al.
(2019)42
Retrospective, but limited
exclusions with acceptable
reasons reported. All
pressure tracings were
reviewed for high signal
quality, and FFR and
resting Pd/Pa ratio
analysed offline by
experienced investigators
blinded to QFR. A total of
8.7% excluded (reasons
provided)
Y Y + N Y Y + Y Y + Y Y N +
SYNTAX II:
Asano et al.
(2019)15
Large percentage (29%)
of lesions excluded owing
to lack of appropriate
projections, but no other
significant concerns.
FFR blinded because
performed before QFR
(retrospective). FFR
performed only in iFR
grey zone (0.86–0.93)
patients
N UC + N Y Y + UC Y + N N N –
Ties et al.
(2018)43
Very large proportion of
excluded vessels (69.6%),
mostly owing to ‘lack of
basic requirements’
(insufficient details).
FFR blinded because
performed before QFR
(retrospective). A total of
69.7% excluded (reasons
provided)
UC N ? N Y Y + Y Y + Y N N +
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Applicability assessment
Applicability concern 1: are there concerns that the included patients do not match the
review question?
Applicability concern 2: are there concerns that the index test, its conduct or interpretation differ from
the review question (e.g. QFR cut-off point not 0.8 or unusual QFR mode used for main analysis)?
Applicability concern 3: are there concerns that the reference standard, its conduct or interpretation
differ from the review question?
TABLE 36 Risk-of-bias assessment with justifications (continued )
Study Comments SQ1 SQ2 PS SQ3 SQ4 SQ5 IT SQ6 SQ7 RS SQ8 SQ9 SQ10 FT
Tu et al.
(2014)45
Three were excluded;
reasons included (1) the
interrogated vessel had
too much overlap or
foreshortening (> 90%),
(2) the image quality of
the hyperemic projection
was not sufficient to
evaluate by frame count
and (3) the mean pressure
of the guiding catheter or
blood haematocrit value
was not documented
Y UC + N Y Y + Y Y + Y Y N +
van Rosendael
et al. (2017)48
Prospectively recruited.
No notes on how many
were excluded (and
reasons for exclusion).
Very small sample (n = 17
patients). No reporting of
blinding. No reporting on
number excluded and
reasons for exclusion
UC UC ? Y Y UC – Y UC – Y UC Y ?
Watari et al.
(2019)49
Consecutive, prospective.
iFR was the only
reference standard
Y N + Y Y Y + UC Y + N Y Y +
WIFI II:
Westra et al.
(2018)51
Intention to exclude as
few as possible based on
impaired angiographic
quality
Y Y + Y Y Y + Y Y + Y Y Y +
Yazaki et al.
(2017)53
Consecutive, prospective Y Y + Y Y Y + Y UC – Y Y Y +
?, insufficient information to rate risk of bias; +, rated as being at low risk of bias; –, rated as being at high risk of bias;
FT, flow and timing; IT, index test; N, no; Pa, aortic pressure; Pd, distal coronary pressure; PS, patient selection; RS, reference
standard; SQ, signalling question; TIMI, thrombolysis in myocardial infarction; UC, unclear risk of bias; Y, yes.
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TABLE 37 Applicability assessment with justifications
Study Comments
Patient
selection
Index
test
Reference
standard
Cortés et al. (2019)17 Minority with intermediate stenosis and stable CAD.
A total of 100% STEMI with > 50% DS in non-culprit
arteries. Offline assessment
– – +
Emori et al. (2018)20 Percentage of stable CAD unknown; only most severe
arteries selected in case of multiple lesions. Offline
assessment
? – +
Emori et al. (2018)21 Percentage of stable CAD unknown. Offline
assessment
? – +
FAST: Masdjedi et al.
(2020)56 [CAAS vFFR]
Majority with intermediate stenosis and stable CAD.
A total of 60% stable CAD; 26% acute intermediate
stenosis. Large number of exclusions. Offline
assessment
– – +
FAVOR II China: Xu et al.
(2017)52
Minority with intermediate stenosis and stable CAD.
A total of 34% stable CAD; 61% unstable angina.
Online assessment
– + +
FAVOR II Europe–Japan:
Westra et al. (2018)50
Majority with intermediate stenosis and stable CAD.
Online assessment
+ + +
FAVOR pilot: Tu et al.
(2016)46
Majority with intermediate stenosis and stable CAD.
All stable angina. Offline assessment
+ – +
Hamaya et al. (2019)23 Majority with intermediate stenosis and stable CAD.
100% stable CAD; only 10% with three-vessel disease.
Offline assessment
+ – +
Hwang et al. (2019)24 Majority with intermediate stenosis and stable CAD.
A total of 69% stable CAD, 31% acute; however, the
large rate of exclusion is potentially concerning.
Offline assessment
– – +
ILUMIEN I: Ely Pizzato
et al. (2019)19
Majority with intermediate stenosis and stable CAD.
A total of 63% stable angina, 22.1% unstable; 10.9%
STEMI. Offline assessment
+ – +
Kleczyński et al. (2019)33 Majority with intermediate stenosis and stable CAD.
Offline assessment
+ – +
Kołtowski et al. (2018)32 Majority with intermediate stenosis and stable CAD.
A total of 100% stable CAD. Offline assessment
+ – +
Liontou et al. (2019)34 Majority with intermediate stenosis and stable CAD.
Different population: all in-stent restenosis, ≥ 50% DS
in stent, although 69% had stable angina (26%
unstable angina, 6% acute MI). Offline assessment
– – +
Mejia-Renteria et al.
(2019)37
Majority with intermediate stenosis and stable CAD.
A total of 70% stable angina; 30% ACS. Offline
assessment
+ – +
Smit et al. (2019)40 Majority with intermediate stenosis and stable CAD.
All referred from diagnostic-only setting, so likely to
be stable. All intermediate stenoses (30–90%). Offline
assessment
+ – +
Spitaleri et al. (2018)41
[cohort B, diagnostic
accuracy]
Minority with intermediate stenosis and stable CAD.
All STEMI with multivessel disease patients
(assessment of non-culprit vessels). Offline assessment
– – +
Stähli et al. (2019)42 Majority with intermediate stenosis and stable CAD.
A total of 72% stable CAD; 4% acute; most/all other
unstable angina. All intermediate stenoses. Offline
assessment
+ – +
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TABLE 37 Applicability assessment with justifications (continued )
Study Comments
Patient
selection
Index
test
Reference
standard
SYNTAX II: Asano et al.
(2019)15
All three-vessel disease (potentially harder to
diagnose). Stable or unstable angina, or atypical chest
pain (n/% not reported). Offline assessment
– – +
Ties et al. (2018)43 Majority with intermediate stenosis and stable CAD.
A total of 51% stable CAD; 16.7% acute (NSTEMI).
Most patients excluded. Offline assessment
– – +
Tu et al. (2014)45 Majority with intermediate stenosis and stable CAD.
A total of 76.5% stable angina; 8.8% silent ischaemia;
64% bifurcation lesions. Offline (China, Hungary) and
online (Belgium) assessment
+ – +
van Rosendael et al.
(2017)48
Majority with intermediate stenosis and stable CAD.
All stable CAD, though DS low. Online assessment
+ + +
Watari et al. (2019)49 Majority with intermediate stenosis and stable CAD.
Online assessment
+ + +
WIFI II: Westra et al.
(2018)51
Minority with intermediate stenosis and stable CAD.
A total of 31% stable angina; 34% atypical angina;
31% non-specific angina. Online assessment
– + +
Yazaki et al. (2017)53 Majority with intermediate stenosis and stable CAD.
A total of 50.7% stable angina; 99.3% CAD. Offline
assessment
+ – +
+, no significant concern; –, significant concern; ?, insufficient information to assess; AC, applicabilty concern;
ACS, adult cardiac surgery.
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Appendix 4 Further meta-analysis results
Study
Mode = QFR
Heterogeneity: I2 = 20%, τ2 = 0.277; p = 0.27
Mode = cQFR
Heterogeneity: I2 = 65%, τ2 = 0.1798; p < 0.01
Mode = fQFR
Heterogeneity: I2 = 68%, τ2 = 0.1682; p < 0.01
Heterogeneity: I2 = 65%, τ2 = 0.1685; p < 0.01
Events (n) Total (n) PPV (95% CI)
14
106
90
11
41
29
63
18
44
66
41 53
86
653
61
22
81
32
45
13
118
124
18
1 1
73 84
7167
20 25
3 4
203
12 18
276
121 142
1715
75
407
84
474
1714
16 16
1229
75 99
18
132
4 4
154
26
180116
72
12 18
86
567
0.2 0.4 0.6 0.8 1.0
0.78  (0.52 to 0.94)
0.85  (0.78 to 0.91)
0.76  (0.68 to 0.84)
0.85  (0.55 to 0.98)
0.91  (0.79 to 0.98)
0.91  (0.75 to 0.98)
0.78  (0.67 to 0.86)
0.82  (0.60 to 0.95)
0.72  (0.59 to 0.83)
0.77  (0.66 to 0.85)
0.77  (0.64 to 0.88)
0.80  (0.77 to 0.83)
0.80  (0.76 to 0.84)
0.87  (0.78 to 0.93)
0.94  (0.86 to 0.98)
0.80  (0.59 to 0.93)
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FIGURE 28 Metaregression of sensitivity, specificity and DOR by proportion with diabetes: (a) sensitivity; (b) specificity;
and (c) log-DOR.
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FIGURE 30 Metaregression of sensitivity, specificity and DOR by proportion with multivessel disease: (a) sensitivity;
(b) specificity; and (c) log-DOR.
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TABLE 38 Regression parameters and p-values from metaregression analyses
Variable Log-DOR (95% CI; p-value) Sensitivity (95% CI; p-value) Specificity (95% CI; p-value)
Mean age,
years
0.01 (–0.1 to 0.1; 0.822) 0.05 (–1.11 to 1.11; 0.936) –0.12 (–1.1 to 1.1; 0.813)
Sex –2.14 (–8.23 to 8.23; 0.501) 19.99 (–42.18 to 42.18; 0.538) –33.84 (–84.29 to 84.29; 0.207)
Diabetes 2.07 (–0.51 to 0.51; 0.136) 27.6 (2.8 to –2.8; 0.044) –1.53 (–25.35 to 25.35; 0.901)
Mean DS 0.01 (–0.06 to 0.06; 0.753) 0.6 (–0.17 to 0.17; 0.149) –0.25 (–0.89 to 0.89; 0.466)
Stable angina –0.7 (–2.99 to 2.99; 0.574) –13.8 (–35.41 to 35.41; 0.266) 5.25 (–4.62 to 4.62; 0.345)
Stable CAD –2.57 (–4.18 to 4.18; 0.014) –1.89 (–29.97 to 29.97; 0.898) –20.69 (–46.25 to 46.25; 0.151)
Previous MI 0.28 (–3.89 to 3.89; 0.899) 10.67 (–25.87 to 25.87; 0.579) –14.04 (–48.13 to 48.13; 0.437)
Acute MI 0.23 (–0.99 to 0.99; 0.719) 4.85 (–8.74 to 8.74; 0.495) –0.3 (–12.51 to 12.51; 0.963)
Multivessel
disease
2.87 (1.74 to –1.74; 0.016) 5.28 (–20.21 to 20.21; 0.712) 29.05 (7.64 to –7.64; 0.076)
Diffuse CAD –7.76 (–15.72 to 15.72; 0.307) –28.98 (–299.8 to 299.8; 0.868) –59.17 (–165.3 to 165.3; 0.472)
Previous PCI 0.37 (–3.34 to 3.34; 0.848) 27.43 (–13.32 to 13.32; 0.216 –25.99 (–62.63 to 62.63; 0.195)
Mean FFR
(per 0.1 FFR)
0.01 (–1.45 to 1.45; 0.988) –18.77 (–30.62 to 30.62; 0.008) 14.59 (3.84 to –3.84; 0.019)
Percentage with
a FFR < 0.8
–0.01 (–0.04 to 0.04; 0.595) 0.32 (0.06 to –0.06; 0.026) –0.3 (–0.52 to 0.52; 0.012)
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FIGURE 32 Sensitivity and specificity by patient subgroups.
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FIGURE 33 Diagnostic odds ratios by patient subgroups.
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FIGURE 34 Bivariate meta-analyses according to QUADAS-2 risk-of-bias classification: (a) flow; (b) index text; (c) patient
selection; and (d) reference standard. (continued )
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FIGURE 34 Bivariate meta-analyses according to QUADAS-2 risk-of-bias classification: (a) flow; (b) index text; (c) patient
selection; and (d) reference standard.
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FIGURE 35 Bivariate meta-analyses according to QUADAS-2 applicability classification: (a) index test; (b) patient
selection; and (c) reference standard. (continued )
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FIGURE 35 Bivariate meta-analyses according to QUADAS-2 applicability classification: (a) index test; (b) patient
selection; and (c) reference standard.
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FIGURE 36 Bivariate meta-analyses according to other factors that might cause bias: (a) blinding; (b) both tests;
(c) complete data; (d) online test; (e) same exam; and (f) stable CAD. (continued )
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FIGURE 36 Bivariate meta-analyses according to other factors that might cause bias: (a) blinding; (b) both tests;
(c) complete data; (d) online test; (e) same exam; and (f) stable CAD.
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FIGURE 37 Bivariate meta-analysis of extracted figure data.
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TABLE 39 Comparison of diagnostic accuracy based on figure data and text/table data
Study
Data extracted from figures Data extracted from text/tables
n
Sensitivity
(%)
Specificity
(%) n
Sensitivity
(%)
Specificity
(%)
Cliff and Ong (2019)16 39 87.50 82.61
Cortés et al. (2019)17 15 100.00 100.00 11 100.00 100.00
Emori et al. (2018)20 143 93.90 88.52 150 93.59 84.72
Emori et al. (2018)21 100 97.10 87.10
FAVOR II China: Xu et al. (2017)52 252 90.70 86.75 328 94.64 91.67
FAVOR II Europe–Japan:
Westra et al. (2018)50
238 85.06 85.43 317 86.54 86.85
FAVOR pilot: Tu et al. (2016)46 84 74.07 91.23
Hamaya et al. (2019)23 136 94.20 73.13
Hwang et al. (2019)24 274 83.46 89.80 358 92.31 89.77
Kajita et al. (2019)27 28 60.00 95.65
Kameyama et al. (2016)28 24 80.00 88.89 25 78.57 81.82
Kanno et al. (2019)29 381 86.29 71.84 504 85.29 72.56
Kirigaya et al. (2019)31 89 79.17 90.24 95 80.39 90.91
Kołtowski et al. (2018)32 205 84.04 83.78 306 89.23 63.64
Liontou et al. (2019)34 72 90.00 76.19
Liu et al. (2017)35 40 85.71 76.92
Mejia-Renteria et al. (2019)37 278 86.29 87.66 300 88.97 87.20
Sato et al. (2018)39 64 90.91 90.32 63 90.63 90.32
Smit et al. (2019)40 240 63.38 94.67 320 69.23 92.14
Spitaleri et al. (2018)41 42 94.12 96.00 45 93.75 93.10
Stähli et al. (2019)42 267 73.44 97.54 516 75.00 97.84
SYNTAX II: Asano et al. (2019)15 809 73.73 73.93
Ties et al. (2018)43 101 66.67 96.25
Toi et al. (2018)44 34 68.75 66.67
Tu et al. (2014)45 78 76.92 90.38 77 78.26 92.59
van Rosendael et al. (2017)48 26 100.00 75.00
Watari et al. (2019)49 150 84.62 82.65
WIFI II: Westra et al. (2018)51 206 73.75 82.54 240 75.00 86.84
Yazaki et al. (2017)53 129 89.19 88.04 151 89.13 88.57
Ziubryte et al. (2019)54 69 84.21 100.00
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FIGURE 38 Fractional flow reserve and QFR data showing QFR grey zone between 0.78 and 0.84.
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FIGURE 39 Difference between FFR and QFR values in the grey zone: (a) FN; (b) FP; (c) TN; and (d) TP. (continued )
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FIGURE 40 Diagnostic accuracy of QFR with and without using the grey zone.
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TABLE 40 Approximate grey-zone thresholds required for sensitivity and specificity of 90% or 95%
Sensitivity (%) Specificity (%)
Grey-zone threshold
Lower Upper
90 90 0.78 0.82
90 95 0.75 0.82
95 90 0.78 0.85
95 95 0.75 0.85
Specif icity (%)
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FIGURE 41 Diagnostic meta-analysis using FFR/QFR thresholds of 0.75 and 0.80.
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TABLE 41 Studies included in the meta-analysis 2D ICA
Study
Number of patients,
vessel (lesion) (n)
Unit of
analysis
Sensitivity,
% (95% CI)
Specificity,
% (95% CI) AUC (95% CI) Correlation
ICA cut-off
point, %
FFR cut-off
point
FAVOR II China and
FAVOR II Europe–Japan:
Ding et al. (2019)62
576 (645) Vessel 47.1 (40.5 to 53.6) 74.4 (70.2 to 78.6) 0.66 (0.62 to 0.71) r = 0.59 ≥ 50 ≤ 0.80
Kim et al. (2016)63 463 (724) Vessel 78 (72 to 82) 48 (43 to 53) NR r = 0.49 ≥ 50 < 0.80
Mejia-Renteria et al. (2017),64
conference abstract
196 (246) Vessel 82 41 0.67 (0.61 to 0.74) r = –0.39 ≥ 50 ≤ 0.80
DAN-NICAD: Serj-Hansen
et al. (2020)65
176 (232) Patient NR NR NR ρ = 0.30 ≥ 50 ≤ 0.80
ACS, adult cardiac surgery; NR, not reported; SA, stable angina; SI, silent ischaemia; UA, unstable angina.
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Appendix 5 Further narrative synthesis results
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TABLE 42 Results of QAngio studies not included in the meta-analysis
Study Population Design Test
Unit of
analysis
Sensitivity,
% (95% CI)
Specificity,
% (95% CI) PPV (%) NPV (%)
AUC
(95% CI) Correlation
MD
(FFR-QFR)
WIFI prototype
study: Andersen
et al. (2017),14
conference
abstract
l Stable angina
and secondary
evaluation after
acute MI
l 93 patients
Prospective QAngio XA
3D/QFR
(prototype)
Patient 0.64
(0.48 to 0.77)
0.8
(0.66 to 0.89)
74.0 71.0 0.77
(0.67 to 0.87)
NR –0.02 (0.12)
Retrospective
reanalysis
QAngio XA
3D/QFR
(modified
prototype)
Patient 0.66
(0.51 to 0.79)
0.86
(0.73 to 0.93)
81.0 74.0 0.87
(0.79 to 0.94)
NR 0.0 (0.07)
NR ICA (3D DS) Patient NR NR NR NR 0.75
(0.65 to 0.85)
NR NR
Neylon et al.
(2016),38
conference
abstract
l NR
l 38 vessels
(36 patients)
Retrospective QAngio XA
3D/QFR
Lesion NR NR NR NR 0.78
(0.67 to 0.96)
NR –0.01 (NR)
Goto et al.
(2019),22
conference
abstract
l Intermediate LM
stenosis. Mostly LM
bifurcation (85%)
l 62 patients
Retrospective QAngio XA
3D/QFR
NR 84.8 68.2 84.8 68.2 0.82
(0.71 to 0.93)
r = 0.578 NR
Kleczyński
et al. (2019)33
l Intermediate
stenosis
l 123 vessels
(50 patients)
Retrospective QAngio XA
3D/QFR
Vessel 91.8 97.3 NR NR 0.98
(0.94 to 1.00)
NR NR
Mehta et al.
(2019),36
conference
abstract
l NR
l 85 vessels
Retrospective QAngio XA
3D/QFR
Lesion 84 92 76 95 0.94 r = 0.801 NR
Van Diemen
et al. (2019),47
conference
abstract
l NR
l 152 (fQFR)
l 140 (cQFR)
Retrospective QAngio XA
3D/QFR
Vessel fQFR: 76
(59 to 89);
cQFR: 71
(53 to 86)
fQFR: 94
(88 to 98);
cQFR: 93
(86 to 97)
fQFR: 79
(64 to 89);
cQFR: 74
(59 to 85)
fQFR: 93
(88 to 96);
cQFR: 92
(86 to 95)
NR NR NR
LM, left main; NR, not reported.
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TABLE 43 Results for alternative QAngio modes (aQFR, iQFR, lQFR, vQFR)
Study Population Design Test
Unit of
analysis
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
%
AUC
(95% CI) Correlation
MD
(FFR-QFR)
Kołtowski et al.
(2018)32
Stable CAD;
268 patients;
306 lesions
Retrospective vQFR Lesion 90.5 69.7 68.8 90.8 0.900 r = 0.78 0.03 (0.07)
lQFR Lesion 48.6 96.5 91.1 71.7 0.822 r = 0.7 –0.06 (0.07)
iQFR Lesion 83.8 86.6 82.2 87.9 0.936 r = 0.85 –0.002 (0.054)
FAVOR pilot:
Tu et al. (2016)46
73 patients;
84 vessels
Retrospective aQFR Patient 78.0 89.0 80.0 88.0 0.90
(0.81 to 0.96)
NR NR
aQFR Vessel 78.0 91.0 81.0 90.0 0.91
(0.83 to 0.96)
r = 0.72 –0.001 (0.065)
van Rosendael
et al. (2017)48
15 vessels;
non-acute
CAD
Retrospective aQFR
(observer 1)
Vessel 100 92.9 50 100 NR NR 0.01 (0.04)
aQFR
(observer 1)
Vessel 100 92.3 50 100 NR NR NR
NR, not reported.
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TABLE 44 Subgroup analyses from QAngio studies stratified by vessel characteristics
Study Subgroup na Test
Sensitivity,
%
Specificity,
%
PPV,
%
NPV,
%
AUC
(95% CI) Correlation
Kanno et al. (2019)29 High IMR 155 patients cQFR 96.7 64.2 63.0 96.8 NR NR
Kanno et al. (2019)29 Low IMR 349 patients cQFR 81.5 77.2 78.8 80.0 NR NR
Mejia-Renteria et al.
(2019)37,57
High IMR 83 vessels cQFR 86 69 67 87 0.88 (NR) 0.77
Mejia-Renteria et al.
(2019)37,57
Low IMR 217 vessels cQFR 90 94 93 92 0.96 0.86
Stähli et al. (2019)42,60 Small vessel disease
(≤ 2.8 mm reference
diameter)
225 vessels cQFR 80.0 98.5 94.6 94.0 0.89
(0.85 to 0.93)
r = 0.84
Stähli et al. (2019)42 Small vessel disease
(≤ 2.8 mm reference
diameter)
225 vessels fQFR 73.9 96.6 87.3 92.1 NR r = 0.83
Stähli et al. (2019)42 No small vessel
disease
154 vessels cQFR 65.7 97.2 79.3 94.5 0.81
(0.76 to 0.86)
r = 0.77
Stähli et al. (2019)42 No small vessel
disease
154 vessels fQFR 68.6 96.7 77.4 94.9 NR r = 0.74
WIFI II: Westra et al.
(2018)51
Multiple lesions 81 lesions QAngio NR NR NR NR NR MD= 0.01 ± 0.09
WIFI II: Westra et al.
(2018)51
Single lesion 174 lesions QAngio NR NR NR NR NR MD= 0.01 ± 0.07
FAVOR II China: Xu
et al. (2017)52
DS 40–80% 273 patients QAngio 92.2 92.3 82.6 96.8 NR NR
FAVOR II China: Xu
et al. (2017)52
DS 40–80% 272 patients ICA
(2D DS)
54.5 60.0 50.5 22.9 NR NR
Emori et al. (2018)21 LADb 63 vessels cQFR 95.0 83.0 93.0 88.0 NR NR
Emori et al. (2018)21 Non-LADb 37 vessels cQFR 100.0 92.0 96.0 100.0 NR NR
NR, not reported.
a Unit used in analyses: IMR, LAD, CAD, CKD, MI and DS.
b Not review protocol specified.
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TABLE 45 Subgroup analyses from QAngio studies stratified by comorbidities
Study Subgroup n Test Sensitivity, % Specificity, % PPV, % NPV, % AUC (95% CI) Correlation
Smit et al. (2019)58 Diabetic 66 patients QAngio (NS) 75.0 95.0 90.0 97.0 NR NR
Non-diabetic 193 patients QAngio (NS) 69.0 88.0 75.0 85.0 NR NR
Diabetic 82 vessels QAngio (NS) 71.0 95.0 85.0 89.0 0.91 (0.84 to 0.99) r = 0.74
Non-diabetic 238 vessels QAngio (NS) 69.0 91.0 74.0 88.0 0.93 (0.89 to 0.96) r = 0.83
Stähli et al. (2019)42 Diabetes 98 patients QAngio (NS) NR NR NR NR 0.84 (0.76 to 0.90) r = 0.82
Stähli et al. (2019)42 No diabetes 338 patients QAngio (NS) NR NR NR NR 0.87 (0.83 to 0.90) r = 0.81
Kołtowski et al. (2018)32 Diabetes 21 patients/vessels QAngio (NS) NR NR NR NR NR MD= –0.059 ± 0.07
Kołtowski et al. (2018)32 No diabetes 173 patients/vessels QAngio (NS) NR NR NR NR NR MD= –0.027 ± 0.074
Emori et al. (2018)20 Prior MI 75 patients/vessels fQFR 94.0 62.0 69.4 92.3 0.90 (0.81 to 0.95) r = 0.84
Emori et al. (2018)20 Prior MI 75 patients/vessels cQFR 92.0 82.0 82.5 91.4 0.93 (0.86 to 0.97) r = 0.88
Emori et al. (2018)20 No prior MI 75 patients/vessels fQFR 98.0 73.0 82.0 96.0 0.97 (0.93 to 0.99) r = 0.91
Emori et al. (2018)20 No prior MI 75 patients/vessels cQFR 95.0 88.0 90.9 93.5 0.97 (0.93 to 0.99) r = 0.94
Hwang et al. (2019)24 Stable CADa 253 vessels fQFR 90.1 89.5 82.8 94.2 0.946 r = 0.86
Hwang et al. (2019)24 MI non-culprita 105 vessels fQFR 96.2 90.6 90.9 96.0 0.967 r = 0.88
Kołtowski et al. (2018)32 CKDa 32 patients QAngio (NS) NR NR NR NR 0.67 (0.46 to 0.88) r = 0.63
Kołtowski et al. (2018)32 No CKDa 170 patients QAngio (NS) NR NR NR NR 0.89 (0.84 to 0.94) r = 0.79
NR, not reported; NS, not significant.
a Not review protocol specified.
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TABLE 46 Results from multivariate regression analyses
Variable
Study
FAVOR II Europe–Japan:
Westra et al. (2018)50
Mejia-Renteria et al.
(2018,57 201937)
WIFI II: Westra
et al. (2018)51
SYNTAX II: Asano
et al. (2019)15
ACS/acute MI
(not previous MI)
OR 3.97 (95% CI
1.78 to 8.86)
Adenosine route No
Age No No No
Bifurcation/trifurcation OR 1.81 (95% CI
1.10 to 2.98)
BMI No No
Chronic total inclusion
(main vessel)
No
Diabetes OR 2.88 (95% CI
1.30 to 6.43)
No
DS No No No
Ejection fraction
eGFR
FFR No r = –1.17 (SE 0.53)
Hypertension No
IMR OR 1.05 (95% CI
1.02 to 1.08)
LAD No
Left circumflex artery No
Left marginal artery No
Lesion length No
Lesion location
LM/LCA/left main
coronary artery
MI history/previous MI No
MLD No
Multivessel disease No
Pa No
Previous PCI No
Proximal/mid-segment
location
No
Right coronary artery
Reference diameter No
Sex No No No
Side branch location OR 2.07 (95% CI
1.14 to 3.76)
Small vessel OR 1.67 (95% CI
1.14 to 2.44)
Smoker No No
Vessel No No
ACS, adult cardiac surgery; BMI, body mass index; eGFR, estimated glomerular filtration rate; LCA, left coronary artery;
LM, left main; MLD, minimal lumen diameter; Pa, aortic pressure.
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TABLE 47 Patient and vessel exclusions and test failures from diagnostic accuracy studies
Study
Failed/
excluded, n % Unit Reasons (n or %)
QAngio (prospective studies)
FAVOR II Europe–Japan:
Westra et al. (2018)50
57 17 Patient Lesion > 90% and no additional lesions with FFR
measurement (8), no lesions > 30% apart (6), AF (1),
acute MI (1), ostial right coronary artery (1), stepdown (1),
protocol violation (7), FFR not measured (2), overlap (1),
poor image quality (3), projection < 25% apart (1), technical
issue (1), drift (9), damping (15). The authors stated that
bifurcation lesions were excluded but numbers NR
Toi et al. (2018),44
conference abstract
NR NR NR NR
van Rosendael et al.
(2017)48
NR NR NR NR
Watari et al. (2019)49 11 7 Vessel Non-optimal angiographic projections for QFR analysis (9)
or incomplete pressure wire measurement (2)
WIFI prototype study:
Andersen (2017),14
conference abstract
NR NR NR NR
FAVOR II China:
Xu et al. (2017)52
29 9 Patients Two enrolled patients [three vessels, including data for
QFR (2), poor image quality (1)]. Withdrew informed
consent (4), atrial fibrillation during coronary angiography
(1), total occlusion lesion (1), lesion DS < 30% or > 90% in
all vessels (9), ineligible for diagnostic intervention or FFR
examination (12)
WIFI II: Westra et al.
(2018)51
190 52 Patient Lesion > 90% and no FFR measurement (51), no
confirmed lesion with DS > 30% (86), FFR not measured
(34), drift (4), dampening (5), no sign of adenosine effect
(1), other angiographic or procedural criteria (9)
Lesions excluded owing to unsuccessful QFR computation
(15), comprising overlap at the lesion segment of interest
(6), excessive foreshortening in stenotic segments (7),
insufficient contrast flow quality (1) and inability to
contour a tight stenosis because of poor contrast filling (1)
QAngio (retrospective studies)
Cliff and Ong (2019),16
conference abstract
NR NR NR NR
Cortés et al. (2019)17 134 92 Patient Suboptimal angiographic images (46, of which 13 were
primary, 33 staged procedure), retrospective (88)
Emori et al. (2018)20 13 8 Patient Incomplete CAG (9), ostial lesions (3), collateral donor
artery (1)
Emori et al. (2018)21 6 6 Patient Incomplete coronary angiography (4), ostial lesion (1),
collateral donor artery (1)
FAVOR pilot: Tu et al.
(2016)46
15 17 Patient Excessive overlap of vessels (5), incomplete data (3),
excessive pressure wire drift (3), noisy angiograms (2),
< 25° apart (1), no sign of induced hyperaemia (1)
Goto et al. (2019),22
conference abstract
NR NR NR NR
Hamaya et al. (2019)23 140 20 Patient Small (< 2mm) right coronary artery left circumflex
coronary artery (52), arrhythmia during ICA (32), ineligible
coronary anatomy (98), insufficient image quality (10)
continued
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TABLE 47 Patient and vessel exclusions and test failures from diagnostic accuracy studies (continued )
Study
Failed/
excluded, n % Unit Reasons (n or %)
Hwang et al. (2019)24 127 35 Vessel Calibration failure (49), ostium lesion (35), insufficient
projection (25), tortuous vessel (7), overlapped vessel (7),
inadequate contrast filling (3), no iFR (1)
Ishihara et al. (2019),25
conference abstract
NR NR NR NR
Jin et al. (2019),26
conference abstract
20 20 Patients Unsuitable coronary anatomy, invalid FFR measurements,
poor image quality and lack of two projections ≥ 25° apart
(20 total)
Kajita (2019),27
conference abstract
NR NR NR NR
Kameyama et al.
(2016),28 conference
abstract
9 26 Vessel Poor angiographic images (9)
Kanno et al. (2019)29 NR NR NR NR
Kanno et al. (2019)30 NR NR NR NR
Kirigaya et al. (2019),31
conference abstract
NR NR NR NR
Kleczyński et al. (2019)33 NR NR NR NR
Kołtowski et al. (2018)32 551 64 Lesion Lack of proper angiographic projections (299). Other
reasons: bifurcation lesion (43), AF (41), vessel overlap/
shortening (37), low image quality (28), ostial lesion (26),
tandem lesion (21), collateral (18), bypass grafting (15)
Liontou et al. (2019)34 124 61 Vessels History of CABG, ostial left main or ostial right coronary
artery lesions, occlusive restenosis, bioresorbable
scaffolds, incompatibility of angiographic images (90).
Lack of at least two angiographic projections > 25° apart,
severe vessel tortuosity and/or overlap limiting QFR
analysis (34)
Liu et al. (2017),35
conference abstract
NR NR NR NR
Mehta et al. (2019),36
conference abstract
NR NR NR NR
Mejia-Renteria et al.
(2019)37
101 26 Vessel Ostial in left main or right coronary artery (10), grafted
target vessels (2), inadequate projections (28), significant
overlapping (17), inadequate ICA quality (19), resting
haemodynamic data not available (6), contrast filling not
optimal for TIMI frame count analysis (19)
Neylon et al. (2016),38
conference abstract
NR NR NR NR
Sato et al. (2018),39
conference abstract
NR NR NR NR
Smit et al. (2019)40 52 13 Vessels Insufficient image quality (17), presence of a coronary
stent (4), excessive overlap and/or foreshortening of
coronary arteries (18), absence of angiographic views with
projection angles > 25° apart (6), ostial stenosis (5) or
aneurysm (2)
Spitaleri et al. (2018)41 31 41 Patients No successful PCI on culprit lesion (3), diffuse disease
in non-culprit vessel (8), severe tortuosity (2), vessel
< 2.5 mm (2), operator preferred not to perform FFR (16)
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TABLE 47 Patient and vessel exclusions and test failures from diagnostic accuracy studies (continued )
Study
Failed/
excluded, n % Unit Reasons (n or %)
Stähli et al. (2019)42 43 9 Patients Lack of two projections 25° apart (24), insufficient image
quality (12), vessel overlap/shortening (10), low-contrast
filling (7), technical issues (4), plus 14 patients with
incomplete FFR measurement
SYNTAX II: Asano et al.
(2019)15
341 29 Vessel No two appropriate projections (311), lumen diameter
< 2.0 mm (12), ostial lesion near aorta (4), other (14)
Ties et al. (2018)43 232 70 Vessel Lack of basic requirements (200), insufficient image
quality (17), inappropriate reference diameter function (8),
overlap/foreshortening (5), no perpendicularity (1), true
bifurcation (1)
Tu et al. (2014)45 3 4 Vessel Too much overlap or foreshortening (> 90%), insufficient
image quality, mean pressure of the guiding catheter or
blood haematocrit value not documented
Van Diemen et al.
(2019),47 conference
abstract
266 48 Vessels No FFR (72). QFR analysis succeeded in 286 (52%) of the
remaining 552 arteries. No further details reported
WIFI II: Westra et al.
(2018)51
190 52 Patient Lesion > 90% and no FFR measurement (51), no
confirmed lesion > 30% (86), FFR not measured (34), drift
(4), dampening (5), no sign of adenosine effect (1), other
angiographic or procedural criteria (9)
Lesions excluded owing to unsuccessful QFR computation
(15), comprising overlap at the lesion segment of interest
(6), excessive foreshortening in stenotic segments (7),
insufficient contrast flow quality (1), and inability to
contour a tight stenosis because of poor contrast filling (1)
Yazaki et al. (2017)53 20 12 Vessel Lacking two optimal angiographic projections at least 25°
apart, overlapping vessels, no preferred references in
proximal or distal vessels, insufficient contrast, target
lesion at ostium of left or right artery
Ziubryte et al. (2019),54
conference abstract
NR NR NR NR
CAAS vFFR
FAST-EXTEND: Daemen
et al. (2019)18
NR NR NR NR
FAST: Masdjedi et al.
202056 [CAAS vFFR]
170 63 Patients Inadequate pressure waveform (25), STEMI (16), bypass
graft (3), left main lesion (2), collaterals (5), lack of two
adequate orthogonal views > 30° (58), overlap or
foreshortening (35), no invasive blood pressure available
(15), unknown position of FFR pressure wire (11)
ILUMIEN I: Ely Pizzato
et al. (2019)19
405 (pre
and post
PCI)
65 Lesions Unavailability of at least two angiographic projections
(172; 42.5%), table movement while acquiring
angiographic images (104; 25.7%), angiography pixel/
resolution incompatibility (61; 15%), < 30° angle between
projections (26; 6.4%), multiple reasons (21; 5.2%), other
(calibration issues, missing SID value, CABG, occluded
vessel, total 21; 5.2%)
AF, atrial fibrillation; NR, not reported; TIMI, thrombolysis in myocardial infarction.
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TABLE 48 Mortality, morbidity and major cardiovascular outcomes from QAngio studies
Study Population Outcomes
Spitaleri et al. (2018)41 l NCL lesions in STEMI
patients (n= 110)
l QFR ≤ 0.80 group: at least one
untreated NCL with QFR
≤ 0.80 (n= 56)
l QFR > 0.80 group: all untreated
NCL with QFR > 0.80 (n= 54)
POCE (5 years):
l QFR ≤ 0.80: 46%
l QFR > 0.80: 24%
l HR 2.3 (95% CI 1.2 to 4.5; p = 0.01)
Cardiovascular death (at 5 years):
l QFR ≤ 0.80: 18%
l QFR > 0.80: 6%; p = 0.09
All-cause mortality (at 5 years):
l QFR ≤ 0.80: 21%
l QFR > 0.80: 9%; p = 0.1
Any reinfarction (at 5 years):
l QFR ≤ 0.80: 1%
l QFR > 0.80: 1%; p < 0.9
Any revascularisation (at 5 years):
l QFR ≤ 0.80: 25%
l QFR > 0.80: 14%; p < 0.9
Hamaya et al. (2019)23 l Stable CAD, three-vessel
disease (n = 549)
MACE (median 2.2 years):
l Patients with MACE had lower cQFR in all three
vessels than those without MACE [2.76 (95% CI
2.64 to 2.88) vs. 2.64 (95% CI 2.49 to 2.73);
p < 0.001]
l Three-vessel cQFR was a statistically significant
predictor of MACE in multivariate analyses
(HR 0.97, 95% CI 0.96 to 0.99). Other statistically
significant predictors –
¢ diabetes (HR 1.68, 95% CI 0.97 to 2.91)
¢ previous MI (HR 1.89, 95% CI 1.07 to 3.28)
¢ hs-cTnI (HR 1.48, 95% CI 1.13 to 1.91)
¢ multivessel disease (1.33, 95% CI 0.57 to 3.00)
¢ Gensini score (HR 0.996, 95% CI 0.98 to 1.01)
Remote revascularisation (≥ 3 months):
l cQFR – AUC 0.73 (95% CI 0.65 to 0.79)
l DS – AUC 0.66 (95% CI 0.56 to 0.74; p = 0.043)
Kanno et al. (2019),30
conference abstract
l Intermediate stenosis, de novo,
deferred revascularisation
(FFR > 0.8) (n = 212)
l Median FFR and cQFR: 0.87
l cQFR: 22.2%
MACE (4 years):
l 5.7% overall
l baseline cQFR in MACE – mean or mediana 0.80
l baseline cQFR in non-MACE – 0.87
l odds of MACE in cQFR ≤ 0.8 – OR 5.60 (95% CI
1.69 to 18.6; p = 0.005)
hs-cTnI, high-sensitivity cardiac troponin I.
a Not reported.
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TABLE 49 Adenosine and FFR procedures reduced: ‘grey-zone’ strategy models from included studies
Study Grey zone
Diagnostic accuracy of grey-zone
strategy (QFR vs. FFR)
Percentage of adenosine/
FFR procedures avoided
FAVOR II Europe–Japan:
Westra et al. (2018)50
0.77–0.86 Sensitivity and specificity > 95% 64
Kanno et al. (2019),29
conference abstract
0.73–0.84 PPV and NPV > 90% 52
Mejia-Renteria et al. (2019),37
Lauri et al. (2018)171
0.74–0.84 > 95% agreement 59
Smit et al. (2019)40 0.77–0.86 Sensitivity: 95%; specificity: 92.5% 61
WIFI II Westra et al. (2018)51 0.78–0.87 Sensitivity and specificity > 90% 68
0.71–0.90 Sensitivity and specificity > 95% 42
TABLE 50 Interobserver reliability results
Study Index test
Number of observations/
observers blinding Results
Cortés et al. (2019)17 QAngio XA
3D/QFR
(prototype)
20 selected patients assessed by
two analysts. No blinding reported
l r = 0.991 (95% CI
0.960 to 0.997)
FAST: Masdjedi et al. (2020)56
[CAAS vFFR]
CAAS vFFR 100 vessels assessed independently
by two blinded analysts
l r = 0.95
l MD 0.004 (SD 0.0236)
Hwang et al. (2019)24 QAngio XA
3D/QFR 1.2
30 randomly selected vessels
assessed independently by two
analysts
l MD 0.002
(SD 0.107) vs. 0.794
(SD 0.109); p = 0.919]
Ishihara et al. (2019),25
conference abstract
QAngio
(no further
details)
100 vessels (94 patients) assessed
independently by three analysts
twice
l ICC (mean value of
three raters) 0.614
(95% CI 0.464
to 0.728)
Jin et al. (2019),26 conference
abstract
QAngio XA
3D/QFR;
CAAS vFFR
101 vessels independently analysed
by two analysts
l fQFR: MD= 0.001 ±
0.036; p = 0.847
l cQFR: MD =−0.001 ±
0.049; p = 0.910,
l vFFR: MD=−0.005 ±
0.037; p = 0.393
Kajita et al. (2019),27 conference
abstract (data from
Hideo-Kajita et al.159)
QAngio XA
3D/QFR 1.0
34 vessels analysed by two analysts l fQFR: R2= 0.70
l cQFR: R2 = 0.82
l DS: R2 = 0.67
Kleczyński et al. (2019)33 QAngio XA
3D/QFR
2.1.12.2
NR l ICC 0.990 (95% CI
0.987 to 0.992)
Tu et al. (2014)45 QAngio XA
3D/QFR 1.0
10 randomly selected vessels
assessed independently by two
blinded analysts
l MD 0.01 (SD 0.03)
NR, not reported.
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TABLE 51 Intraobserver reliability results
Study Index test
Number of observations/
observers Results
Cliff and Ong (2019),16
conference abstract
QAngio XA
3D/QFR
17 anonymised lesions
reanalysed after 2 weeks
MD = 0.01 (0.05)
Cortés et al. (2019)17 QAngio XA
3D/QFR
(prototype)
20 lesions assessed by two
independent analysts
reanalysed oncea
r = 0.958 (95% CI 0.877 to 0.984)
Ishihara et al. (2019),25
conference abstract
QAngio (no
further details)
100 vessels (94 patients)
assessed independently by
three analysts twice
ICC per rater:
1 – 0.695 (95% CI 0.579 to 0.784)
2 – 0.820 (95% CI 0.733 to 0.879)
3 – 0.479 (95% CI 0.313 to 0.617)
Average of all three raters: ICC 0.806
(95% CI 0.711 to 0.869)
Intrarater reliability of
measurements: ICC = 0.428
Jin et al. (2019),26
conference abstract
QAngio XA
3D/QFR;
CAAS vFFR
101 vessels assessed by
two independent analysts
reanalysed oncea
cQFR: MD 0.009 ± 0.053; p = 0.230
fQFR: MD 0.016 ± 0.060; p = 0.066
vFFR: MD 0.008 ± 0.040; p = 0.175
Kajita et al. (2019),27
conference abstract
(data from
Hideo-Kajita et al.159)
QAngio XA
3D/QFR 1.0
34 vessels reanalysed after
1 week
fQFR: R2= 0.91
cQFR: R2= 0.94
DS: R2 = 0.76
Kleczyński et al.
(2019)33
QAngio XA
3D/QFR
2.1.12.2
NR ICC: 0.991 (95% CI 0.988 to 0.993)
Tu et al. (2014)45 QAngio XA
3D/QFR 1.0
10 randomly selected
vessels reanalysed after
1 week
Mean 0.00 (SD 0.03)
Ziubryte et al. (2019),54
conference abstract
QAngio XA
3D/QFR
69 lesions measured three
times with 3-day intervals
between measurements
r = 0.997 (p < 0.001)
NR, not reported.
a Duration between measurements and actual number of measurements analysed not reported.
TABLE 52 Patient and vessel exclusions and test failures from diagnostic accuracy studies
Study
Failed/
excluded, n % Unit Reasons (n or %)
QAngio (prospective studies)
FAVOR II Europe–Japan:
Westra et al. (2018)50
57 17 Patient Lesion > 90% and no additional lesions with FFR
measurement (8), no lesions > 30% apart (6), AF (1), acute
MI (1), ostial right coronary artery (1), stepdown (1),
protocol violation (7), FFR not measured (2), overlap (1),
poor image quality (3), projection < 25% apart (1), technical
issue (1), drift (9), damping (15). The authors stated that
bifurcation lesions were excluded but numbers were
not reported
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TABLE 52 Patient and vessel exclusions and test failures from diagnostic accuracy studies (continued )
Study
Failed/
excluded, n % Unit Reasons (n or %)
Toi et al. (2018),44
conference abstract
NR NR NR NR
van Rosendael et al.
(2017)48
NR NR NR NR
Watari et al. (2019)49 11 7 Vessel Non-optimal angiographic projections for QFR analysis (9)
or incomplete pressure wire measurement (2)
WIFI prototype study:
Andersen et al. (2017),14
conference abstract
NR NR NR NR
FAVOR II China:
Xu et al. (2017)52
29 9 Patients Two enrolled patients [three vessels, including data for
QFR (2), poor image quality (1)]. Withdrew informed
consent (4), atrial fibrillation during coronary angiography
(1), total occlusion lesion (1), lesion DS < 30% or > 90% in
all vessels (9), ineligible for diagnostic intervention or FFR
examination (12)
WIFI II: Westra et al.
(2018)51
190 52 Patient Lesion > 90% and no FFR measurement (51), no confirmed
lesion with DS > 30% (86), FFR not measured (34), drift
(4), dampening (5), no sign of adenosine effect (1), other
angiographic or procedural criteria (9)
Lesions excluded owing to unsuccessful QFR computation
(15), including: overlap at the lesion segment of interest
(6), excessive foreshortening in stenotic segments (7),
insufficient contrast flow quality (1) and inability to
contour a tight stenosis because of poor contrast filling (1)
QAngio (retrospective studies)
Cliff and Ong (2019),16
conference abstract
NR NR NR NR
Cortés et al. (2019)17 134 92 Patient Suboptimal angiographic images (46, of which 13 were
primary, 33 staged procedure), retrospective (88)
Emori et al. (2018)20 13 8 Patient Incomplete CAG (9), ostial lesions (3), collateral donor
artery (1)
Emori et al. (2018)21 6 6 Patient Incomplete coronary angiography (4), ostial lesion (1),
collateral donor artery (1)
FAVOR pilot: Tu et al.
(2016)46
15 17 Patient Excessive overlap of vessels (5), incomplete data (3),
excessive pressure wire drift (3), noisy angiograms (2),
< 25° apart (1), no sign induced hypermia (1)
Goto et al. (2019),22
conference abstract
NR NR NR NR
Hamaya et al. (2019)23 140 20 Patient Small (< 2mm) right coronary artery or left circumflex
coronary artery (52), arrhythmia during ICA (32), ineligible
coronary anatomy (98), insufficient image quality (10)
Hwang et al. (2019)24 127 35 Vessel Calibration failure (49), ostium lesion (35), insufficient
projection (25), tortuous vessel (7), overlapped vessel (7),
inadequate contrast filling (3), no iFR (1)
Ishihara et al. (2019),25
conference abstract
NR NR NR NR
continued
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
181
TABLE 52 Patient and vessel exclusions and test failures from diagnostic accuracy studies (continued )
Study
Failed/
excluded, n % Unit Reasons (n or %)
Jin et al. (2019),26
conference abstract
20 20 Patients Unsuitable coronary anatomy, invalid FFR measurements,
poor image quality and lack of two projections ≥ 25° apart
(20 total)
Kajita et al. (2019),27
conference abstract
NR NR NR NR
Kameyama et al.
(2016),28 conference
abstract
9 26 Vessel Poor angiographic images (9)
Kanno et al. (2019)29 NR NR NR NR
Kanno et al. (2019)30 NR NR NR NR
Kirigaya et al. (2019),31
conference abstract
NR NR NR NR
Kleczyński et al. (2019)33 NR NR NR NR
Kołtowski et al. (2018)32 551 64 Lesion Lack of proper angiographic projections (299). Other
reasons: bifurcation lesion (43), AF (41), vessel overlap/
shortening (37), low image quality (28), ostial lesion (26),
tandem lesion (21), collateral (18), bypass grafting (15)
Liontou et al. (2019)34 124 61 Vessels History of CABG, ostial left main or ostial right coronary
artery lesions, occlusive restenosis, bioresorbable scaffolds,
incompatibility of angiographic images (90). Lack of at least
two angiographic projections > 25° apart, severe vessel
tortuosity and/or overlap limiting QFR analysis (34)
Liu et al. (2017),35
conference abstract
NR NR NR NR
Mehta et al. (2019),36
conference abstract
NR NR NR NR
Mejia-Renteria et al.
(2019)37
101 26 Vessel Ostial in LM or right coronary artery (10), grafted target
vessels (2), inadequate projections (28), significant
overlapping (17), inadequate ICA quality (19), resting
haemodynamic data no available (6) contrast filling not
optimal for TIMI frame count analysis (19)
Neylon et al. (2016),38
conference abstract
NR NR NR NR
Sato et al. (2018),39
conference abstract
NR NR NR NR
Smit et al. (2019)40 52 13 Vessels Insufficient image quality (17), presence of a coronary
stent (4), excessive overlap and/or foreshortening of
coronary arteries (18), absence of angiographic views with
projection angles > 25° apart (6), ostial stenosis (5) or
aneurysm (2)
Spitaleri et al. (2018)41 31 41 Patients No successful PCI on culprit lesion (3), diffuse disease
in non-culprit vessel (8), severe tortuosity (2), vessel
< 2.5 mm (2), operator preferred not to perform FFR (16)
Stähli et al. (2019)42 43 9 Patients Lack of two projections 25° apart (24), insufficient image
quality (12), vessel overlap/shortening (10), low-contrast
filling (7), technical issues (4), plus 14 patients with
incomplete FFR measurement
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TABLE 52 Patient and vessel exclusions and test failures from diagnostic accuracy studies (continued )
Study
Failed/
excluded, n % Unit Reasons (n or %)
SYNTAX II: Asano et al.
(2019)15
341 29 Vessel No two appropriate projections (311), lumen diameter
< 2.0 mm (12), ostial lesion near aorta (4), other (14)
Ties et al. (2018)43 232 70 Vessel Lack of basic requirements (200), insufficient image quality
(17), inappropriate reference diameter function (8),
overlap/foreshortening (5), no perpendicularity (1), true
bifurcation (1)
Tu et al. (2014)45 3 4 Vessel Too much overlap or foreshortening (> 90%), insufficient
image quality, mean pressure of the guiding catheter or
blood haematocrit value not documented
Van Diemen et al.
(2019),47 conference
abstract
266 48 Vessels No FFR (72). QFR analysis succeeded in 286 (52%) of the
remaining 552 arteries. No further details reported
WIFI II: Westra et al.
(2018)51
190 52 Patient Lesion > 90% and no FFR measurement (51), no confirmed
lesion > 30% (86), FFR not measured (34), drift (4),
dampening (5), no sign of adenosine effect (1), other
angiographic or procedural criteria (9)
Lesions excluded owing to unsuccessful QFR computation
(15), including: overlap at the lesion segment of interest
(6), excessive foreshortening in stenotic segments (7),
insufficient contrast flow quality (1) and inability to
contour a tight stenosis because of poor contrast filling (1)
Yazaki et al. (2017)53 20 12 Vessel Lacking two optimal angiographic projections at least 25°
apart, overlapping vessels, no preferred references in
proximal or distal vessels, insufficient contrast, target
lesion at ostium of left or right artery
Ziubryte et al. (2019),54
conference abstract
NR NR NR NR
CAAS vFFR
FAST-EXTEND: Daemen
et al. (2019)18
NR NR NR NR
FAST: Masdjedi et al.
(2020)56 [CAAS vFFR]
170 63 Patients Inadequate pressure waveform (25), STEMI (16), bypass
graft (3), left main lesion (2), collaterals (5), lack of two
adequate orthogonal views > 30° (58), overlap or
foreshortening (35), no invasive blood pressure available
(15), unknown position of FFR pressure wire (11)
ILUMIEN I: Ely Pizzato
et al. (2019)19
405 (pre
and post
PCI)
65 Lesions Unavailability of at least two angiographic projections
(172, 42.5%), table movement while acquiring angiographic
images (104, 25.7%), angiography pixel/resolution
incompatibility (61, 15%), < 30° angle between projections
(26, 6.4%), multiple reasons (21, 5.2%), other (21, 5.2%)
AF, atrial fibrillation; LM, left main coronary artery disease; NR, not reported; TIMI, thrombolysis in myocardial infarction.
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TABLE 53 Timing of QFR results
Study Design Population Index test Data acquisition duration
WIFI prototype:
Andersen et al. (2017),14
conference abstracta
Prospective/
retrospective
n = 93; unselected,
consecutive
population
referred to FFR
QAngio
(prototype)
l Mean total time to QFR:
10 minutes (SD 3)a
Kołtowski et al. (2018)32 Retrospective n = 306 lesions
(268 patients);
stable CAD,
intermediate
stenosis
QAngio XA
3D/QFR
(model NR)
Substantially decreased with
number of analysed cases
l First 50 cases: mean 5 minutes
59 seconds (IQR 5 minutes
5 seconds to 6 minutes 43 seconds)
l Last 50 cases: mean 2 minutes
7 seconds (IQR 1 minute
47 seconds to 2 minutes 28 seconds)
Tu et al. (2014)45 Retrospective n = 77 vessels
(68 patients)
QAngio XA
3D/QFR
1.0
l The complete analysis took
< 10 minutes, including
approximately 1 minute per
bifurcation reconstruction,
including the time required by user
interaction, 1 minute was to
generate the interior meshes after
3D and 5 minutes for the CFD
simulation on a workstation
FAVOR II China:
Xu et al. (2017)52
Prospective n = 330 vessels
(306 patients)
QAngio
(AngioPlus)
l 4.36 (SD 2.55) minutes (including 3D
angiographic reconstruction and
frame count analysis)
Yazaki et al. (2017)53 Retrospective n = 151 vessels
(142 patients)
QAngio XA
3D/QFR
l Median 4.43 minutes (IQR
3.01–5.53 minutes) including time
selecting two angiographic images
FAVOR II
Europe–Japan:
Westra et al. (2018)50
Prospective n = 295 lesions QAngio XA
3D/QFR
l Median 5.0 minutes (IQR
3.5–6.1 minutes) vs. FFR 7.0 minutes
(IQR 5.0–10.0 minutes); p< 0.001
l Including time for selection of a
different view where needed, and
excluding transfer time from
angiographic equipment to the
QFR workstation
l FFR time excluded time for
preparing and zeroing
pressure system
CFD, computational fluid dynamic; IQR, interquartile range; NR, not reported.
a The application required essential modifications during the study and blinded in-centre core laboratory (QFR and 3D
quantitative coronary angiography) reanalysis was performed with the final version of QFR. It was not clear which
analysis informed these results.
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184
Appendix 6 Further simulation study results
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FIGURE 43 Simulation study: MACEs prevented.
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FIGURE 42 Example simulation MACEs. The upper-left shaded region shows the FNs where QFR > 0.8 but FFR ≤ 0.8;
the lower-right shaded region shows the FPs where QFR ≤ 0.8 but FFR > 0.8.
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Appendix 7 Review of decision models
evaluating invasive coronary angiography
Search strategies
QAngio literature: cost-effectiveness 18 October 2019
Database search strategies
Database searches were carried out to identify cost-effectiveness studies in which ICA (alone and/or
with FFR) was one of the interventions under comparison.
Databases searched: EconLit (via Ovid), EMBASE (via Ovid), HTA database (via CRD), MEDLINE, NHS
EED (via CRD).
Total number of records identified: 1740.
Total number of records identified after deduplication in EndNote X.9.2 (Clarivate Analytics)
bibliographic software: 1264.
EconLit (via Ovid)
Search date: 18 October 2019.
Date range searched: 1886 to 3 October 2019.
Records retrieved: 2.
Search strategy
1 coronary angiograph$.mp. (2).
EMBASE (via Ovid)
Search date: 18 October 2019.
Date range searched: 1974 to 17 October 2019.
Records retrieved: 858.
Search strategy
1. *Coronary Angiography/ (3060)
2. coronary angiography.ti,ab. (50,830)
3. 1 or 2 (51,869)
4. Economics/ (234,606)
5. Cost/ (57,396)
6. exp Health Economics/ (818,928)
7. Budget/ (27,893)
8. budget*.ti,ab,kw. (37,185)
9. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ti,kw. (268,523)
DOI: 10.3310/hta25560 Health Technology Assessment 2021 Vol. 25 No. 56
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Duarte et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
187
10. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ab./freq = 2 (382,513)
11. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kw.
(216,418)
12. (value adj2 (money or monetary)).ti,ab,kw. (3124)
13. Statistical Model/ (157,315)
14. economic model*.ab,kw. (4585)
15. Probability/ (97,263)
16. markov.ti,ab,kw. (27,735)
17. monte carlo method/ (37,601)
18. monte carlo.ti,ab,kw. (46,807)
19. Decision Theory/ (1711)
20. Decision Tree/ (11,762)
21. (decision* adj2 (tree* or analy* or model*)).ti,ab,kw. (31,964)
22. or/4-21 (1,560,379)
23. 3 and 22 (1858)
24. limit 23 to yr = “2000 -Current” (1596)
25. limit 24 to embase (858).
Health Technology Assessment database
Searched via the CRD’s website (URL: www.crd.york.ac.uk/CRDWeb).
Search date: 18 October 2019.
Date range searched: inception to 1 October 2019.
Records identified: 62.
Search strategy
MEDLINE (via Ovid)
Search date: 18 October 2019.
Records identified: 665.
Date range searched: 1946 to 17 October 2019.
Search strategy
1. *Coronary Angiography/ (18,583)
2. coronary angiography.ti,ab. (30,052)
3. 1 or 2 (41,395)
4. Economics/ (27,093)
5. exp “Costs and Cost Analysis”/ (229,217)
6. Economics, Nursing/ (3994)
7. Economics, Medical/ (9035)
8. Economics, Pharmaceutical/ (2894)
9. exp Economics, Hospital/ (23,942)
10. Economics, Dental/ (1908)
11. exp “Fees and Charges”/ (29,932)
12. exp Budgets/ (13,585)
13. budget*.ti,ab,kf. (28,234)
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14. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ti,kf. (218,635)
15. (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*
or pharmaco-economic* or expenditure or expenditures or expense or expenses or financial or
finance or finances or financed).ab./freq = 2 (272,429)
16. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.
(152,531)
17. (value adj2 (money or monetary)).ti,ab,kf. (2256)
18. exp models, economic/ (14,432)
19. economic model*.ab,kf. (3128)
20. markov chains/ (13,736)
21. markov.ti,ab,kf. (21,125)
22. monte carlo method/ (27,269)
23. monte carlo.ti,ab,kf. (46,880)
24. exp Decision Theory/ (11,629)
25. (decision* adj2 (tree* or analy* or model*)).ti,ab,kf. (22,091)
26. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 (696,909)
27. 3 and 26 (855)
28. limit 27 to yr = “2000 -Current” (665).
NHS Economic Evaluation Database
Searched via CRD website (URL: www.crd.york.ac.uk/CRDWeb).
Search date: 18 October 2019.
Date range searched: inception to 1 October 2019.
Records identified: 161.
Search results and excluded studies
TABLE 54 Results of the search
Database
Number of records retrieved
before deduplication
Number of records
after deduplication
MEDLINE Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE
Daily and Ovid MEDLINE
665 660
EMBASE (via Ovid) 858 468
EconLit (via Ovid) 2 1
NHS EED 161 87
HTA 62 48
Total in EndNote 1748 1264
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TABLE 55 Summary of excluded studies
Study Reason for rejection
Bosch et al. (2005) Different patient population (acute coronary syndrome)
Goehler et al. (2011) Different patient population (acute chest pain) and does not include long-term outcomes
Kent et al. (2013) Different patient population (NSTEMI)
Nam et al. (2015) Different patient population (NSTEMI)
Full references of the excluded studies are available on request.
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Studies included in the review and extracted data
TABLE 56 Summary of included studies
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Amemiya and
Takao (2009),69
Brazil
1. No examination and no
treatment – patients
receive testing and
treatment only when a
cardiac event occurs that
requires revascularisation
or conservative
treatment (medication)
2. Medication – all patients
receive medication for
CAD, but undergo no
tests, and are not
revascularised until a
cardiac event occurs
3. Routine ICA followed
by optimal treatment
including elective
revascularisation – all
patients undergo ICA
and those with a positive
test result receive
medication for CAD.
All patients with LM
require revascularisation.
For other vessel diseases,
14.5% underwent elective
revascularisation within
the first year
4. CCTA – all patients
undergo CCTA and those
with a positive test result
receive medication for
l Men aged 60 years with a
history of chest pain, but
without a definitive
diagnosis of CAD
l Pretest probability of
CAD: 50%
l Decision tree plus
Markov model
l Lifetime horizon
l Decision tree classifies
patients in each strategy
according to disease
severity category
(no CAD, one-, two- or
three-vessel disease/LM),
test given to all patients
(none, ICA or CCTA)
and attributes a
treatment (no medication,
medication, medication/
revascularisation).
Patients enter the Markov
model after treatment
l Markov model: healthy
(no CAD), angina, angina
free, post MI, post PCI/
CABG with or without
angina, dead
l People without CAD remain
healthy until death
l For patients who undergo
revascularisation, those with
one- or two-vessel disease
receive PCI, and those with
three-vessel disease or
left main trunk disease
receive CABG
l For patients with CAD the
risks of death, non-fatal MI
and revascularisation, and
proportion of patients with
relief of angina are modified to
different extents by medication.
PCI and CABG are assumed
more effective than medication
for up to 10 years. Annual
rates of cardiac events after
revascularisation are calculated
separately for the first year
and for the following 9 years
l All live patients had a health
state utility of 1, except those
in the angina and post-MI
states, who had a utility of 0.88
l A probability of ICA
complications is reported, but
it is unclear if this has an
impact on costs or HRQoL
l Misclassification is not modelled
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
CAD, some of whom
go on to elective
revascularisation. If
revascularisation is
planned, the patient will
have ICA for further
evaluation as a work-up
study; 12% of CCTA-
positive patients would
also undergo ICA, but
not revascularisation
Bertoldi et al.
(2016),68 Brazil
1. Ex-ECG plus stress
ECHO plus ICA
2. Ex-ECG plus CCTA
plus ICA
3. Ex-ECG plus SPECT
plus ICA
4. Ex-ECG plus ICA
5. SPECT plus ICA
6. Stress ECHO plus ICA
7. Stress ECHO plus CCTA
plus ICA
8. Stress CMR plus ICA
9. CCTA plus ICA
10. ICA plus stress ECHO
11. ICA plus SPECT
l Patients progress to the
next test if results of the
previous one are positive
or inconclusive. ICA is the
reference test. A positive
result at the last test in
the sequence classifies
the patient as moderate
(one- or two-vessel CAD)
l Patients aged 60 years at
risk of stable CAD
l Pretest probability of
CAD: 50%
l Decision tree plus
Markov model
l Lifetime horizon
l The decision tree classifies
patients into CV risk
categories, based on the
results of testing strategy,
and whether or not they
were correctly classified
in their risk category.
The risk categories are
high risk, moderate risk,
low risk, high risk with FN,
moderate risk with FN
and low risk with FP
l Markov model: stable,
CV event, PCI or CABG,
CV death, cancer death
and other-cause death
l ICA is a perfect test
l No indeterminate results from
the last test in the strategy
l 10% of initially misdiagnosed
cases are correctly rediagnosed
in the first year, with increasing
numbers until the 10th year,
by which time all have been
properly rediagnosed
l TN patients have a low risk of CV
events and of revascularisation;
TP patients have a higher risk of
CV events and lead to more
revascularisation procedures. FN
patients have a high risk of CV
events but are misdiagnosed as
low risk, which further increases
CV risk but results in fewer
revascularisation procedures.
FP patients have low risk of CV
events, but misdiagnosis leads
to more revascularisation
procedures
l Procedure-related mortality is
considered for PCI and CABG
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
or high risk (three-vessel
disease or associated left
ventricular dysfunction).
Patients who test negative
are classified as low risk
(without significant CAD).
Treatment is not specified
based on risk category but
rates of revascularisation
(PCI and CABG) vary
across risk categories
l The proportion of patients who
undergo CABG among those
who receive revascularisation
is assumed to vary across
risk categories
l Disutility is incurred when
patients have PCI, CABG and MI
l CCTA, SPECT and ICA are
assumed to have an average
radiation dose of 10 mSv
that increases the lifetime
risk of cancer after a 10-year
latency period
Boldt et al. (2013),78
Germany
1. CMR plusICA
2. SPECTplus ICA
3. ICA
l Patients progress to the
next test if results of the
previous one are positive
or inconclusive. ICA is the
reference test
l Patients with
suspected CAD
l Pretest probability of
CAD: 10–100%
l Bayesian
mathematical model
l 10-year horizon
l Two sets of equations
allow estimating the
mean total costs and
incremental QALY. No
health states are defined
l ICA is a perfect test
l A correct diagnosis of CAD
is assumed to increase the
number of QALYs by 3 years
over the time horizon
l The annual mortality rate
varies according to the tests
received by the patient and
whether or not CAD-positive
patients were incorrectly
classified as negatives.
Complications associated with
test procedures include death
and MI. Procedure-related
death are assumed to subtract
10 years of life, while deaths
caused by FN (missed CAD)
subtract 5 years
l A disutility of 0.1 was applied
annually for complications
caused by test and missed CAD
l Only short-term costs
associated with tests and test
procedural complications (MI)
are included
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Burgers et al.
(2017);71 Westwood
et al. (2013),79 UK
1. ICA
2. NGCCT
3. NGCCT plus ICA–only
NGCCT-positive patients
undergo further testing
with ICA
l Patients with known or
suspected CAD, who are
difficult to image for the
following reasons: obese,
coronary calcium score of
> 400, arrhythmias, previous
revascularisation, heart rate
of > 65 beats per minute,
and intolerance of
beta-blockers
l The two populations (known
CAD and suspected CAD)
are evaluated separately
l Pretest probability of CAD:
10–29% for suspected CAD
and 39.5% for known CAD
l Decision tree plus four
Markov models
l Lifetime horizon
l The decision tree divides
the patient cohort
according to classification
according to ‘true’ disease
status, test results,
treatment options and
immediate complications
from revascularisation
and testing procedures.
Patients with suspected
CAD then enter the:
i. CAD progression model
if they are TP or FN,
and have not suffered
a stroke due to ICA
or revascularisation
ii. Stroke model if they
have a procedure-
related stroke
iii. General population
model if they are TN
or FP, and have not
suffered a stroke due to
the tests.This model
only accrues QALYs
l For the known CAD
population, the key
difference is that TN all
have CAD and enter the
CAD progression model if
they have not suffered a
stroke due to the tests
l All patients accrue costs
and disutility due to
radiation-induced cancer
based on the radiation
dose of the diagnostic
l ICA is a perfect test
l Rates of revascularisation
following the test pathway
for patients with CAD were
assumed the same as those of
a previous study, despite the
differences between study
populations. The suspected
CAD population had three
treatment options (PCI, CABG
and medication), whereas the
known CAD population could
be treated only with CABG
or a PCI. The proportion of
patients undergoing each
treatment was based on
expert opinion. The baseline
probabilities in the CAD
progression model depend
on the treatment received
(medication, CABG or PCI).
The probability of non-fatal CV
events varies with time. Risk
equations are derived from the
EUROPA trial90 and adjusted to
reflect the study populations.
Four equations allow
estimating the probabilities of
(1) any event that will occur in
a cycle (3 months), (2) that
event being fatal, (3) a
subsequent event in the first
year after a first non-fatal
event and (4) a subsequent
event after 1 year
l A proportion of the FN
patients are identified as TP
every cycle in the CAD
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
tests and treatments,
through the radiation
model
l CAD progression model:
start, CV death, non-fatal
primary event in current
year (MI/cardiac arrest),
history of non-fatal event,
and non-CV death
l Stroke model: alive or dead
l Radiation model: no
health states. The model
keeps track of cumulative
radiation exposure and
estimates risk of cancer
and cancer-related death.
The model also estimates
the costs and QALYs
for patients who
develop cancer
l General population: alive
or dead
progression model, and are
treated accordingly. Their
prognosis is the same as for TP
patients who were identified
directly by the diagnostic test
l The diagnostic accuracy
estimates differ for the
different difficult-to-image
groups
l The baseline characteristics
used to parameterise risk
equations in the CAD
progression model were
informed by the patient
characteristics in the diagnostic
accuracy studies. These
characteristics differed by
population and difficult-to-
image groups
l The model distinguishes
between ICA and
revascularisation complication
rates. When a PCI is
performed after an ICA,
the mortality of PCI only is
used (PCI is assumed to be
performed at the same time
as ICA)
l HRQoL in the model was
based on age, sex, baseline
CCS classification and
whether or not the patient
had undergone treatment.
A utility decrement was
assumed for non-fatal events
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Espinosa and
Annapragada
(2013),76 USA
1. ICA only
2. CCTA using conventional
iodine-based contrast
agent plus ICA
3. CCTA using a BPCA
plus ICA
l Patients progress to the
next test if results of the
previous one are positive.
ICA is the reference test
l Treatment conditional
on test results is not
considered in the model
l Men aged 55 years with
a history of chest pain,
presenting at an emergency
department with acute chest
pain, normal cardiac enzyme
levels and either non-
diagnostic or normal
ECG results
l Pretest probability of
CAD: 30%
l Decision tree
l 1-year time horizon
l The decision tree splits
patients according to
testing complications, and
then by classification
according to ‘true’ disease
status and test results
l ICA is a perfect test
l CAD positivity was defined as
luminal stenosis of ≥ 50%
l The diagnostic accuracy of
CCTA with BPCA was
assumed the same as with a
conventional contrast agent
l It was assumed that patients
were not screened for renal
comorbidities prior to testing
l The complications from ICA
include MI, stroke, ventricular,
arrhythmias, local vascular
injury, contrast agent reactions
or nephropathy. However,
only mortality seems to be
considered in the model.
CV events over the follow-up
period are considered and
conditional on patient
classification (TP, FP, FN or TN).
Patients who have a CV event
have an additional mortality
risk over the time horizon
l Utility weights were attributed
to patients according to their
classification as TP, FP, FN or
TN, with a disutility incurred
by those who experience a
CV event. It is unclear when
events are assumed to incur
(and, thus, for how long
disutility is applied)
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Fearon et al.
(2003),87 USA
1. Nuclear stress imaging
2. FFR
3. No testing (stent all
intermediate lesions)
l All patients undergo ICA
(not reference test).
Strategy 1 implies
delaying PCI until the test
is performed, whereas the
other two strategies do
not impose further delays
to revascularisation
l Strategy 3 does not
consider any further
testing, with all patients
receiving PCI
l Patients tested with
nuclear stress imaging
receive PCI if ischaemia
is detected and have
to return to the
catheterisation
laboratory; those without
ischaemia are treated
with medication
l 55-year-old patients with
chest pain who underwent
coronary angiography before
stress perfusion imaging, and
who had an intermediate
coronary lesion of unclear
physiological significance.
The population only
includes patients with
one-vessel disease
l Pretest probability of
functional ischaemia: 40%
l Decision tree
l Lifetime horizon
l The decision tree
illustrates the diagnostic
pathway and subsequent
treatment. Patients who
are tested with FFR
receive PCI if the
FFR is < 0.75 and
medication otherwise
l It is unclear what the
reference test is. Nuclear
stress imaging is assumed to
have the same diagnostic
accuracy as FFR (88%
sensitivity and 96% specificity)
l Deferral of PCI owing to
nuclear imaging results in
additional hospital costs, but
not to prognostic changes
l The model assumes that 30%
of patients would have angina
relief with medical therapy and
70% of patients with PCI.
Angina relief would be
maintained for 4 years, and the
quality-of-life adjustment for
living with angina was 0.9.
A risk of death was assumed
for PCI, regardless of whether
it was deferred or performed
immediately
l FFR also had increased the risk
of death
l It is assumed that survival of
patients remains the same,
regardless of treatment.
However, HRQoL is higher for
those who obtain angina relief.
The quality-adjusted survival
benefits are considered in the
model as a QALY pay-off.
Lifetime costs are considered
in a similar manner
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Genders et al.
(2009),83 UK, USA,
the Netherlands
1. CCTA plus ICA
2. ICA
l In strategy 1, only
patients with positive
CCTA undergo ICA.
Patients who test
positive in the last
test in the sequence,
are treated with a
combination of
medication, PCI
and CABG
l Patients with
suspected CAD
l Pretest probability of
CAD: < 40%
l Decision tree plus
Markov model
l Lifetime horizon
l The decision tree splits
patients according to
whether or not they
survive the test, and then
by classification according
to ‘true’ disease status
and test results
l Markov model: alive, CV
event, post-CV event, CV
death, non-CV death
l CV events included
coronary death, MI,
coronary insufficiency,
angina, stroke, cardiac
arrest, peripheral arterial
disease and heart failure
l ICA is a perfect test
l Diagnostic accuracy was
assumed to be independent
of age, sex, risk factors
and presentation
l Significant CAD was defined as
a luminal diameter reduction
of ≥ 50%
l Risk of CV events and death
l Treatment is assumed to
reduce the rates of CV events.
The model allows for
reintervention, but it is not
clear what this consists of or
how it is implemented in
the model
l Untreated CAD patients (FNs)
have higher rates of CV events
and lower HRQoL due
to angina
l FN patients are assumed to
remain undiagnosed and
untreated until they have a CV
event (after which they would
be correctly diagnosed and
treated as FP)
l CV events are associated with
a utility decrement
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Genders et al.
(2015),74 UK, USA,
the Netherlands
1. No imaging
2. CCTA (plus FFR)
3. CSI
4. CCTA plus CSI
5. ICA (plus FFR)
l In strategy 4, only
patients with positive
CCTA follow through to
CSI. In all strategies, FFR
is performed only if CSI
was not done before CAG
l All strategies were analysed
as both conservative and
invasive diagnostic work-
ups. In the invasive
diagnostic work-up,
patients with obstructive
CAD on CCTA (≥ 50%
stenosis in ≥ 1 vessel,
regardless of severity) and
patients with inducible
ischaemia CSI (regardless of
severity) were referred for
ICA. In the conservative
diagnostic work-up,
patients with moderate
CAD on CCTA or mild
inducible ischaemia on CSI
received OMTwithout
referral to ICA
l CSI includes CMR, SPECT
and stress ECHO
l Treatment was dependent
on disease severity: risk
factor management in
patients with normal
coronary arteries, mild
CAD, and moderate CAD
l 60-year-old patients with
stable chest pain and
without a history of CAD,
PCI or CABG
l Pretest probability of
CAD: 30%
l Microsimulation model
comprising a decision tree
plus state-transition
model
l Lifetime horizon
l Decision tree divides the
cohort according to
disease severity, test
results and subsequent
treatment
l State-transition model:
alive, post MI, dead
l ICA is a perfect test
l The MACE (revascularisation,
non-fatal MI and cardiac death)
risk was dependent on disease
severity and modified by treatment
l FN patients were assumed to
return to their physicians with
persistent symptoms, have
additional testing, and began
receiving appropriate treatment
within the first year (except for
patients with moderate CAD
without ischaemia, for whom
it was assumed that only
25% returned)
l Patients without obstructive
CAD and without inducible
ischaemia had age- and sex-
adjusted general population
HRQoL. Patients with CAD and
on treatment had treatment-
specific utility values sourced
from clinical trial data
l The model considers procedural
complications (death and MI), but
does not distinguish between
test and treatment-related
complications
l The model estimates cumulative
radiation exposure for each
pathway, but does not model the
effects of radiation exposure
l CCTA was assumed to produce
incidental findings of
indeterminate clinical importance
that resulted in additional
radiation exposure, decreased
HRQoL and increased diagnostic
costs (due to follow-up testing)
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
without ischaemia; OMT
for patients with mild
ischaemia and moderate
to severe CAD; PCI for
patients with severe CAD
and severe ischaemia; and
CABG for patients with
three-vessel disease or LM
Goeree et al.
(2013),75 Canada
1. CCTA plus ICA
2. ICA
l In strategy 1, only
patients with positive
CCTA undergo ICA. All
patients identified with
CAD receive treatment
l Patients with
suspected CAD
l Pretest probability of
CAD: 30%
l Decision tree plus
Markov model
l Lifetime horizon
l The decision tree splits
patients according to
whether or not they
survive the test, and then
by classification according
to ‘true’ disease status
and test results
l Markov model: no event,
CV event (MI first year),
subsequent CV event
(MI), death
l ICA is a perfect test
l Treatment is assumed to be a
combination of medication,
CABG and PCI, and to reduce
the rate of CV events
l Testing is assumed to have no
impact on HRQoL, but both
tests have an associated
mortality risk
l CV events and mortality
rates depend on on age, sex,
whether or not CAD was
previously diagnosed and
treated (past or current),
whether or not the patient had
a FN diagnosis, and whether or
not the patient had a previous
MI (increased increased risk of
a subsequent MI and death)
l The ‘no event’ health state
considers different HRQoL
estimates depending on whether
patients had CAD or not, and if
they had CADwhether they
were receiving treatment
(controlled symptoms) and or not
(undiagnosed CAD). Occurrence
of CV events result on disutility
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Hayashino et al.
(2004),88 USA
1. No screening
2. Ex-ECG plus ICA
3. Exercise ECHO plus ICA
4. SPECT plus ICA
l For all strategies involving
two tests, only patients
who test positive on
the first test receive
the second test in the
sequence. Patients who
tested negative or were
not screened received no
specific therapy. Treatment
conditional on ICA results
was PCI for patients with
one- or two-vessel CAD on
angiography underwent
and CABG for patients
with three-vessel disease
or LM
l Asymptomatic 55-year-old
men with diabetes, two
additional atherogenic risk
factors (smokers and
hypertension), without a
history of angina/MI, and
suspected CAD
l Pretest probability of
CAD: 23.5%
l Decision tree plus
Markov model
l 30-year horizon
l The decision tree
structure is not described,
but the model appears to
split patients according to
disease severity (no CAD,
one-, two- or three-vessel
disease/LM), and considers
whether or not the
patients have silent
ischaemia (not treated
under strategy 1)
l Markov model: normal
(no CAD), silent
ischaemia, symptomatic
ischaemia, history of MI,
post PCI, post CABG
and death
l All patients received aspirin
and simvastatin
l Patients with MI develop
relevant symptoms and receive
the appropriate treatment, and
patients with silent myocardial
ischaemia do not receive
specific therapy
l Patients with silent myocardial
ischaemia detected by initial
screening and patients with
symptomatic myocardial
ischaemia developing in the
years following screening
received PCI or CABG
l Patients with FN results by
screening tests and those with
silent myocardial ischaemia
developing in the years
following do not receive
specific therapy
l PCI and CABG reduces late MI
with revascularisation, and
annual risk of revascularisation.
CABG also reduces the risk
of death
l The model considers
procedural complications
(death and non-fatal MI)
for ICA, PCI and CABG.
The rate of complications is
independent of number of
vessels involved for ICA,
but not for PCI
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Hernandez and
Vale (2007);85
Mowatt et al.
(2004),86 UK
1. Ex-ECG plus SPECT
plus ICA
2. Ex-ECG plus ICA
3. SPECT plus ICA
4. ICA
l Patients progress to the
next test if results of the
previous one are positive
or inconclusive. ICA is the
reference test. Treatment
is not specified based on
risk category, but rates
of revascularisation
(PCI and CABG) vary
across risk categories
l Patients aged 60 years
with chest pain and
suspected CAD
l Pretest probability of
CAD: 10.5%
l Decision tree plus
Markov model
l 25-year time horizon
l The decision tree
classifies patients into CV
risk categories, based on
the results of testing
strategy, and whether or
not they were correctly
classified in their risk
category. The risk
categories are low risk,
medium risk, high risk, FN
(high risk), FN (medium
risk) and FP (medium
risk). It also accounts for
death due to either tests
or revascularisation
procedures for patients
identified as being at high
or moderate risk
l Markov model: low risk,
medium risk, high risk, FN
(high risk), FN (medium
risk), FP (medium risk),
revascularisation,
MI, death
l ICA is a perfect test
l All misclassified patients
correctly diagnosed over a
10-year period as a result
of an additional scan or a
non-fatal MI
l Mortality and MI risk varies by
risk category
l Procedure-related mortality is
considered for PCI and CABG
l The proportion of patients who
undergo CABG among those
who receive revascularisation
is assumed to vary across
risk categories
l PCI and CABG reduce
mortality and MI risk, but to
different extents
l It is assumed that patients
who have a MI or are
revascularised will lose some
HRQoL for the subsequent
3 months. Revascularisation
does not result in an
improvement of HRQoL
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Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Kreisz et al.
(2009),84 Australia
1. CCTA plus ICA
2. ICA
l Patients progress to the
next test if results of the
previous one are positive.
ICA is the reference test.
Treatment is not specified
based on test results
l Individuals with suspected
significant obstructive CAD
l Pretest probability: 10–90%
l Decision tree
l 10-year time horizon
l The decision tree splits
the cohort according
to the results of CCTA,
and whether or not they
were correctly classified
(TN, FN,TP or TP). Patients
who undergo ICA [directly,
as a confirmatory test (TP
and FPwith strategy 1) or
as a late referral (FP for
strategy 1)] are split into
three categories: no
complications, complications
and death
l ICA is a perfect test
l ICA complications include
acute MI, major vascular
complications requiring
surgery, transient ischaemic
attack, major and minor stroke,
and death. Although the risk of
complications is stated to be
associated with pretest
probability of CAD in the study
populations, the authors
assumed the same rate of
complications to be
independent of CAD pretest
probability in the base case
l Patients with CAD who are
correctly diagnosed are
assumed to have a higher
HRQoL for the full time
horizon due to appropriate
treatment. FN have 3 months
with a lower HRQoL, after
which they are assumed to be
tested with ICA and receive
appropriate treatment. The
model does not appear to
account for any long-term
differences in mortality
between strategies. The
majority of complications from
ICA cause temporary disutility.
Major stroke is the only
complication that causes a
permanent loss in utility. It is
unclear what utility weight is
attributed to individuals who
are TN
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Ladapo et al.
(2009),82 USA
1. CCTA plus ETT
2. ETT plus CCTA
3. CCTA
4. ETT
5. Stress ECHO
6. SPECT
7. ICA
l No diagnostic testing
l In strategy 1, all patients
are tested with CCTA,
and those identified as
having severe CAD
(three-vessel or LM) are
tested with ICA. Positives
on ICA are treated with
medical therapy and
revascularised (PCI or
CABG). Patients with
one- or two-vessel CAD
according to CCTA are
tested with Ex-ECG, and
those who test positive
and markedly abnormal
on ETT are treated with
medical therapy and
revascularised after
confirmatory ICA. Those
with of one- or two-vessel
CAD according to CCTA
whose stress test results
are positive but not
l 55-year-old individuals with
stable chest pain and
suspected CAD
l Pretest probability: 30% and
70% (men and women,
respectively)
l Microsimulation
l Lifetime horizon
l The simulation model
tracks patients through
the diagnostic pathways
defined by each strategy.
Patients then enter a
natural history model,
where they can
experience non-fatal
adverse (MI and stroke)
events, medical and
surgical interventions,
and death
l The model also considers
incidental findings of
pulmonar nodes
with CCTA
l ICA is a perfect test
l Patients were assumed to have
no prior history of CAD, MI,
atrial fibrillation, diabetes
mellitus or LM
l The distribution of CAD,
proportion of mildly stenosed
arteries, number and position of
vessels affected was assumed to
vary depending on sex
l CAD is defined as a ≥ 50%
stenosis in the left main coronary
artery or ≥ 70% stenosis in any
other coronary artery
l The model considers mortality
risks associated with testing
procedures, PCI, CABG, repeat
revascularisation and pulmonary
procedures (follow-up on
incidental findings). Rates of
revascularisation were higher for
patients managed initially with
aggressive medical therapy alone
or with bare metal stent-based
PCI, and these were lower for
patients managed with drug-
eluting stents and CABG
l The model assumes that
patients with CAD who are FN
have a constant 5% annual
probability of being correctly
diagnosed
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
markedly abnormal are
initially managed with
medical therapy alone.
Patients without
significant CAD based on
CCTA receive baseline
care. When the results of
the CCTA differ from
those of the ETT are
treated with e-medical
therapy only patients with
a post-test probability of
disease exceeding 50%
are treated
l In strategy 2, all patients
are tested with ETT.
Patients with markedly
abnormal results are
tested with ICA, and
positives are treated with
medical therapy and
revascularisation. Patients
whose ETT is positive but
not markedly abnormal
receive a CCTA test, and
those with severe CAD
are further tested with
ICA and positives are
treated as above. Patients
with one- or two-vessel
CAD according to CCTA
are initially treated with
medication alone. Patients
not found to have CAD
receive baseline care
l Treatment for CAD reduces
mortality and rate of CV
events compared with
untreated CAD. Treatment
effects on mortality depend on
the number of vessels and
location of stenosis
l It was assumed that lung
nodes had no direct impact
on survival
l HRQoL estimates depended on
whether or not patients had
CAD and its severity, as well as
the incidence of non-fatal CV
events and angina relief from
treatment. The combination of
aggressive medical therapy
with PCI or CABG was
assumed more effective in
relieving angina symptoms,
than aggressive medical
therapy alone, and that CABG
was marginally more effective
than PCI
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
l In strategy 3, all patients
are tested with CCTA,
and those considered to
have significant CAD are
tested with ICA. Patients
with one- or two-vessel
CAD according to ICA
receive medical therapy
alone; those with three-
vessel disease and LM
receive medical therapy
plus revascularisation.
Patients not found to
have CAD receive
baseline care
l In strategy 4, all patients
whose ETT is positive but
not markedly abnormal
are treated with
medication alone. Those
who test positive and
markedly abnormal on
Ex-ECG are treated with
medical therapy and
revascularised after
confirmatory ICA
l Strategies 5 and 6 are
similar to strategy 4 but
use stress ECHO and
SPECT, respectively
l Strategy 7 tests all
patients with ICA, and
treats based on that test
as per other strategies
l In strategy 8 patients are
not evaluated for CAD
and receive baseline care
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Lee et al. (2015),73
the Republic of
Korea
1. CCTA plus second test
(ICA or SPECT)
2. SPECT plus second test
(ICA or CCTA)
l In all strategies, patients
with a positive on the first
test were referred to ICA
or a second non-invasive
test. ICA was the reference
test. The pathway for
patients who have
inconclusive test results is
not clear
l Patients could be treated
with observation without
medication, medication
only, PCI or CABG. Only
patients with a positive
ICA result could undergo
revascularisation. The
other treatment options
were possible for all
patients regardless of
testing strategy and
test results
l Individuals with chest pain
and suspected CAD
l Pretest probability of CAD:
10–90% [this was stratified
into three subgroups
(10–29%, 30–60% and
61–90%) that were
evaluated separately]
l Decision tree
l 1-year time horizon
l The decision tree split the
cohort according to test
results, underlying disease
status and subsequent
treatment, and considered
the following 1-year
outcomes: no event, event
and death related to CAD
l ICA is not a perfect test.
Diagnostic accuracy was
estimated based on a
retrospective cohort study,
with a correction to sensitivity
and specificity. The correction
was necessary because not all
patients underwent ICA in the
study, and clinicians were more
likely to refer patients with
positive non-invasive test
results to ICA
l Positive ICA defined as any
luminal stenosis ≥ 70% in any
of the major coronary arteries
l The events considered in the
model were MI and unstable
angina requiring hospital
admission
l HRQoL was assumed to depend
on whether or not patients
received appropriate treatment
and re-experienced CAD during
the 1-year follow-up
l Transition probabilities were
estimated based on data from
the same retrospective study
that informed the diagnostic
accuracy data
Min et al. (2010),81
USA
1. CCTA plus ICA for
positive or inconclusive
findings
2. CCTA plus ICA for
positive findings and
SPECT for inconclusive
findings
3. SPECT plus ICA for
positive or inconclusive
findings
l 55-year-old man with chest
pain and no prior history
of CAD
l Pretest probability of
CAD: 30%
l Decision tree (although
not described as such)
plus Markov model
l Lifetime horizon
l The decision tree splits
the cohort according to
test results, underlying
disease status and
severity of disease
l Markov model: no CAD
(no treatment), mild CAD
(no treatment), moderate
CAD (no treatment),
severe CAD (no
l ICA is a perfect test
l Obstructive CAD defined
as a luminal stenosis
severity ≥ 50% in the left
main coronary artery or
≥ 70% in any other major
epicardial artery
l Baseline risks in the Markov
model depend on disease
severity. Medication, PCI and
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
4. SPECT plus ICA for
positive findings and
CCTA for inconclusive
findings
5. ICA
l ICA is the reference test.
Individuals received no
treatment if identified as
having no CAD, were
treated with medical
therapy if they had CAD
of any severity. In
addition, patients with
moderate CAD received
PCI, and those with
severe CAD, CABG
treatment), no CAD
(treatment), mild CAD
(treatment), moderate
CAD (treatment), severe
CAD (treatment), death
l Patients in the
Markov model could
suffer MI events and
revascularisation/
repeat revascularisation
CABG reduce risks of death
and CV events
l 90% of patients with CAD that
were not diagnosed by the
initial test are assumed to be
correctly diagnosed within
10 years in the model
l HRQoL varies according to
CAD severity with MI and
revascularisation events
imposing a disutility
l ICA, PCI and CABG have an
associated immediate
mortality risk
l CCTA is assumed to produce
incidental findings that impose
a one-off cost
Min et al. (2017),70
USA
1. ETT plus ICA for positive
or inconclusive findings
2. ETT plus stress ECHO
for inconclusive findings
and ICA for positive
findings
3. ETT plus MPS for
inconclusive findings and
ICA for positive findings
4. ETT plus CCTA for
inconclusive findings and
ICA for positive findings
5. Stress ECHO plus ICA
for positive or
inconclusive findings
6. Stress ECHO plus CCTA
for inconclusive findings
and ETT
7. MPS plus ICA for
positive or
inconclusive findings
l 55-year-old man with chest
pain and no prior history
of CAD
l Pretest probability of
CAD: 20%
l Decision tree (although
not described as such)
plus Markov model
l Lifetime horizon
l The decision tree splits
the cohort according to
test results, underlying
disease status and
severity of disease
l The model accounts for
outcomes and costs of
treatment for those
correctly diagnosed with
CAD, diagnosis of FN,
and clinical events such
as revascularisation,
MI and death. However,
the model states are
not clearly described
or depicted
l ICA is a perfect test
l Mild CAD: non-obstructive
stenosis 1–69% in all affected
vessels, not including the left
main artery
l Moderate CAD: ≥ 70%
stenosis in one or two major
epicardial coronary artery
vessels, not including the left
main artery
l Severe CAD: ≥ 50% stenosis in
the left main artery or ≥ 70%
stenosis in any other major
epicardial artery. Patients
experiencing post-test MI
were also considered to have
severe CAD
l ICA, PCI and CABG have an
associated immediate
mortality risk
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
8. MPS plus CCTA for
inconclusive findings and
ICA for positive findings
9. CCTA plus ICA for
positive or inconclusive
findings
10. CCTA plus stress ECHO
for inconclusive findings
and ICA for positive
findings
11. CCTA plus MPS for
inconclusive findings and
ICA for positive findings
12. ICA
l ICA is the reference tests.
Individuals received no
treatment if identified as
having no CAD, and were
treated with medical
therapy if they had CAD
of any severity. Patients
with moderate CAD were
managed with medical
therapy (50%) or PCI plus
medical therapy (50%).
Patients with severe CAD
were managed with PCI
plus medical therapy
(50%) or CABG plus
medical therapy (50%)
l Baseline risks in the Markov
model depend on disease
severity. Medication, PCI and
CABG reduce risks of death
and CV events
l HRQoL depended on whether
or not individuals had CAD and
the severity of pain for those
who had CAD. Patients who
underwent revascularisation had
a temporary improvement in
their HRQoL. MI events impose
a disutility
l 20% of patients with CAD that
were not diagnosed by the
initial test are assumed to be
correctly diagnosed within
5 years in the model
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
Pletscher et al.
(2016),72
Switzerland
1. ETT plus ICA
2. Stress ECHO plus ICA
3. SPECT plus ICA
4. CCTA plus ICA
5. CCTA plus SPECT
for intermediate or
indeterminate scans
plus ICA
l 60-year-old men with
suspected CCS grade 2
coronary heart disease and a
prior likelihood of stenosis
of 39.5%
l The model is equivalent to the
model developed by Walker
et al. (2011),77 with updated
parameters to reflect the Swiss
health-care system context
l For strategies 1 to 6, all
positive and inconclusive
test results progress to
the next test in the
sequence. ICA is the
reference test
l Patients who test positive
in their overall diagnostic
sequence are managed
with revascularisation.
Patients with CAD but no
significant stenosis are
managed with
medical therapy
Priest et al.,
(2011),80 USA
6. ETT plus ICA
7. Stress ECHO plus ICA
8. SPECT plus ICA
9. CCTA plus ICA
10. CCTA plus SPECT
for intermediate or
indeterminate scans
plus ICA
l Patients presenting to an
emergency department with
chest pain and at low risk
of CAD
l Pretest probability of
CAD: 2–30%
l Decision tree
l 1-year time horizon
l The decision tree splits the
cohort according to test
results and underlying
disease status. It also
captures the occurrence
of CV events (death, MI)
during the time horizon
l ICA is a perfect test
l TP have an increased risk of CV
events compared with patients
who had negative results
l Patients with positive diagnostic
tests who subsequently tested
negative on ICA were assumed
to have an annual risk of a CV
event compared with patients
with normal test results
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Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
l Positive results with any
test require confirmation
with ICA, which is the
reference test. There is no
explicit link between test
results and treatment (not
explicitly modelled). CV
event rates are dependent
on testing strategy alone
l Patients with negative test
results on the initial screen
had CV event rates that were
conditional on tests undertaken
l TN were assumed to have the
population norm HRQoL, and
TP had a lower HRQoL
(equivalent to patients with
angina). FP incurred disutility
from stress associated with
misdiagnosis and from
undergoing ICA unnecessarily.
Patients who have a MI are
subject to a reduction in
HRQoL too. It is unclear what
is the HRQoL of FN
Walker et al.
(2011),77 UK
1. ICA
2. ETT plus ICA
3. ETT plus CMR plus ICA
4. ETT plus SPECT plus ICA
5. CMR plus ICA
6. SPECT plus ICA
7. ETT plus ICA if positive or
CMR if ETT inconclusive
plus ICA
8. ETT plus ICA if positive
or SPECT if ETT is
inconclusive plus ICA
l For strategies 1–6, all
positive and inconclusive
test results progress to
the next test in the
sequence. ICA is the
reference test
l 60-year-old men referred to
cardiologists with suspected
CAD (CSS 2)
l Pretest probability of
significant stenosis requiring
revascularisation: 39.5%
l Decision tree plus
Markov model
l 50-year time horizon
l The decision tree groups
individuals into three
groups according to test
results, their underlying
disease status and
whether they suffer
procedural death from ICA
or revascularisation: TP,
FN, TN with angina, TN
without angina and death
l Markov model is composed
of three submodels for
patients:
i. with significant stenosis
– entry FN, entry TP,
non-fatal CV event,
non-fatal CV event post
12 months, CV death,
non-CV death
l ICA is a perfect test
l Diagnostic accuracy estimates
for all tests were calculated
conditional on positive/
uncertain results in earlier
tests in the strategy based on
a single study. These allowed
accounting for correlations
between tests within
diagnostic strategies
l The proportion of patients
with significant stenosis
receive PCI or CABG was
sourced from the literature
l Risks of long-term CV
mortality and CV events
(including increased risk of
further CV events during
1 year after a CV event) was
continued
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TABLE 56 Summary of included studies (continued )
Study, country
Testing (and management)
strategies
Patient population
(base case where
clearly stated) Model type Health states Key assumptions/comments
l Patients who test positive
in their overall diagnostic
sequence are managed
with revascularisation.
Patients with CAD but
no significant stenosis
are managed with
medical therapy
ii. without significant
stenosis but with
angina – entry TN with
angina non-fatal CV
event, non-fatal CV
event post 12 months,
CV death, non-CV death
iii. without significant
stenosis or angina –
alive and dead
estimated based on risk
equations from the EUROPA
study.90 The model accounted
for cancer-related mortality
conditional on radiation
exposure associated with tests
and revascularisation procedures
(ICA, SPECT and PCI)
l The proportion of FN assumed
to be diagnosed (and
subsequently receive appropriate
revascularisation) within 1 year
in the model was informed by
expert elicitation and is
conditional on CCS grade
l HRQoL for patients with CAD
varies by age, sex, initial CCS
grade and treatment status.
HRQoL reductions for patients
experiencing angina are
assumed to be a fixed
proportion of the HRQoL of
the general population by age.
Revascularisation is assumed
to improve HRQoL, through
angina relief but have no effect
on the risk of CV events
BPCA, blood-pool contrast agent; CHD, coronary heart disease; CMR, cardiovascular magnetic resonance; CSI, cardiac stress imaging; CV, cardiovascular; ECG, electrocardiography;
ECHO, echocardiography; ETT, exercise treadmill testing; Ex-ECG, exercise electrocardiography; LM, left main trunk disease; NGCCT, new-generation dual-source coronary CT with
> 64 slices; SPECT, single-photon emission computed tomography.
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TABLE 57 Annual rates of MACE in Genders et al.74
Disease status
Annual rate of MACE
Treatment receivedaNo treatment
Treatment
First year Subsequent years
Normal coronary arteries 0.0008 0.0008 0.0008 RF
Mild CAD 0.025 0.025 0.025 RF
Moderate CAD
No inducible ischaemia 0.025 0.025 0.025 RF
Mild inducible ischaemia 0.246 [rate × (1/HR)] 0.172 0.071 RF plus OMT
Severe CAD
Mild inducible ischaemia 0.246 [rate × (1/HR)] 0.172 0.071 RF plus OMT
Severe inducible ischaemia 0.157 [rate × (1/HR)] 0.110 0.043 RF plus OMT plus PCI
Three-vessel disease/LM
Mild inducible ischaemia 0.137 [rate × (1/HR)] 0.096 0.031 RF plus OMT plus CABG
Severe inducible ischaemia 0.137 [rate × (1/HR)] 0.096 0.031 RF plus OMT plus CABG
LM, left main; RF, risk factor.
a If correctly identified.
TABLE 58 Base-case utility estimates for an individual aged 60 years in Genders et al.74
Disease status
No treatment
Treatment
Treatment receiveda
First year Subsequent years
Male Female Male Female Male Female
Normal coronary arteries 0.851 0.824 0.851 0.824 0.851 0.824 RF
Mild CAD 0.851 0.824 0.851 0.824 0.851 0.824 RF
Moderate CAD
No inducible ischaemia 0.851 0.824 0.851 0.824 0.851 0.824 RF
Mild inducible ischaemia 0.699 0.677 0.734 0.711 0.749 0.726 RF plus OMT
Severe CAD
Mild inducible ischaemia 0.699 0.677 0.734 0.711 0.749 0.726 RF plus OMT
Severe inducible ischaemia 0.699 0.677 0.740 0.716 0.760 0.736 RF plus OMT plus PCI
Three-vessel/LM
Mild inducible ischaemia 0.659 0.638 0.740 0.716 0.820 0.794 RF plus OMT plus CABG
Severe inducible ischaemia 0.659 0.638 0.740 0.716 0.820 0.794 RF plus OMT plus CABG
LM, left main; RF, risk factor.
a If correctly identified.
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TABLE 59 Medication use in Genders et al.74
Disease status
Medication use (%)
Platelet inhibitor:
aspirin (80mg per day)
Statin: simvastatin
(40mg per day)
Nitrate: isosorbide
mononitrate
(60mg per day)
ACE inhibitor:
enalapril
(20 mg per day)
Baseline 48 22 0 0
No CAD 12 17 1 7
Mild CAD 32 31 5 11
Moderate CAD without
inducible ischaemia
73 72 11 27
OMTa 95 92 61 62
PCI plus OMTa 95 93 47 64
CABG plus OMTa 83 86 8b 53
a At 3 years unless otherwise stated.
b At 1 year.
APPENDIX 7
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Appendix 8 Supplemental data used to
inform the cost-effectiveness analysis
TABLE 60 The ICA procedures in the NHS
Centre Number of centres
ICA procedures
SourceTotal number
Average number
per centrea
NHS interventional centre 98 205,085 2093 BCIS audit returns98
Diagnostic-only centre 60 35,017 584
Total 158 240,102 1520
a Calculated based on number of centres and ICA procedures.
TABLE 61 The FFR/iFR serious procedural complication rates
Serious procedural complication
aORBITA97
(N= 95), n (%)
RIPCORD101
(N= 200), n (%)
IRIS-FFR registry
(N= 8633), n (%)
Major bleeding 1 (1.05) – –
Converted to PCI for procedural complication 4 (4.21) – –
Pulmonary oedema 1 (1.05) – –
Vessel occlusion – 1 (0.5) –
Deep-vein thrombosis – 1 (0.5) –
Conduction disturbance requiring treatment – – 3 (0.03)
Bronchospasm – – 2 (0.02)
Coronary dissection – 1 (0.5) 3 (0.03)
Ventricular arrhythmiab – 1 (0.5) 2 (0.02)
Thrombus formation – – 1 (0.01)
a Placebo arm of the trial.
b Ventricular fibrillation in the RIPCORD trial.101
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0.15
1.37
0.15
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≥0.91
FIGURE 46 Baseline risk of MACE by FFR value in the first year after FFR measurement.
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TABLE 62 Summary of RCTs comparing revascularisation in addition to OMT vs. OMT alone in stable CAD
Study Region Main inclusion criteria N
Revascularisation procedure
vs. OMT*
Follow-up
(years) Primary end points Main findings
DEFER (2001)109 Europe, Asia SCAD, > 50% DS, FFR ≥ 0.75,
no evidence of reversible
ischaemia by non-invasive
testing in previous 2 months
325 PCI for a FFR ≥ 0.75,
performance group; PCI for a
FFR < 0.75, reference group;
OMT for a FFR ≥ 0.75,
deferral group
2 l MACE, defined as
composite of all-cause
mortality, MI, CABG, PCI
and any procedure-related
complication necessitating
major intervention or
prolonged hospital stay
l Event-free survival was similar
between the deferral and
performance groups (92% vs. 89%
at 12 months and 89% vs. 83% at
24 months), but was significantly
lower in the reference group
(80% at 12 months and 78% at
24 months)
l FFR identifies those who will
benefit from PCI the most
TIME (2001)106 Switzerland SCAD, aged ≥ 75 years,
CCSC ≥ 2 despite treatment
with at least two antianginal
agents
305 PCI, CABG, OMT 1 l MACE, defined as
composite of all-cause
mortality, MI, hospital
admission for ACS with
or without the need
for revascularisation
l HRQoL at 6 months
(SF-36, DASI, Rose
Angina Questionnaire)
l Significant difference in MACE
between invasive group and
medical therapy group (19% vs.
49% at a mean follow-up of
184.4 days). The difference was
mainly due to higher rates of
hospital admission for ACS
l After 6 months, angina severity
decreased and measures of
HRQoL increased in both
treatment groups; however,
these improvements were
significantly greater
after revascularisation
MASS II (2007,
2006)107,127,187
Brazil SCAD, ≥ 70% proximal
multivessel stenosis and
documented ischaemia
611 PCI, CABG, OMT 10 l MACE, defined as
composite of all-cause
mortality, MI, refractory
angina requiring
revascularisation107
l HRQoL measured at the
6-month and 1-year
follow-ups (SF-36)127
l At the 5-year follow-up,
significant difference in MACE
for CABG (21.2%) compared
with PCI (32.7%) and OMT (36%)
l No statistically significant
difference in overall mortality
among the three groups
l Significant difference in repeat
revascularisation procedures for
CABG (3.9%) compared with
PCI (11.2%) and OMT (9.4%)
continued
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TABLE 62 Summary of RCTs comparing revascularisation in addition to OMT vs. OMT alone in stable CAD (continued )
Study Region Main inclusion criteria N
Revascularisation procedure
vs. OMT*
Follow-up
(years) Primary end points Main findings
l Significance difference in MI for
CABG (8.3%) compared with
PCI (11.2%) and OMT (15.3%)
l Protective effect of CABG but
no significance difference in
MACE between PCI and OMT
l The 10-year survival rates
were 74.9% with CABG, 75.1%
with PCI and 69% with OMT.
The 10-year rates of MI were
10.3% with CABG, 13.3% with
PCI and 20.7% with MT. The
10-year rates of additional
revascularisations were 7.4%
with CABG, 41.9% with PCI and
39.4% with MT. 10-year rates
of freedom from angina were
64% with CABG, 59% with PCI
and 43% with MT
l HRQoL was better in both
CABG and PCI groups than in
OMT after 1 year of follow-up.
CABG group presented the
greater and progressive
improvement in HRQoL
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Study Region Main inclusion criteria N
Revascularisation procedure
vs. OMT*
Follow-up
(years) Primary end points Main findings
COURAGE
(2007, 2008)91,128
North
America
SCAD, ≥ 70% in ≥ 1 proximal
epicardial coronary artery
and evidence of myocardial
ischaemia or at least one
coronary stenosis of ≥ 80%
and classic angina
2287 PCI, OMT 4.6 l Primary outcome was
composite of all-cause
mortality and MI.
Secondary outcome was
MACE (including all-cause
mortality, MI, stroke and
hospitalisation for unstable
angina with negative
biomarkers)91
l HRQoL at the 1-year
follow-up (SAQ)128
l No statistically significant
difference in cumulative
primary event rates between
PCI group and OMT group
(19.0% vs. 18.5%) (HR for the
PCI group 1.05, 95% CI 0.87 to
1.27; p = 0.62) at 4.6 years’
median follow-up
l No statistically significant
difference between the PCI
group and the OMT group in
the composite of death, MI and
stroke (20.0% vs. 19.5%; HR
1.05, 95% CI 0.87 to 1.27;
p = 0.62); hospitalisation for
ACS (12.4% vs. 11.8%; HR 1.07,
95% CI 0.84 to 1.37; p = 0.56);
or MI (13.2% vs. 12.3%;
HR 1.13, 95% CI 0.89 to 1.43;
p = 0.33)
l Statistically significant
difference between PCI group
(21.1%) and OMT group
(32.6%) requiring additional
revascularisation (HR 0.60,
95% CI 0.51 to 0.71; p < 0.001)
l Very modest improvement in
SAQ score for PCI group
compared with OMT group
JSAP (2008)111 Japan SCAD, ≥ 75% coronary
stenosis
384 PCI, OMT 3.3 l MACE, defined as
composite of all-cause
mortality, ACS, stroke,
cerebrovascular
accident and emergency
hospitalisation
l No statistically significant
difference in MACE between
PCI group (2.9%) and OMT
group (3.9%). However, the
cumulative risk of death plus
ACS was significantly smaller in
PCI group
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TABLE 62 Summary of RCTs comparing revascularisation in addition to OMT vs. OMT alone in stable CAD (continued )
Study Region Main inclusion criteria N
Revascularisation procedure
vs. OMT*
Follow-up
(years) Primary end points Main findings
BARI 2D (2009,
2011)110,129,188
North and
South
America,
Europe
SCAD plus type 2 diabetes,
≥ 50% DS of a major
epicardial coronary artery
with positive stress test or
≥ 70% stenosis of a major
epicardial coronary artery
and classic angina
2368 PCI, CABG, OMT 5 l MACE, defined as
composite of all-cause
mortality, MI and stroke110
l Worsening of angina,
freedom from angina,
occurrence of new angina
and subsequent coronary
revascularisation188
l HRQoL (DASI, RAND for
energy/fatigue, health
distress, and self-rated
health)129
l No statistically significant
difference in event-free survival
between revascularisation
group (77.2%) and OMT group
(75.9%) in MACE
l No statistically significant
difference in overall mortality
between revascularisation
and OMT
l In the CABG stratum, the rate
of MACE was significantly
lower in the revascularisation
group (22.4%) than in the
medical therapy group (30.5%)
l Statistically significant
difference in worsening of
angina (8% vs. 13%), new
angina (37% vs. 51%), and
subsequent coronary
revascularisations (18% vs.
33%) and a higher rate of
angina-free status (66% vs.
58%) in revascularisation group
compared with OMT at the
3-year follow-up
l CABG had the greatest benefits
from revascularisation
l Compared with OMT,
revascularisation was
associated with significantly
greater improvements in DASI
(1.32 points), energy (1.36 points)
and self-rated health (1.77
points) but not health distress
(0.47 points). These treatment
effects were largely maintained
over 4 years’ follow-up. The
effect was significantly larger
for CABG
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Study Region Main inclusion criteria N
Revascularisation procedure
vs. OMT*
Follow-up
(years) Primary end points Main findings
FAME II
(2014)108,130
Europe,
North
America
SCAD, ≥ 50% DS, FFR < 0.8 888 FFR-guided PCI for a FFR
≤ 0.8, PCI group; OMT for
a FFR > 0.8, OMT group
2 l MACE, defined as a
composite of all-cause
mortality, MI or unplanned
hospitalisation leading to
urgent revascularisation
within 2 years108
l HRQoL (EQ-5D) by FFR at
the 1-month and 1-year
follow-ups130
l Significantly lower rate of MACE
in the PCI group than in the OMT
group (8.1% vs. 19.5%; HR 0.39,
95% CI 0.26 to 0.57). The
difference in MACE rates was
driven by the lower rate of urgent
revascularisation in the PCI group
(4.0% vs. 16.3%; HR 0.23, 95% CI
0.14 to 0.38; p< 0.001). No
significant between-group
differences were found in the
rates of death and MI
l HRQoL improved significantly
after PCI in each abnormal FFR
tertile, whereas it did not
change in the OMT group. The
lower FFR subgroups had the
greater HRQoL improvement
ORBITA (2018)97 UK SCAD, ≥ 70 DS single-vessel,
FFR, iFR
200 PCI, OMT 6 weeks l HRQoL (SAQ, EQ-5D-5L) l No statistically significant
difference in HRQoL for PCI
compared with OMT
l No detectable evidence of
interaction with pre randomisation
based on FFR and iFR
l PCI resulted in more patient-
reported freedom from angina
than placebo (49.5% vs. 31.5%;
OR 2.47, 95% CI 1.30 to 4.72;
p = 0.006)
ISCHEMIA
(2019)95,131,189,190
USA SCAD, ≥ 50% DS of a major
epicardial coronary artery
with positive stress test or
≥ 70% stenosis of a proximal
or mid-vessel
5179 PCI (74% of revascularisation
group), CABG (26% of
revascularisation group), OMT
3.2 l MACE, defined as a
composite of CV mortality,
MI, hospitalisation for
unstable angina, heart
failure or resuscitated
cardiac arrest95,189
l HRQoL at 3, 12 and
36 months (SAQ)131,190
l No statistically significant
difference in MACE between
revascularisation group and
OMT group
l Very low rates of procedure-
related stroke and death
l Significant, durable improvements
in angina control and HRQoL
with the revascularisation
strategy, compared with OMT
ACS, adult cardiac surgery; CCSC, Canadian Cardiovascular Society classification; CV, cardiovascular; SCAD, spontaneous coronary artery dissection.
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TABLE 63 The QALY loss associated with testing and revascularisation procedures
Procedure Mean QALY loss (95% CI) Source
ICA 0 Assumed to cancel across strategies
FFR/iFR 0.0056 (0.0051 to 0.0062) Assumed the same as for PCI
PCI 0.0056 (0.0051 to 0.0062) Bagust et al. (2006)126
CABG 0.033 (0.031 to 0.035) Bagust et al. (2006)126
TABLE 64 Summary of QAngio XA 3D/QFR costs reported by Medis Medical Imaging Systems BV
Voucher
Software licence feea,b
Training and certification fee for up to
four members of staffa
Euro GBP Euro GBP
10 patients 5000 4314.75 3500 3020.33
50 patients 25,000 21,573.75 3500 3020.33
100 patients 49,000 42,284.55 Included in the licence fee
a Costs exclude VAT.
b Vouchers also include the cost of customer support/service and software upgrades during the period of usage.
TABLE 65 QAngio XA 3D/QFR: staff time and costs associated with training and certification
Staff Staff numbers
Time (hours)
Unit
costa (£) Source
Total
cost (£)Training Certification
Cardiologist 1 0.5 – 109 Consultant: surgical;
PSSRU (2019)137
54.50
Cardiac physiologist 3 5 1.5 37 Allied professional
(band 5);b PSSRU (2019)137
721.50
Total 4 16.5 4.5 – – 776.00
a Per working hour.
b Assumed the same as for radiographer.
TABLE 66 Costs of QAngio XA 3D/QFR for an annual throughput of 200 patients
Cost element Total cost (£) Cost per patient tested (£)
Software licence fee 84,569.10 422.85
Training and certification fee – –
Training and certification staff costs 1552.00 7.76
Total 86,121.10 430.61
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
222
TABLE 67 Summary of CAAS vFRR software licence, annual maintenance and training costs reported by Pie Medical
Imaging BV
Pricing
model
Software licence feea Annual maintenance feea Training feea,b
Euro GBP Conditions Euro GBP
Starting
from Platform Euro GBP
1 37,000 31,929 Perpetual
licence
5500 4746 Year 2 e-learning – –
2 200 173 Per patient 3500 3020 Year 1 Webex 250 216
On site 2500 2157
a Costs exclude VAT.
b Independent of pricing model.
TABLE 68 CAAS vFRR: staff time and costs associated with training
Staff
Staff
numbers
Time (hours)
Unit
costa (£) Source
Total cost (£)
Webex or
e-learning On site
Webex or
e-learning On site
Cardiologist 1 2 4 109 Consultant: surgical,
PSSRU 2019137
218 436
Cardiac
physiologist
3 2 4 37 Allied professional
(band 5b), PSSRU 2019137
222 444
Total 4 8 16 – – 440 880
a Per working hour.
b Assumed the same as for radiographer.
TABLE 69 Costs of CAAS vFFR for an annual throughput of 200 patients
Cost element
Total cost (£)
Cost per patient testeda (£)Webex or e-learning On-site
Software licence fee 31,929.15 31,929.15 159.65
Training fee 215.74 2157.38 5.93
Staff training costs 440.00 880.00 6.60
Maintenance cost – – –
Total 32,584.89 34,966.53 172.18
a Average of on-site and online learning.
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FIGURE 47 Comparison of QAngio XA 3D/QFR and CAAS vFFR test cost at different throughputs.
TABLE 70 Costs of revascularisation in the model
Cost category Currency codes Unit cost (£)
PCIa EY40A–D and EY41A–D, across all HRG codes 3005.07
PCI as day case EY40A–D and EY41A–D, day case 2178.95
CABGa ED26A–C, ED27A–C and ED28A–C, across all HRG codes 10,898.58
a Base-case assumption.
TABLE 71 Fractional flow reserve serious procedural complications events
Procedural complication Rate (%) Source Unit cost (£) Currency codes/assumptions
Coronary dissection 0.03 IRIS13 3005.07 Activity-weighted average of the PCI currency codes
(EY40A–D and EY41A–D, across all HRG codes
codes). It is assumed that PCI is required to repair
coronary dissection. This cost is incurred only if
patients do not subsequently undergo PCI as a
result of testing positive for significant stenosis
Ventricular arrhythmia 0.02 IRIS13 974.90 Activity-weighted average of the arrhythmia or
conduction disorders currency codes (EB07A–E,
across all HRG codes)
Conduction disturbance
requiring treatment
0.03 IRIS13 974.90 Activity-weighted average of the arrhythmia or
conduction disorders currency codes (EB07A–E,
across all HRG codes)
Thrombus formation 0.01 IRIS13 928.12 Assumed average of unit cost of other complications,
excluding coronary dissection
Bronchospasm 0.02 IRIS13 834.57 Activity-weighted average of the asthma without
interventions currency codes (DZ15N, P–R, across
all HRG codes)
Death 0.015 Fearon et al.
(2003)87
0.00 Assumption
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
224
TABLE 72 Health state and clinical event costs
Health state/clinical event Cost (£) Source
No event 0.00 Assumption
MI 2317.53 Activity-weighted average of HRG codes for actual or
suspected MI (EB10A–E), across all HRG codes (NHS
reference costs 2017/18)138
Post MI 0.00 Assumption
Unplanned revascularisation 4812.23 Activity-weighted average of HRG codes for PCI and CABG
(EY40A–D, EY41A–D, ED26A–C, ED27A–C and ED28A–C),
non-elective long stays – NHS reference costs 2017/18138
Post unplanned revascularisation 0.00 Assumption
Cardiovascular death 0.00 Assumption
Other-cause death 0.00 Assumption
TABLE 73 Base-case parameters
Parameter Values Source/assumptions Probabilistic model set-up
Patient characteristics
Age 64 IRIS-FFR13 NA
Proportion of male individuals 0.72 IRIS-FFR13 NA
Proportion with clinically
significant stenosis
(i.e. FFR < 0.8)
0.402 Recreated individual level FFR
measurements in the QAngio
diagnostic accuracy studies (cQFR
and non-specified QFR mode)
Calculated from each 5000
bootstrapped samples of the
joint FFR and QFR distribution
Number of patients with stenosis of uncertain clinical significance
Annual throughput 200 BCIS audit returns98 and clinical
opinion
NA
Diagnostic accuracy
FFR/iFR
Sensitivity 100% Assumption NA
Specificity 100%
ICA
Sensitivity 62.61% Bivariate meta-analysis (see
Chapter 3,Meta-analysis of extracted
figure data for two-dimensional
invasive coronary angiography)
Multivariate log-normal
distribution fitted to log-odds
sensitivity and specificitySpecificity 61.59%
QAngio
Sensitivity 84.34% Bivariate meta-analysis
(see Table 3) for combined cQFR
and non-specified QFR mode
Multivariate log-normal
distribution fitted to log-odds
sensitivity and specificitySpecificity 89.80%
CAAS vFRR
Sensitivity 97.00% FAST-EXTEND18 Independent beta distributions
fitted to the diagnostic accuracy
2 × 2 tables
l Sensitivity: α = 118, β = 4
l Specificity: α = 47, β = 134
Specificity 74.00%
continued
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TABLE 73 Base-case parameters (continued )
Parameter Values Source/assumptions Probabilistic model set-up
Joint probability of FFR and QFR
QFR < 0.78 and FFR ≤ 0.80 0.744 Recreated individual level FFR and
QFR measurements in the QAngio
diagnostic accuracy studies (cQFR
and non-specified QFR mode)
Calculated from each 5000
bootstrapped samples of the
joint FFR and QFR distributionQFR 0.78–0.84 and FFR ≤ 0.80 0.188
QFR ≥ 0.84 and FFR ≤ 0.80 0.069
QFR < 0.78 and FFR > 0.80 0.095
QFR 0.78–0.84 and FFR > 0.80 0.212
QFR ≥ 0.84 and FFR > 0.80 0.693
Procedural adverse events
FFR/iFR complications
Conduction disturbance
requiring treatment
0.03% IRIS-FFR13 Beta distribution: α = 3, β = 8630
Bronchospasm 0.02% Beta distribution: α = 2, β = 8631
Coronary dissection 0.03% Beta distribution: α = 3, β = 8630
Ventricular arrhythmia 0.02% Beta distribution: α = 1, β = 8631
Thrombus formation 0.01% Beta distribution: α = 1, β = 8632
Death 0.015% Fearon et al., 200387 NA
Revascularisation complications
PCI death 0.17% 2019 NCAP Annual Report103 NA
CABG death 0.99% ACS 2019 summary report102 NA
Revascularisation death 0.277% Calculated NA
Proportion per revascularisation procedure
PCI 87% BCIS audit returns98 NA
CABG 13% NA
Clinical event rates
Non-cardiovascular mortality Age and sex
dependent
ONS mortality data120,121 NA
Baseline MACE rates Dependent
on the
underlying FFR
distribution
IRIS-FFR13 The underlying FFR distribution
was calculated from each 5000
bootstrapped samples of the
joint FFR and QFR (or DS, where
applicable) distribution
HR of revascularisation on
MACE rates
1.0 Assumption of no treatment effect NA
HRQoL
Procedural disutility
ICA 0.0000 Assumption NA
FFR/iFR 0.0056 Assumed same as PCI Gamma distribution: mean
0.0056, SE 0.003
PCI 0.0056 Bagust et al. (2006)126 Gamma distribution: mean
0.0056, SE 0.003
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TABLE 73 Base-case parameters (continued )
Parameter Values Source/assumptions Probabilistic model set-up
CABG 0.033 Bagust et al. (2006)126 Gamma distribution: mean
0.033, SE 0.001
Revascularisation 0.0092 Calculated NA
Baseline utility in the
prognostic model
Age and sex
dependent
Calculated based on Ara and
Brazier (2010)134 and Nishi et al.
(2018)130
Beta distribution fitted to
reference group baseline utility:
mean 0.821, SE 0.0112
Utility increments
FN 0.015 Nishi et al. (2018)130 Beta distribution: mean 0.015,
SE 0.0094
TN 0.000 Calculated based on Nishi et al.
(2018)130 and the underlying
distribution of FFR
NA
FP 0.000 NA
TP 0.000 The underlying FFR distribution
was calculated from each 5000
bootstrapped samples of the
joint FFR and QFR (or DS where
applicable) distribution
Beta distributions were fitted to
the utility increment by FFR
category (see Table 11)
Health states and clinical events disutility
MI 0.0626 Sullivan et al. (2011)135 Gamma distribution: mean
0.0626, SE 0.0132
Post-MI 0.0368 Sullivan et al. (2011)135 Gamma distribution: mean
0.0368, SE 0.0257
Unplanned revascularisation 0.0091 Calculated NA
Costs
Tests (per patient tested)
Qangio XA £430.61 Calculated NA
CAAS vFFR £172.18 Calculated NA
FFR/iFR £436.80 NHS reference costs 2017/18138
and uprated to 2018/19 costs137
NA
ICA £0 Assumption NA
Optimal medication treatment (annual cost)
OMT only £163.63 Calculated based on Nishi et al.
(2018)130 COURAGE,91 SYNTAX59
and the BNF141
NA
OMT only (FN) £168.68 NA
OMT in addition to PCI £150.10 NA
OMT in addition to CABG £126.27 NA
OMT in addition to
revascularisation
£147.00 Calculated NA
Interventional procedures
PCI £3005.07 NHS reference costs 2017/18138
and uprated to 2018/19 costs137
NA
CABG £10,898.58 NA
Revascularisation £4031.22 Calculated NA
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TABLE 73 Base-case parameters (continued )
Parameter Values Source/assumptions Probabilistic model set-up
Treatment of revascularisation complications
Coronary dissection £3005.07 NHS reference costs 2017/18138
and uprated to 2018/19 costs137
NA
Ventricular arrhythmia £974.90 NA
Conduction disturbance
requiring treatment
£974.90 NA
Bronchospasm £928.12 NA
Thrombus formation £834.57 Assumed average of unit cost of
other complications, excluding
coronary dissection
NA
Death £0.00 Assumption NA
Health states and clinical events costs
No event £0.00 Assumption NA
MI £2317.53 NHS reference costs 2017/18138
and uprated to 2018/19 costs137
NA
Unplanned revascularisation £4812.23 NA
Post MI £0.00 Assumption NA
Post unplanned
revascularisation
£0.00 Assumption NA
Death (cardiovascular and
other causes)
£0.00 Assumption NA
ACS, Adult Cardiac Surgery; NA, not applicable; NCAP, National Cardiac Audit Programme; ONS, Office for
National Statistics.
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Appendix 9 Deterministic results of the
cost-effectiveness analysis
TABLE 74 Summary of deterministic cost-effectiveness results of the base-case and scenario analyses
Scenario
Strategy
1. ICA alone 2. ICA plus FFR 3. ICA plus QFR
4. ICA plus QFR plus
confirmatory FFR 5. vFFR
Base case 0.029 0.020 0.016 0.016
1 0.029 0.019 0.016 0.016
2 0.029 0.023 0.016 0.016
3a 0.008
4 0.029 0.020 0.016 –0.031
5 0.029 0.020 0.016 0.024
6 0.029 0.020 0.016 0.034
7 0.018 0.010 0.006 0.005
8 0.048 0.036
9 0.029 0.020 0.016 0.016
10 0.061 0.039 0.042 0.042
11 0.032 0.023 0.019 0.020
12 0.033 0.023 0.019 0.020
13 0.033 0.023 0.020 0.021
14 0.026 0.021 0.017 0.008
15 0.025 0.017 0.014 0.018
16 0.033 0.025 0.019 0.012
17 0.004 0.006 –0.004 –0.011
18 –0.010 –0.002 –0.015 –0.025
19 0.002 0.021 0.011 0.016
20 0.030 0.020 0.016 0.016
21 0.026 0.020 0.016 0.016
22 0.025 0.020 0.016 0.016
23 –0.060 0.020 –0.002 0.016
24 –0.060 0.020 –0.002 0.021
a Incremental net benefit compared with strategy 2.
Results of the cost-effective strategy for each analysis are shaded in blue.
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